dental radiology data set

dental.jsonl

{"id": "case_0001", "images": ["images/placeholder_0001.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Amlodipine, Calcichew-D3, Bufomix Easyhaler, Betolvex, Losartan, Levaxin. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 36–46.", "answer": "Review of CBCT volume dated 210506. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 15: bone height ≈ 17.4 mm; implant space ≈ 15.6 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 20.5 mm; implant space ≈ 14.0 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 6.4 mm; implant space ≈ 1.0 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 16.7 mm; implant space ≈ 14.2 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 9.6 mm; implant space ≈ 1.8 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 9.2 mm; implant space ≈ 4.3 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 15.1 mm; implant space ≈ 8.7 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 13.4 mm; implant space ≈ 11.7 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 15.0 mm; implant space ≈ 11.6 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Cyst-like well-defined radiolucency near 44, likely radicular cyst."}
{"id": "case_0002", "images": ["images/placeholder_0002.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Insulin glargine, Bricanyl, Metoprolol, Losartan, Bufomix Easyhaler, Trulicity. Desired treatment: Report any signs of peri-implantitis and root resorption in 37–47.", "answer": "Review of CBCT volume dated 221114. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 44: bone height ≈ 16.9 mm; implant space ≈ 13.9 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 7.1 mm; implant space ≈ 3.3 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 12.9 mm; implant space ≈ 9.1 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 16.3 mm; implant space ≈ 10.4 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 15.8 mm; implant space ≈ 10.8 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 14.6 mm; implant space ≈ 9.5 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 5.5 mm; implant space ≈ 1.2 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 12.0 mm; implant space ≈ 6.6 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 6.6 mm; implant space ≈ 2.4 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 4.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0003", "images": ["images/placeholder_0003.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Esomeprazole, Duroferon, Amlodipine, Trulicity, Calcichew-D3, Bricanyl, Duloxetine, Atorvastatin. Desired treatment: Quantify vertical bone loss around implants in 17–27 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 210511. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 9.7 mm; implant space ≈ 1.4 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 9.9 mm; implant space ≈ 5.1 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 11.9 mm; implant space ≈ 7.6 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 16.1 mm; implant space ≈ 8.4 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 9.7 mm; implant space ≈ 6.5 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 21.3 mm; implant space ≈ 17.5 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 6.4 mm; implant space ≈ 1.9 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 11.7 mm; implant space ≈ 8.1 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 6.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 17.1 mm; implant space ≈ 11.4 mm; nearest critical structure: mandibular canal. Periapical radiolucency present near 36; lamina dura loss noted. Secondary small radiolucency adjacent to 41. Streak artifacts from metallic restorations locally reduce interpretability. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0004", "images": ["images/placeholder_0004.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Insulin glargine, Esomeprazole, Calcichew-D3, Bricanyl, Metoprolol, Trulicity, Losartan, Levaxin, Bufomix Easyhaler. Desired treatment: Report any signs of peri-implantitis and root resorption in 37–47.", "answer": "Review of CBCT volume dated 241018. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 17: bone height ≈ 19.5 mm; implant space ≈ 14.2 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 15.5 mm; implant space ≈ 9.1 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 20.5 mm; implant space ≈ 16.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 13.1 mm; implant space ≈ 9.6 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 18.4 mm; implant space ≈ 10.5 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 5.7 mm; implant space ≈ 3.6 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 9.1 mm; implant space ≈ 5.0 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 20.9 mm; implant space ≈ 14.3 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 10.3 mm; implant space ≈ 6.4 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 7.9 mm; implant space ≈ 3.2 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Cyst-like well-defined radiolucency near 22, likely radicular cyst."}
{"id": "case_0005", "images": ["images/placeholder_0005.png"], "question": "Planning for implant planning evaluation. Brief history/status: Bricanyl, Betolvex, Bufomix Easyhaler, Metoprolol, Calcichew-D3, Insulin glargine. Desired treatment: Evaluate periapical status of teeth 16, 33, and 17, and overall sinus condition.", "answer": "Review of CBCT volume dated 220221. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 19.0 mm; implant space ≈ 14.5 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 7.1 mm; implant space ≈ 1.4 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 10.8 mm; implant space ≈ 3.6 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 8.9 mm; implant space ≈ 0.4 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 20.4 mm; implant space ≈ 18.4 mm; nearest critical structure: sinus floor. Region 48: bone height ≈ 11.7 mm; implant space ≈ 5.3 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 20.8 mm; implant space ≈ 18.0 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 14.5 mm; implant space ≈ 7.4 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 11.1 mm; implant space ≈ 2.7 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 19.8 mm; implant space ≈ 15.2 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Vertical root fracture suspected at 46; recommend clinical correlation."}
{"id": "case_0006", "images": ["images/placeholder_0006.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Calcichew-D3, Duloxetine, Bricanyl, Bufomix Easyhaler, Insulin glargine, Esomeprazole, Duroferon. Desired treatment: Report any signs of peri-implantitis and root resorption in 17–27.", "answer": "Review of CBCT volume dated 200716. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 28: bone height ≈ 14.5 mm; implant space ≈ 12.0 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 10.3 mm; implant space ≈ 4.4 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 7.8 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 10.1 mm; implant space ≈ 1.8 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 5.6 mm; implant space ≈ 0.7 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 8.5 mm; implant space ≈ 5.2 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 12.4 mm; implant space ≈ 8.5 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 9.7 mm; implant space ≈ 8.0 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 16.2 mm; implant space ≈ 7.4 mm; nearest critical structure: sinus floor. Impression: Findings consistent with chronic apical periodontitis at 38 and 25."}
{"id": "case_0007", "images": ["images/placeholder_0007.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Bufomix Easyhaler, Duloxetine, Metoprolol, Bricanyl, Calcichew-D3, Trulicity, Esomeprazole, Betolvex, Losartan. Desired treatment: Quantify vertical bone loss around implants in 17–27 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 221107. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 24: bone height ≈ 19.8 mm; implant space ≈ 13.9 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 10.6 mm; implant space ≈ 3.4 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 17.2 mm; implant space ≈ 13.0 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 11.9 mm; implant space ≈ 4.8 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 21.7 mm; implant space ≈ 13.1 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 9.4 mm; implant space ≈ 6.8 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 7.0 mm; implant space ≈ 4.0 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 14.3 mm; implant space ≈ 7.1 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 4.1 mm; implant space ≈ 2.6 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 21.8 mm; implant space ≈ 17.9 mm; nearest critical structure: sinus floor. Periapical radiolucency present near 23; lamina dura loss noted. Secondary small radiolucency adjacent to 11. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0008", "images": ["images/placeholder_0008.png"], "question": "Planning for sinus-related complaints. Brief history/status: Esomeprazole, Betolvex, Calcichew-D3, Bufomix Easyhaler, Bricanyl, Amlodipine, Losartan, Duroferon, Atorvastatin. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 35–45.", "answer": "Review of CBCT volume dated 210215. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 44: bone height ≈ 14.3 mm; implant space ≈ 6.8 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 17.2 mm; implant space ≈ 12.2 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 9.6 mm; implant space ≈ 5.6 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 9.6 mm; implant space ≈ 0.8 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 11.6 mm; implant space ≈ 5.2 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 10.3 mm; implant space ≈ 4.4 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 19.7 mm; implant space ≈ 13.7 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 19.0 mm; implant space ≈ 15.0 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 16.9 mm; implant space ≈ 15.3 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 21.7 mm; implant space ≈ 17.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0009", "images": ["images/placeholder_0009.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Bufomix Easyhaler, Amlodipine, Levaxin, Metoprolol, Esomeprazole, Calcichew-D3, Insulin glargine. Desired treatment: Measure crest-to-canal distances mandibularly in 36–46, and implant feasibility maxillary 17–27.", "answer": "Review of CBCT volume dated 201028. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 12: bone height ≈ 20.0 mm; implant space ≈ 16.1 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 9.4 mm; implant space ≈ 6.9 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 12.1 mm; implant space ≈ 3.8 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 18.3 mm; implant space ≈ 9.9 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 7.0 mm; implant space ≈ 1.6 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 19.4 mm; implant space ≈ 16.8 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 6.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 12.7 mm; implant space ≈ 4.1 mm; nearest critical structure: sinus floor. Region 45: bone height ≈ 11.6 mm; implant space ≈ 7.3 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0010", "images": ["images/placeholder_0010.png"], "question": "Planning for sinus-related complaints. Brief history/status: Duloxetine, Losartan, Bufomix Easyhaler, Amlodipine, Atorvastatin, Betolvex, Metoprolol, Trulicity. Desired treatment: Evaluate periapical status of teeth 41, 12, and 44, and overall sinus condition.", "answer": "Review of CBCT volume dated 251105. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 14: bone height ≈ 4.2 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 14.3 mm; implant space ≈ 5.7 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 4.6 mm; implant space ≈ 1.4 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 16.8 mm; implant space ≈ 14.5 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 16.6 mm; implant space ≈ 13.4 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 21.0 mm; implant space ≈ 12.4 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 5.7 mm; implant space ≈ 0.8 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 8.1 mm; implant space ≈ 6.1 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 23; lamina dura loss noted. Secondary small radiolucency adjacent to 44. Impression: Peri-implant bone loss at 23 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0011", "images": ["images/placeholder_0011.png"], "question": "Planning for implant site evaluation. Brief history/status: Amlodipine, Losartan, Esomeprazole, Levaxin, Metoprolol, Betolvex. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.", "answer": "Review of CBCT volume dated 230306. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 8.5 mm; implant space ≈ 3.5 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 15.6 mm; implant space ≈ 11.9 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 15.7 mm; implant space ≈ 6.8 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 14.1 mm; implant space ≈ 7.0 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 21.1 mm; implant space ≈ 13.9 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 8.0 mm; implant space ≈ 0.6 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 19.9 mm; implant space ≈ 14.8 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 20.6 mm; implant space ≈ 13.6 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 8.1 mm; implant space ≈ 1.2 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 10.9 mm; implant space ≈ 6.7 mm; nearest critical structure: nasal floor. Impression: Peri-implant bone loss at 31 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0012", "images": ["images/placeholder_0012.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Calcichew-D3, Metoprolol, Duloxetine, Levaxin, Trulicity, Esomeprazole, Amlodipine, Betolvex. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 15–25.", "answer": "Review of CBCT volume dated 220513. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 36: bone height ≈ 8.7 mm; implant space ≈ 1.5 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 20.2 mm; implant space ≈ 17.4 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 9.2 mm; implant space ≈ 5.6 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 20.9 mm; implant space ≈ 12.8 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 7.6 mm; implant space ≈ 4.4 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 7.1 mm; implant space ≈ 4.3 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 21.2 mm; implant space ≈ 14.2 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 16.4 mm; implant space ≈ 12.2 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 23 and 18."}
{"id": "case_0013", "images": ["images/placeholder_0013.png"], "question": "Planning for full-arch restoration. Brief history/status: Bricanyl, Atorvastatin, Losartan, Amlodipine, Duloxetine, Duroferon, Esomeprazole, Bufomix Easyhaler. Desired treatment: Quantify vertical bone loss around implants in 36–46 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 240608. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 33: bone height ≈ 15.7 mm; implant space ≈ 8.7 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 4.3 mm; implant space ≈ 2.2 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 8.5 mm; implant space ≈ 1.1 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 10.4 mm; implant space ≈ 8.5 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 22.0 mm; implant space ≈ 18.0 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 14.7 mm; implant space ≈ 9.6 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 12.0 mm; implant space ≈ 10.0 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 10.5 mm; implant space ≈ 3.4 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 14.7 mm; implant space ≈ 6.2 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 37; lamina dura loss noted. Secondary small radiolucency adjacent to 26. Streak artifacts from metallic restorations locally reduce interpretability. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0014", "images": ["images/placeholder_0014.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Trulicity, Metoprolol, Duroferon, Amlodipine, Betolvex, Duloxetine, Insulin glargine, Bricanyl, Bufomix Easyhaler. Desired treatment: Please report bone height and available implant space for regions 37–47 and 35–45.", "answer": "Review of CBCT volume dated 220209. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 31: bone height ≈ 14.4 mm; implant space ≈ 11.2 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 16.2 mm; implant space ≈ 9.7 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 16.6 mm; implant space ≈ 14.9 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 20.4 mm; implant space ≈ 13.0 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 13.2 mm; implant space ≈ 10.1 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 14.1 mm; implant space ≈ 10.6 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 14.3 mm; implant space ≈ 8.1 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 16.1 mm; implant space ≈ 14.3 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 10.4 mm; implant space ≈ 5.0 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 12.4 mm; implant space ≈ 3.5 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 24; lamina dura loss noted. Secondary small radiolucency adjacent to 14. Impression: Vertical root fracture suspected at 14; recommend clinical correlation."}
{"id": "case_0015", "images": ["images/placeholder_0015.png"], "question": "Planning for implant site evaluation. Brief history/status: Bricanyl, Duroferon, Trulicity, Calcichew-D3, Metoprolol, Bufomix Easyhaler. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.", "answer": "Review of CBCT volume dated 210705. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 46: bone height ≈ 7.8 mm; implant space ≈ 3.4 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 10.1 mm; implant space ≈ 3.2 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 14.6 mm; implant space ≈ 9.1 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 4.3 mm; implant space ≈ 1.1 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 7.3 mm; implant space ≈ 3.6 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 17.6 mm; implant space ≈ 15.9 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 7.9 mm; implant space ≈ 2.3 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 20.3 mm; implant space ≈ 17.8 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 20.3 mm; implant space ≈ 12.6 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 21.2 mm; implant space ≈ 17.2 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 38; lamina dura loss noted. Secondary small radiolucency adjacent to 18. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0016", "images": ["images/placeholder_0016.png"], "question": "Planning for sinus-related complaints. Brief history/status: Insulin glargine, Metoprolol, Levaxin, Esomeprazole, Atorvastatin. Desired treatment: Evaluate periapical status of teeth 16, 46, and 22, and overall sinus condition.", "answer": "Review of CBCT volume dated 251001. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 27: bone height ≈ 17.4 mm; implant space ≈ 11.7 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 13.0 mm; implant space ≈ 9.5 mm; nearest critical structure: incisive canal. Region 21: bone height ≈ 7.9 mm; implant space ≈ 0.7 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 9.3 mm; implant space ≈ 2.1 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 6.2 mm; implant space ≈ 0.4 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 14.8 mm; implant space ≈ 10.1 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 17.1 mm; implant space ≈ 13.9 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 6.5 mm; implant space ≈ 4.9 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 21.1 mm; implant space ≈ 13.4 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 9.6 mm; implant space ≈ 4.9 mm; nearest critical structure: mandibular canal. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0017", "images": ["images/placeholder_0017.png"], "question": "Planning for implant planning evaluation. Brief history/status: Calcichew-D3, Trulicity, Esomeprazole, Metoprolol, Insulin glargine, Levaxin. Desired treatment: Provide measurements relevant to guided surgery stent planning for 37–47 and 16–26.", "answer": "Review of CBCT volume dated 240404. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 5.4 mm; implant space ≈ 0.7 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 7.7 mm; implant space ≈ 0.2 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 10.5 mm; implant space ≈ 5.4 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 17.2 mm; implant space ≈ 9.2 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 18.6 mm; implant space ≈ 10.2 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 16.0 mm; implant space ≈ 8.4 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 12.3 mm; implant space ≈ 3.5 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 20.5 mm; implant space ≈ 17.5 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 8.3 mm; implant space ≈ 3.6 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 11.1 mm; implant space ≈ 9.3 mm; nearest critical structure: nasal floor. Periapical radiolucency present near 22; lamina dura loss noted. Secondary small radiolucency adjacent to 18. Impression: Impaction of third molar in quadrant 4 with mesioangular inclination."}
{"id": "case_0018", "images": ["images/placeholder_0018.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Atorvastatin, Duloxetine, Losartan, Duroferon, Bufomix Easyhaler, Esomeprazole, Insulin glargine, Calcichew-D3. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 17–27.", "answer": "Review of CBCT volume dated 251008. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 14: bone height ≈ 8.4 mm; implant space ≈ 4.7 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 18.8 mm; implant space ≈ 15.6 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 14.6 mm; implant space ≈ 9.8 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 19.2 mm; implant space ≈ 15.2 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 21.5 mm; implant space ≈ 15.9 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 11.8 mm; implant space ≈ 4.2 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 13.2 mm; implant space ≈ 5.8 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 7.5 mm; implant space ≈ 2.5 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Periapical radiolucency present near 41; lamina dura loss noted. Secondary small radiolucency adjacent to 46. Impression: Vertical root fracture suspected at 25; recommend clinical correlation."}
{"id": "case_0019", "images": ["images/placeholder_0019.png"], "question": "Planning for full-arch restoration. Brief history/status: Calcichew-D3, Amlodipine, Levaxin, Losartan, Bufomix Easyhaler, Trulicity, Insulin glargine. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 210302. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 11: bone height ≈ 9.3 mm; implant space ≈ 2.4 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 16.6 mm; implant space ≈ 10.5 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 21.0 mm; implant space ≈ 14.7 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 11.5 mm; implant space ≈ 10.0 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 11.2 mm; implant space ≈ 5.3 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 17.7 mm; implant space ≈ 12.6 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 21.3 mm; implant space ≈ 13.5 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 11.8 mm; implant space ≈ 6.0 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 15.6 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 9.9 mm; implant space ≈ 7.8 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 42; lamina dura loss noted. Secondary small radiolucency adjacent to 47. Impression: Findings consistent with chronic apical periodontitis at 33 and 31."}
{"id": "case_0020", "images": ["images/placeholder_0020.png"], "question": "Planning for sinus-related complaints. Brief history/status: Duroferon, Duloxetine, Losartan, Bufomix Easyhaler, Betolvex, Amlodipine, Atorvastatin. Desired treatment: Please report bone height and available implant space for regions 17–27 and 16–26.", "answer": "Review of CBCT volume dated 250911. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 47: bone height ≈ 15.8 mm; implant space ≈ 13.4 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 17.0 mm; implant space ≈ 12.2 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 6.8 mm; implant space ≈ 2.0 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 9.7 mm; implant space ≈ 1.0 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 15.0 mm; implant space ≈ 12.3 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 12.4 mm; implant space ≈ 8.4 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 21.4 mm; implant space ≈ 14.0 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 17.1 mm; implant space ≈ 11.7 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 16.0 mm; implant space ≈ 9.4 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 5.8 mm; implant space ≈ 1.2 mm; nearest critical structure: nasal floor. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0021", "images": ["images/placeholder_0021.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Esomeprazole, Metoprolol, Calcichew-D3, Trulicity, Duloxetine, Betolvex. Desired treatment: Report any signs of peri-implantitis and root resorption in 17–27.", "answer": "Review of CBCT volume dated 230725. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 36: bone height ≈ 10.2 mm; implant space ≈ 3.9 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 5.5 mm; implant space ≈ 0.7 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 13.4 mm; implant space ≈ 9.6 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 14.4 mm; implant space ≈ 9.3 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 18.0 mm; implant space ≈ 13.9 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 18.7 mm; implant space ≈ 12.3 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 10.5 mm; implant space ≈ 8.0 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 19.2 mm; implant space ≈ 15.0 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 6.9 mm; implant space ≈ 4.9 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 15.7 mm; implant space ≈ 9.1 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0022", "images": ["images/placeholder_0022.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Losartan, Bufomix Easyhaler, Betolvex, Insulin glargine, Trulicity, Duloxetine, Calcichew-D3, Amlodipine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 37–47.", "answer": "Review of CBCT volume dated 230722. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 13: bone height ≈ 21.9 mm; implant space ≈ 15.1 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 16.5 mm; implant space ≈ 13.4 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 17.3 mm; implant space ≈ 11.8 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 21.0 mm; implant space ≈ 17.0 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 14.6 mm; implant space ≈ 12.3 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 14.5 mm; implant space ≈ 6.6 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 7.5 mm; implant space ≈ 5.2 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 14.8 mm; implant space ≈ 11.4 mm; nearest critical structure: nasal floor. Periapical radiolucency present near 24; lamina dura loss noted. Secondary small radiolucency adjacent to 44. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0023", "images": ["images/placeholder_0023.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Amlodipine, Calcichew-D3, Levaxin, Bufomix Easyhaler, Bricanyl. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 17–27.", "answer": "Review of CBCT volume dated 230408. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 11: bone height ≈ 11.0 mm; implant space ≈ 5.1 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 11.5 mm; implant space ≈ 5.9 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 19.9 mm; implant space ≈ 12.3 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 5.9 mm; implant space ≈ 3.2 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 19.6 mm; implant space ≈ 16.7 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 10.6 mm; implant space ≈ 4.7 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 18.4 mm; implant space ≈ 13.8 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 15.7 mm; implant space ≈ 11.8 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 12.1 mm; implant space ≈ 7.7 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 11.6 mm; implant space ≈ 7.4 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 27; lamina dura loss noted. Secondary small radiolucency adjacent to 33. Impression: Cyst-like well-defined radiolucency near 37, likely radicular cyst."}
{"id": "case_0024", "images": ["images/placeholder_0024.png"], "question": "Planning for implant planning evaluation. Brief history/status: Trulicity, Calcichew-D3, Duroferon, Levaxin, Insulin glargine, Losartan, Atorvastatin, Bufomix Easyhaler, Metoprolol. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 16–26.", "answer": "Review of CBCT volume dated 201023. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 23: bone height ≈ 13.7 mm; implant space ≈ 8.2 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 7.2 mm; implant space ≈ 2.6 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 20.4 mm; implant space ≈ 12.8 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 16.1 mm; implant space ≈ 9.3 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 11.5 mm; implant space ≈ 3.9 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 20.0 mm; implant space ≈ 18.5 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 14.5 mm; implant space ≈ 8.0 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 16.6 mm; implant space ≈ 8.3 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 9.1 mm; implant space ≈ 6.6 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 7.0 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Findings consistent with chronic apical periodontitis at 31 and 32."}
{"id": "case_0025", "images": ["images/placeholder_0025.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Levaxin, Bricanyl, Amlodipine, Bufomix Easyhaler, Duroferon, Metoprolol. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 15–25.", "answer": "Review of CBCT volume dated 251102. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 35: bone height ≈ 7.1 mm; implant space ≈ 2.0 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 21.9 mm; implant space ≈ 14.6 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 10.3 mm; implant space ≈ 7.1 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 21.6 mm; implant space ≈ 15.7 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 10.8 mm; implant space ≈ 1.9 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 14.8 mm; implant space ≈ 10.1 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 8.3 mm; implant space ≈ 3.0 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 11.7 mm; implant space ≈ 9.9 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 17.4 mm; implant space ≈ 15.4 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 9.1 mm; implant space ≈ 4.0 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Cyst-like well-defined radiolucency near 16, likely radicular cyst."}
{"id": "case_0026", "images": ["images/placeholder_0026.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Trulicity, Bricanyl, Levaxin, Amlodipine, Atorvastatin, Duroferon, Esomeprazole, Metoprolol. Desired treatment: Please report bone height and available implant space for regions 16–26 and 17–27.", "answer": "Review of CBCT volume dated 250920. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 17: bone height ≈ 19.9 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 15.3 mm; implant space ≈ 12.5 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 18.4 mm; implant space ≈ 12.7 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 13.7 mm; implant space ≈ 5.4 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 14.5 mm; implant space ≈ 6.4 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 18.5 mm; implant space ≈ 11.1 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 17.4 mm; implant space ≈ 11.2 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 7.8 mm; implant space ≈ 5.8 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 6.0 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 17.4 mm; implant space ≈ 9.3 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 21; lamina dura loss noted. Secondary small radiolucency adjacent to 48. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0027", "images": ["images/placeholder_0027.png"], "question": "Planning for implant site evaluation. Brief history/status: Metoprolol, Esomeprazole, Atorvastatin, Bufomix Easyhaler, Betolvex, Calcichew-D3, Duloxetine, Levaxin, Duroferon. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 17–27.", "answer": "Review of CBCT volume dated 241210. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 36: bone height ≈ 5.1 mm; implant space ≈ 3.4 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 7.5 mm; implant space ≈ 5.2 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 15.7 mm; implant space ≈ 9.2 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 4.7 mm; implant space ≈ 2.8 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 5.9 mm; implant space ≈ 3.7 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 13.6 mm; implant space ≈ 7.6 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 10.4 mm; implant space ≈ 2.5 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 7.9 mm; implant space ≈ 1.8 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 6.6 mm; implant space ≈ 5.0 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 10.0 mm; implant space ≈ 3.8 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 4 with mesioangular inclination."}
{"id": "case_0028", "images": ["images/placeholder_0028.png"], "question": "Planning for sinus-related complaints. Brief history/status: Bufomix Easyhaler, Levaxin, Esomeprazole, Trulicity, Betolvex. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 15–25.", "answer": "Review of CBCT volume dated 250125. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 27: bone height ≈ 10.6 mm; implant space ≈ 4.0 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 6.6 mm; implant space ≈ 2.6 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 18.9 mm; implant space ≈ 17.1 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 19.0 mm; implant space ≈ 16.1 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 6.9 mm; implant space ≈ 5.3 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 14.1 mm; implant space ≈ 11.7 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 7.5 mm; implant space ≈ 3.3 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 12.3 mm; implant space ≈ 3.5 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 14.1 mm; implant space ≈ 11.2 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 9.8 mm; implant space ≈ 4.3 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Impaction of third molar in quadrant 3 with mesioangular inclination."}
{"id": "case_0029", "images": ["images/placeholder_0029.png"], "question": "Planning for implant site evaluation. Brief history/status: Levaxin, Losartan, Duloxetine, Trulicity, Calcichew-D3, Insulin glargine, Bufomix Easyhaler, Esomeprazole, Amlodipine. Desired treatment: Measure crest-to-canal distances mandibularly in 36–46, and implant feasibility maxillary 35–45.", "answer": "Review of CBCT volume dated 220702. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 9.1 mm; implant space ≈ 1.1 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 15.9 mm; implant space ≈ 13.7 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 16.9 mm; implant space ≈ 15.0 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 4.7 mm; implant space ≈ 1.7 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 14.2 mm; implant space ≈ 11.3 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 16.4 mm; implant space ≈ 8.1 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 6.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 14.2 mm; implant space ≈ 9.4 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 12.4 mm; implant space ≈ 4.8 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 16.7 mm; implant space ≈ 11.7 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0030", "images": ["images/placeholder_0030.png"], "question": "Planning for sinus-related complaints. Brief history/status: Betolvex, Insulin glargine, Duloxetine, Calcichew-D3, Trulicity. Desired treatment: Report any signs of peri-implantitis and root resorption in 16–26.", "answer": "Review of CBCT volume dated 200326. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 38: bone height ≈ 10.3 mm; implant space ≈ 1.3 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 12.6 mm; implant space ≈ 10.2 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 19.8 mm; implant space ≈ 12.8 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 18.8 mm; implant space ≈ 12.3 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 9.3 mm; implant space ≈ 4.9 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 10.5 mm; implant space ≈ 8.9 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 6.7 mm; implant space ≈ 2.5 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 14.3 mm; implant space ≈ 10.7 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 13.3 mm; implant space ≈ 8.0 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 9.1 mm; implant space ≈ 4.6 mm; nearest critical structure: mandibular canal. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0031", "images": ["images/placeholder_0031.png"], "question": "Planning for implant site evaluation. Brief history/status: Atorvastatin, Metoprolol, Amlodipine, Bricanyl, Bufomix Easyhaler, Insulin glargine. Desired treatment: Please report bone height and available implant space for regions 17–27 and 36–46.", "answer": "Review of CBCT volume dated 240128. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 24: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 20.1 mm; implant space ≈ 17.9 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 14.3 mm; implant space ≈ 10.9 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 9.0 mm; implant space ≈ 4.7 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 15.9 mm; implant space ≈ 11.1 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 6.8 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 16.6 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 17.1 mm; implant space ≈ 11.2 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 12.2 mm; implant space ≈ 7.9 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 15.9 mm; implant space ≈ 11.9 mm; nearest critical structure: incisive canal. Periapical radiolucency present near 33; lamina dura loss noted. Secondary small radiolucency adjacent to 27. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0032", "images": ["images/placeholder_0032.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Duloxetine, Levaxin, Insulin glargine, Esomeprazole, Bufomix Easyhaler. Desired treatment: Please report bone height and available implant space for regions 35–45 and 37–47.", "answer": "Review of CBCT volume dated 231023. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 37: bone height ≈ 7.5 mm; implant space ≈ 5.7 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 9.4 mm; implant space ≈ 3.9 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 8.4 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 20.5 mm; implant space ≈ 13.1 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 18.0 mm; implant space ≈ 12.6 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 12.4 mm; implant space ≈ 5.2 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 15.0 mm; implant space ≈ 9.6 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 12.3 mm; implant space ≈ 8.9 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 4.9 mm; implant space ≈ 0.6 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 37; lamina dura loss noted. Secondary small radiolucency adjacent to 32. Impression: Findings consistent with chronic apical periodontitis at 25 and 36."}
{"id": "case_0033", "images": ["images/placeholder_0033.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Betolvex, Atorvastatin, Esomeprazole, Bufomix Easyhaler, Trulicity, Calcichew-D3, Insulin glargine, Amlodipine. Desired treatment: Please report bone height and available implant space for regions 16–26 and 36–46.", "answer": "Review of CBCT volume dated 200210. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 10.9 mm; implant space ≈ 5.4 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 14.2 mm; implant space ≈ 10.5 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 16.4 mm; implant space ≈ 11.8 mm; nearest critical structure: sinus floor. Region 22: bone height ≈ 20.1 mm; implant space ≈ 17.0 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 15.5 mm; implant space ≈ 7.7 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 19.6 mm; implant space ≈ 17.9 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 11.4 mm; implant space ≈ 3.5 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 12.9 mm; implant space ≈ 7.2 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 16.0 mm; implant space ≈ 12.3 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 21.3 mm; implant space ≈ 19.6 mm; nearest critical structure: mandibular canal. Impression: Peri-implant bone loss at 26 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0034", "images": ["images/placeholder_0034.png"], "question": "Planning for implant site evaluation. Brief history/status: Metoprolol, Losartan, Insulin glargine, Calcichew-D3, Levaxin, Amlodipine, Betolvex, Esomeprazole. Desired treatment: Provide measurements relevant to guided surgery stent planning for 36–46 and 35–45.", "answer": "Review of CBCT volume dated 250510. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 17.3 mm; implant space ≈ 11.2 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 15.7 mm; implant space ≈ 11.9 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 4.5 mm; implant space ≈ 0.9 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 9.5 mm; implant space ≈ 2.2 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 16.9 mm; implant space ≈ 11.1 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 11.4 mm; implant space ≈ 2.7 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 19.3 mm; implant space ≈ 10.7 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 14.5 mm; implant space ≈ 11.5 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 12.8 mm; implant space ≈ 5.6 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 21.1 mm; implant space ≈ 13.1 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0035", "images": ["images/placeholder_0035.png"], "question": "Planning for follow-up after extraction. Brief history/status: Trulicity, Duloxetine, Duroferon, Calcichew-D3, Levaxin. Desired treatment: Please report bone height and available implant space for regions 37–47 and 35–45.", "answer": "Review of CBCT volume dated 210527. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 43: bone height ≈ 21.8 mm; implant space ≈ 13.1 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 12.0 mm; implant space ≈ 9.3 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 16.6 mm; implant space ≈ 8.9 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 16.5 mm; implant space ≈ 9.7 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 19.8 mm; implant space ≈ 13.4 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 7.5 mm; implant space ≈ 1.0 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 5.7 mm; implant space ≈ 2.4 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 12.4 mm; implant space ≈ 5.6 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 14.8 mm; implant space ≈ 7.7 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Peri-implant bone loss at 31 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0036", "images": ["images/placeholder_0036.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Losartan, Bufomix Easyhaler, Calcichew-D3, Metoprolol, Bricanyl, Atorvastatin, Duroferon, Trulicity. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.", "answer": "Review of CBCT volume dated 220423. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 16.8 mm; implant space ≈ 9.7 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 13.4 mm; implant space ≈ 10.3 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 6.2 mm; implant space ≈ 2.5 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 11.3 mm; implant space ≈ 9.1 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 15.6 mm; implant space ≈ 11.6 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 8.4 mm; implant space ≈ 2.7 mm; nearest critical structure: sinus floor. Region 48: bone height ≈ 7.8 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 18.2 mm; implant space ≈ 15.1 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 12.1 mm; implant space ≈ 10.1 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 15.2 mm; implant space ≈ 10.7 mm; nearest critical structure: sinus floor. Periapical radiolucency present near 26; lamina dura loss noted. Secondary small radiolucency adjacent to 22. Impression: Cyst-like well-defined radiolucency near 11, likely radicular cyst."}
{"id": "case_0037", "images": ["images/placeholder_0037.png"], "question": "Planning for follow-up after extraction. Brief history/status: Atorvastatin, Esomeprazole, Betolvex, Metoprolol, Duroferon, Bricanyl, Trulicity, Levaxin, Insulin glargine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 16–26.", "answer": "Review of CBCT volume dated 211117. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 47: bone height ≈ 18.9 mm; implant space ≈ 12.2 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 13.7 mm; implant space ≈ 5.0 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 16.1 mm; implant space ≈ 7.4 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 6.4 mm; implant space ≈ 0.1 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 20.9 mm; implant space ≈ 18.5 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 10.1 mm; implant space ≈ 4.5 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 4.2 mm; implant space ≈ 2.1 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 8.6 mm; implant space ≈ 3.9 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 18.8 mm; implant space ≈ 12.3 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination."}
{"id": "case_0038", "images": ["images/placeholder_0038.png"], "question": "Planning for sinus-related complaints. Brief history/status: Metoprolol, Duroferon, Betolvex, Calcichew-D3, Bufomix Easyhaler, Esomeprazole, Amlodipine. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 220224. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 31: bone height ≈ 7.0 mm; implant space ≈ 3.9 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 14.6 mm; implant space ≈ 9.8 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 21.7 mm; implant space ≈ 16.6 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 9.2 mm; implant space ≈ 5.0 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 9.5 mm; implant space ≈ 0.7 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 19.6 mm; implant space ≈ 15.6 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 11.8 mm; implant space ≈ 9.0 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 7.8 mm; implant space ≈ 3.0 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 11.5 mm; implant space ≈ 7.9 mm; nearest critical structure: incisive canal. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0039", "images": ["images/placeholder_0039.png"], "question": "Planning for implant planning evaluation. Brief history/status: Duroferon, Levaxin, Losartan, Calcichew-D3, Atorvastatin, Amlodipine. Desired treatment: Please report bone height and available implant space for regions 17–27 and 15–25.", "answer": "Review of CBCT volume dated 241019. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 21: bone height ≈ 17.0 mm; implant space ≈ 8.8 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 17.6 mm; implant space ≈ 11.4 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 7.4 mm; implant space ≈ 3.0 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 12.5 mm; implant space ≈ 3.8 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 13.1 mm; implant space ≈ 5.5 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 9.5 mm; implant space ≈ 7.6 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 11.1 mm; implant space ≈ 6.5 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 8.9 mm; implant space ≈ 4.7 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 10.9 mm; implant space ≈ 7.0 mm; nearest critical structure: nasal floor. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination."}
{"id": "case_0040", "images": ["images/placeholder_0040.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Metoprolol, Bufomix Easyhaler, Calcichew-D3, Losartan, Amlodipine, Bricanyl, Esomeprazole, Duroferon. Desired treatment: Please report bone height and available implant space for regions 15–25 and 35–45.", "answer": "Review of CBCT volume dated 220723. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 44: bone height ≈ 19.2 mm; implant space ≈ 10.9 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 7.6 mm; implant space ≈ 1.3 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 10.1 mm; implant space ≈ 6.6 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 17.8 mm; implant space ≈ 15.6 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 14.0 mm; implant space ≈ 6.1 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 4.6 mm; implant space ≈ 1.2 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 8.1 mm; implant space ≈ 5.2 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 16.2 mm; implant space ≈ 9.3 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 7.1 mm; implant space ≈ 1.2 mm; nearest critical structure: mental foramen. Region 37: bone height ≈ 10.1 mm; implant space ≈ 2.3 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 45; lamina dura loss noted. Secondary small radiolucency adjacent to 15. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Cyst-like well-defined radiolucency near 22, likely radicular cyst."}
{"id": "case_0041", "images": ["images/placeholder_0041.png"], "question": "Planning for implant planning evaluation. Brief history/status: Calcichew-D3, Bufomix Easyhaler, Betolvex, Atorvastatin, Amlodipine, Losartan, Duloxetine. Desired treatment: Please report bone height and available implant space for regions 15–25 and 17–27.", "answer": "Review of CBCT volume dated 240621. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 11.5 mm; implant space ≈ 8.7 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 9.6 mm; implant space ≈ 8.0 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 17.9 mm; implant space ≈ 10.0 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 11.0 mm; implant space ≈ 3.5 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 15.7 mm; implant space ≈ 12.5 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 21.0 mm; implant space ≈ 13.5 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 16.9 mm; implant space ≈ 12.0 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 5.9 mm; implant space ≈ 0.4 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 24; lamina dura loss noted. Secondary small radiolucency adjacent to 26. Streak artifacts from metallic restorations locally reduce interpretability. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0042", "images": ["images/placeholder_0042.png"], "question": "Planning for full-arch restoration. Brief history/status: Losartan, Bricanyl, Duloxetine, Bufomix Easyhaler, Levaxin, Duroferon, Amlodipine, Betolvex, Metoprolol. Desired treatment: Please report bone height and available implant space for regions 17–27 and 36–46.", "answer": "Review of CBCT volume dated 250428. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 16: bone height ≈ 14.9 mm; implant space ≈ 9.6 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 20.6 mm; implant space ≈ 12.7 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 5.4 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 14.2 mm; implant space ≈ 6.5 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 9.3 mm; implant space ≈ 4.6 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 12.9 mm; implant space ≈ 9.9 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 6.1 mm; implant space ≈ 2.3 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 11.9 mm; implant space ≈ 5.6 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 11.3 mm; implant space ≈ 4.4 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 38 and 16."}
{"id": "case_0043", "images": ["images/placeholder_0043.png"], "question": "Planning for full-arch restoration. Brief history/status: Esomeprazole, Atorvastatin, Bufomix Easyhaler, Insulin glargine, Trulicity, Calcichew-D3. Desired treatment: Evaluate periapical status of teeth 37, 43, and 45, and overall sinus condition.", "answer": "Review of CBCT volume dated 211007. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 23: bone height ≈ 11.4 mm; implant space ≈ 2.8 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 18.7 mm; implant space ≈ 14.8 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 15.3 mm; implant space ≈ 8.4 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 18.1 mm; implant space ≈ 14.6 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 7.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 17.3 mm; implant space ≈ 14.3 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 5.3 mm; implant space ≈ 1.1 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 15.3 mm; implant space ≈ 7.9 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 15.4 mm; implant space ≈ 7.6 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 17.1 mm; implant space ≈ 10.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 28; lamina dura loss noted. Secondary small radiolucency adjacent to 16. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Findings consistent with chronic apical periodontitis at 22 and 15."}
{"id": "case_0044", "images": ["images/placeholder_0044.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Duloxetine, Metoprolol, Atorvastatin, Amlodipine, Betolvex. Desired treatment: Provide measurements relevant to guided surgery stent planning for 37–47 and 15–25.", "answer": "Review of CBCT volume dated 200813. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 42: bone height ≈ 14.0 mm; implant space ≈ 11.1 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 10.1 mm; implant space ≈ 1.4 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 14.3 mm; implant space ≈ 6.6 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 4.7 mm; implant space ≈ 2.5 mm; nearest critical structure: mental foramen. Region 37: bone height ≈ 5.1 mm; implant space ≈ 0.1 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 20.4 mm; implant space ≈ 12.9 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 6.2 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 15.1 mm; implant space ≈ 8.2 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 19.0 mm; implant space ≈ 13.7 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 6.5 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 35 and 25."}
{"id": "case_0045", "images": ["images/placeholder_0045.png"], "question": "Planning for sinus-related complaints. Brief history/status: Duloxetine, Losartan, Duroferon, Metoprolol, Trulicity, Bufomix Easyhaler, Esomeprazole, Calcichew-D3, Betolvex. Desired treatment: Evaluate periapical status of teeth 33, 37, and 14, and overall sinus condition.", "answer": "Review of CBCT volume dated 211121. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 38: bone height ≈ 9.3 mm; implant space ≈ 1.2 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 21.4 mm; implant space ≈ 12.7 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 10.8 mm; implant space ≈ 6.6 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 6.2 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 13.5 mm; implant space ≈ 11.9 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 8.3 mm; implant space ≈ 2.4 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 13.7 mm; implant space ≈ 5.2 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 5.8 mm; implant space ≈ 1.2 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 9.1 mm; implant space ≈ 3.3 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 18.4 mm; implant space ≈ 11.7 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 17; lamina dura loss noted. Secondary small radiolucency adjacent to 32. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Peri-implant bone loss at 25 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0046", "images": ["images/placeholder_0046.png"], "question": "Planning for follow-up after extraction. Brief history/status: Bricanyl, Duloxetine, Amlodipine, Bufomix Easyhaler, Duroferon, Levaxin, Calcichew-D3, Betolvex, Insulin glargine. Desired treatment: Quantify vertical bone loss around implants in 36–46 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 231103. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 26: bone height ≈ 11.5 mm; implant space ≈ 3.7 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 17.9 mm; implant space ≈ 15.6 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 15.8 mm; implant space ≈ 10.3 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 19.2 mm; implant space ≈ 13.4 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 15.3 mm; implant space ≈ 12.0 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 12.0 mm; implant space ≈ 4.1 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 7.3 mm; implant space ≈ 3.7 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 15.8 mm; implant space ≈ 10.4 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 11.8 mm; implant space ≈ 9.8 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 38; lamina dura loss noted. Secondary small radiolucency adjacent to 16. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0047", "images": ["images/placeholder_0047.png"], "question": "Planning for implant planning evaluation. Brief history/status: Betolvex, Calcichew-D3, Duroferon, Bricanyl, Metoprolol, Losartan. Desired treatment: Evaluate periapical status of teeth 16, 26, and 18, and overall sinus condition.", "answer": "Review of CBCT volume dated 220112. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 11.6 mm; implant space ≈ 3.7 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 21.2 mm; implant space ≈ 16.5 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 19.1 mm; implant space ≈ 15.3 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 12.8 mm; implant space ≈ 7.7 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 11.6 mm; implant space ≈ 6.3 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 12.5 mm; implant space ≈ 6.1 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 18.9 mm; implant space ≈ 17.2 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 19.2 mm; implant space ≈ 14.6 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 15.9 mm; implant space ≈ 12.9 mm; nearest critical structure: incisive canal. Periapical radiolucency present near 37; lamina dura loss noted. Secondary small radiolucency adjacent to 28. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0048", "images": ["images/placeholder_0048.png"], "question": "Planning for implant planning evaluation. Brief history/status: Esomeprazole, Amlodipine, Duroferon, Bricanyl, Insulin glargine. Desired treatment: Report any signs of peri-implantitis and root resorption in 37–47.", "answer": "Review of CBCT volume dated 230521. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 11.5 mm; implant space ≈ 5.1 mm; nearest critical structure: mental foramen. Region 27: bone height ≈ 14.8 mm; implant space ≈ 7.4 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 9.8 mm; implant space ≈ 4.3 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 19.9 mm; implant space ≈ 13.3 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 13.0 mm; implant space ≈ 5.0 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 14.7 mm; implant space ≈ 6.9 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 19.8 mm; implant space ≈ 10.9 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 15.0 mm; implant space ≈ 6.3 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 6.8 mm; implant space ≈ 5.2 mm; nearest critical structure: anterior loop. Periapical radiolucency present near 17; lamina dura loss noted. Secondary small radiolucency adjacent to 35. Impression: Findings consistent with chronic apical periodontitis at 18 and 38."}
{"id": "case_0049", "images": ["images/placeholder_0049.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Atorvastatin, Losartan, Insulin glargine, Calcichew-D3, Amlodipine, Esomeprazole. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 35–45.", "answer": "Review of CBCT volume dated 201218. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 46: bone height ≈ 7.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 6.3 mm; implant space ≈ 4.6 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 13.9 mm; implant space ≈ 8.6 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 15.8 mm; implant space ≈ 10.2 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 17.2 mm; implant space ≈ 12.1 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 12.9 mm; implant space ≈ 8.7 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 14.1 mm; implant space ≈ 8.8 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 14.7 mm; implant space ≈ 10.0 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 9.3 mm; implant space ≈ 1.0 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 9.3 mm; implant space ≈ 0.5 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Cyst-like well-defined radiolucency near 35, likely radicular cyst."}
{"id": "case_0050", "images": ["images/placeholder_0050.png"], "question": "Planning for implant site evaluation. Brief history/status: Losartan, Calcichew-D3, Duloxetine, Levaxin, Esomeprazole, Duroferon, Atorvastatin, Bricanyl. Desired treatment: Measure crest-to-canal distances mandibularly in 16–26, and implant feasibility maxillary 37–47.", "answer": "Review of CBCT volume dated 250502. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 48: bone height ≈ 19.2 mm; implant space ≈ 12.2 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 4.7 mm; implant space ≈ 1.7 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 12.1 mm; implant space ≈ 9.5 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 10.4 mm; implant space ≈ 3.1 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 6.4 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 18.8 mm; implant space ≈ 16.0 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 10.4 mm; implant space ≈ 3.9 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 19.6 mm; implant space ≈ 13.8 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 13.6 mm; implant space ≈ 6.4 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 20.4 mm; implant space ≈ 11.9 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Impaction of third molar in quadrant 3 with mesioangular inclination."}
{"id": "case_0051", "images": ["images/placeholder_0051.png"], "question": "Planning for full-arch restoration. Brief history/status: Losartan, Levaxin, Calcichew-D3, Trulicity, Duroferon, Duloxetine, Bufomix Easyhaler, Bricanyl, Esomeprazole. Desired treatment: Report any signs of peri-implantitis and root resorption in 36–46.", "answer": "Review of CBCT volume dated 210918. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 19.5 mm; implant space ≈ 12.2 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 15.6 mm; implant space ≈ 8.4 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 6.0 mm; implant space ≈ 3.7 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 14.7 mm; implant space ≈ 9.4 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 12.1 mm; implant space ≈ 3.9 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 9.6 mm; implant space ≈ 7.4 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 8.2 mm; implant space ≈ 1.5 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 7.3 mm; implant space ≈ 0.1 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 8.8 mm; implant space ≈ 0.9 mm; nearest critical structure: anterior loop. Periapical radiolucency present near 36; lamina dura loss noted. Secondary small radiolucency adjacent to 37. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0052", "images": ["images/placeholder_0052.png"], "question": "Planning for sinus-related complaints. Brief history/status: Atorvastatin, Insulin glargine, Duroferon, Calcichew-D3, Betolvex, Levaxin, Amlodipine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 17–27.", "answer": "Review of CBCT volume dated 210612. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 27: bone height ≈ 12.1 mm; implant space ≈ 3.7 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 11.2 mm; implant space ≈ 3.6 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 6.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 9.3 mm; implant space ≈ 3.8 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 21.8 mm; implant space ≈ 14.5 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 6.1 mm; implant space ≈ 2.8 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 9.1 mm; implant space ≈ 0.6 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 11.9 mm; implant space ≈ 6.4 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 12.3 mm; implant space ≈ 6.6 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 12.2 mm; implant space ≈ 8.3 mm; nearest critical structure: mandibular canal. Periapical radiolucency present near 45; lamina dura loss noted. Secondary small radiolucency adjacent to 18. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Cyst-like well-defined radiolucency near 13, likely radicular cyst."}
{"id": "case_0053", "images": ["images/placeholder_0053.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Losartan, Calcichew-D3, Insulin glargine, Betolvex, Bricanyl, Metoprolol, Esomeprazole, Bufomix Easyhaler, Levaxin. Desired treatment: Quantify vertical bone loss around implants in 37–47 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 250926. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 22: bone height ≈ 18.9 mm; implant space ≈ 16.2 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 20.3 mm; implant space ≈ 13.9 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 10.5 mm; implant space ≈ 5.4 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 16.0 mm; implant space ≈ 10.1 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 13.1 mm; implant space ≈ 6.0 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 16.3 mm; implant space ≈ 9.7 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 4.6 mm; implant space ≈ 1.4 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 6.6 mm; implant space ≈ 4.3 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 13.8 mm; implant space ≈ 9.1 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0054", "images": ["images/placeholder_0054.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Amlodipine, Levaxin, Calcichew-D3, Duroferon, Betolvex, Bufomix Easyhaler. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 210904. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 27: bone height ≈ 13.2 mm; implant space ≈ 7.1 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 13.3 mm; implant space ≈ 10.8 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 5.3 mm; implant space ≈ 1.5 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 7.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 17.3 mm; implant space ≈ 14.8 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 21.3 mm; implant space ≈ 13.7 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 8.3 mm; implant space ≈ 2.1 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 11.6 mm; implant space ≈ 6.1 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 9.3 mm; implant space ≈ 5.9 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 22; lamina dura loss noted. Secondary small radiolucency adjacent to 32. Impression: Vertical root fracture suspected at 33; recommend clinical correlation."}
{"id": "case_0055", "images": ["images/placeholder_0055.png"], "question": "Planning for implant planning evaluation. Brief history/status: Bricanyl, Duloxetine, Bufomix Easyhaler, Trulicity, Esomeprazole, Metoprolol, Duroferon, Betolvex. Desired treatment: Measure crest-to-canal distances mandibularly in 37–47, and implant feasibility maxillary 16–26.", "answer": "Review of CBCT volume dated 250216. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 14.4 mm; implant space ≈ 10.2 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 5.4 mm; implant space ≈ 1.1 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 10.8 mm; implant space ≈ 3.7 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 4.1 mm; implant space ≈ 1.2 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 12.8 mm; implant space ≈ 9.1 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 4.5 mm; implant space ≈ 1.8 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 16.3 mm; implant space ≈ 14.3 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 9.8 mm; implant space ≈ 7.2 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 4.5 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 47; lamina dura loss noted. Secondary small radiolucency adjacent to 28. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0056", "images": ["images/placeholder_0056.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Bufomix Easyhaler, Insulin glargine, Duloxetine, Betolvex, Levaxin. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 16–26.", "answer": "Review of CBCT volume dated 240114. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 31: bone height ≈ 21.2 mm; implant space ≈ 19.4 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 9.5 mm; implant space ≈ 7.1 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 10.7 mm; implant space ≈ 2.1 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 13.8 mm; implant space ≈ 8.3 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 21.8 mm; implant space ≈ 13.1 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 11.9 mm; implant space ≈ 4.5 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 15.4 mm; implant space ≈ 10.4 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 11.6 mm; implant space ≈ 7.5 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 12.1 mm; implant space ≈ 6.5 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 18.8 mm; implant space ≈ 9.8 mm; nearest critical structure: sinus floor. Periapical radiolucency present near 22; lamina dura loss noted. Secondary small radiolucency adjacent to 18. Streak artifacts from metallic restorations locally reduce interpretability. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0057", "images": ["images/placeholder_0057.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Metoprolol, Levaxin, Calcichew-D3, Duroferon, Bufomix Easyhaler, Esomeprazole, Trulicity, Bricanyl, Atorvastatin. Desired treatment: Please report bone height and available implant space for regions 15–25 and 36–46.", "answer": "Review of CBCT volume dated 200713. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 38: bone height ≈ 21.9 mm; implant space ≈ 15.4 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 4.8 mm; implant space ≈ 3.0 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 15.8 mm; implant space ≈ 12.6 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 18.1 mm; implant space ≈ 14.3 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 5.4 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 9.8 mm; implant space ≈ 5.6 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 16.4 mm; implant space ≈ 8.3 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 21.4 mm; implant space ≈ 18.9 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 4.7 mm; implant space ≈ 0.6 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 6.4 mm; implant space ≈ 0.3 mm; nearest critical structure: anterior loop. Impression: Impaction of third molar in quadrant 3 with mesioangular inclination."}
{"id": "case_0058", "images": ["images/placeholder_0058.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Insulin glargine, Losartan, Metoprolol, Betolvex, Trulicity, Amlodipine, Esomeprazole. Desired treatment: Report any signs of peri-implantitis and root resorption in 17–27.", "answer": "Review of CBCT volume dated 240203. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 48: bone height ≈ 7.7 mm; implant space ≈ 3.4 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 19.3 mm; implant space ≈ 17.2 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 20.7 mm; implant space ≈ 18.5 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 18.4 mm; implant space ≈ 11.9 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 20.7 mm; implant space ≈ 14.0 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 18.0 mm; implant space ≈ 11.6 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 18.6 mm; implant space ≈ 13.5 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 15.2 mm; implant space ≈ 6.4 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 8.8 mm; implant space ≈ 2.7 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0059", "images": ["images/placeholder_0059.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Atorvastatin, Losartan, Betolvex, Calcichew-D3, Esomeprazole. Desired treatment: Please report bone height and available implant space for regions 17–27 and 35–45.", "answer": "Review of CBCT volume dated 250223. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 38: bone height ≈ 13.6 mm; implant space ≈ 9.8 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 15.6 mm; implant space ≈ 12.7 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 18.4 mm; implant space ≈ 16.6 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 14.6 mm; implant space ≈ 9.7 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 8.4 mm; implant space ≈ 2.4 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 13.8 mm; implant space ≈ 9.8 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 7.0 mm; implant space ≈ 2.8 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 7.2 mm; implant space ≈ 0.3 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 15.1 mm; implant space ≈ 12.9 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Vertical root fracture suspected at 24; recommend clinical correlation."}
{"id": "case_0060", "images": ["images/placeholder_0060.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Duroferon, Duloxetine, Calcichew-D3, Bricanyl, Losartan, Metoprolol, Esomeprazole, Atorvastatin, Levaxin. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.", "answer": "Review of CBCT volume dated 210425. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 37: bone height ≈ 15.4 mm; implant space ≈ 10.7 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 9.6 mm; implant space ≈ 3.5 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 19.8 mm; implant space ≈ 11.4 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 13.1 mm; implant space ≈ 6.6 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 13.4 mm; implant space ≈ 10.9 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 12.4 mm; implant space ≈ 8.2 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 8.6 mm; implant space ≈ 4.9 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 9.6 mm; implant space ≈ 3.2 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 21.8 mm; implant space ≈ 13.0 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 6.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Findings consistent with chronic apical periodontitis at 28 and 43."}
{"id": "case_0061", "images": ["images/placeholder_0061.png"], "question": "Planning for sinus-related complaints. Brief history/status: Amlodipine, Losartan, Trulicity, Insulin glargine, Atorvastatin, Betolvex, Levaxin, Metoprolol. Desired treatment: Measure crest-to-canal distances mandibularly in 17–27, and implant feasibility maxillary 37–47.", "answer": "Review of CBCT volume dated 200217. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 25: bone height ≈ 6.3 mm; implant space ≈ 1.4 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 4.9 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 15.6 mm; implant space ≈ 13.1 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 8.2 mm; implant space ≈ 4.2 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 14.3 mm; implant space ≈ 9.1 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 21.9 mm; implant space ≈ 17.7 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 18.3 mm; implant space ≈ 10.2 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 8.5 mm; implant space ≈ 4.7 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 16.7 mm; implant space ≈ 10.0 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 44; lamina dura loss noted. Secondary small radiolucency adjacent to 33. Impression: Cyst-like well-defined radiolucency near 12, likely radicular cyst."}
{"id": "case_0062", "images": ["images/placeholder_0062.png"], "question": "Planning for follow-up after extraction. Brief history/status: Atorvastatin, Amlodipine, Betolvex, Insulin glargine, Duroferon, Levaxin, Metoprolol, Calcichew-D3, Trulicity. Desired treatment: Evaluate periapical status of teeth 38, 33, and 46, and overall sinus condition.", "answer": "Review of CBCT volume dated 230328. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 18.8 mm; implant space ≈ 16.5 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 14.7 mm; implant space ≈ 12.8 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 15.4 mm; implant space ≈ 10.3 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 9.5 mm; implant space ≈ 7.4 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 9.1 mm; implant space ≈ 1.5 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 18.2 mm; implant space ≈ 15.7 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 12.0 mm; implant space ≈ 10.5 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 9.0 mm; implant space ≈ 4.1 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 14.8 mm; implant space ≈ 8.6 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 32; lamina dura loss noted. Secondary small radiolucency adjacent to 46. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0063", "images": ["images/placeholder_0063.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Amlodipine, Bricanyl, Atorvastatin, Insulin glargine, Duroferon. Desired treatment: Evaluate periapical status of teeth 15, 41, and 23, and overall sinus condition.", "answer": "Review of CBCT volume dated 200525. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 23: bone height ≈ 21.3 mm; implant space ≈ 17.5 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 6.6 mm; implant space ≈ 1.1 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 8.7 mm; implant space ≈ 5.5 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 13.4 mm; implant space ≈ 6.4 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 17.4 mm; implant space ≈ 11.6 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 12.6 mm; implant space ≈ 9.0 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 12.2 mm; implant space ≈ 7.6 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 5.8 mm; implant space ≈ 3.8 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 19.0 mm; implant space ≈ 12.0 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 5.3 mm; implant space ≈ 1.8 mm; nearest critical structure: incisive canal. Periapical radiolucency present near 28; lamina dura loss noted. Secondary small radiolucency adjacent to 16. Impression: Peri-implant bone loss at 11 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0064", "images": ["images/placeholder_0064.png"], "question": "Planning for implant site evaluation. Brief history/status: Calcichew-D3, Duloxetine, Esomeprazole, Metoprolol, Bufomix Easyhaler, Bricanyl, Atorvastatin, Duroferon. Desired treatment: Evaluate periapical status of teeth 32, 15, and 47, and overall sinus condition.", "answer": "Review of CBCT volume dated 230309. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 47: bone height ≈ 11.8 mm; implant space ≈ 5.6 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 5.8 mm; implant space ≈ 4.3 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 13.6 mm; implant space ≈ 5.2 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 11.5 mm; implant space ≈ 5.9 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 17.5 mm; implant space ≈ 13.9 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 19.6 mm; implant space ≈ 18.0 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 19.5 mm; implant space ≈ 16.7 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 19.0 mm; implant space ≈ 13.7 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 20.4 mm; implant space ≈ 18.8 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0065", "images": ["images/placeholder_0065.png"], "question": "Planning for implant planning evaluation. Brief history/status: Levaxin, Bufomix Easyhaler, Bricanyl, Losartan, Metoprolol, Trulicity. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.", "answer": "Review of CBCT volume dated 250103. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 28: bone height ≈ 17.2 mm; implant space ≈ 11.2 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 19.4 mm; implant space ≈ 10.8 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 15.0 mm; implant space ≈ 8.9 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 6.6 mm; implant space ≈ 2.7 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 14.7 mm; implant space ≈ 7.7 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 10.5 mm; implant space ≈ 4.8 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 9.2 mm; implant space ≈ 6.1 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 16.1 mm; implant space ≈ 9.6 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 20.5 mm; implant space ≈ 18.5 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 16; lamina dura loss noted. Secondary small radiolucency adjacent to 47. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Vertical root fracture suspected at 47; recommend clinical correlation."}
{"id": "case_0066", "images": ["images/placeholder_0066.png"], "question": "Planning for follow-up after extraction. Brief history/status: Esomeprazole, Metoprolol, Insulin glargine, Levaxin, Trulicity, Betolvex, Bricanyl. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 15–25.", "answer": "Review of CBCT volume dated 211208. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 24: bone height ≈ 8.7 mm; implant space ≈ 4.7 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 6.5 mm; implant space ≈ 2.5 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 10.2 mm; implant space ≈ 6.9 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 20.6 mm; implant space ≈ 17.3 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 14.0 mm; implant space ≈ 5.9 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 5.7 mm; implant space ≈ 3.5 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 5.6 mm; implant space ≈ 0.1 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 15.7 mm; implant space ≈ 9.5 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 18.3 mm; implant space ≈ 9.9 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 5.4 mm; implant space ≈ 1.3 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 3 with mesioangular inclination."}
{"id": "case_0067", "images": ["images/placeholder_0067.png"], "question": "Planning for full-arch restoration. Brief history/status: Insulin glargine, Amlodipine, Duloxetine, Losartan, Duroferon, Metoprolol. Desired treatment: Please report bone height and available implant space for regions 36–46 and 15–25.", "answer": "Review of CBCT volume dated 240828. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 46: bone height ≈ 11.9 mm; implant space ≈ 8.4 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 11.7 mm; implant space ≈ 7.8 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 15.1 mm; implant space ≈ 6.3 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 7.6 mm; implant space ≈ 1.2 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 6.7 mm; implant space ≈ 3.1 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 7.4 mm; implant space ≈ 3.7 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 13.3 mm; implant space ≈ 7.0 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 18.2 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 14.1 mm; implant space ≈ 6.4 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 15.7 mm; implant space ≈ 8.7 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 23; lamina dura loss noted. Secondary small radiolucency adjacent to 24. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0068", "images": ["images/placeholder_0068.png"], "question": "Planning for implant site evaluation. Brief history/status: Trulicity, Bricanyl, Insulin glargine, Duloxetine, Amlodipine. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.", "answer": "Review of CBCT volume dated 200503. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 37: bone height ≈ 11.9 mm; implant space ≈ 8.1 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 7.9 mm; implant space ≈ 3.1 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 17.8 mm; implant space ≈ 10.1 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 6.8 mm; implant space ≈ 3.8 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 10.6 mm; implant space ≈ 8.0 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 6.6 mm; implant space ≈ 1.3 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 21.7 mm; implant space ≈ 19.4 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 9.7 mm; implant space ≈ 3.1 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 14.4 mm; implant space ≈ 9.6 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 18.2 mm; implant space ≈ 15.2 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination."}
{"id": "case_0069", "images": ["images/placeholder_0069.png"], "question": "Planning for follow-up after extraction. Brief history/status: Insulin glargine, Trulicity, Bufomix Easyhaler, Esomeprazole, Duloxetine, Calcichew-D3, Amlodipine, Losartan, Bricanyl. Desired treatment: Evaluate periapical status of teeth 26, 22, and 48, and overall sinus condition.", "answer": "Review of CBCT volume dated 240527. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 44: bone height ≈ 4.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 20.9 mm; implant space ≈ 16.3 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 13.8 mm; implant space ≈ 6.7 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 21.1 mm; implant space ≈ 14.9 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 12.3 mm; implant space ≈ 9.6 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 15.0 mm; implant space ≈ 8.5 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 8.3 mm; implant space ≈ 1.2 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 4.5 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 20.6 mm; implant space ≈ 12.8 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 14.2 mm; implant space ≈ 7.4 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 24 and 11."}
{"id": "case_0070", "images": ["images/placeholder_0070.png"], "question": "Planning for full-arch restoration. Brief history/status: Metoprolol, Bricanyl, Levaxin, Trulicity, Losartan, Duroferon, Duloxetine. Desired treatment: Please report bone height and available implant space for regions 36–46 and 35–45.", "answer": "Review of CBCT volume dated 200119. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 17: bone height ≈ 19.0 mm; implant space ≈ 17.5 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 11.8 mm; implant space ≈ 4.0 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 17.4 mm; implant space ≈ 14.3 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 17.7 mm; implant space ≈ 8.8 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 17.3 mm; implant space ≈ 9.8 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 20.5 mm; implant space ≈ 17.8 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 6.6 mm; implant space ≈ 5.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 21.1 mm; implant space ≈ 16.4 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 16.6 mm; implant space ≈ 10.4 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 20.7 mm; implant space ≈ 18.8 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Peri-implant bone loss at 22 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0071", "images": ["images/placeholder_0071.png"], "question": "Planning for implant planning evaluation. Brief history/status: Duloxetine, Duroferon, Losartan, Atorvastatin, Amlodipine. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.", "answer": "Review of CBCT volume dated 231110. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 21.1 mm; implant space ≈ 14.2 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 13.3 mm; implant space ≈ 6.8 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 19.5 mm; implant space ≈ 13.6 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 16.2 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 11.3 mm; implant space ≈ 2.3 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 21.0 mm; implant space ≈ 13.4 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 6.2 mm; implant space ≈ 0.8 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 8.0 mm; implant space ≈ 6.1 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 16.2 mm; implant space ≈ 11.1 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination."}
{"id": "case_0072", "images": ["images/placeholder_0072.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Calcichew-D3, Amlodipine, Bufomix Easyhaler, Levaxin, Losartan, Trulicity, Metoprolol, Duroferon, Atorvastatin. Desired treatment: Please report bone height and available implant space for regions 35–45 and 17–27.", "answer": "Review of CBCT volume dated 211109. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 43: bone height ≈ 18.3 mm; implant space ≈ 14.4 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 5.2 mm; implant space ≈ 1.7 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 12.4 mm; implant space ≈ 10.3 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 6.1 mm; implant space ≈ 1.3 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 12.8 mm; implant space ≈ 6.6 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 12.2 mm; implant space ≈ 9.1 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 21.0 mm; implant space ≈ 12.6 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 5.3 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 7.9 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 16.4 mm; implant space ≈ 9.8 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Cyst-like well-defined radiolucency near 11, likely radicular cyst."}
{"id": "case_0073", "images": ["images/placeholder_0073.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Calcichew-D3, Trulicity, Bufomix Easyhaler, Bricanyl, Esomeprazole, Duroferon. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 37–47.", "answer": "Review of CBCT volume dated 230901. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 43: bone height ≈ 5.1 mm; implant space ≈ 2.4 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 21.3 mm; implant space ≈ 15.8 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 15.4 mm; implant space ≈ 6.4 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 13.1 mm; implant space ≈ 8.2 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 11.6 mm; implant space ≈ 8.5 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 16.1 mm; implant space ≈ 7.8 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 20.8 mm; implant space ≈ 17.2 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 14.5 mm; implant space ≈ 8.9 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 15.8 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 6.7 mm; implant space ≈ 2.1 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0074", "images": ["images/placeholder_0074.png"], "question": "Planning for implant site evaluation. Brief history/status: Levaxin, Calcichew-D3, Betolvex, Duloxetine, Duroferon, Bricanyl, Trulicity, Metoprolol, Atorvastatin. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.", "answer": "Review of CBCT volume dated 220908. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 45: bone height ≈ 18.8 mm; implant space ≈ 13.8 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 17.4 mm; implant space ≈ 15.1 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 5.0 mm; implant space ≈ 2.0 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 7.6 mm; implant space ≈ 1.1 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 16.3 mm; implant space ≈ 12.4 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 9.6 mm; implant space ≈ 7.1 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 9.5 mm; implant space ≈ 4.1 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 18.2 mm; implant space ≈ 9.4 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 19.3 mm; implant space ≈ 12.4 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 5.1 mm; implant space ≈ 3.2 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 45; lamina dura loss noted. Secondary small radiolucency adjacent to 28. Impression: Vertical root fracture suspected at 27; recommend clinical correlation."}
{"id": "case_0075", "images": ["images/placeholder_0075.png"], "question": "Planning for follow-up after extraction. Brief history/status: Betolvex, Amlodipine, Atorvastatin, Bricanyl, Metoprolol, Insulin glargine, Esomeprazole, Duloxetine, Trulicity. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 17–27.", "answer": "Review of CBCT volume dated 251117. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 45: bone height ≈ 21.7 mm; implant space ≈ 14.9 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 6.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 19.5 mm; implant space ≈ 16.0 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 6.9 mm; implant space ≈ 4.4 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 15.9 mm; implant space ≈ 9.8 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 21.4 mm; implant space ≈ 16.5 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 20.1 mm; implant space ≈ 17.3 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 16.5 mm; implant space ≈ 10.0 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0076", "images": ["images/placeholder_0076.png"], "question": "Planning for full-arch restoration. Brief history/status: Amlodipine, Betolvex, Levaxin, Bufomix Easyhaler, Losartan, Duloxetine, Calcichew-D3, Metoprolol. Desired treatment: Provide measurements relevant to guided surgery stent planning for 37–47 and 36–46.", "answer": "Review of CBCT volume dated 210810. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 32: bone height ≈ 4.2 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 6.5 mm; implant space ≈ 3.5 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 17.7 mm; implant space ≈ 10.6 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 9.3 mm; implant space ≈ 3.7 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 19.6 mm; implant space ≈ 16.2 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 10.8 mm; implant space ≈ 7.1 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 13.2 mm; implant space ≈ 6.2 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 11.2 mm; implant space ≈ 5.2 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 16.3 mm; implant space ≈ 10.6 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 12.5 mm; implant space ≈ 9.9 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 34; lamina dura loss noted. Secondary small radiolucency adjacent to 43. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0077", "images": ["images/placeholder_0077.png"], "question": "Planning for sinus-related complaints. Brief history/status: Duloxetine, Metoprolol, Duroferon, Amlodipine, Levaxin, Betolvex, Losartan, Bufomix Easyhaler. Desired treatment: Report any signs of peri-implantitis and root resorption in 16–26.", "answer": "Review of CBCT volume dated 220828. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 33: bone height ≈ 15.5 mm; implant space ≈ 9.2 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 19.5 mm; implant space ≈ 10.9 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 18.8 mm; implant space ≈ 16.1 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 15.5 mm; implant space ≈ 8.6 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 12.0 mm; implant space ≈ 6.8 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 7.4 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 20.1 mm; implant space ≈ 15.6 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 21.3 mm; implant space ≈ 13.8 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 8.6 mm; implant space ≈ 5.8 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 21.1 mm; implant space ≈ 17.2 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0078", "images": ["images/placeholder_0078.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Esomeprazole, Losartan, Amlodipine, Trulicity, Metoprolol, Insulin glargine, Duloxetine, Bricanyl, Betolvex. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 35–45.", "answer": "Review of CBCT volume dated 211102. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 26: bone height ≈ 21.9 mm; implant space ≈ 14.9 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 16.8 mm; implant space ≈ 11.7 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 19.1 mm; implant space ≈ 11.7 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 18.9 mm; implant space ≈ 15.0 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 21.5 mm; implant space ≈ 16.9 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 21.6 mm; implant space ≈ 15.6 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 21.1 mm; implant space ≈ 18.1 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 20.0 mm; implant space ≈ 16.3 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 19.2 mm; implant space ≈ 10.7 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Vertical root fracture suspected at 27; recommend clinical correlation."}
{"id": "case_0079", "images": ["images/placeholder_0079.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Duroferon, Bufomix Easyhaler, Amlodipine, Bricanyl, Metoprolol, Atorvastatin. Desired treatment: Measure crest-to-canal distances mandibularly in 15–25, and implant feasibility maxillary 36–46.", "answer": "Review of CBCT volume dated 240602. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 27: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 13.4 mm; implant space ≈ 6.9 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 13.1 mm; implant space ≈ 5.7 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 18.9 mm; implant space ≈ 14.0 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 11.3 mm; implant space ≈ 2.5 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 11.5 mm; implant space ≈ 6.8 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 11.7 mm; implant space ≈ 5.9 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 8.1 mm; implant space ≈ 2.6 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 21.5 mm; implant space ≈ 19.6 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 13.8 mm; implant space ≈ 11.7 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 38; lamina dura loss noted. Secondary small radiolucency adjacent to 31. Impression: Findings consistent with chronic apical periodontitis at 46 and 42."}
{"id": "case_0080", "images": ["images/placeholder_0080.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Amlodipine, Levaxin, Betolvex, Duroferon, Metoprolol, Atorvastatin, Duloxetine, Bricanyl. Desired treatment: Report any signs of peri-implantitis and root resorption in 36–46.", "answer": "Review of CBCT volume dated 250411. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 25: bone height ≈ 10.9 mm; implant space ≈ 3.2 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 16.5 mm; implant space ≈ 13.1 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 8.9 mm; implant space ≈ 6.6 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 20.7 mm; implant space ≈ 15.3 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 6.4 mm; implant space ≈ 1.4 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 20.4 mm; implant space ≈ 14.8 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 18.3 mm; implant space ≈ 13.7 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 18.1 mm; implant space ≈ 13.3 mm; nearest critical structure: mental foramen. Region 37: bone height ≈ 18.1 mm; implant space ≈ 14.0 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 10.6 mm; implant space ≈ 4.9 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 35; lamina dura loss noted. Secondary small radiolucency adjacent to 44. Impression: Peri-implant bone loss at 42 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0081", "images": ["images/placeholder_0081.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Levaxin, Betolvex, Amlodipine, Losartan, Trulicity. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 15–25.", "answer": "Review of CBCT volume dated 211228. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 28: bone height ≈ 21.0 mm; implant space ≈ 15.5 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 7.3 mm; implant space ≈ 2.8 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 9.5 mm; implant space ≈ 5.0 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 18.6 mm; implant space ≈ 14.3 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 19.2 mm; implant space ≈ 15.9 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 20.3 mm; implant space ≈ 12.4 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 20.9 mm; implant space ≈ 13.1 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 12.8 mm; implant space ≈ 6.5 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 5.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 19.7 mm; implant space ≈ 13.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Vertical root fracture suspected at 17; recommend clinical correlation."}
{"id": "case_0082", "images": ["images/placeholder_0082.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Duloxetine, Trulicity, Calcichew-D3, Atorvastatin, Levaxin. Desired treatment: Measure crest-to-canal distances mandibularly in 17–27, and implant feasibility maxillary 15–25.", "answer": "Review of CBCT volume dated 220904. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 22: bone height ≈ 17.9 mm; implant space ≈ 14.1 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 4.8 mm; implant space ≈ 2.4 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 13.7 mm; implant space ≈ 12.0 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 17.5 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 19.6 mm; implant space ≈ 14.6 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 8.2 mm; implant space ≈ 3.1 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 13.7 mm; implant space ≈ 11.9 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 8.0 mm; implant space ≈ 5.9 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 9.8 mm; implant space ≈ 8.1 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 13.2 mm; implant space ≈ 8.4 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0083", "images": ["images/placeholder_0083.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Amlodipine, Esomeprazole, Bricanyl, Duloxetine, Bufomix Easyhaler. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 250925. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 6.4 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 13.2 mm; implant space ≈ 4.9 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 10.9 mm; implant space ≈ 6.9 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 6.7 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 18.4 mm; implant space ≈ 14.8 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 13.1 mm; implant space ≈ 11.3 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 13.4 mm; implant space ≈ 8.9 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 18.3 mm; implant space ≈ 13.1 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 8.6 mm; implant space ≈ 0.6 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 21.3 mm; implant space ≈ 13.4 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination."}
{"id": "case_0084", "images": ["images/placeholder_0084.png"], "question": "Planning for sinus-related complaints. Brief history/status: Atorvastatin, Levaxin, Amlodipine, Metoprolol, Esomeprazole, Betolvex. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 17–27.", "answer": "Review of CBCT volume dated 250605. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 16: bone height ≈ 9.8 mm; implant space ≈ 7.7 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 17.8 mm; implant space ≈ 14.1 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 8.1 mm; implant space ≈ 4.2 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 17.8 mm; implant space ≈ 13.5 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 21.1 mm; implant space ≈ 18.8 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 6.0 mm; implant space ≈ 0.9 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 17.7 mm; implant space ≈ 11.0 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 8.3 mm; implant space ≈ 0.3 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 13.9 mm; implant space ≈ 11.7 mm; nearest critical structure: nasal floor. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0085", "images": ["images/placeholder_0085.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Esomeprazole, Atorvastatin, Levaxin, Trulicity, Insulin glargine, Metoprolol, Calcichew-D3. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 201206. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 21: bone height ≈ 8.9 mm; implant space ≈ 6.2 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 7.9 mm; implant space ≈ 1.0 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 8.0 mm; implant space ≈ 5.6 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 21.2 mm; implant space ≈ 15.5 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 15.7 mm; implant space ≈ 10.8 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 14.6 mm; implant space ≈ 9.3 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 12.1 mm; implant space ≈ 3.9 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 7.1 mm; implant space ≈ 3.8 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 11.4 mm; implant space ≈ 7.1 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 14; lamina dura loss noted. Secondary small radiolucency adjacent to 46. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination."}
{"id": "case_0086", "images": ["images/placeholder_0086.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Calcichew-D3, Trulicity, Atorvastatin, Metoprolol, Amlodipine, Losartan, Bufomix Easyhaler, Betolvex. Desired treatment: Measure crest-to-canal distances mandibularly in 15–25, and implant feasibility maxillary 37–47.", "answer": "Review of CBCT volume dated 220604. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 35: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 15.0 mm; implant space ≈ 9.4 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 13.1 mm; implant space ≈ 9.6 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 10.9 mm; implant space ≈ 5.0 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 13.8 mm; implant space ≈ 5.3 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 17.5 mm; implant space ≈ 13.4 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 21.0 mm; implant space ≈ 13.8 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 16.5 mm; implant space ≈ 10.0 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 13.2 mm; implant space ≈ 7.6 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 19.2 mm; implant space ≈ 15.4 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 16; lamina dura loss noted. Secondary small radiolucency adjacent to 42. Impression: Vertical root fracture suspected at 11; recommend clinical correlation."}
{"id": "case_0087", "images": ["images/placeholder_0087.png"], "question": "Planning for implant site evaluation. Brief history/status: Calcichew-D3, Esomeprazole, Bricanyl, Metoprolol, Betolvex. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 17–27.", "answer": "Review of CBCT volume dated 201221. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 24: bone height ≈ 19.2 mm; implant space ≈ 10.9 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 5.9 mm; implant space ≈ 4.1 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 12.9 mm; implant space ≈ 8.6 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 13.7 mm; implant space ≈ 9.4 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 13.5 mm; implant space ≈ 9.5 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 15.7 mm; implant space ≈ 9.2 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 20.1 mm; implant space ≈ 12.4 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 6.9 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 20.8 mm; implant space ≈ 19.2 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 13.1 mm; implant space ≈ 11.1 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0088", "images": ["images/placeholder_0088.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Esomeprazole, Metoprolol, Atorvastatin, Insulin glargine, Amlodipine. Desired treatment: Measure crest-to-canal distances mandibularly in 15–25, and implant feasibility maxillary 36–46.", "answer": "Review of CBCT volume dated 250610. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 37: bone height ≈ 12.8 mm; implant space ≈ 7.1 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 21.7 mm; implant space ≈ 14.0 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 12.2 mm; implant space ≈ 5.9 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 12.4 mm; implant space ≈ 7.1 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 9.7 mm; implant space ≈ 5.8 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 15.0 mm; implant space ≈ 8.9 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 20.2 mm; implant space ≈ 17.2 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 7.9 mm; implant space ≈ 5.2 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 4.3 mm; implant space ≈ 0.5 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 10.5 mm; implant space ≈ 8.2 mm; nearest critical structure: incisive canal. Periapical radiolucency present near 11; lamina dura loss noted. Secondary small radiolucency adjacent to 21. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0089", "images": ["images/placeholder_0089.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Insulin glargine, Esomeprazole, Betolvex, Amlodipine, Duloxetine, Metoprolol, Levaxin, Atorvastatin, Losartan. Desired treatment: Please report bone height and available implant space for regions 36–46 and 37–47.", "answer": "Review of CBCT volume dated 220128. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 14: bone height ≈ 14.5 mm; implant space ≈ 8.2 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 16.5 mm; implant space ≈ 8.2 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 8.1 mm; implant space ≈ 0.4 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 14.1 mm; implant space ≈ 12.5 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 9.4 mm; implant space ≈ 5.4 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 8.4 mm; implant space ≈ 0.2 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 18.6 mm; implant space ≈ 10.8 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 9.6 mm; implant space ≈ 4.5 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 14.8 mm; implant space ≈ 8.8 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 11.3 mm; implant space ≈ 8.2 mm; nearest critical structure: anterior loop. Impression: Peri-implant bone loss at 43 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0090", "images": ["images/placeholder_0090.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Duroferon, Betolvex, Duloxetine, Amlodipine, Levaxin, Losartan, Metoprolol. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 16–26.", "answer": "Review of CBCT volume dated 210715. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 17.3 mm; implant space ≈ 12.6 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 19.7 mm; implant space ≈ 14.1 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 16.1 mm; implant space ≈ 9.4 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 4.9 mm; implant space ≈ 1.7 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 11.6 mm; implant space ≈ 7.8 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 13.3 mm; implant space ≈ 11.2 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 7.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 11.7 mm; implant space ≈ 3.5 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 10.8 mm; implant space ≈ 5.4 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 8.0 mm; implant space ≈ 1.4 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Cyst-like well-defined radiolucency near 48, likely radicular cyst."}
{"id": "case_0091", "images": ["images/placeholder_0091.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Amlodipine, Levaxin, Duroferon, Bricanyl, Duloxetine, Esomeprazole, Trulicity, Bufomix Easyhaler. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 35–45.", "answer": "Review of CBCT volume dated 201104. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 32: bone height ≈ 5.6 mm; implant space ≈ 3.9 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 11.4 mm; implant space ≈ 8.9 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 14.0 mm; implant space ≈ 10.4 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 15.7 mm; implant space ≈ 8.6 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 11.6 mm; implant space ≈ 8.7 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 9.5 mm; implant space ≈ 3.5 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 7.7 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 14.0 mm; implant space ≈ 12.0 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 17.2 mm; implant space ≈ 11.3 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 12.0 mm; implant space ≈ 8.5 mm; nearest critical structure: mandibular canal. Impression: Peri-implant bone loss at 45 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0092", "images": ["images/placeholder_0092.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Betolvex, Atorvastatin, Metoprolol, Duroferon, Insulin glargine, Calcichew-D3, Duloxetine, Bricanyl. Desired treatment: Measure crest-to-canal distances mandibularly in 35–45, and implant feasibility maxillary 35–45.", "answer": "Review of CBCT volume dated 221011. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 25: bone height ≈ 8.2 mm; implant space ≈ 2.2 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 11.3 mm; implant space ≈ 3.6 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 8.9 mm; implant space ≈ 2.8 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 9.0 mm; implant space ≈ 3.7 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 15.1 mm; implant space ≈ 6.6 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 7.0 mm; implant space ≈ 1.0 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 13.8 mm; implant space ≈ 6.3 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 17.5 mm; implant space ≈ 9.4 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 9.6 mm; implant space ≈ 2.5 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 13.9 mm; implant space ≈ 10.8 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 21; lamina dura loss noted. Secondary small radiolucency adjacent to 16. Impression: Cyst-like well-defined radiolucency near 16, likely radicular cyst."}
{"id": "case_0093", "images": ["images/placeholder_0093.png"], "question": "Planning for full-arch restoration. Brief history/status: Esomeprazole, Losartan, Calcichew-D3, Bufomix Easyhaler, Betolvex, Bricanyl. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 36–46.", "answer": "Review of CBCT volume dated 220820. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 44: bone height ≈ 10.0 mm; implant space ≈ 3.7 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 6.1 mm; implant space ≈ 4.1 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 13.9 mm; implant space ≈ 10.7 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 14.9 mm; implant space ≈ 8.1 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 12.7 mm; implant space ≈ 4.1 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 11.2 mm; implant space ≈ 7.6 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 11.0 mm; implant space ≈ 4.4 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 15.1 mm; implant space ≈ 8.3 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 15.0 mm; implant space ≈ 9.5 mm; nearest critical structure: mandibular canal. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Findings consistent with chronic apical periodontitis at 21 and 25."}
{"id": "case_0094", "images": ["images/placeholder_0094.png"], "question": "Planning for implant site evaluation. Brief history/status: Atorvastatin, Duloxetine, Losartan, Bricanyl, Calcichew-D3, Trulicity. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 15–25.", "answer": "Review of CBCT volume dated 230510. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 15.1 mm; implant space ≈ 8.8 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 16.7 mm; implant space ≈ 14.2 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 13.5 mm; implant space ≈ 10.0 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 6.6 mm; implant space ≈ 1.1 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 11.4 mm; implant space ≈ 8.7 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 8.2 mm; implant space ≈ 2.6 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 14.3 mm; implant space ≈ 10.8 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 15.1 mm; implant space ≈ 11.8 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 7.9 mm; implant space ≈ 3.5 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 36; lamina dura loss noted. Secondary small radiolucency adjacent to 43. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination."}
{"id": "case_0095", "images": ["images/placeholder_0095.png"], "question": "Planning for implant site evaluation. Brief history/status: Metoprolol, Bufomix Easyhaler, Bricanyl, Betolvex, Duroferon, Duloxetine, Amlodipine, Trulicity, Insulin glargine. Desired treatment: Please report bone height and available implant space for regions 15–25 and 35–45.", "answer": "Review of CBCT volume dated 251114. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 24: bone height ≈ 10.6 mm; implant space ≈ 3.6 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 10.8 mm; implant space ≈ 4.5 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 4.5 mm; implant space ≈ 2.1 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 13.6 mm; implant space ≈ 7.9 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 21.2 mm; implant space ≈ 15.4 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 8.3 mm; implant space ≈ 5.9 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 6.2 mm; implant space ≈ 1.8 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 21.2 mm; implant space ≈ 13.7 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 5.2 mm; implant space ≈ 1.0 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 21.1 mm; implant space ≈ 12.2 mm; nearest critical structure: mandibular canal. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination."}
{"id": "case_0096", "images": ["images/placeholder_0096.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Bufomix Easyhaler, Bricanyl, Metoprolol, Levaxin, Amlodipine, Esomeprazole, Atorvastatin. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 220604. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 35: bone height ≈ 7.6 mm; implant space ≈ 1.0 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 18.4 mm; implant space ≈ 16.3 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 10.3 mm; implant space ≈ 6.7 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 21.0 mm; implant space ≈ 15.4 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 8.4 mm; implant space ≈ 1.7 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 8.5 mm; implant space ≈ 2.1 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 8.1 mm; implant space ≈ 4.8 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 14.1 mm; implant space ≈ 8.1 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 9.7 mm; implant space ≈ 2.3 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 15.6 mm; implant space ≈ 13.3 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 18; lamina dura loss noted. Secondary small radiolucency adjacent to 45. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0097", "images": ["images/placeholder_0097.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Insulin glargine, Trulicity, Betolvex, Metoprolol, Esomeprazole, Losartan. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 36–46.", "answer": "Review of CBCT volume dated 240220. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 21: bone height ≈ 11.0 mm; implant space ≈ 8.5 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 6.8 mm; implant space ≈ 0.9 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 14.2 mm; implant space ≈ 8.7 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 19.8 mm; implant space ≈ 15.8 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 4.1 mm; implant space ≈ 2.3 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 11.5 mm; implant space ≈ 6.0 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 10.5 mm; implant space ≈ 6.9 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 8.3 mm; implant space ≈ 4.5 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 21; lamina dura loss noted. Secondary small radiolucency adjacent to 17. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Findings consistent with chronic apical periodontitis at 26 and 21."}
{"id": "case_0098", "images": ["images/placeholder_0098.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Trulicity, Betolvex, Esomeprazole, Metoprolol, Calcichew-D3, Amlodipine, Atorvastatin. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 37–47.", "answer": "Review of CBCT volume dated 240621. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 43: bone height ≈ 11.8 mm; implant space ≈ 8.2 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 16.6 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 17.9 mm; implant space ≈ 12.3 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 10.7 mm; implant space ≈ 4.7 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 18.8 mm; implant space ≈ 12.8 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 10.0 mm; implant space ≈ 6.6 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 16.9 mm; implant space ≈ 9.6 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 18.9 mm; implant space ≈ 14.4 mm; nearest critical structure: incisive canal. Periapical radiolucency present near 46; lamina dura loss noted. Secondary small radiolucency adjacent to 43. Impression: Peri-implant bone loss at 44 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0099", "images": ["images/placeholder_0099.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Duloxetine, Levaxin, Betolvex, Amlodipine, Bricanyl, Insulin glargine, Metoprolol, Trulicity, Atorvastatin. Desired treatment: Quantify vertical bone loss around implants in 35–45 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 241015. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 33: bone height ≈ 12.5 mm; implant space ≈ 8.8 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 17.2 mm; implant space ≈ 9.3 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 9.0 mm; implant space ≈ 0.9 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 16.6 mm; implant space ≈ 7.6 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 6.7 mm; implant space ≈ 2.6 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 7.5 mm; implant space ≈ 4.6 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 9.2 mm; implant space ≈ 0.3 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 8.5 mm; implant space ≈ 6.7 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 6.2 mm; implant space ≈ 3.8 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 19.6 mm; implant space ≈ 16.5 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 44; lamina dura loss noted. Secondary small radiolucency adjacent to 27. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0100", "images": ["images/placeholder_0100.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Atorvastatin, Betolvex, Levaxin, Losartan, Bricanyl, Insulin glargine, Duloxetine. Desired treatment: Measure crest-to-canal distances mandibularly in 17–27, and implant feasibility maxillary 15–25.", "answer": "Review of CBCT volume dated 251027. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 26: bone height ≈ 12.3 mm; implant space ≈ 6.0 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 13.2 mm; implant space ≈ 9.2 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 18.0 mm; implant space ≈ 9.2 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 13.1 mm; implant space ≈ 9.3 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 11.8 mm; implant space ≈ 5.3 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 18.5 mm; implant space ≈ 14.9 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 4.9 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 9.7 mm; implant space ≈ 1.6 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 11.7 mm; implant space ≈ 6.1 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Vertical root fracture suspected at 41; recommend clinical correlation."}
{"id": "case_0001", "images": ["images/placeholder_0001.png"], "question": "Planning for follow-up after extraction. Brief history/status: Insulin glargine, Bricanyl, Losartan, Metoprolol, Bufomix Easyhaler. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 37–47.", "answer": "Review of CBCT volume dated 240117. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 31: bone height ≈ 21.8 mm; implant space ≈ 12.9 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 21.6 mm; implant space ≈ 14.5 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 16.1 mm; implant space ≈ 7.2 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 6.8 mm; implant space ≈ 5.2 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 11.9 mm; implant space ≈ 3.2 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 12.4 mm; implant space ≈ 3.9 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 20.2 mm; implant space ≈ 13.0 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 9.5 mm; implant space ≈ 6.2 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 8.0 mm; implant space ≈ 3.4 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 17.0 mm; implant space ≈ 10.3 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0002", "images": ["images/placeholder_0002.png"], "question": "Planning for follow-up after extraction. Brief history/status: Levaxin, Betolvex, Insulin glargine, Omeprazole, Atorvastatin, Bufomix Easyhaler, Duroferon, Losartan. Desired treatment: Provide measurements relevant to guided surgery stent planning for 37–47 and 15–25.", "answer": "Review of CBCT volume dated 200522. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 41: bone height ≈ 6.3 mm; implant space ≈ 1.7 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 13.2 mm; implant space ≈ 6.2 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 18.2 mm; implant space ≈ 10.3 mm; nearest critical structure: sinus floor. Region 45: bone height ≈ 15.0 mm; implant space ≈ 13.1 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 7.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 19.6 mm; implant space ≈ 14.6 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 7.9 mm; implant space ≈ 4.8 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 8.8 mm; implant space ≈ 6.7 mm; nearest critical structure: sinus floor. Region 48: bone height ≈ 19.6 mm; implant space ≈ 12.6 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 7.6 mm; implant space ≈ 2.0 mm; nearest critical structure: anterior loop. Impression: Cyst-like well-defined radiolucency near 37, likely radicular cyst."}
{"id": "case_0003", "images": ["images/placeholder_0003.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Betolvex, Esomeprazole, Trulicity, Bufomix Easyhaler, Bricanyl, Atorvastatin, Duroferon, Insulin glargine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 37–47 and 15–25.", "answer": "Review of CBCT volume dated 210218. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 27: bone height ≈ 18.8 mm; implant space ≈ 13.5 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 9.6 mm; implant space ≈ 7.5 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 10.9 mm; implant space ≈ 6.4 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 19.1 mm; implant space ≈ 12.2 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 19.5 mm; implant space ≈ 17.2 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 13.6 mm; implant space ≈ 5.5 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 16.6 mm; implant space ≈ 12.0 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 10.7 mm; implant space ≈ 4.5 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 8.9 mm; implant space ≈ 2.3 mm; nearest critical structure: anterior loop. Impression: Peri-implant bone loss at 38 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0004", "images": ["images/placeholder_0004.png"], "question": "Planning for full-arch restoration. Brief history/status: Calcichew-D3, Atorvastatin, Metoprolol, Duroferon, Insulin glargine, Bricanyl. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 17–27.", "answer": "Review of CBCT volume dated 201001. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 13: bone height ≈ 12.8 mm; implant space ≈ 4.8 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 6.7 mm; implant space ≈ 1.2 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 10.5 mm; implant space ≈ 8.1 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 12.2 mm; implant space ≈ 9.8 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 11.7 mm; implant space ≈ 2.8 mm; nearest critical structure: mental foramen. Region 27: bone height ≈ 5.6 mm; implant space ≈ 3.3 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 4.2 mm; implant space ≈ 1.3 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 21.2 mm; implant space ≈ 12.5 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 21.0 mm; implant space ≈ 15.9 mm; nearest critical structure: nasal floor. Periapical radiolucency near 31; lamina dura loss noted. Smaller radiolucency at 25. Impression: Cyst-like well-defined radiolucency near 33, likely radicular cyst."}
{"id": "case_0005", "images": ["images/placeholder_0005.png"], "question": "Planning for implant planning evaluation. Brief history/status: Esomeprazole, Amlodipine, Duloxetine, Omeprazole, Trulicity, Atorvastatin, Insulin glargine, Calcichew-D3, Bufomix Easyhaler. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.", "answer": "Review of CBCT volume dated 200624. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 44: bone height ≈ 15.9 mm; implant space ≈ 14.3 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 9.9 mm; implant space ≈ 7.8 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 17.6 mm; implant space ≈ 11.7 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 8.2 mm; implant space ≈ 4.1 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 16.3 mm; implant space ≈ 13.6 mm; nearest critical structure: mental foramen. Region 27: bone height ≈ 6.5 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 22: bone height ≈ 8.2 mm; implant space ≈ 1.7 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 7.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 16.7 mm; implant space ≈ 10.1 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 16.6 mm; implant space ≈ 12.5 mm; nearest critical structure: mental foramen. Periapical radiolucency near 46; lamina dura loss noted. Smaller radiolucency at 31. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Peri-implant bone loss at 11 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0006", "images": ["images/placeholder_0006.png"], "question": "Planning for sinus-related complaints. Brief history/status: Amlodipine, Insulin glargine, Betolvex, Duloxetine, Esomeprazole, Atorvastatin, Losartan, Calcichew-D3. Desired treatment: Check the bone healing and trabecular fill post extraction sites 36–46.", "answer": "Review of CBCT volume dated 230415. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 22: bone height ≈ 5.3 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 16.8 mm; implant space ≈ 10.0 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 6.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 5.1 mm; implant space ≈ 2.8 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 11.8 mm; implant space ≈ 7.7 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 6.6 mm; implant space ≈ 4.9 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 12.0 mm; implant space ≈ 4.7 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 12.6 mm; implant space ≈ 7.7 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 18.0 mm; implant space ≈ 16.1 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 28; lamina dura loss noted. Smaller radiolucency at 38. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Findings consistent with chronic apical periodontitis at 36 and 48."}
{"id": "case_0007", "images": ["images/placeholder_0007.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Amlodipine, Duloxetine, Bufomix Easyhaler, Trulicity, Insulin glargine, Losartan. Desired treatment: Measure crest-to-canal distances mandibularly in 36–46, and implant feasibility maxillary 36–46.", "answer": "Review of CBCT volume dated 230617. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 34: bone height ≈ 9.8 mm; implant space ≈ 6.7 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 21.7 mm; implant space ≈ 14.0 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 17.4 mm; implant space ≈ 10.5 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 13.5 mm; implant space ≈ 4.9 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 17.3 mm; implant space ≈ 15.1 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 8.4 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 13.0 mm; implant space ≈ 7.7 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 20.3 mm; implant space ≈ 12.4 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 4.0 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 19.5 mm; implant space ≈ 13.2 mm; nearest critical structure: mental foramen. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination."}
{"id": "case_0008", "images": ["images/placeholder_0008.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Atorvastatin, Insulin glargine, Duloxetine, Duroferon, Bufomix Easyhaler, Esomeprazole, Bricanyl. Desired treatment: Evaluate periapical status of teeth 37, 13, and 14, and overall sinus condition.", "answer": "Review of CBCT volume dated 220806. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 41: bone height ≈ 6.0 mm; implant space ≈ 3.8 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 13.3 mm; implant space ≈ 6.4 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 18.1 mm; implant space ≈ 13.5 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 7.1 mm; implant space ≈ 3.9 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 12.6 mm; implant space ≈ 10.1 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 17.7 mm; implant space ≈ 9.1 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 13.4 mm; implant space ≈ 5.6 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 4.0 mm; implant space ≈ 2.3 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 5.4 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0009", "images": ["images/placeholder_0009.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Calcichew-D3, Bricanyl, Betolvex, Omeprazole, Losartan. Desired treatment: Evaluate periapical status of teeth 28, 12, and 44, and overall sinus condition.", "answer": "Review of CBCT volume dated 240308. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 44: bone height ≈ 6.5 mm; implant space ≈ 2.6 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 17.0 mm; implant space ≈ 9.0 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 13.9 mm; implant space ≈ 11.7 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 9.6 mm; implant space ≈ 4.6 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 16.8 mm; implant space ≈ 8.9 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 7.4 mm; implant space ≈ 4.6 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 18.9 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 10.1 mm; implant space ≈ 1.2 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 14.3 mm; implant space ≈ 11.8 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 19.3 mm; implant space ≈ 11.9 mm; nearest critical structure: mandibular canal. Impression: Impaction of third molar in quadrant 4 with mesioangular inclination."}
{"id": "case_0010", "images": ["images/placeholder_0010.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Insulin glargine, Amlodipine, Duloxetine, Betolvex, Atorvastatin, Losartan, Bufomix Easyhaler, Esomeprazole. Desired treatment: Check the bone healing and trabecular fill post extraction sites 15–25.", "answer": "Review of CBCT volume dated 221110. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 25: bone height ≈ 11.0 mm; implant space ≈ 8.0 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 7.2 mm; implant space ≈ 2.5 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 5.8 mm; implant space ≈ 3.7 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 8.8 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 10.6 mm; implant space ≈ 4.9 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 12.1 mm; implant space ≈ 3.9 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 8.3 mm; implant space ≈ 6.4 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 16.1 mm; implant space ≈ 9.0 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 19.9 mm; implant space ≈ 16.1 mm; nearest critical structure: mental foramen. Periapical radiolucency near 45; lamina dura loss noted. Smaller radiolucency at 46. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0011", "images": ["images/placeholder_0011.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Metoprolol, Duroferon, Insulin glargine, Betolvex, Amlodipine, Omeprazole, Bufomix Easyhaler, Calcichew-D3. Desired treatment: Evaluate periapical status of teeth 46, 27, and 15, and overall sinus condition.", "answer": "Review of CBCT volume dated 250601. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 46: bone height ≈ 13.9 mm; implant space ≈ 5.5 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 19.6 mm; implant space ≈ 14.9 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 16.7 mm; implant space ≈ 11.7 mm; nearest critical structure: incisive canal. Region 21: bone height ≈ 13.3 mm; implant space ≈ 5.0 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 16.8 mm; implant space ≈ 9.1 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 11.2 mm; implant space ≈ 9.5 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 15.5 mm; implant space ≈ 8.0 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 15.9 mm; implant space ≈ 10.2 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 15.9 mm; implant space ≈ 12.5 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Impression: Findings consistent with chronic apical periodontitis at 18 and 47."}
{"id": "case_0012", "images": ["images/placeholder_0012.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Omeprazole, Bufomix Easyhaler, Duroferon, Atorvastatin, Insulin glargine, Levaxin, Bricanyl, Trulicity. Desired treatment: Measure crest-to-canal distances mandibularly in 37–47, and implant feasibility maxillary 16–26.", "answer": "Review of CBCT volume dated 200212. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 35: bone height ≈ 15.7 mm; implant space ≈ 10.0 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 8.0 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 19.2 mm; implant space ≈ 16.2 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 10.3 mm; implant space ≈ 3.5 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 7.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 21.9 mm; implant space ≈ 16.4 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 4.1 mm; implant space ≈ 1.0 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 10.1 mm; implant space ≈ 5.1 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 21.5 mm; implant space ≈ 18.8 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 11.8 mm; implant space ≈ 3.3 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 31; lamina dura loss noted. Smaller radiolucency at 48. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Peri-implant bone loss at 41 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0013", "images": ["images/placeholder_0013.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Betolvex, Levaxin, Duroferon, Omeprazole, Bufomix Easyhaler, Metoprolol, Bricanyl, Atorvastatin. Desired treatment: Assess mandibular canal course and distance to apices in 37–47.", "answer": "Review of CBCT volume dated 201004. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 38: bone height ≈ 11.0 mm; implant space ≈ 7.4 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 10.9 mm; implant space ≈ 8.1 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 12.9 mm; implant space ≈ 10.6 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 19.1 mm; implant space ≈ 15.5 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 13.7 mm; implant space ≈ 6.7 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 15.5 mm; implant space ≈ 9.9 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 5.8 mm; implant space ≈ 2.3 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 17.8 mm; implant space ≈ 9.2 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 6.9 mm; implant space ≈ 5.3 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 14.5 mm; implant space ≈ 9.1 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Vertical root fracture suspected at 43; recommend clinical correlation."}
{"id": "case_0014", "images": ["images/placeholder_0014.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Amlodipine, Insulin glargine, Esomeprazole, Levaxin, Atorvastatin, Duroferon, Duloxetine, Bufomix Easyhaler. Desired treatment: Review the sinus floor elevation and ridge thickness for 35–45.", "answer": "Review of CBCT volume dated 230110. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 44: bone height ≈ 18.8 mm; implant space ≈ 14.9 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 18.1 mm; implant space ≈ 11.8 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 14.8 mm; implant space ≈ 9.4 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 7.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 11.1 mm; implant space ≈ 7.3 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 7.8 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 9.3 mm; implant space ≈ 1.8 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 21.1 mm; implant space ≈ 18.8 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 10.5 mm; implant space ≈ 2.1 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0015", "images": ["images/placeholder_0015.png"], "question": "Planning for implant planning evaluation. Brief history/status: Amlodipine, Metoprolol, Duroferon, Atorvastatin, Levaxin, Bufomix Easyhaler, Esomeprazole. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 37–47.", "answer": "Review of CBCT volume dated 240215. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 23: bone height ≈ 10.3 mm; implant space ≈ 6.4 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 12.3 mm; implant space ≈ 4.9 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 9.9 mm; implant space ≈ 3.3 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 6.8 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 6.2 mm; implant space ≈ 3.4 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 9.4 mm; implant space ≈ 2.7 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 9.0 mm; implant space ≈ 0.1 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 10.3 mm; implant space ≈ 3.5 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 21.3 mm; implant space ≈ 18.6 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 16.5 mm; implant space ≈ 8.7 mm; nearest critical structure: sinus floor. Impression: Findings consistent with chronic apical periodontitis at 45 and 18."}
{"id": "case_0016", "images": ["images/placeholder_0016.png"], "question": "Planning for follow-up after extraction. Brief history/status: Duloxetine, Esomeprazole, Losartan, Calcichew-D3, Bufomix Easyhaler. Desired treatment: Please report bone height and available implant space for regions 16–26 and 36–46.", "answer": "Review of CBCT volume dated 250114. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 38: bone height ≈ 17.4 mm; implant space ≈ 12.6 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 20.4 mm; implant space ≈ 13.7 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 12.6 mm; implant space ≈ 5.2 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 18.0 mm; implant space ≈ 14.3 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 14.6 mm; implant space ≈ 9.5 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 4.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 9.9 mm; implant space ≈ 2.0 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 15.8 mm; implant space ≈ 9.3 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 9.7 mm; implant space ≈ 7.5 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 8.8 mm; implant space ≈ 5.0 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 37; lamina dura loss noted. Smaller radiolucency at 35. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination."}
{"id": "case_0017", "images": ["images/placeholder_0017.png"], "question": "Planning for follow-up after extraction. Brief history/status: Bufomix Easyhaler, Metoprolol, Amlodipine, Betolvex, Trulicity. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 15–25.", "answer": "Review of CBCT volume dated 221215. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 48: bone height ≈ 17.2 mm; implant space ≈ 11.3 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 19.1 mm; implant space ≈ 12.5 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 12.6 mm; implant space ≈ 5.2 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 14.7 mm; implant space ≈ 12.8 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 17.5 mm; implant space ≈ 12.3 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 4.7 mm; implant space ≈ 0.8 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 15.0 mm; implant space ≈ 10.8 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 11.0 mm; implant space ≈ 2.5 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 16.7 mm; implant space ≈ 10.6 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 12.1 mm; implant space ≈ 3.3 mm; nearest critical structure: incisive canal. Periapical radiolucency near 37; lamina dura loss noted. Smaller radiolucency at 16. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0018", "images": ["images/placeholder_0018.png"], "question": "Planning for full-arch restoration. Brief history/status: Duroferon, Trulicity, Duloxetine, Esomeprazole, Metoprolol, Omeprazole, Insulin glargine, Amlodipine, Levaxin. Desired treatment: Please report bone height and available implant space for regions 17–27 and 37–47.", "answer": "Review of CBCT volume dated 221219. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 44: bone height ≈ 17.9 mm; implant space ≈ 10.6 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 20.0 mm; implant space ≈ 16.3 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 18.1 mm; implant space ≈ 13.3 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 9.6 mm; implant space ≈ 2.8 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 7.3 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 8.4 mm; implant space ≈ 2.1 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 9.9 mm; implant space ≈ 3.3 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 21.9 mm; implant space ≈ 16.4 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 18.4 mm; implant space ≈ 12.8 mm; nearest critical structure: incisive canal. Periapical radiolucency near 24; lamina dura loss noted. Smaller radiolucency at 46. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Peri-implant bone loss at 28 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0019", "images": ["images/placeholder_0019.png"], "question": "Planning for follow-up after extraction. Brief history/status: Betolvex, Losartan, Atorvastatin, Levaxin, Omeprazole, Duroferon, Amlodipine, Calcichew-D3. Desired treatment: Review the sinus floor elevation and ridge thickness for 37–47.", "answer": "Review of CBCT volume dated 210316. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 22: bone height ≈ 12.3 mm; implant space ≈ 4.5 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 21.4 mm; implant space ≈ 18.1 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 9.6 mm; implant space ≈ 0.9 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 21.7 mm; implant space ≈ 15.1 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 16.7 mm; implant space ≈ 10.7 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 7.7 mm; implant space ≈ 1.3 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 4.9 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 6.3 mm; implant space ≈ 1.8 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Peri-implant bone loss at 21 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0020", "images": ["images/placeholder_0020.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Omeprazole, Levaxin, Esomeprazole, Atorvastatin, Bufomix Easyhaler, Amlodipine, Metoprolol, Calcichew-D3. Desired treatment: Review the sinus floor elevation and ridge thickness for 15–25.", "answer": "Review of CBCT volume dated 241022. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 24: bone height ≈ 19.7 mm; implant space ≈ 12.2 mm; nearest critical structure: sinus floor. Region 22: bone height ≈ 7.1 mm; implant space ≈ 2.8 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 16.2 mm; implant space ≈ 11.5 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 10.2 mm; implant space ≈ 8.0 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 9.0 mm; implant space ≈ 7.4 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 16.2 mm; implant space ≈ 7.8 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 6.8 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 16.4 mm; implant space ≈ 14.5 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 8.1 mm; implant space ≈ 5.8 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 12.6 mm; implant space ≈ 11.1 mm; nearest critical structure: anterior loop. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Peri-implant bone loss at 21 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0021", "images": ["images/placeholder_0021.png"], "question": "Planning for implant site evaluation. Brief history/status: Bufomix Easyhaler, Insulin glargine, Amlodipine, Duloxetine, Duroferon, Esomeprazole, Calcichew-D3. Desired treatment: Review the sinus floor elevation and ridge thickness for 16–26.", "answer": "Review of CBCT volume dated 211216. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 16: bone height ≈ 15.9 mm; implant space ≈ 13.3 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 5.8 mm; implant space ≈ 2.2 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 10.0 mm; implant space ≈ 5.9 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 21.4 mm; implant space ≈ 16.9 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 16.2 mm; implant space ≈ 10.7 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 13.5 mm; implant space ≈ 11.2 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 6.0 mm; implant space ≈ 4.1 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 19.7 mm; implant space ≈ 13.6 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 31; lamina dura loss noted. Smaller radiolucency at 22. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0022", "images": ["images/placeholder_0022.png"], "question": "Planning for implant planning evaluation. Brief history/status: Insulin glargine, Omeprazole, Betolvex, Atorvastatin, Calcichew-D3, Trulicity, Bricanyl. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 250902. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 12: bone height ≈ 17.5 mm; implant space ≈ 8.6 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 19.0 mm; implant space ≈ 15.4 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 10.9 mm; implant space ≈ 7.2 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 21.2 mm; implant space ≈ 18.9 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 13.0 mm; implant space ≈ 10.6 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 9.3 mm; implant space ≈ 5.6 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 8.7 mm; implant space ≈ 5.6 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 5.8 mm; implant space ≈ 3.3 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 14.3 mm; implant space ≈ 7.9 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 43; lamina dura loss noted. Smaller radiolucency at 34. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0023", "images": ["images/placeholder_0023.png"], "question": "Planning for review of post-implant healing. Brief history/status: Trulicity, Duroferon, Duloxetine, Metoprolol, Calcichew-D3. Desired treatment: Report any signs of peri-implantitis and root resorption in 17–27.", "answer": "Review of CBCT volume dated 250226. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 44: bone height ≈ 8.3 mm; implant space ≈ 6.3 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 13.8 mm; implant space ≈ 5.6 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 14.3 mm; implant space ≈ 9.2 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 12.9 mm; implant space ≈ 9.1 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 9.9 mm; implant space ≈ 1.9 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 14.2 mm; implant space ≈ 8.5 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 15.4 mm; implant space ≈ 12.8 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 12.3 mm; implant space ≈ 9.9 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 13.9 mm; implant space ≈ 7.5 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 6.0 mm; implant space ≈ 4.4 mm; nearest critical structure: mental foramen. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0024", "images": ["images/placeholder_0024.png"], "question": "Planning for follow-up after extraction. Brief history/status: Amlodipine, Calcichew-D3, Metoprolol, Duloxetine, Trulicity, Omeprazole, Bufomix Easyhaler. Desired treatment: Evaluate periapical status of teeth 24, 25, and 18, and overall sinus condition.", "answer": "Review of CBCT volume dated 250812. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 34: bone height ≈ 14.2 mm; implant space ≈ 6.6 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 5.0 mm; implant space ≈ 0.4 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 7.0 mm; implant space ≈ 0.2 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 17.6 mm; implant space ≈ 14.8 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 15.9 mm; implant space ≈ 13.0 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 12.7 mm; implant space ≈ 8.4 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 17.6 mm; implant space ≈ 11.8 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 12.7 mm; implant space ≈ 9.3 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 18.9 mm; implant space ≈ 15.3 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 7.7 mm; implant space ≈ 0.6 mm; nearest critical structure: mandibular canal. Periapical radiolucency near 43; lamina dura loss noted. Smaller radiolucency at 27. Impression: Impaction of third molar in quadrant 3 with mesioangular inclination."}
{"id": "case_0025", "images": ["images/placeholder_0025.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Trulicity, Duloxetine, Bufomix Easyhaler, Esomeprazole, Betolvex, Insulin glargine, Losartan, Amlodipine. Desired treatment: Quantify vertical bone loss around implants in 35–45 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 240122. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 46: bone height ≈ 17.5 mm; implant space ≈ 12.1 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 21.1 mm; implant space ≈ 13.3 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 13.1 mm; implant space ≈ 9.4 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 8.7 mm; implant space ≈ 1.0 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 5.0 mm; implant space ≈ 2.6 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 8.6 mm; implant space ≈ 3.3 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 18.1 mm; implant space ≈ 15.7 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 13.9 mm; implant space ≈ 7.4 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 7.9 mm; implant space ≈ 1.4 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 10.4 mm; implant space ≈ 7.6 mm; nearest critical structure: anterior loop. Periapical radiolucency near 12; lamina dura loss noted. Smaller radiolucency at 45. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Findings consistent with chronic apical periodontitis at 46 and 13."}
{"id": "case_0026", "images": ["images/placeholder_0026.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Levaxin, Bufomix Easyhaler, Metoprolol, Atorvastatin, Trulicity, Betolvex. Desired treatment: Measure crest-to-canal distances mandibularly in 16–26, and implant feasibility maxillary 17–27.", "answer": "Review of CBCT volume dated 210711. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 27: bone height ≈ 13.9 mm; implant space ≈ 5.2 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 15.0 mm; implant space ≈ 6.3 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 12.4 mm; implant space ≈ 5.2 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 14.8 mm; implant space ≈ 7.1 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 17.0 mm; implant space ≈ 12.2 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 9.5 mm; implant space ≈ 1.2 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 6.0 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 7.9 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 21.6 mm; implant space ≈ 18.0 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 47; lamina dura loss noted. Smaller radiolucency at 22. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination."}
{"id": "case_0027", "images": ["images/placeholder_0027.png"], "question": "Planning for follow-up after extraction. Brief history/status: Esomeprazole, Duroferon, Duloxetine, Omeprazole, Trulicity, Losartan, Bufomix Easyhaler. Desired treatment: Check the bone healing and trabecular fill post extraction sites 35–45.", "answer": "Review of CBCT volume dated 240117. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 21: bone height ≈ 15.7 mm; implant space ≈ 7.4 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 6.7 mm; implant space ≈ 4.7 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 10.5 mm; implant space ≈ 6.7 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 20.1 mm; implant space ≈ 15.7 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 7.7 mm; implant space ≈ 5.1 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 10.6 mm; implant space ≈ 6.1 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 8.1 mm; implant space ≈ 1.8 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 11.0 mm; implant space ≈ 3.9 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 21.8 mm; implant space ≈ 20.2 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 43; lamina dura loss noted. Smaller radiolucency at 13. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0028", "images": ["images/placeholder_0028.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Duroferon, Insulin glargine, Losartan, Atorvastatin, Betolvex, Bufomix Easyhaler. Desired treatment: Review the sinus floor elevation and ridge thickness for 15–25.", "answer": "Review of CBCT volume dated 251122. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 45: bone height ≈ 13.6 mm; implant space ≈ 8.2 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 15.9 mm; implant space ≈ 7.5 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 14.4 mm; implant space ≈ 10.3 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 9.0 mm; implant space ≈ 3.1 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 13.6 mm; implant space ≈ 4.8 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 20.7 mm; implant space ≈ 17.2 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 10.3 mm; implant space ≈ 2.4 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 20.0 mm; implant space ≈ 16.6 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 21.6 mm; implant space ≈ 19.0 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 11.4 mm; implant space ≈ 4.7 mm; nearest critical structure: mental foramen. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0029", "images": ["images/placeholder_0029.png"], "question": "Planning for implant site evaluation. Brief history/status: Losartan, Metoprolol, Trulicity, Omeprazole, Esomeprazole, Betolvex, Levaxin, Insulin glargine. Desired treatment: Quantify vertical bone loss around implants in 35–45 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 250115. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 33: bone height ≈ 12.4 mm; implant space ≈ 8.3 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 12.7 mm; implant space ≈ 11.0 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 8.9 mm; implant space ≈ 5.4 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 20.8 mm; implant space ≈ 14.5 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 4.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 6.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 4.1 mm; implant space ≈ 2.2 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 4.1 mm; implant space ≈ 1.8 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 20.8 mm; implant space ≈ 13.4 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 14; lamina dura loss noted. Smaller radiolucency at 17. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0030", "images": ["images/placeholder_0030.png"], "question": "Planning for sinus-related complaints. Brief history/status: Duroferon, Losartan, Trulicity, Insulin glargine, Metoprolol, Betolvex, Levaxin. Desired treatment: Check the bone healing and trabecular fill post extraction sites 17–27.", "answer": "Review of CBCT volume dated 210125. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 11: bone height ≈ 7.9 mm; implant space ≈ 1.3 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 10.6 mm; implant space ≈ 4.7 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 16.2 mm; implant space ≈ 10.1 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 9.3 mm; implant space ≈ 2.3 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 20.1 mm; implant space ≈ 12.7 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 16.6 mm; implant space ≈ 8.5 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 19.1 mm; implant space ≈ 13.8 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 18.3 mm; implant space ≈ 12.9 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 15.4 mm; implant space ≈ 10.5 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 11.4 mm; implant space ≈ 4.6 mm; nearest critical structure: mandibular canal. Impression: Findings consistent with chronic apical periodontitis at 31 and 15."}
{"id": "case_0031", "images": ["images/placeholder_0031.png"], "question": "Planning for sinus-related complaints. Brief history/status: Betolvex, Omeprazole, Calcichew-D3, Trulicity, Losartan. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 16–26.", "answer": "Review of CBCT volume dated 241215. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 24: bone height ≈ 20.9 mm; implant space ≈ 14.1 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 15.7 mm; implant space ≈ 8.3 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 9.5 mm; implant space ≈ 5.0 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 16.2 mm; implant space ≈ 11.0 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 10.0 mm; implant space ≈ 1.1 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 7.7 mm; implant space ≈ 3.7 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 21.2 mm; implant space ≈ 13.9 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 12.7 mm; implant space ≈ 9.3 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 6.9 mm; implant space ≈ 3.8 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 45; lamina dura loss noted. Smaller radiolucency at 25. Impression: Vertical root fracture suspected at 32; recommend clinical correlation."}
{"id": "case_0032", "images": ["images/placeholder_0032.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Levaxin, Atorvastatin, Bricanyl, Insulin glargine, Losartan, Amlodipine. Desired treatment: Please report bone height and available implant space for regions 35–45 and 16–26.", "answer": "Review of CBCT volume dated 220723. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 26: bone height ≈ 14.4 mm; implant space ≈ 10.8 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 20.7 mm; implant space ≈ 14.5 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 9.7 mm; implant space ≈ 3.1 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 9.6 mm; implant space ≈ 3.5 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 14.4 mm; implant space ≈ 7.8 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 10.2 mm; implant space ≈ 2.1 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 11.2 mm; implant space ≈ 2.7 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 10.5 mm; implant space ≈ 5.4 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 8.8 mm; implant space ≈ 3.5 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 6.1 mm; implant space ≈ 4.6 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 33; lamina dura loss noted. Smaller radiolucency at 11. Impression: Cyst-like well-defined radiolucency near 15, likely radicular cyst."}
{"id": "case_0033", "images": ["images/placeholder_0033.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Amlodipine, Calcichew-D3, Atorvastatin, Omeprazole, Esomeprazole, Levaxin, Duloxetine, Betolvex. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.", "answer": "Review of CBCT volume dated 241207. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 37: bone height ≈ 8.3 mm; implant space ≈ 3.9 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 4.4 mm; implant space ≈ 2.0 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 9.8 mm; implant space ≈ 5.3 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 10.0 mm; implant space ≈ 2.5 mm; nearest critical structure: incisive canal. Region 21: bone height ≈ 9.7 mm; implant space ≈ 1.2 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 8.7 mm; implant space ≈ 0.4 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 18.4 mm; implant space ≈ 9.6 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 10.1 mm; implant space ≈ 2.9 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Periapical radiolucency near 38; lamina dura loss noted. Smaller radiolucency at 28. Impression: Findings consistent with chronic apical periodontitis at 36 and 24."}
{"id": "case_0034", "images": ["images/placeholder_0034.png"], "question": "Planning for full-arch restoration. Brief history/status: Calcichew-D3, Bricanyl, Bufomix Easyhaler, Atorvastatin, Insulin glargine, Losartan, Omeprazole, Betolvex. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 35–45.", "answer": "Review of CBCT volume dated 220127. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 35: bone height ≈ 4.9 mm; implant space ≈ 0.3 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 7.2 mm; implant space ≈ 0.5 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 19.6 mm; implant space ≈ 10.9 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 13.6 mm; implant space ≈ 4.6 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 17.9 mm; implant space ≈ 12.8 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 17.5 mm; implant space ≈ 14.1 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 4.2 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 6.6 mm; implant space ≈ 3.4 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 9.7 mm; implant space ≈ 7.6 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0035", "images": ["images/placeholder_0035.png"], "question": "Planning for review of post-implant healing. Brief history/status: Bricanyl, Trulicity, Duroferon, Losartan, Metoprolol, Amlodipine, Calcichew-D3, Omeprazole. Desired treatment: Evaluate periapical status of teeth 12, 17, and 47, and overall sinus condition.", "answer": "Review of CBCT volume dated 220528. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 28: bone height ≈ 19.5 mm; implant space ≈ 10.9 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 10.7 mm; implant space ≈ 7.6 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 15.8 mm; implant space ≈ 12.8 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 18.5 mm; implant space ≈ 16.5 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 21.1 mm; implant space ≈ 12.3 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 16.9 mm; implant space ≈ 15.1 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 13.1 mm; implant space ≈ 5.5 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 14.6 mm; implant space ≈ 6.6 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 19.2 mm; implant space ≈ 14.0 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 16.6 mm; implant space ≈ 12.5 mm; nearest critical structure: nasal floor. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0036", "images": ["images/placeholder_0036.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Trulicity, Metoprolol, Levaxin, Bufomix Easyhaler, Losartan, Betolvex. Desired treatment: Quantify vertical bone loss around implants in 35–45 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 240209. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 42: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 7.9 mm; implant space ≈ 0.2 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 11.6 mm; implant space ≈ 8.4 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 5.4 mm; implant space ≈ 0.8 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 16.0 mm; implant space ≈ 9.4 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 11.4 mm; implant space ≈ 6.6 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 10.4 mm; implant space ≈ 7.9 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 10.5 mm; implant space ≈ 7.8 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 11.4 mm; implant space ≈ 5.1 mm; nearest critical structure: sinus floor. Region 48: bone height ≈ 5.0 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 14; lamina dura loss noted. Smaller radiolucency at 24. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Vertical root fracture suspected at 28; recommend clinical correlation."}
{"id": "case_0037", "images": ["images/placeholder_0037.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Bricanyl, Bufomix Easyhaler, Levaxin, Duloxetine, Metoprolol. Desired treatment: Report any signs of peri-implantitis and root resorption in 16–26.", "answer": "Review of CBCT volume dated 240325. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 33: bone height ≈ 10.9 mm; implant space ≈ 3.3 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 18.4 mm; implant space ≈ 13.3 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 20.3 mm; implant space ≈ 17.6 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 8.4 mm; implant space ≈ 5.8 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 12.0 mm; implant space ≈ 4.8 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 13.3 mm; implant space ≈ 7.0 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 21.9 mm; implant space ≈ 19.9 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 13.8 mm; implant space ≈ 9.8 mm; nearest critical structure: sinus floor. Region 48: bone height ≈ 10.3 mm; implant space ≈ 8.2 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 19.2 mm; implant space ≈ 13.9 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 27; lamina dura loss noted. Smaller radiolucency at 45. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Peri-implant bone loss at 36 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0038", "images": ["images/placeholder_0038.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Levaxin, Bufomix Easyhaler, Duroferon, Amlodipine, Insulin glargine, Omeprazole. Desired treatment: Evaluate periapical status of teeth 14, 47, and 21, and overall sinus condition.", "answer": "Review of CBCT volume dated 240223. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 48: bone height ≈ 18.3 mm; implant space ≈ 14.5 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 9.6 mm; implant space ≈ 3.0 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 17.9 mm; implant space ≈ 10.2 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 17.8 mm; implant space ≈ 12.9 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 16.9 mm; implant space ≈ 8.0 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 18.6 mm; implant space ≈ 12.7 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 19.4 mm; implant space ≈ 12.9 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 20.0 mm; implant space ≈ 17.5 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 21.1 mm; implant space ≈ 18.4 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 5.8 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 21; lamina dura loss noted. Smaller radiolucency at 32. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0039", "images": ["images/placeholder_0039.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Bufomix Easyhaler, Losartan, Levaxin, Omeprazole, Trulicity, Insulin glargine, Bricanyl, Esomeprazole. Desired treatment: Assess mandibular canal course and distance to apices in 37–47.", "answer": "Review of CBCT volume dated 231113. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 46: bone height ≈ 14.6 mm; implant space ≈ 8.2 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 6.4 mm; implant space ≈ 3.6 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 11.1 mm; implant space ≈ 6.0 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 8.2 mm; implant space ≈ 2.2 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 12.0 mm; implant space ≈ 3.8 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 14.6 mm; implant space ≈ 10.1 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 7.9 mm; implant space ≈ 3.9 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 21.7 mm; implant space ≈ 14.4 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 4.9 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 16.7 mm; implant space ≈ 11.8 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0040", "images": ["images/placeholder_0040.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Trulicity, Amlodipine, Metoprolol, Omeprazole, Losartan, Atorvastatin. Desired treatment: Assess mandibular canal course and distance to apices in 35–45.", "answer": "Review of CBCT volume dated 220212. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 14: bone height ≈ 19.7 mm; implant space ≈ 16.9 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 19.3 mm; implant space ≈ 15.7 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 11.3 mm; implant space ≈ 7.9 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 16.1 mm; implant space ≈ 14.6 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 6.7 mm; implant space ≈ 0.8 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 17.0 mm; implant space ≈ 15.1 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 14.4 mm; implant space ≈ 6.6 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 21.4 mm; implant space ≈ 15.1 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 17.3 mm; implant space ≈ 13.2 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 16.1 mm; implant space ≈ 10.1 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 22; lamina dura loss noted. Smaller radiolucency at 17. Impression: Peri-implant bone loss at 42 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0041", "images": ["images/placeholder_0041.png"], "question": "Planning for review of post-implant healing. Brief history/status: Esomeprazole, Amlodipine, Bufomix Easyhaler, Trulicity, Duroferon, Duloxetine, Insulin glargine, Metoprolol. Desired treatment: Check the bone healing and trabecular fill post extraction sites 16–26.", "answer": "Review of CBCT volume dated 240120. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 46: bone height ≈ 16.6 mm; implant space ≈ 12.6 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 13.3 mm; implant space ≈ 10.8 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 10.3 mm; implant space ≈ 5.9 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 21.9 mm; implant space ≈ 18.6 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 20.3 mm; implant space ≈ 13.0 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 11.4 mm; implant space ≈ 5.0 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 8.5 mm; implant space ≈ 0.1 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 17.2 mm; implant space ≈ 8.4 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 17.6 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 11; lamina dura loss noted. Smaller radiolucency at 35. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0042", "images": ["images/placeholder_0042.png"], "question": "Planning for sinus-related complaints. Brief history/status: Bricanyl, Trulicity, Bufomix Easyhaler, Insulin glargine, Losartan, Esomeprazole, Duroferon. Desired treatment: Provide measurements relevant to guided surgery stent planning for 35–45 and 16–26.", "answer": "Review of CBCT volume dated 230818. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 42: bone height ≈ 9.6 mm; implant space ≈ 1.8 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 14.9 mm; implant space ≈ 12.8 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 17.3 mm; implant space ≈ 15.6 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 7.4 mm; implant space ≈ 4.8 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 12.9 mm; implant space ≈ 4.9 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 11.6 mm; implant space ≈ 8.6 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 10.4 mm; implant space ≈ 8.8 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 19.2 mm; implant space ≈ 14.3 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 21.9 mm; implant space ≈ 19.8 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 17.4 mm; implant space ≈ 14.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 48; lamina dura loss noted. Smaller radiolucency at 16. Impression: Vertical root fracture suspected at 41; recommend clinical correlation."}
{"id": "case_0043", "images": ["images/placeholder_0043.png"], "question": "Planning for sinus-related complaints. Brief history/status: Amlodipine, Omeprazole, Levaxin, Losartan, Calcichew-D3, Esomeprazole. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 36–46.", "answer": "Review of CBCT volume dated 230703. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 28: bone height ≈ 15.4 mm; implant space ≈ 9.7 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 21.7 mm; implant space ≈ 17.9 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 10.8 mm; implant space ≈ 3.6 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 11.0 mm; implant space ≈ 2.9 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 7.7 mm; implant space ≈ 1.2 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 14.4 mm; implant space ≈ 12.0 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 12.2 mm; implant space ≈ 10.1 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 20.9 mm; implant space ≈ 14.7 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 19.4 mm; implant space ≈ 16.3 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 4.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0044", "images": ["images/placeholder_0044.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Losartan, Atorvastatin, Levaxin, Calcichew-D3, Esomeprazole. Desired treatment: Review the sinus floor elevation and ridge thickness for 36–46.", "answer": "Review of CBCT volume dated 250315. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 16: bone height ≈ 8.9 mm; implant space ≈ 0.8 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 20.2 mm; implant space ≈ 14.5 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 17.7 mm; implant space ≈ 16.2 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 20.1 mm; implant space ≈ 15.5 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 10.1 mm; implant space ≈ 8.4 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 12.1 mm; implant space ≈ 4.0 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 18.5 mm; implant space ≈ 10.8 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 20.6 mm; implant space ≈ 17.9 mm; nearest critical structure: sinus floor. Region 22: bone height ≈ 21.4 mm; implant space ≈ 18.2 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 19.1 mm; implant space ≈ 15.3 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 47; lamina dura loss noted. Smaller radiolucency at 33. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0045", "images": ["images/placeholder_0045.png"], "question": "Planning for sinus-related complaints. Brief history/status: Metoprolol, Trulicity, Insulin glargine, Levaxin, Duloxetine, Losartan, Esomeprazole, Atorvastatin. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 15–25.", "answer": "Review of CBCT volume dated 220824. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 48: bone height ≈ 13.6 mm; implant space ≈ 11.2 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 18.5 mm; implant space ≈ 13.2 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 21.2 mm; implant space ≈ 17.1 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 22.0 mm; implant space ≈ 18.5 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 9.5 mm; implant space ≈ 4.9 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 8.7 mm; implant space ≈ 2.1 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 4.2 mm; implant space ≈ 1.9 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 12.2 mm; implant space ≈ 10.5 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 21.1 mm; implant space ≈ 15.8 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 10.0 mm; implant space ≈ 5.2 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 37; lamina dura loss noted. Smaller radiolucency at 38. Impression: Cyst-like well-defined radiolucency near 36, likely radicular cyst."}
{"id": "case_0046", "images": ["images/placeholder_0046.png"], "question": "Planning for implant planning evaluation. Brief history/status: Trulicity, Omeprazole, Losartan, Atorvastatin, Duloxetine, Amlodipine, Levaxin, Bufomix Easyhaler. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 240920. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 47: bone height ≈ 7.0 mm; implant space ≈ 2.2 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 20.4 mm; implant space ≈ 12.6 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 20.3 mm; implant space ≈ 12.4 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 16.0 mm; implant space ≈ 7.7 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 21.7 mm; implant space ≈ 14.6 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 4.4 mm; implant space ≈ 0.1 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 10.6 mm; implant space ≈ 7.2 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 7.1 mm; implant space ≈ 2.1 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 18.7 mm; implant space ≈ 16.3 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 12.9 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0047", "images": ["images/placeholder_0047.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Duloxetine, Bricanyl, Metoprolol, Duroferon, Esomeprazole, Trulicity, Losartan, Calcichew-D3, Insulin glargine. Desired treatment: Quantify vertical bone loss around implants in 37–47 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 230720. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 26: bone height ≈ 12.0 mm; implant space ≈ 6.8 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 20.5 mm; implant space ≈ 17.6 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 15.2 mm; implant space ≈ 7.5 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 21.7 mm; implant space ≈ 18.2 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 11.3 mm; implant space ≈ 7.8 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 5.8 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 20.6 mm; implant space ≈ 18.6 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 5.0 mm; implant space ≈ 2.2 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 19.4 mm; implant space ≈ 13.8 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 6.5 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Periapical radiolucency near 37; lamina dura loss noted. Smaller radiolucency at 38. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Findings consistent with chronic apical periodontitis at 13 and 27."}
{"id": "case_0048", "images": ["images/placeholder_0048.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Atorvastatin, Duroferon, Levaxin, Amlodipine, Losartan, Omeprazole, Bufomix Easyhaler, Esomeprazole, Betolvex. Desired treatment: Check the bone healing and trabecular fill post extraction sites 35–45.", "answer": "Review of CBCT volume dated 230428. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 17: bone height ≈ 17.4 mm; implant space ≈ 9.9 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 18.5 mm; implant space ≈ 16.9 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 18.4 mm; implant space ≈ 9.8 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 10.6 mm; implant space ≈ 3.4 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 9.1 mm; implant space ≈ 2.6 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 14.5 mm; implant space ≈ 9.6 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 15.5 mm; implant space ≈ 10.2 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 20.7 mm; implant space ≈ 11.8 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 14.2 mm; implant space ≈ 9.5 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 13.6 mm; implant space ≈ 9.4 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Impaction of third molar in quadrant 3 with mesioangular inclination."}
{"id": "case_0049", "images": ["images/placeholder_0049.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Calcichew-D3, Duroferon, Metoprolol, Duloxetine, Bricanyl, Bufomix Easyhaler. Desired treatment: Check the bone healing and trabecular fill post extraction sites 16–26.", "answer": "Review of CBCT volume dated 250219. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 46: bone height ≈ 14.3 mm; implant space ≈ 7.7 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 18.6 mm; implant space ≈ 12.6 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 13.5 mm; implant space ≈ 6.8 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 8.1 mm; implant space ≈ 2.3 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 20.1 mm; implant space ≈ 12.6 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 6.3 mm; implant space ≈ 3.2 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 16.0 mm; implant space ≈ 9.1 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 18.6 mm; implant space ≈ 13.1 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 14.9 mm; implant space ≈ 8.9 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 21.4 mm; implant space ≈ 16.8 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0050", "images": ["images/placeholder_0050.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Trulicity, Levaxin, Esomeprazole, Duroferon, Duloxetine, Metoprolol, Omeprazole, Betolvex. Desired treatment: Report any signs of peri-implantitis and root resorption in 37–47.", "answer": "Review of CBCT volume dated 250220. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 27: bone height ≈ 13.9 mm; implant space ≈ 5.0 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 17.1 mm; implant space ≈ 10.3 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 19.9 mm; implant space ≈ 17.4 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 5.6 mm; implant space ≈ 3.8 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 14.1 mm; implant space ≈ 5.9 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 17.2 mm; implant space ≈ 13.6 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 21.9 mm; implant space ≈ 17.4 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 12.6 mm; implant space ≈ 7.0 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 21.5 mm; implant space ≈ 16.5 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination."}
{"id": "case_0051", "images": ["images/placeholder_0051.png"], "question": "Planning for follow-up after extraction. Brief history/status: Betolvex, Trulicity, Duloxetine, Metoprolol, Levaxin, Atorvastatin. Desired treatment: Review the sinus floor elevation and ridge thickness for 16–26.", "answer": "Review of CBCT volume dated 210913. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 24: bone height ≈ 13.3 mm; implant space ≈ 5.4 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 9.5 mm; implant space ≈ 5.3 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 16.4 mm; implant space ≈ 10.3 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 19.2 mm; implant space ≈ 17.5 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 21.6 mm; implant space ≈ 17.6 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 19.5 mm; implant space ≈ 11.6 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 19.7 mm; implant space ≈ 11.0 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 5.4 mm; implant space ≈ 1.6 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 18.2 mm; implant space ≈ 16.6 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 6.5 mm; implant space ≈ 2.4 mm; nearest critical structure: incisive canal. Periapical radiolucency near 25; lamina dura loss noted. Smaller radiolucency at 13. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Cyst-like well-defined radiolucency near 33, likely radicular cyst."}
{"id": "case_0052", "images": ["images/placeholder_0052.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Duroferon, Calcichew-D3, Bufomix Easyhaler, Levaxin, Trulicity, Losartan, Duloxetine, Bricanyl. Desired treatment: Measure crest-to-canal distances mandibularly in 15–25, and implant feasibility maxillary 35–45.", "answer": "Review of CBCT volume dated 230410. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 34: bone height ≈ 20.5 mm; implant space ≈ 16.9 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 14.4 mm; implant space ≈ 10.7 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 16.0 mm; implant space ≈ 12.6 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 18.7 mm; implant space ≈ 15.5 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 15.5 mm; implant space ≈ 11.2 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 12.9 mm; implant space ≈ 4.6 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 10.2 mm; implant space ≈ 5.2 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 21.1 mm; implant space ≈ 12.2 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 14.0 mm; implant space ≈ 11.9 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 7.8 mm; implant space ≈ 1.7 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Impaction of third molar in quadrant 4 with mesioangular inclination."}
{"id": "case_0053", "images": ["images/placeholder_0053.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Losartan, Metoprolol, Betolvex, Trulicity, Duroferon. Desired treatment: Measure crest-to-canal distances mandibularly in 15–25, and implant feasibility maxillary 37–47.", "answer": "Review of CBCT volume dated 250407. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 38: bone height ≈ 19.7 mm; implant space ≈ 15.8 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 20.5 mm; implant space ≈ 14.2 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 9.9 mm; implant space ≈ 5.2 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 12.6 mm; implant space ≈ 6.4 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 21.0 mm; implant space ≈ 17.0 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 9.9 mm; implant space ≈ 7.8 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 5.8 mm; implant space ≈ 3.3 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 4.5 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 15.4 mm; implant space ≈ 12.6 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 4.7 mm; implant space ≈ 3.2 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 32; lamina dura loss noted. Smaller radiolucency at 15. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0054", "images": ["images/placeholder_0054.png"], "question": "Planning for implant site evaluation. Brief history/status: Esomeprazole, Amlodipine, Bufomix Easyhaler, Levaxin, Trulicity, Duroferon, Betolvex, Calcichew-D3, Losartan. Desired treatment: Assess mandibular canal course and distance to apices in 17–27.", "answer": "Review of CBCT volume dated 210517. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 32: bone height ≈ 13.0 mm; implant space ≈ 10.4 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 8.9 mm; implant space ≈ 3.7 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 8.8 mm; implant space ≈ 1.2 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 19.9 mm; implant space ≈ 15.8 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 9.7 mm; implant space ≈ 5.8 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 18.4 mm; implant space ≈ 9.4 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 7.3 mm; implant space ≈ 1.7 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 19.3 mm; implant space ≈ 16.2 mm; nearest critical structure: mandibular canal. Periapical radiolucency near 21; lamina dura loss noted. Smaller radiolucency at 34. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0055", "images": ["images/placeholder_0055.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Duroferon, Trulicity, Amlodipine, Omeprazole, Duloxetine, Metoprolol. Desired treatment: Quantify vertical bone loss around implants in 35–45 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 230912. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 12: bone height ≈ 18.4 mm; implant space ≈ 9.6 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 9.2 mm; implant space ≈ 7.3 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 6.6 mm; implant space ≈ 3.0 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 7.0 mm; implant space ≈ 5.4 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 11.6 mm; implant space ≈ 5.7 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 12.0 mm; implant space ≈ 6.1 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 11.6 mm; implant space ≈ 6.7 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 10.6 mm; implant space ≈ 3.8 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 10.4 mm; implant space ≈ 5.7 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 12.3 mm; implant space ≈ 9.9 mm; nearest critical structure: anterior loop. Periapical radiolucency near 11; lamina dura loss noted. Smaller radiolucency at 21. Impression: Cyst-like well-defined radiolucency near 14, likely radicular cyst."}
{"id": "case_0056", "images": ["images/placeholder_0056.png"], "question": "Planning for full-arch restoration. Brief history/status: Bufomix Easyhaler, Levaxin, Betolvex, Duloxetine, Calcichew-D3, Amlodipine, Omeprazole, Bricanyl. Desired treatment: Assess mandibular canal course and distance to apices in 36–46.", "answer": "Review of CBCT volume dated 220210. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 12: bone height ≈ 10.6 mm; implant space ≈ 7.1 mm; nearest critical structure: sinus floor. Region 22: bone height ≈ 20.7 mm; implant space ≈ 17.6 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 8.4 mm; implant space ≈ 5.9 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 20.7 mm; implant space ≈ 19.0 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 13.2 mm; implant space ≈ 5.7 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 17.8 mm; implant space ≈ 13.9 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 6.5 mm; implant space ≈ 0.9 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 20.0 mm; implant space ≈ 18.5 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 18.9 mm; implant space ≈ 12.3 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 10.7 mm; implant space ≈ 4.5 mm; nearest critical structure: anterior loop. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0057", "images": ["images/placeholder_0057.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Metoprolol, Duroferon, Bricanyl, Losartan, Esomeprazole, Omeprazole, Calcichew-D3, Amlodipine. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 251205. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 25: bone height ≈ 8.1 mm; implant space ≈ 3.5 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 13.4 mm; implant space ≈ 8.7 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 14.7 mm; implant space ≈ 10.1 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 12.0 mm; implant space ≈ 10.1 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 14.2 mm; implant space ≈ 9.8 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 6.2 mm; implant space ≈ 2.3 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 12.7 mm; implant space ≈ 7.4 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 14.3 mm; implant space ≈ 9.4 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 19.6 mm; implant space ≈ 17.5 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0058", "images": ["images/placeholder_0058.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Duroferon, Amlodipine, Insulin glargine, Bufomix Easyhaler, Omeprazole, Betolvex, Levaxin, Losartan. Desired treatment: Check the bone healing and trabecular fill post extraction sites 35–45.", "answer": "Review of CBCT volume dated 230522. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 26: bone height ≈ 22.0 mm; implant space ≈ 15.3 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 14.7 mm; implant space ≈ 5.9 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 21.5 mm; implant space ≈ 15.3 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 11.7 mm; implant space ≈ 4.0 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 19.2 mm; implant space ≈ 12.5 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 14.0 mm; implant space ≈ 5.3 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 10.1 mm; implant space ≈ 2.8 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 13.4 mm; implant space ≈ 9.4 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 10.8 mm; implant space ≈ 7.1 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0059", "images": ["images/placeholder_0059.png"], "question": "Planning for implant planning evaluation. Brief history/status: Losartan, Esomeprazole, Levaxin, Duroferon, Calcichew-D3. Desired treatment: Assess mandibular canal course and distance to apices in 16–26.", "answer": "Review of CBCT volume dated 201206. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 22: bone height ≈ 16.4 mm; implant space ≈ 13.4 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 13.2 mm; implant space ≈ 4.2 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 7.2 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 4.3 mm; implant space ≈ 2.8 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 18.1 mm; implant space ≈ 10.8 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 6.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 9.7 mm; implant space ≈ 6.3 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 8.3 mm; implant space ≈ 1.8 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 10.4 mm; implant space ≈ 3.6 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 12.8 mm; implant space ≈ 5.0 mm; nearest critical structure: incisive canal. Periapical radiolucency near 16; lamina dura loss noted. Smaller radiolucency at 18. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination."}
{"id": "case_0060", "images": ["images/placeholder_0060.png"], "question": "Planning for sinus-related complaints. Brief history/status: Amlodipine, Losartan, Levaxin, Calcichew-D3, Duloxetine, Trulicity, Omeprazole, Insulin glargine. Desired treatment: Check the bone healing and trabecular fill post extraction sites 37–47.", "answer": "Review of CBCT volume dated 200314. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 24: bone height ≈ 20.8 mm; implant space ≈ 13.2 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 16.5 mm; implant space ≈ 10.8 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 20.5 mm; implant space ≈ 12.2 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 14.8 mm; implant space ≈ 11.0 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 4.5 mm; implant space ≈ 2.9 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 12.9 mm; implant space ≈ 7.8 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 8.6 mm; implant space ≈ 5.0 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 17.6 mm; implant space ≈ 15.8 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 20.1 mm; implant space ≈ 16.5 mm; nearest critical structure: mandibular canal. Periapical radiolucency near 27; lamina dura loss noted. Smaller radiolucency at 17. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0061", "images": ["images/placeholder_0061.png"], "question": "Planning for follow-up after extraction. Brief history/status: Duloxetine, Betolvex, Esomeprazole, Atorvastatin, Insulin glargine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 36–46 and 37–47.", "answer": "Review of CBCT volume dated 241021. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 14: bone height ≈ 10.2 mm; implant space ≈ 4.3 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 19.7 mm; implant space ≈ 10.9 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 11.7 mm; implant space ≈ 4.7 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 5.6 mm; implant space ≈ 2.5 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 20.1 mm; implant space ≈ 18.2 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 9.3 mm; implant space ≈ 3.6 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 7.3 mm; implant space ≈ 0.8 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 22.0 mm; implant space ≈ 17.5 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 16.7 mm; implant space ≈ 13.1 mm; nearest critical structure: mandibular canal. Periapical radiolucency near 44; lamina dura loss noted. Smaller radiolucency at 25. Impression: Findings consistent with chronic apical periodontitis at 47 and 31."}
{"id": "case_0062", "images": ["images/placeholder_0062.png"], "question": "Planning for implant planning evaluation. Brief history/status: Esomeprazole, Bufomix Easyhaler, Metoprolol, Atorvastatin, Amlodipine, Losartan, Omeprazole. Desired treatment: Assess mandibular canal course and distance to apices in 17–27.", "answer": "Review of CBCT volume dated 220811. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 48: bone height ≈ 8.6 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 11.3 mm; implant space ≈ 4.4 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 20.0 mm; implant space ≈ 16.8 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 6.5 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 21.0 mm; implant space ≈ 16.8 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 11.9 mm; implant space ≈ 6.2 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 7.3 mm; implant space ≈ 4.6 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 21.9 mm; implant space ≈ 17.8 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 14.7 mm; implant space ≈ 6.3 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 13.4 mm; implant space ≈ 10.9 mm; nearest critical structure: nasal floor. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0063", "images": ["images/placeholder_0063.png"], "question": "Planning for full-arch restoration. Brief history/status: Amlodipine, Losartan, Duroferon, Omeprazole, Betolvex, Trulicity. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 220702. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 35: bone height ≈ 18.7 mm; implant space ≈ 13.1 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 21.3 mm; implant space ≈ 14.6 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 6.2 mm; implant space ≈ 2.4 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 18.4 mm; implant space ≈ 15.4 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 5.5 mm; implant space ≈ 3.6 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 19.7 mm; implant space ≈ 14.0 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 5.2 mm; implant space ≈ 0.7 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 6.0 mm; implant space ≈ 4.0 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 9.3 mm; implant space ≈ 4.0 mm; nearest critical structure: mental foramen. Region 37: bone height ≈ 21.9 mm; implant space ≈ 14.2 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Cyst-like well-defined radiolucency near 41, likely radicular cyst."}
{"id": "case_0064", "images": ["images/placeholder_0064.png"], "question": "Planning for full-arch restoration. Brief history/status: Bufomix Easyhaler, Losartan, Trulicity, Levaxin, Insulin glargine. Desired treatment: Assess mandibular canal course and distance to apices in 15–25.", "answer": "Review of CBCT volume dated 241204. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 15: bone height ≈ 15.6 mm; implant space ≈ 12.1 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 13.2 mm; implant space ≈ 6.0 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 18.2 mm; implant space ≈ 12.3 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 6.5 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 6.3 mm; implant space ≈ 1.3 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 9.7 mm; implant space ≈ 4.4 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 17.9 mm; implant space ≈ 14.9 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 17.8 mm; implant space ≈ 15.1 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 21.1 mm; implant space ≈ 12.9 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination."}
{"id": "case_0065", "images": ["images/placeholder_0065.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Omeprazole, Amlodipine, Levaxin, Losartan, Bricanyl, Esomeprazole, Bufomix Easyhaler, Metoprolol, Betolvex. Desired treatment: Check the bone healing and trabecular fill post extraction sites 35–45.", "answer": "Review of CBCT volume dated 200527. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 17: bone height ≈ 7.1 mm; implant space ≈ 5.1 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 6.1 mm; implant space ≈ 3.1 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 9.2 mm; implant space ≈ 4.3 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 17.3 mm; implant space ≈ 10.2 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 18.4 mm; implant space ≈ 11.6 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 7.7 mm; implant space ≈ 3.9 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 5.0 mm; implant space ≈ 1.4 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 7.2 mm; implant space ≈ 2.5 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 8.9 mm; implant space ≈ 0.8 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 8.4 mm; implant space ≈ 1.3 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 33; lamina dura loss noted. Smaller radiolucency at 31. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0066", "images": ["images/placeholder_0066.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Duloxetine, Betolvex, Metoprolol, Trulicity, Omeprazole, Calcichew-D3, Insulin glargine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 36–46 and 15–25.", "answer": "Review of CBCT volume dated 250305. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 35: bone height ≈ 6.8 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 18.0 mm; implant space ≈ 11.5 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 7.1 mm; implant space ≈ 5.2 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 15.7 mm; implant space ≈ 10.2 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 8.9 mm; implant space ≈ 4.1 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 10.5 mm; implant space ≈ 3.7 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 18.8 mm; implant space ≈ 11.6 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 5.0 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 7.4 mm; implant space ≈ 3.3 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Findings consistent with chronic apical periodontitis at 22 and 27."}
{"id": "case_0067", "images": ["images/placeholder_0067.png"], "question": "Planning for follow-up after extraction. Brief history/status: Betolvex, Omeprazole, Metoprolol, Trulicity, Calcichew-D3. Desired treatment: Provide measurements relevant to guided surgery stent planning for 35–45 and 35–45.", "answer": "Review of CBCT volume dated 220713. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 17: bone height ≈ 17.5 mm; implant space ≈ 14.0 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 4.9 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 19.9 mm; implant space ≈ 13.8 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 4.2 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 14.5 mm; implant space ≈ 9.3 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 8.5 mm; implant space ≈ 5.6 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 10.3 mm; implant space ≈ 8.7 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 4.0 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 17.7 mm; implant space ≈ 14.1 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 18.2 mm; implant space ≈ 13.1 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 44; lamina dura loss noted. Smaller radiolucency at 38. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0068", "images": ["images/placeholder_0068.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Calcichew-D3, Insulin glargine, Omeprazole, Esomeprazole, Betolvex, Losartan. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.", "answer": "Review of CBCT volume dated 200225. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 23: bone height ≈ 8.2 mm; implant space ≈ 0.6 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 18.5 mm; implant space ≈ 15.8 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 10.7 mm; implant space ≈ 8.6 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 16.1 mm; implant space ≈ 10.8 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 7.7 mm; implant space ≈ 1.1 mm; nearest critical structure: incisive canal. Region 21: bone height ≈ 19.0 mm; implant space ≈ 11.9 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 12.8 mm; implant space ≈ 8.9 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 12.8 mm; implant space ≈ 6.8 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 6.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 18.9 mm; implant space ≈ 13.8 mm; nearest critical structure: nasal floor. Periapical radiolucency near 26; lamina dura loss noted. Smaller radiolucency at 11. Impression: Findings consistent with chronic apical periodontitis at 46 and 24."}
{"id": "case_0069", "images": ["images/placeholder_0069.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Metoprolol, Duloxetine, Duroferon, Calcichew-D3, Omeprazole, Esomeprazole. Desired treatment: Evaluate periapical status of teeth 45, 46, and 33, and overall sinus condition.", "answer": "Review of CBCT volume dated 230221. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 34: bone height ≈ 16.5 mm; implant space ≈ 14.8 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 19.0 mm; implant space ≈ 11.9 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 15.0 mm; implant space ≈ 6.3 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 16.2 mm; implant space ≈ 10.2 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 17.1 mm; implant space ≈ 14.0 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 18.9 mm; implant space ≈ 15.2 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 9.6 mm; implant space ≈ 7.7 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 10.1 mm; implant space ≈ 5.3 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 9.6 mm; implant space ≈ 6.5 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 35; lamina dura loss noted. Smaller radiolucency at 26. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0070", "images": ["images/placeholder_0070.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Betolvex, Bricanyl, Duroferon, Levaxin, Atorvastatin, Amlodipine, Calcichew-D3, Insulin glargine, Metoprolol. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 35–45.", "answer": "Review of CBCT volume dated 230125. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 32: bone height ≈ 7.5 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 9.4 mm; implant space ≈ 3.3 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 16.8 mm; implant space ≈ 9.4 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 17.0 mm; implant space ≈ 9.7 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 21.0 mm; implant space ≈ 13.9 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 7.2 mm; implant space ≈ 5.3 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 11.4 mm; implant space ≈ 9.1 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 17.5 mm; implant space ≈ 11.5 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 21.4 mm; implant space ≈ 14.5 mm; nearest critical structure: nasal floor. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0071", "images": ["images/placeholder_0071.png"], "question": "Planning for sinus-related complaints. Brief history/status: Duloxetine, Atorvastatin, Levaxin, Metoprolol, Omeprazole, Bufomix Easyhaler, Calcichew-D3, Trulicity. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 250704. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 32: bone height ≈ 7.4 mm; implant space ≈ 5.8 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 7.7 mm; implant space ≈ 2.4 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 9.6 mm; implant space ≈ 0.7 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 13.5 mm; implant space ≈ 10.5 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 19.9 mm; implant space ≈ 13.7 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 14.6 mm; implant space ≈ 12.4 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 13.5 mm; implant space ≈ 7.8 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 20.7 mm; implant space ≈ 11.8 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 4.1 mm; implant space ≈ 1.2 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 19.1 mm; implant space ≈ 10.9 mm; nearest critical structure: nasal floor. Periapical radiolucency near 35; lamina dura loss noted. Smaller radiolucency at 21. Impression: Cyst-like well-defined radiolucency near 14, likely radicular cyst."}
{"id": "case_0072", "images": ["images/placeholder_0072.png"], "question": "Planning for review of post-implant healing. Brief history/status: Metoprolol, Omeprazole, Betolvex, Duroferon, Losartan, Trulicity, Insulin glargine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 16–26.", "answer": "Review of CBCT volume dated 230114. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 47: bone height ≈ 15.1 mm; implant space ≈ 10.8 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 9.7 mm; implant space ≈ 3.9 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 6.5 mm; implant space ≈ 4.8 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 16.9 mm; implant space ≈ 14.4 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 21.4 mm; implant space ≈ 14.4 mm; nearest critical structure: sinus floor. Region 22: bone height ≈ 10.7 mm; implant space ≈ 4.0 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 13.8 mm; implant space ≈ 11.1 mm; nearest critical structure: mental foramen. Region 27: bone height ≈ 15.6 mm; implant space ≈ 13.0 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 5.1 mm; implant space ≈ 0.5 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0073", "images": ["images/placeholder_0073.png"], "question": "Planning for implant site evaluation. Brief history/status: Betolvex, Bufomix Easyhaler, Duroferon, Omeprazole, Levaxin. Desired treatment: Measure crest-to-canal distances mandibularly in 36–46, and implant feasibility maxillary 16–26.", "answer": "Review of CBCT volume dated 210920. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 17: bone height ≈ 8.7 mm; implant space ≈ 2.4 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 9.3 mm; implant space ≈ 1.4 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 19.6 mm; implant space ≈ 11.4 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 20.9 mm; implant space ≈ 12.6 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 16.7 mm; implant space ≈ 9.6 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 21.1 mm; implant space ≈ 16.3 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 11.2 mm; implant space ≈ 4.6 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 14.0 mm; implant space ≈ 5.1 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 11.4 mm; implant space ≈ 8.0 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 14.8 mm; implant space ≈ 12.5 mm; nearest critical structure: nasal floor. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0074", "images": ["images/placeholder_0074.png"], "question": "Planning for review of post-implant healing. Brief history/status: Bricanyl, Atorvastatin, Omeprazole, Losartan, Esomeprazole, Duloxetine, Levaxin, Insulin glargine, Duroferon. Desired treatment: Quantify vertical bone loss around implants in 37–47 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 211011. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 48: bone height ≈ 15.1 mm; implant space ≈ 11.8 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 17.2 mm; implant space ≈ 8.6 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 12.0 mm; implant space ≈ 10.2 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 19.5 mm; implant space ≈ 12.1 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 18.1 mm; implant space ≈ 9.4 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 19.1 mm; implant space ≈ 17.2 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 5.6 mm; implant space ≈ 3.6 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 11.2 mm; implant space ≈ 4.3 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 13.2 mm; implant space ≈ 5.5 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 33; lamina dura loss noted. Smaller radiolucency at 15. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0075", "images": ["images/placeholder_0075.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Betolvex, Amlodipine, Duloxetine, Losartan, Duroferon, Bufomix Easyhaler, Calcichew-D3. Desired treatment: Please report bone height and available implant space for regions 37–47 and 15–25.", "answer": "Review of CBCT volume dated 250624. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 15: bone height ≈ 7.5 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 19.3 mm; implant space ≈ 14.2 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 8.7 mm; implant space ≈ 6.4 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 16.7 mm; implant space ≈ 14.3 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 11.9 mm; implant space ≈ 4.8 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 19.0 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 4.5 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 14.5 mm; implant space ≈ 11.5 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 9.3 mm; implant space ≈ 6.8 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 18.8 mm; implant space ≈ 10.1 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Vertical root fracture suspected at 47; recommend clinical correlation."}
{"id": "case_0076", "images": ["images/placeholder_0076.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Metoprolol, Duroferon, Insulin glargine, Omeprazole, Amlodipine, Levaxin, Bricanyl. Desired treatment: Provide measurements relevant to guided surgery stent planning for 35–45 and 36–46.", "answer": "Review of CBCT volume dated 251027. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 48: bone height ≈ 5.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 13.1 mm; implant space ≈ 8.2 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 7.5 mm; implant space ≈ 5.8 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 7.2 mm; implant space ≈ 3.9 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 5.0 mm; implant space ≈ 1.0 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 15.6 mm; implant space ≈ 10.1 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 21.6 mm; implant space ≈ 18.8 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 13.1 mm; implant space ≈ 5.9 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 21.9 mm; implant space ≈ 16.8 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 18.7 mm; implant space ≈ 10.8 mm; nearest critical structure: sinus floor. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0077", "images": ["images/placeholder_0077.png"], "question": "Planning for implant planning evaluation. Brief history/status: Esomeprazole, Bufomix Easyhaler, Losartan, Calcichew-D3, Levaxin, Metoprolol, Omeprazole. Desired treatment: Review the sinus floor elevation and ridge thickness for 15–25.", "answer": "Review of CBCT volume dated 251212. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 13: bone height ≈ 13.3 mm; implant space ≈ 11.2 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 20.0 mm; implant space ≈ 14.2 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 16.6 mm; implant space ≈ 9.2 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 16.1 mm; implant space ≈ 14.3 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 8.2 mm; implant space ≈ 6.3 mm; nearest critical structure: incisive canal. Region 21: bone height ≈ 19.5 mm; implant space ≈ 10.6 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 17.4 mm; implant space ≈ 15.8 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 16.2 mm; implant space ≈ 13.0 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 16.4 mm; implant space ≈ 12.3 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 14.5 mm; implant space ≈ 8.0 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 42; lamina dura loss noted. Smaller radiolucency at 37. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0078", "images": ["images/placeholder_0078.png"], "question": "Planning for full-arch restoration. Brief history/status: Metoprolol, Duloxetine, Betolvex, Duroferon, Amlodipine, Calcichew-D3, Esomeprazole, Trulicity. Desired treatment: Check the bone healing and trabecular fill post extraction sites 37–47.", "answer": "Review of CBCT volume dated 240118. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 31: bone height ≈ 15.4 mm; implant space ≈ 11.8 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 21.4 mm; implant space ≈ 12.9 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 11.1 mm; implant space ≈ 3.9 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 10.7 mm; implant space ≈ 4.5 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 10.8 mm; implant space ≈ 3.6 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 7.7 mm; implant space ≈ 2.0 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 11.2 mm; implant space ≈ 4.4 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 19.6 mm; implant space ≈ 12.6 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 7.5 mm; implant space ≈ 3.4 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Periapical radiolucency near 32; lamina dura loss noted. Smaller radiolucency at 16. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Peri-implant bone loss at 42 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0079", "images": ["images/placeholder_0079.png"], "question": "Planning for review of post-implant healing. Brief history/status: Omeprazole, Metoprolol, Calcichew-D3, Bufomix Easyhaler, Bricanyl, Atorvastatin, Losartan, Trulicity, Amlodipine. Desired treatment: Please report bone height and available implant space for regions 35–45 and 36–46.", "answer": "Review of CBCT volume dated 220620. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 25: bone height ≈ 7.9 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 5.5 mm; implant space ≈ 2.1 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 14.7 mm; implant space ≈ 12.8 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 20.7 mm; implant space ≈ 15.6 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 8.0 mm; implant space ≈ 3.2 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 10.2 mm; implant space ≈ 6.0 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 10.0 mm; implant space ≈ 8.3 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 13.6 mm; implant space ≈ 10.1 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 5.4 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 18.6 mm; implant space ≈ 13.9 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Peri-implant bone loss at 44 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0080", "images": ["images/placeholder_0080.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Calcichew-D3, Bricanyl, Levaxin, Bufomix Easyhaler, Atorvastatin, Omeprazole. Desired treatment: Provide measurements relevant to guided surgery stent planning for 35–45 and 35–45.", "answer": "Review of CBCT volume dated 230407. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 31: bone height ≈ 7.3 mm; implant space ≈ 4.2 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 7.4 mm; implant space ≈ 2.5 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 20.6 mm; implant space ≈ 13.4 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 17.9 mm; implant space ≈ 15.7 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 12.0 mm; implant space ≈ 9.1 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 21.3 mm; implant space ≈ 18.3 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 8.2 mm; implant space ≈ 4.6 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 15.4 mm; implant space ≈ 10.4 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 10.2 mm; implant space ≈ 7.3 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Impression: Peri-implant bone loss at 27 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0081", "images": ["images/placeholder_0081.png"], "question": "Planning for review of post-implant healing. Brief history/status: Losartan, Amlodipine, Betolvex, Calcichew-D3, Duloxetine. Desired treatment: Report any signs of peri-implantitis and root resorption in 16–26.", "answer": "Review of CBCT volume dated 210601. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 36: bone height ≈ 20.2 mm; implant space ≈ 14.5 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 20.1 mm; implant space ≈ 11.9 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 19.2 mm; implant space ≈ 15.1 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 5.8 mm; implant space ≈ 1.9 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 11.5 mm; implant space ≈ 7.5 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 21.2 mm; implant space ≈ 18.4 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 21.1 mm; implant space ≈ 16.8 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 12.8 mm; implant space ≈ 7.7 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 13.2 mm; implant space ≈ 8.3 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 12.7 mm; implant space ≈ 4.9 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 15; lamina dura loss noted. Smaller radiolucency at 16. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Vertical root fracture suspected at 18; recommend clinical correlation."}
{"id": "case_0082", "images": ["images/placeholder_0082.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Calcichew-D3, Insulin glargine, Amlodipine, Metoprolol, Betolvex, Duloxetine, Levaxin, Trulicity, Bufomix Easyhaler. Desired treatment: Check the bone healing and trabecular fill post extraction sites 16–26.", "answer": "Review of CBCT volume dated 250227. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 21: bone height ≈ 8.9 mm; implant space ≈ 2.6 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 12.5 mm; implant space ≈ 3.9 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 8.4 mm; implant space ≈ 0.8 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 9.9 mm; implant space ≈ 6.4 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 7.5 mm; implant space ≈ 5.0 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 6.7 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 12.8 mm; implant space ≈ 5.2 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 9.1 mm; implant space ≈ 5.6 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 21.2 mm; implant space ≈ 16.6 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 21; lamina dura loss noted. Smaller radiolucency at 41. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0083", "images": ["images/placeholder_0083.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Metoprolol, Insulin glargine, Bufomix Easyhaler, Omeprazole, Bricanyl. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 210416. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 12: bone height ≈ 20.9 mm; implant space ≈ 13.9 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 12.0 mm; implant space ≈ 8.4 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 8.0 mm; implant space ≈ 2.3 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 19.7 mm; implant space ≈ 12.3 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 13.6 mm; implant space ≈ 4.9 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 12.8 mm; implant space ≈ 11.1 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 5.1 mm; implant space ≈ 0.3 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 14.6 mm; implant space ≈ 12.7 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 10.1 mm; implant space ≈ 6.1 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 7.9 mm; implant space ≈ 4.4 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 47; lamina dura loss noted. Smaller radiolucency at 21. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0084", "images": ["images/placeholder_0084.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Duloxetine, Bricanyl, Bufomix Easyhaler, Duroferon, Omeprazole, Amlodipine, Metoprolol, Esomeprazole. Desired treatment: Review the sinus floor elevation and ridge thickness for 35–45.", "answer": "Review of CBCT volume dated 240511. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 42: bone height ≈ 10.7 mm; implant space ≈ 8.7 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 10.0 mm; implant space ≈ 3.5 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 19.1 mm; implant space ≈ 16.8 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 18.2 mm; implant space ≈ 10.6 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 20.2 mm; implant space ≈ 16.8 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 6.4 mm; implant space ≈ 0.9 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 13.8 mm; implant space ≈ 6.8 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 8.1 mm; implant space ≈ 6.5 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 14.5 mm; implant space ≈ 8.2 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Impaction of third molar in quadrant 4 with mesioangular inclination."}
{"id": "case_0085", "images": ["images/placeholder_0085.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Trulicity, Calcichew-D3, Betolvex, Metoprolol, Omeprazole, Amlodipine, Levaxin, Bufomix Easyhaler, Bricanyl. Desired treatment: Quantify vertical bone loss around implants in 17–27 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 200127. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 33: bone height ≈ 5.7 mm; implant space ≈ 3.1 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 16.7 mm; implant space ≈ 8.6 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 18.1 mm; implant space ≈ 14.0 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 10.4 mm; implant space ≈ 5.5 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 12.9 mm; implant space ≈ 10.4 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 13.2 mm; implant space ≈ 4.8 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 4.4 mm; implant space ≈ 0.7 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 7.3 mm; implant space ≈ 4.1 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 6.5 mm; implant space ≈ 2.5 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 14.2 mm; implant space ≈ 7.6 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0086", "images": ["images/placeholder_0086.png"], "question": "Planning for full-arch restoration. Brief history/status: Amlodipine, Metoprolol, Calcichew-D3, Duroferon, Insulin glargine, Esomeprazole. Desired treatment: Assess mandibular canal course and distance to apices in 36–46.", "answer": "Review of CBCT volume dated 210920. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 23: bone height ≈ 17.8 mm; implant space ≈ 10.2 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 14.2 mm; implant space ≈ 9.2 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 11.6 mm; implant space ≈ 7.4 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 9.9 mm; implant space ≈ 2.8 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 6.3 mm; implant space ≈ 2.3 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 16.8 mm; implant space ≈ 13.0 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 12.6 mm; implant space ≈ 9.9 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 9.3 mm; implant space ≈ 6.8 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 20.2 mm; implant space ≈ 16.9 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 27; lamina dura loss noted. Smaller radiolucency at 44. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0087", "images": ["images/placeholder_0087.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Duroferon, Losartan, Betolvex, Metoprolol, Omeprazole, Insulin glargine, Esomeprazole, Bricanyl. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 35–45.", "answer": "Review of CBCT volume dated 200214. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 13: bone height ≈ 13.6 mm; implant space ≈ 7.2 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 12.6 mm; implant space ≈ 6.0 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 6.5 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 11.8 mm; implant space ≈ 5.0 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 19.2 mm; implant space ≈ 14.1 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 11.4 mm; implant space ≈ 8.8 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 14.0 mm; implant space ≈ 11.3 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 14.4 mm; implant space ≈ 8.2 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 9.8 mm; implant space ≈ 0.9 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 18.8 mm; implant space ≈ 10.1 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0088", "images": ["images/placeholder_0088.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Insulin glargine, Bricanyl, Calcichew-D3, Amlodipine, Atorvastatin. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 37–47.", "answer": "Review of CBCT volume dated 230410. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 11: bone height ≈ 14.6 mm; implant space ≈ 12.9 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 4.5 mm; implant space ≈ 0.5 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 9.1 mm; implant space ≈ 3.2 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 17.4 mm; implant space ≈ 12.3 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 22.0 mm; implant space ≈ 18.1 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 21.7 mm; implant space ≈ 16.2 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 5.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 14.7 mm; implant space ≈ 9.5 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 4.4 mm; implant space ≈ 0.7 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 15.7 mm; implant space ≈ 10.4 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 28; lamina dura loss noted. Smaller radiolucency at 26. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Findings consistent with chronic apical periodontitis at 13 and 41."}
{"id": "case_0089", "images": ["images/placeholder_0089.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Trulicity, Calcichew-D3, Atorvastatin, Omeprazole, Bufomix Easyhaler, Metoprolol, Losartan. Desired treatment: Check the bone healing and trabecular fill post extraction sites 35–45.", "answer": "Review of CBCT volume dated 221119. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 25: bone height ≈ 18.0 mm; implant space ≈ 12.5 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 11.5 mm; implant space ≈ 8.6 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 5.0 mm; implant space ≈ 3.0 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 10.4 mm; implant space ≈ 5.1 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 17.1 mm; implant space ≈ 10.8 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 12.7 mm; implant space ≈ 5.3 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 10.2 mm; implant space ≈ 5.5 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 12.0 mm; implant space ≈ 8.5 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 12.9 mm; implant space ≈ 8.8 mm; nearest critical structure: mental foramen. Periapical radiolucency near 42; lamina dura loss noted. Smaller radiolucency at 31. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0090", "images": ["images/placeholder_0090.png"], "question": "Planning for sinus-related complaints. Brief history/status: Amlodipine, Betolvex, Duloxetine, Levaxin, Metoprolol, Duroferon, Esomeprazole, Bufomix Easyhaler, Atorvastatin. Desired treatment: Report any signs of peri-implantitis and root resorption in 16–26.", "answer": "Review of CBCT volume dated 210423. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 43: bone height ≈ 11.8 mm; implant space ≈ 7.8 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 11.2 mm; implant space ≈ 9.1 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 21.6 mm; implant space ≈ 17.2 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 18.7 mm; implant space ≈ 16.2 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 15.5 mm; implant space ≈ 13.2 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 9.6 mm; implant space ≈ 7.4 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 10.7 mm; implant space ≈ 5.7 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 14.6 mm; implant space ≈ 10.8 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 7.7 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 14.9 mm; implant space ≈ 12.4 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 48; lamina dura loss noted. Smaller radiolucency at 14. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0091", "images": ["images/placeholder_0091.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Bricanyl, Duloxetine, Duroferon, Calcichew-D3, Levaxin, Betolvex, Bufomix Easyhaler, Losartan. Desired treatment: Evaluate periapical status of teeth 44, 37, and 33, and overall sinus condition.", "answer": "Review of CBCT volume dated 200714. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 28: bone height ≈ 16.1 mm; implant space ≈ 9.3 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 22.0 mm; implant space ≈ 16.0 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 14.4 mm; implant space ≈ 12.3 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 20.2 mm; implant space ≈ 11.8 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 15.1 mm; implant space ≈ 11.5 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 9.5 mm; implant space ≈ 3.5 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 17.6 mm; implant space ≈ 10.9 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 6.0 mm; implant space ≈ 2.6 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 17.2 mm; implant space ≈ 9.1 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 41; lamina dura loss noted. Smaller radiolucency at 12. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0092", "images": ["images/placeholder_0092.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Calcichew-D3, Esomeprazole, Omeprazole, Betolvex, Amlodipine, Atorvastatin. Desired treatment: Please report bone height and available implant space for regions 15–25 and 16–26.", "answer": "Review of CBCT volume dated 240823. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 16: bone height ≈ 11.3 mm; implant space ≈ 8.9 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 10.0 mm; implant space ≈ 2.6 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 7.6 mm; implant space ≈ 1.9 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 21.9 mm; implant space ≈ 15.3 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 16.5 mm; implant space ≈ 12.8 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 19.2 mm; implant space ≈ 14.9 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 10.8 mm; implant space ≈ 6.5 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 19.0 mm; implant space ≈ 12.6 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 6.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 13.3 mm; implant space ≈ 6.1 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0093", "images": ["images/placeholder_0093.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Levaxin, Metoprolol, Bufomix Easyhaler, Bricanyl, Losartan, Omeprazole, Insulin glargine, Atorvastatin, Betolvex. Desired treatment: Check the bone healing and trabecular fill post extraction sites 17–27.", "answer": "Review of CBCT volume dated 251115. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 23: bone height ≈ 12.3 mm; implant space ≈ 3.3 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 6.0 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 6.7 mm; implant space ≈ 0.9 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 13.1 mm; implant space ≈ 7.4 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 8.8 mm; implant space ≈ 7.2 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 14.8 mm; implant space ≈ 9.1 mm; nearest critical structure: mental foramen. Region 37: bone height ≈ 21.8 mm; implant space ≈ 15.0 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 11.2 mm; implant space ≈ 6.6 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 5.3 mm; implant space ≈ 3.5 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 14.9 mm; implant space ≈ 10.5 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0094", "images": ["images/placeholder_0094.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Atorvastatin, Metoprolol, Calcichew-D3, Bufomix Easyhaler, Omeprazole, Amlodipine, Betolvex. Desired treatment: Review the sinus floor elevation and ridge thickness for 37–47.", "answer": "Review of CBCT volume dated 250112. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 11: bone height ≈ 6.8 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 45: bone height ≈ 16.1 mm; implant space ≈ 10.3 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 14.8 mm; implant space ≈ 9.0 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 21.7 mm; implant space ≈ 13.3 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 20.9 mm; implant space ≈ 17.4 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 17.2 mm; implant space ≈ 15.1 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 16.0 mm; implant space ≈ 13.1 mm; nearest critical structure: mental foramen. Region 27: bone height ≈ 20.1 mm; implant space ≈ 17.5 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 15.6 mm; implant space ≈ 10.1 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 18.2 mm; implant space ≈ 13.5 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0095", "images": ["images/placeholder_0095.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Losartan, Atorvastatin, Duroferon, Calcichew-D3, Bufomix Easyhaler, Insulin glargine, Trulicity, Bricanyl. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 17–27.", "answer": "Review of CBCT volume dated 230819. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 11: bone height ≈ 13.0 mm; implant space ≈ 9.6 mm; nearest critical structure: sinus floor. Region 45: bone height ≈ 19.9 mm; implant space ≈ 12.5 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 7.4 mm; implant space ≈ 1.7 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 12.3 mm; implant space ≈ 4.5 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 16.6 mm; implant space ≈ 7.8 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 7.6 mm; implant space ≈ 4.6 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 14.8 mm; implant space ≈ 11.5 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 14.2 mm; implant space ≈ 7.8 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 20.8 mm; implant space ≈ 15.5 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 12.9 mm; implant space ≈ 10.2 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 11; lamina dura loss noted. Smaller radiolucency at 34. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0096", "images": ["images/placeholder_0096.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Bricanyl, Insulin glargine, Trulicity, Duloxetine, Amlodipine, Atorvastatin, Betolvex, Omeprazole. Desired treatment: Check the bone healing and trabecular fill post extraction sites 35–45.", "answer": "Review of CBCT volume dated 221025. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 25: bone height ≈ 5.4 mm; implant space ≈ 1.7 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 15.1 mm; implant space ≈ 8.0 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 11.6 mm; implant space ≈ 7.5 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 17.0 mm; implant space ≈ 15.3 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 11.2 mm; implant space ≈ 9.1 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 10.3 mm; implant space ≈ 2.8 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 10.0 mm; implant space ≈ 5.5 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 21.7 mm; implant space ≈ 13.0 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 8.0 mm; implant space ≈ 1.9 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 13.3 mm; implant space ≈ 8.7 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 44 and 43."}
{"id": "case_0097", "images": ["images/placeholder_0097.png"], "question": "Planning for full-arch restoration. Brief history/status: Atorvastatin, Duloxetine, Omeprazole, Esomeprazole, Duroferon, Trulicity. Desired treatment: Assess mandibular canal course and distance to apices in 35–45.", "answer": "Review of CBCT volume dated 220917. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 41: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 21.3 mm; implant space ≈ 14.2 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 17.7 mm; implant space ≈ 11.6 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 9.5 mm; implant space ≈ 6.1 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 10.6 mm; implant space ≈ 7.5 mm; nearest critical structure: sinus floor. Region 45: bone height ≈ 11.0 mm; implant space ≈ 9.3 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 18.1 mm; implant space ≈ 14.0 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 16.0 mm; implant space ≈ 11.1 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 10.7 mm; implant space ≈ 8.6 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0098", "images": ["images/placeholder_0098.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Duroferon, Bricanyl, Levaxin, Amlodipine, Atorvastatin, Duloxetine, Insulin glargine, Trulicity, Metoprolol. Desired treatment: Please report bone height and available implant space for regions 35–45 and 37–47.", "answer": "Review of CBCT volume dated 210220. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 38: bone height ≈ 6.8 mm; implant space ≈ 4.5 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 6.1 mm; implant space ≈ 0.2 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 16.4 mm; implant space ≈ 9.5 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 21.6 mm; implant space ≈ 13.0 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 10.0 mm; implant space ≈ 3.5 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 16.6 mm; implant space ≈ 14.3 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 19.6 mm; implant space ≈ 12.5 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 10.5 mm; implant space ≈ 9.0 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 6.9 mm; implant space ≈ 3.4 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 21.0 mm; implant space ≈ 18.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0099", "images": ["images/placeholder_0099.png"], "question": "Planning for full-arch restoration. Brief history/status: Betolvex, Bufomix Easyhaler, Duloxetine, Esomeprazole, Omeprazole, Levaxin. Desired treatment: Review the sinus floor elevation and ridge thickness for 16–26.", "answer": "Review of CBCT volume dated 240724. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 47: bone height ≈ 17.0 mm; implant space ≈ 8.2 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 8.1 mm; implant space ≈ 0.3 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 18.6 mm; implant space ≈ 9.7 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 19.1 mm; implant space ≈ 13.7 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 10.1 mm; implant space ≈ 1.7 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 7.9 mm; implant space ≈ 0.4 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 5.7 mm; implant space ≈ 1.2 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 4.9 mm; implant space ≈ 0.5 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 7.8 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 11.2 mm; implant space ≈ 5.5 mm; nearest critical structure: mental foramen. Periapical radiolucency near 13; lamina dura loss noted. Smaller radiolucency at 24. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0100", "images": ["images/placeholder_0100.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Omeprazole, Insulin glargine, Amlodipine, Duroferon, Atorvastatin, Duloxetine, Bufomix Easyhaler, Losartan, Calcichew-D3. Desired treatment: Quantify vertical bone loss around implants in 37–47 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 240904. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 12: bone height ≈ 17.5 mm; implant space ≈ 13.6 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 4.4 mm; implant space ≈ 0.9 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 18.1 mm; implant space ≈ 10.1 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 14.0 mm; implant space ≈ 11.3 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 19.3 mm; implant space ≈ 15.9 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 15.4 mm; implant space ≈ 7.2 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 12.6 mm; implant space ≈ 8.8 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 14.5 mm; implant space ≈ 8.4 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 15.7 mm; implant space ≈ 10.8 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 17.5 mm; implant space ≈ 12.2 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Peri-implant bone loss at 41 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0101", "images": ["images/placeholder_0101.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Insulin glargine, Atorvastatin, Esomeprazole, Bufomix Easyhaler, Amlodipine, Trulicity, Metoprolol, Omeprazole. Desired treatment: Report any signs of peri-implantitis and root resorption in 16–26.", "answer": "Review of CBCT volume dated 240221. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 34: bone height ≈ 9.7 mm; implant space ≈ 7.8 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 15.3 mm; implant space ≈ 11.1 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 17.5 mm; implant space ≈ 8.6 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 17.4 mm; implant space ≈ 10.9 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 9.5 mm; implant space ≈ 7.2 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 21.8 mm; implant space ≈ 16.5 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 20.1 mm; implant space ≈ 18.0 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 18.8 mm; implant space ≈ 15.2 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 12.4 mm; implant space ≈ 10.9 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0102", "images": ["images/placeholder_0102.png"], "question": "Planning for follow-up after extraction. Brief history/status: Losartan, Levaxin, Insulin glargine, Duroferon, Bufomix Easyhaler, Amlodipine, Calcichew-D3. Desired treatment: Quantify vertical bone loss around implants in 36–46 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 200112. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 36: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 17.4 mm; implant space ≈ 9.6 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 17.2 mm; implant space ≈ 10.0 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 11.9 mm; implant space ≈ 8.2 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 16.7 mm; implant space ≈ 11.2 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 6.9 mm; implant space ≈ 5.1 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 17.5 mm; implant space ≈ 11.7 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 15.4 mm; implant space ≈ 12.2 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 14.5 mm; implant space ≈ 7.9 mm; nearest critical structure: nasal floor. Periapical radiolucency near 15; lamina dura loss noted. Smaller radiolucency at 16. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Findings consistent with chronic apical periodontitis at 25 and 26."}
{"id": "case_0103", "images": ["images/placeholder_0103.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Esomeprazole, Levaxin, Trulicity, Calcichew-D3, Duroferon, Insulin glargine, Bufomix Easyhaler. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 37–47.", "answer": "Review of CBCT volume dated 240616. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 27: bone height ≈ 5.1 mm; implant space ≈ 2.9 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 15.2 mm; implant space ≈ 11.1 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 12.5 mm; implant space ≈ 4.3 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 18.8 mm; implant space ≈ 13.5 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 11.8 mm; implant space ≈ 4.6 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 16.9 mm; implant space ≈ 15.2 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 12.2 mm; implant space ≈ 5.7 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 15.2 mm; implant space ≈ 13.3 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 11.3 mm; implant space ≈ 6.6 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 15.6 mm; implant space ≈ 13.6 mm; nearest critical structure: mental foramen. Impression: Findings consistent with chronic apical periodontitis at 28 and 46."}
{"id": "case_0104", "images": ["images/placeholder_0104.png"], "question": "Planning for implant site evaluation. Brief history/status: Levaxin, Betolvex, Amlodipine, Calcichew-D3, Bufomix Easyhaler, Bricanyl. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.", "answer": "Review of CBCT volume dated 201015. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 46: bone height ≈ 12.9 mm; implant space ≈ 8.1 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 18.3 mm; implant space ≈ 13.7 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 9.9 mm; implant space ≈ 4.1 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 13.3 mm; implant space ≈ 9.0 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 16.5 mm; implant space ≈ 12.7 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 18.8 mm; implant space ≈ 11.4 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 8.1 mm; implant space ≈ 3.7 mm; nearest critical structure: mental foramen. Region 27: bone height ≈ 15.4 mm; implant space ≈ 11.6 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 18.4 mm; implant space ≈ 10.2 mm; nearest critical structure: anterior loop. Impression: Vertical root fracture suspected at 45; recommend clinical correlation."}
{"id": "case_0105", "images": ["images/placeholder_0105.png"], "question": "Planning for review of post-implant healing. Brief history/status: Amlodipine, Duloxetine, Duroferon, Calcichew-D3, Trulicity. Desired treatment: Quantify vertical bone loss around implants in 35–45 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 241124. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 38: bone height ≈ 15.4 mm; implant space ≈ 12.6 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 10.8 mm; implant space ≈ 6.8 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 7.8 mm; implant space ≈ 1.0 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 7.1 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 12.7 mm; implant space ≈ 7.7 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 7.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 20.8 mm; implant space ≈ 15.7 mm; nearest critical structure: sinus floor. Region 45: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 5.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 17.8 mm; implant space ≈ 10.7 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 42; lamina dura loss noted. Smaller radiolucency at 21. Impression: Cyst-like well-defined radiolucency near 42, likely radicular cyst."}
{"id": "case_0106", "images": ["images/placeholder_0106.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Atorvastatin, Trulicity, Calcichew-D3, Amlodipine, Duloxetine. Desired treatment: Check the bone healing and trabecular fill post extraction sites 35–45.", "answer": "Review of CBCT volume dated 210119. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 48: bone height ≈ 7.6 mm; implant space ≈ 1.4 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 17.4 mm; implant space ≈ 15.5 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 17.7 mm; implant space ≈ 11.5 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 19.0 mm; implant space ≈ 14.9 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 16.4 mm; implant space ≈ 10.4 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 5.9 mm; implant space ≈ 3.8 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 18.8 mm; implant space ≈ 16.8 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 16.9 mm; implant space ≈ 13.2 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 15.5 mm; implant space ≈ 10.7 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 19.1 mm; implant space ≈ 11.5 mm; nearest critical structure: incisive canal. Periapical radiolucency near 23; lamina dura loss noted. Smaller radiolucency at 31. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Vertical root fracture suspected at 31; recommend clinical correlation."}
{"id": "case_0107", "images": ["images/placeholder_0107.png"], "question": "Planning for full-arch restoration. Brief history/status: Levaxin, Metoprolol, Esomeprazole, Amlodipine, Trulicity. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 37–47.", "answer": "Review of CBCT volume dated 230322. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 47: bone height ≈ 7.2 mm; implant space ≈ 4.9 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 14.1 mm; implant space ≈ 10.7 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 14.2 mm; implant space ≈ 8.7 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 9.8 mm; implant space ≈ 1.8 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 13.7 mm; implant space ≈ 7.5 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 14.9 mm; implant space ≈ 10.8 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 20.7 mm; implant space ≈ 19.0 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 18.1 mm; implant space ≈ 10.9 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 19.7 mm; implant space ≈ 14.1 mm; nearest critical structure: mental foramen. Periapical radiolucency near 46; lamina dura loss noted. Smaller radiolucency at 48. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0108", "images": ["images/placeholder_0108.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Insulin glargine, Esomeprazole, Amlodipine, Bricanyl, Omeprazole, Levaxin, Calcichew-D3, Trulicity. Desired treatment: Evaluate periapical status of teeth 11, 42, and 46, and overall sinus condition.", "answer": "Review of CBCT volume dated 240504. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 37: bone height ≈ 9.1 mm; implant space ≈ 6.9 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 5.8 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 10.5 mm; implant space ≈ 7.3 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 17.7 mm; implant space ≈ 14.5 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 6.7 mm; implant space ≈ 3.9 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 15.5 mm; implant space ≈ 6.5 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 21.3 mm; implant space ≈ 12.5 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 10.4 mm; implant space ≈ 7.1 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 20.3 mm; implant space ≈ 16.1 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 12.8 mm; implant space ≈ 8.1 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 32 and 34."}
{"id": "case_0109", "images": ["images/placeholder_0109.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Insulin glargine, Duloxetine, Atorvastatin, Omeprazole, Duroferon, Esomeprazole, Metoprolol. Desired treatment: Check the bone healing and trabecular fill post extraction sites 16–26.", "answer": "Review of CBCT volume dated 220802. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 14: bone height ≈ 12.2 mm; implant space ≈ 3.5 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 19.4 mm; implant space ≈ 15.2 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 15.5 mm; implant space ≈ 6.7 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 7.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 6.2 mm; implant space ≈ 2.0 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 4.8 mm; implant space ≈ 0.4 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 21.2 mm; implant space ≈ 17.4 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 11.7 mm; implant space ≈ 5.8 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 20.7 mm; implant space ≈ 17.3 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 9.9 mm; implant space ≈ 7.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 43 and 12."}
{"id": "case_0110", "images": ["images/placeholder_0110.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Levaxin, Omeprazole, Amlodipine, Calcichew-D3, Duroferon, Losartan. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.", "answer": "Review of CBCT volume dated 230415. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 33: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 19.6 mm; implant space ≈ 11.8 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 12.3 mm; implant space ≈ 6.5 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 20.8 mm; implant space ≈ 13.3 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 18.6 mm; implant space ≈ 13.8 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 17.7 mm; implant space ≈ 10.7 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 12.5 mm; implant space ≈ 9.6 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 11.0 mm; implant space ≈ 3.8 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 17.4 mm; implant space ≈ 10.2 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 20.4 mm; implant space ≈ 16.1 mm; nearest critical structure: nasal floor. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0111", "images": ["images/placeholder_0111.png"], "question": "Planning for implant planning evaluation. Brief history/status: Duroferon, Trulicity, Esomeprazole, Bricanyl, Duloxetine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 16–26.", "answer": "Review of CBCT volume dated 210324. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 43: bone height ≈ 6.9 mm; implant space ≈ 1.6 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 21.2 mm; implant space ≈ 19.4 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 15.7 mm; implant space ≈ 12.4 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 16.3 mm; implant space ≈ 12.4 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 8.3 mm; implant space ≈ 1.3 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 18.1 mm; implant space ≈ 12.2 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 19.8 mm; implant space ≈ 11.0 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 11.4 mm; implant space ≈ 8.6 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 14.9 mm; implant space ≈ 9.3 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 14.2 mm; implant space ≈ 10.5 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0112", "images": ["images/placeholder_0112.png"], "question": "Planning for implant site evaluation. Brief history/status: Atorvastatin, Levaxin, Bricanyl, Duroferon, Bufomix Easyhaler. Desired treatment: Quantify vertical bone loss around implants in 36–46 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 241027. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 16: bone height ≈ 15.2 mm; implant space ≈ 8.2 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 20.1 mm; implant space ≈ 13.1 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 16.7 mm; implant space ≈ 11.4 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 17.8 mm; implant space ≈ 10.3 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 15.9 mm; implant space ≈ 10.9 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 16.1 mm; implant space ≈ 9.9 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 14.5 mm; implant space ≈ 12.3 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 10.1 mm; implant space ≈ 7.5 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 15.0 mm; implant space ≈ 11.8 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 17.8 mm; implant space ≈ 9.0 mm; nearest critical structure: mandibular canal. Periapical radiolucency near 33; lamina dura loss noted. Smaller radiolucency at 37. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0113", "images": ["images/placeholder_0113.png"], "question": "Planning for review of post-implant healing. Brief history/status: Losartan, Duroferon, Trulicity, Amlodipine, Calcichew-D3, Insulin glargine, Duloxetine. Desired treatment: Measure crest-to-canal distances mandibularly in 15–25, and implant feasibility maxillary 17–27.", "answer": "Review of CBCT volume dated 240715. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 12: bone height ≈ 12.6 mm; implant space ≈ 7.4 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 15.4 mm; implant space ≈ 10.5 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 13.6 mm; implant space ≈ 10.6 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 9.7 mm; implant space ≈ 3.9 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 8.3 mm; implant space ≈ 0.2 mm; nearest critical structure: sinus floor. Region 48: bone height ≈ 13.3 mm; implant space ≈ 10.9 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 5.8 mm; implant space ≈ 3.0 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 16.3 mm; implant space ≈ 8.7 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 8.6 mm; implant space ≈ 5.1 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 10.5 mm; implant space ≈ 6.2 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 42 and 35."}
{"id": "case_0114", "images": ["images/placeholder_0114.png"], "question": "Planning for sinus-related complaints. Brief history/status: Levaxin, Omeprazole, Amlodipine, Metoprolol, Insulin glargine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 35–45.", "answer": "Review of CBCT volume dated 210923. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 16: bone height ≈ 10.2 mm; implant space ≈ 4.1 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 6.5 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 17.2 mm; implant space ≈ 15.2 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 12.5 mm; implant space ≈ 9.4 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 6.1 mm; implant space ≈ 0.5 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 8.1 mm; implant space ≈ 4.2 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 19.1 mm; implant space ≈ 10.6 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 10.7 mm; implant space ≈ 5.1 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 12.2 mm; implant space ≈ 10.0 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 10.8 mm; implant space ≈ 2.9 mm; nearest critical structure: anterior loop. Periapical radiolucency near 33; lamina dura loss noted. Smaller radiolucency at 18. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Vertical root fracture suspected at 36; recommend clinical correlation."}
{"id": "case_0115", "images": ["images/placeholder_0115.png"], "question": "Planning for sinus-related complaints. Brief history/status: Amlodipine, Insulin glargine, Duloxetine, Esomeprazole, Atorvastatin, Losartan, Levaxin, Bufomix Easyhaler, Duroferon. Desired treatment: Please report bone height and available implant space for regions 15–25 and 16–26.", "answer": "Review of CBCT volume dated 201119. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 16: bone height ≈ 21.7 mm; implant space ≈ 16.9 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 16.5 mm; implant space ≈ 12.3 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 6.0 mm; implant space ≈ 1.0 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 11.8 mm; implant space ≈ 9.4 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 22.0 mm; implant space ≈ 20.4 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 20.9 mm; implant space ≈ 13.1 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 18.6 mm; implant space ≈ 13.4 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 20.4 mm; implant space ≈ 14.0 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 8.9 mm; implant space ≈ 1.4 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0116", "images": ["images/placeholder_0116.png"], "question": "Planning for review of post-implant healing. Brief history/status: Insulin glargine, Duroferon, Duloxetine, Atorvastatin, Levaxin, Metoprolol, Bricanyl. Desired treatment: Report any signs of peri-implantitis and root resorption in 36–46.", "answer": "Review of CBCT volume dated 210426. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 17: bone height ≈ 18.5 mm; implant space ≈ 14.0 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 18.9 mm; implant space ≈ 14.3 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 12.7 mm; implant space ≈ 5.2 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 9.7 mm; implant space ≈ 6.8 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 4.7 mm; implant space ≈ 2.6 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 12.0 mm; implant space ≈ 5.6 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 20.0 mm; implant space ≈ 15.7 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 13.2 mm; implant space ≈ 4.9 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 14.9 mm; implant space ≈ 7.1 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 14.4 mm; implant space ≈ 5.7 mm; nearest critical structure: mental foramen. Periapical radiolucency near 33; lamina dura loss noted. Smaller radiolucency at 31. Impression: Findings consistent with chronic apical periodontitis at 42 and 26."}
{"id": "case_0117", "images": ["images/placeholder_0117.png"], "question": "Planning for full-arch restoration. Brief history/status: Metoprolol, Amlodipine, Atorvastatin, Insulin glargine, Omeprazole, Trulicity, Calcichew-D3. Desired treatment: Provide measurements relevant to guided surgery stent planning for 35–45 and 37–47.", "answer": "Review of CBCT volume dated 251119. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 24: bone height ≈ 8.1 mm; implant space ≈ 6.4 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 13.7 mm; implant space ≈ 10.8 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 13.6 mm; implant space ≈ 6.7 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 20.2 mm; implant space ≈ 17.5 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 17.7 mm; implant space ≈ 12.9 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 19.8 mm; implant space ≈ 11.1 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 7.9 mm; implant space ≈ 3.6 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 15.9 mm; implant space ≈ 9.7 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 7.7 mm; implant space ≈ 2.6 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 15.7 mm; implant space ≈ 12.5 mm; nearest critical structure: anterior loop. Periapical radiolucency near 25; lamina dura loss noted. Smaller radiolucency at 27. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0118", "images": ["images/placeholder_0118.png"], "question": "Planning for follow-up after extraction. Brief history/status: Atorvastatin, Losartan, Calcichew-D3, Levaxin, Trulicity, Omeprazole, Esomeprazole, Betolvex. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 200103. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 45: bone height ≈ 9.6 mm; implant space ≈ 2.4 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 17.7 mm; implant space ≈ 9.5 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 14.7 mm; implant space ≈ 10.0 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 18.3 mm; implant space ≈ 13.3 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 15.8 mm; implant space ≈ 8.7 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 9.7 mm; implant space ≈ 7.7 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 17.8 mm; implant space ≈ 12.2 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 20.2 mm; implant space ≈ 14.2 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 20.0 mm; implant space ≈ 18.2 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0119", "images": ["images/placeholder_0119.png"], "question": "Planning for implant planning evaluation. Brief history/status: Duroferon, Atorvastatin, Trulicity, Insulin glargine, Losartan, Bricanyl, Amlodipine, Levaxin, Calcichew-D3. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 16–26.", "answer": "Review of CBCT volume dated 250818. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 17: bone height ≈ 12.4 mm; implant space ≈ 5.5 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 5.8 mm; implant space ≈ 1.1 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 7.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 20.5 mm; implant space ≈ 12.7 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 10.6 mm; implant space ≈ 6.6 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 19.2 mm; implant space ≈ 13.7 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 17.0 mm; implant space ≈ 8.0 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 5.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 13.9 mm; implant space ≈ 8.7 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 37; lamina dura loss noted. Smaller radiolucency at 13. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0120", "images": ["images/placeholder_0120.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Bufomix Easyhaler, Losartan, Insulin glargine, Atorvastatin, Bricanyl, Amlodipine, Calcichew-D3, Omeprazole. Desired treatment: Assess mandibular canal course and distance to apices in 17–27.", "answer": "Review of CBCT volume dated 201106. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 22: bone height ≈ 14.3 mm; implant space ≈ 11.4 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 15.4 mm; implant space ≈ 12.5 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 9.1 mm; implant space ≈ 4.7 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 21.5 mm; implant space ≈ 15.1 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 15.0 mm; implant space ≈ 12.3 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 6.9 mm; implant space ≈ 1.9 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 13.1 mm; implant space ≈ 9.5 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 17.9 mm; implant space ≈ 10.7 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 10.5 mm; implant space ≈ 5.5 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 6.3 mm; implant space ≈ 3.9 mm; nearest critical structure: mental foramen. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Findings consistent with chronic apical periodontitis at 11 and 33."}
{"id": "case_0121", "images": ["images/placeholder_0121.png"], "question": "Planning for follow-up after extraction. Brief history/status: Omeprazole, Losartan, Bricanyl, Betolvex, Duroferon, Duloxetine, Esomeprazole. Desired treatment: Review the sinus floor elevation and ridge thickness for 36–46.", "answer": "Review of CBCT volume dated 250415. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 22: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 10.6 mm; implant space ≈ 3.3 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 21.9 mm; implant space ≈ 16.3 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 18.0 mm; implant space ≈ 16.2 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 20.4 mm; implant space ≈ 14.6 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 13.0 mm; implant space ≈ 7.7 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 17.0 mm; implant space ≈ 9.5 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 16.5 mm; implant space ≈ 14.9 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 16.5 mm; implant space ≈ 13.7 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 7.6 mm; implant space ≈ 0.5 mm; nearest critical structure: mental foramen. Periapical radiolucency near 14; lamina dura loss noted. Smaller radiolucency at 35. Impression: Cyst-like well-defined radiolucency near 37, likely radicular cyst."}
{"id": "case_0122", "images": ["images/placeholder_0122.png"], "question": "Planning for sinus-related complaints. Brief history/status: Losartan, Trulicity, Levaxin, Esomeprazole, Insulin glargine, Metoprolol, Betolvex, Amlodipine, Bricanyl. Desired treatment: Quantify vertical bone loss around implants in 37–47 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 230326. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 37: bone height ≈ 19.9 mm; implant space ≈ 11.6 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 7.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 5.1 mm; implant space ≈ 2.2 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 6.2 mm; implant space ≈ 2.7 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 8.5 mm; implant space ≈ 6.3 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 13.2 mm; implant space ≈ 7.9 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 19.0 mm; implant space ≈ 15.3 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 10.5 mm; implant space ≈ 5.8 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 19.0 mm; implant space ≈ 14.9 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 18.4 mm; implant space ≈ 14.1 mm; nearest critical structure: mandibular canal. Impression: Peri-implant bone loss at 21 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0123", "images": ["images/placeholder_0123.png"], "question": "Planning for implant planning evaluation. Brief history/status: Calcichew-D3, Trulicity, Bricanyl, Losartan, Bufomix Easyhaler, Amlodipine, Betolvex. Desired treatment: Check the bone healing and trabecular fill post extraction sites 16–26.", "answer": "Review of CBCT volume dated 201216. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 12: bone height ≈ 6.0 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 11.8 mm; implant space ≈ 4.2 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 14.8 mm; implant space ≈ 12.0 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 18.5 mm; implant space ≈ 13.8 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 15.8 mm; implant space ≈ 10.1 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 17.8 mm; implant space ≈ 16.0 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 12.6 mm; implant space ≈ 9.4 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 9.9 mm; implant space ≈ 7.7 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 15.1 mm; implant space ≈ 12.5 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 14.0 mm; implant space ≈ 5.2 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 44; lamina dura loss noted. Smaller radiolucency at 35. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0124", "images": ["images/placeholder_0124.png"], "question": "Planning for sinus-related complaints. Brief history/status: Duloxetine, Atorvastatin, Omeprazole, Losartan, Duroferon, Metoprolol, Trulicity, Esomeprazole, Betolvex. Desired treatment: Assess mandibular canal course and distance to apices in 35–45.", "answer": "Review of CBCT volume dated 220303. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 34: bone height ≈ 4.7 mm; implant space ≈ 1.6 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 8.6 mm; implant space ≈ 0.2 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 6.8 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 11.8 mm; implant space ≈ 10.2 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 15.7 mm; implant space ≈ 13.7 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 17.7 mm; implant space ≈ 15.3 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 14.7 mm; implant space ≈ 7.4 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 7.6 mm; implant space ≈ 3.6 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 21.5 mm; implant space ≈ 13.9 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 13.9 mm; implant space ≈ 8.1 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 26; lamina dura loss noted. Smaller radiolucency at 21. Impression: Findings consistent with chronic apical periodontitis at 12 and 28."}
{"id": "case_0125", "images": ["images/placeholder_0125.png"], "question": "Planning for implant site evaluation. Brief history/status: Omeprazole, Levaxin, Bricanyl, Betolvex, Trulicity, Insulin glargine, Duloxetine. Desired treatment: Evaluate periapical status of teeth 18, 16, and 17, and overall sinus condition.", "answer": "Review of CBCT volume dated 220804. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 12: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 15.1 mm; implant space ≈ 6.2 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 16.3 mm; implant space ≈ 14.0 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 5.5 mm; implant space ≈ 1.0 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 4.9 mm; implant space ≈ 1.8 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 14.2 mm; implant space ≈ 6.8 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 21.8 mm; implant space ≈ 15.1 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 19.0 mm; implant space ≈ 13.1 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 21.4 mm; implant space ≈ 15.9 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 8.9 mm; implant space ≈ 6.6 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 28; lamina dura loss noted. Smaller radiolucency at 33. Impression: Findings consistent with chronic apical periodontitis at 47 and 28."}
{"id": "case_0126", "images": ["images/placeholder_0126.png"], "question": "Planning for review of post-implant healing. Brief history/status: Insulin glargine, Bufomix Easyhaler, Losartan, Levaxin, Metoprolol, Omeprazole, Duloxetine. Desired treatment: Measure crest-to-canal distances mandibularly in 37–47, and implant feasibility maxillary 16–26.", "answer": "Review of CBCT volume dated 220318. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 44: bone height ≈ 12.0 mm; implant space ≈ 6.7 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 21.7 mm; implant space ≈ 19.6 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 14.1 mm; implant space ≈ 11.7 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 19.5 mm; implant space ≈ 15.4 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 13.5 mm; implant space ≈ 5.8 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 20.1 mm; implant space ≈ 15.5 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 10.1 mm; implant space ≈ 5.3 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 17.0 mm; implant space ≈ 11.2 mm; nearest critical structure: nasal floor. Periapical radiolucency near 33; lamina dura loss noted. Smaller radiolucency at 48. Impression: Findings consistent with chronic apical periodontitis at 23 and 13."}
{"id": "case_0127", "images": ["images/placeholder_0127.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Betolvex, Losartan, Insulin glargine, Metoprolol, Esomeprazole, Atorvastatin, Bricanyl, Levaxin, Calcichew-D3. Desired treatment: Check the bone healing and trabecular fill post extraction sites 17–27.", "answer": "Review of CBCT volume dated 200223. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 23: bone height ≈ 14.7 mm; implant space ≈ 8.1 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 15.3 mm; implant space ≈ 8.3 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 4.2 mm; implant space ≈ 0.8 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 17.3 mm; implant space ≈ 15.5 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 4.9 mm; implant space ≈ 2.8 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 14.0 mm; implant space ≈ 5.4 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 8.6 mm; implant space ≈ 4.0 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 5.4 mm; implant space ≈ 1.6 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 15.6 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 11.6 mm; implant space ≈ 3.9 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 38; lamina dura loss noted. Smaller radiolucency at 47. Impression: Cyst-like well-defined radiolucency near 32, likely radicular cyst."}
{"id": "case_0128", "images": ["images/placeholder_0128.png"], "question": "Planning for implant planning evaluation. Brief history/status: Insulin glargine, Bufomix Easyhaler, Duroferon, Losartan, Trulicity, Esomeprazole. Desired treatment: Please report bone height and available implant space for regions 37–47 and 16–26.", "answer": "Review of CBCT volume dated 210206. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 21: bone height ≈ 21.9 mm; implant space ≈ 18.8 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 17.0 mm; implant space ≈ 13.8 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 12.0 mm; implant space ≈ 4.5 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 7.5 mm; implant space ≈ 1.2 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 12.2 mm; implant space ≈ 6.4 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 6.0 mm; implant space ≈ 3.2 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 16.8 mm; implant space ≈ 7.9 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 13.2 mm; implant space ≈ 10.9 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 42; lamina dura loss noted. Smaller radiolucency at 38. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0129", "images": ["images/placeholder_0129.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Trulicity, Metoprolol, Atorvastatin, Esomeprazole, Duroferon. Desired treatment: Review the sinus floor elevation and ridge thickness for 37–47.", "answer": "Review of CBCT volume dated 240613. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 41: bone height ≈ 13.5 mm; implant space ≈ 9.0 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 15.9 mm; implant space ≈ 12.0 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 9.6 mm; implant space ≈ 8.1 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 20.8 mm; implant space ≈ 13.3 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 20.9 mm; implant space ≈ 13.1 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 10.6 mm; implant space ≈ 8.6 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 8.5 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 13.9 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 10.9 mm; implant space ≈ 2.7 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 16.7 mm; implant space ≈ 8.7 mm; nearest critical structure: mental foramen. Periapical radiolucency near 35; lamina dura loss noted. Smaller radiolucency at 47. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Peri-implant bone loss at 42 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0130", "images": ["images/placeholder_0130.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Omeprazole, Metoprolol, Levaxin, Esomeprazole, Losartan, Betolvex, Duroferon. Desired treatment: Evaluate periapical status of teeth 15, 38, and 35, and overall sinus condition.", "answer": "Review of CBCT volume dated 230307. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 46: bone height ≈ 10.9 mm; implant space ≈ 5.8 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 12.2 mm; implant space ≈ 5.4 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 4.4 mm; implant space ≈ 1.7 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 15.9 mm; implant space ≈ 7.6 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 21.3 mm; implant space ≈ 13.8 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 11.9 mm; implant space ≈ 8.0 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 9.4 mm; implant space ≈ 4.1 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 9.8 mm; implant space ≈ 3.3 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 7.9 mm; implant space ≈ 3.9 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 7.7 mm; implant space ≈ 1.8 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Cyst-like well-defined radiolucency near 43, likely radicular cyst."}
{"id": "case_0131", "images": ["images/placeholder_0131.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Atorvastatin, Bufomix Easyhaler, Duroferon, Betolvex, Losartan, Calcichew-D3. Desired treatment: Measure crest-to-canal distances mandibularly in 16–26, and implant feasibility maxillary 17–27.", "answer": "Review of CBCT volume dated 211106. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 24: bone height ≈ 19.8 mm; implant space ≈ 14.6 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 15.8 mm; implant space ≈ 12.4 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 13.4 mm; implant space ≈ 4.7 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 21.5 mm; implant space ≈ 18.1 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 13.6 mm; implant space ≈ 11.1 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 17.7 mm; implant space ≈ 11.6 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 13.5 mm; implant space ≈ 11.9 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 12.5 mm; implant space ≈ 5.9 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 18.1 mm; implant space ≈ 14.1 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 28; lamina dura loss noted. Smaller radiolucency at 16. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0132", "images": ["images/placeholder_0132.png"], "question": "Planning for sinus-related complaints. Brief history/status: Betolvex, Metoprolol, Duloxetine, Bricanyl, Duroferon, Levaxin, Amlodipine. Desired treatment: Quantify vertical bone loss around implants in 36–46 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 210110. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 47: bone height ≈ 7.7 mm; implant space ≈ 0.3 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 16.5 mm; implant space ≈ 14.3 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 9.3 mm; implant space ≈ 4.7 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 8.4 mm; implant space ≈ 3.9 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 13.7 mm; implant space ≈ 6.9 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 7.8 mm; implant space ≈ 2.1 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 16.1 mm; implant space ≈ 11.6 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 16.5 mm; implant space ≈ 13.6 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 12.7 mm; implant space ≈ 6.2 mm; nearest critical structure: mental foramen. Periapical radiolucency near 36; lamina dura loss noted. Smaller radiolucency at 26. Impression: Cyst-like well-defined radiolucency near 46, likely radicular cyst."}
{"id": "case_0133", "images": ["images/placeholder_0133.png"], "question": "Planning for follow-up after extraction. Brief history/status: Amlodipine, Omeprazole, Betolvex, Insulin glargine, Esomeprazole, Metoprolol. Desired treatment: Please report bone height and available implant space for regions 36–46 and 37–47.", "answer": "Review of CBCT volume dated 210606. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 35: bone height ≈ 15.4 mm; implant space ≈ 11.3 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 14.4 mm; implant space ≈ 12.1 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 19.6 mm; implant space ≈ 11.3 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 9.0 mm; implant space ≈ 3.3 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 12.7 mm; implant space ≈ 10.4 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 16.9 mm; implant space ≈ 13.8 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 9.1 mm; implant space ≈ 5.4 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 18.8 mm; implant space ≈ 15.5 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 5.1 mm; implant space ≈ 0.9 mm; nearest critical structure: incisive canal. Periapical radiolucency near 42; lamina dura loss noted. Smaller radiolucency at 34. Impression: Peri-implant bone loss at 16 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0134", "images": ["images/placeholder_0134.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Calcichew-D3, Bufomix Easyhaler, Trulicity, Duloxetine, Esomeprazole, Bricanyl, Omeprazole. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 17–27.", "answer": "Review of CBCT volume dated 201028. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 23: bone height ≈ 7.9 mm; implant space ≈ 5.3 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 20.4 mm; implant space ≈ 18.1 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 9.4 mm; implant space ≈ 4.8 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 11.6 mm; implant space ≈ 8.5 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 17.0 mm; implant space ≈ 9.1 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 11.2 mm; implant space ≈ 7.7 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 13.5 mm; implant space ≈ 11.6 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 13.2 mm; implant space ≈ 9.0 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 4.3 mm; implant space ≈ 0.2 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 13.0 mm; implant space ≈ 8.1 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0135", "images": ["images/placeholder_0135.png"], "question": "Planning for implant planning evaluation. Brief history/status: Atorvastatin, Bricanyl, Insulin glargine, Losartan, Duroferon, Esomeprazole, Omeprazole. Desired treatment: Check the bone healing and trabecular fill post extraction sites 36–46.", "answer": "Review of CBCT volume dated 210228. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 13: bone height ≈ 15.1 mm; implant space ≈ 10.6 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 13.8 mm; implant space ≈ 8.6 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 20.4 mm; implant space ≈ 14.9 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 21.0 mm; implant space ≈ 19.0 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 4.0 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 6.7 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 12.6 mm; implant space ≈ 3.6 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 18.4 mm; implant space ≈ 11.2 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 6.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 11; lamina dura loss noted. Smaller radiolucency at 23. Impression: Cyst-like well-defined radiolucency near 22, likely radicular cyst."}
{"id": "case_0136", "images": ["images/placeholder_0136.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Omeprazole, Amlodipine, Insulin glargine, Calcichew-D3, Esomeprazole, Trulicity, Bufomix Easyhaler, Losartan, Betolvex. Desired treatment: Quantify vertical bone loss around implants in 37–47 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 211110. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 18: bone height ≈ 11.8 mm; implant space ≈ 9.9 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 13.2 mm; implant space ≈ 7.9 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 14.1 mm; implant space ≈ 8.2 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 13.5 mm; implant space ≈ 8.3 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 21.3 mm; implant space ≈ 19.0 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 6.9 mm; implant space ≈ 2.9 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 17.6 mm; implant space ≈ 11.7 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 12.1 mm; implant space ≈ 7.2 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 18.2 mm; implant space ≈ 11.0 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 12.4 mm; implant space ≈ 5.2 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 32; lamina dura loss noted. Smaller radiolucency at 13. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0137", "images": ["images/placeholder_0137.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Duloxetine, Losartan, Atorvastatin, Levaxin, Omeprazole, Metoprolol, Betolvex. Desired treatment: Evaluate periapical status of teeth 17, 37, and 22, and overall sinus condition.", "answer": "Review of CBCT volume dated 221219. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 14: bone height ≈ 18.1 mm; implant space ≈ 9.5 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 17.0 mm; implant space ≈ 10.6 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 16.8 mm; implant space ≈ 14.4 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 16.2 mm; implant space ≈ 12.3 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 10.8 mm; implant space ≈ 8.7 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 18.0 mm; implant space ≈ 14.5 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 11.2 mm; implant space ≈ 6.7 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 22.0 mm; implant space ≈ 13.2 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 17.6 mm; implant space ≈ 15.4 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 9.4 mm; implant space ≈ 3.5 mm; nearest critical structure: mandibular canal. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0138", "images": ["images/placeholder_0138.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Trulicity, Insulin glargine, Metoprolol, Losartan, Bricanyl, Duroferon, Duloxetine, Bufomix Easyhaler, Calcichew-D3. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 36–46.", "answer": "Review of CBCT volume dated 241116. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 41: bone height ≈ 7.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 18.7 mm; implant space ≈ 15.5 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 20.2 mm; implant space ≈ 17.7 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 6.0 mm; implant space ≈ 2.2 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 13.7 mm; implant space ≈ 5.1 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 16.9 mm; implant space ≈ 9.8 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 16.1 mm; implant space ≈ 8.3 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 9.3 mm; implant space ≈ 0.5 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 11.5 mm; implant space ≈ 8.6 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 17.9 mm; implant space ≈ 9.0 mm; nearest critical structure: anterior loop. Periapical radiolucency near 14; lamina dura loss noted. Smaller radiolucency at 44. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Vertical root fracture suspected at 22; recommend clinical correlation."}
{"id": "case_0139", "images": ["images/placeholder_0139.png"], "question": "Planning for sinus-related complaints. Brief history/status: Trulicity, Duroferon, Esomeprazole, Insulin glargine, Omeprazole, Metoprolol, Atorvastatin, Duloxetine. Desired treatment: Evaluate periapical status of teeth 45, 46, and 25, and overall sinus condition.", "answer": "Review of CBCT volume dated 250811. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 12: bone height ≈ 15.1 mm; implant space ≈ 8.4 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 15.2 mm; implant space ≈ 6.7 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 4.1 mm; implant space ≈ 1.6 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 12.0 mm; implant space ≈ 8.8 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 15.9 mm; implant space ≈ 11.1 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 21.9 mm; implant space ≈ 20.0 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 15.4 mm; implant space ≈ 11.8 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 9.1 mm; implant space ≈ 2.3 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 10.0 mm; implant space ≈ 8.5 mm; nearest critical structure: sinus floor. Region 48: bone height ≈ 20.1 mm; implant space ≈ 12.6 mm; nearest critical structure: mandibular canal. Periapical radiolucency near 15; lamina dura loss noted. Smaller radiolucency at 27. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0140", "images": ["images/placeholder_0140.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Esomeprazole, Betolvex, Insulin glargine, Omeprazole, Duloxetine, Bufomix Easyhaler, Levaxin. Desired treatment: Report any signs of peri-implantitis and root resorption in 36–46.", "answer": "Review of CBCT volume dated 250105. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 32: bone height ≈ 15.8 mm; implant space ≈ 8.8 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 20.5 mm; implant space ≈ 17.9 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 10.2 mm; implant space ≈ 8.6 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 11.8 mm; implant space ≈ 8.1 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 8.0 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 11.6 mm; implant space ≈ 5.6 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 8.8 mm; implant space ≈ 3.9 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 20.5 mm; implant space ≈ 12.8 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 11.9 mm; implant space ≈ 4.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 28; lamina dura loss noted. Smaller radiolucency at 25. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0141", "images": ["images/placeholder_0141.png"], "question": "Planning for sinus-related complaints. Brief history/status: Bricanyl, Insulin glargine, Bufomix Easyhaler, Atorvastatin, Betolvex, Omeprazole, Calcichew-D3, Levaxin, Duroferon. Desired treatment: Measure crest-to-canal distances mandibularly in 37–47, and implant feasibility maxillary 15–25.", "answer": "Review of CBCT volume dated 241211. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 33: bone height ≈ 19.7 mm; implant space ≈ 12.7 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 10.5 mm; implant space ≈ 3.8 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 4.6 mm; implant space ≈ 1.3 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 13.0 mm; implant space ≈ 9.0 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 17.4 mm; implant space ≈ 10.9 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 11.7 mm; implant space ≈ 7.1 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 8.0 mm; implant space ≈ 0.2 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 21.5 mm; implant space ≈ 14.4 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 18.6 mm; implant space ≈ 11.5 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Vertical root fracture suspected at 23; recommend clinical correlation."}
{"id": "case_0142", "images": ["images/placeholder_0142.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Betolvex, Duloxetine, Calcichew-D3, Bufomix Easyhaler, Bricanyl. Desired treatment: Please report bone height and available implant space for regions 15–25 and 35–45.", "answer": "Review of CBCT volume dated 220926. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 44: bone height ≈ 19.8 mm; implant space ≈ 17.6 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 21.1 mm; implant space ≈ 16.1 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 7.3 mm; implant space ≈ 0.2 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 10.4 mm; implant space ≈ 8.1 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 8.9 mm; implant space ≈ 4.5 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 18.0 mm; implant space ≈ 11.5 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 17.2 mm; implant space ≈ 11.1 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 9.0 mm; implant space ≈ 1.4 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 15.9 mm; implant space ≈ 10.9 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 8.7 mm; implant space ≈ 1.8 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0143", "images": ["images/placeholder_0143.png"], "question": "Planning for implant site evaluation. Brief history/status: Atorvastatin, Levaxin, Bricanyl, Betolvex, Losartan, Esomeprazole, Bufomix Easyhaler. Desired treatment: Assess mandibular canal course and distance to apices in 16–26.", "answer": "Review of CBCT volume dated 221223. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 15: bone height ≈ 19.2 mm; implant space ≈ 11.9 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 14.0 mm; implant space ≈ 8.1 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 12.4 mm; implant space ≈ 3.6 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 17.7 mm; implant space ≈ 15.1 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 6.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 14.0 mm; implant space ≈ 7.5 mm; nearest critical structure: sinus floor. Region 22: bone height ≈ 16.6 mm; implant space ≈ 7.8 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 11.1 mm; implant space ≈ 7.1 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 15.8 mm; implant space ≈ 13.1 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 16.9 mm; implant space ≈ 8.3 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 12; lamina dura loss noted. Smaller radiolucency at 23. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0144", "images": ["images/placeholder_0144.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Esomeprazole, Duroferon, Bufomix Easyhaler, Betolvex, Levaxin. Desired treatment: Report any signs of peri-implantitis and root resorption in 16–26.", "answer": "Review of CBCT volume dated 241001. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 38: bone height ≈ 19.8 mm; implant space ≈ 11.2 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 16.1 mm; implant space ≈ 10.9 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 12.7 mm; implant space ≈ 9.2 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 17.2 mm; implant space ≈ 9.8 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 12.8 mm; implant space ≈ 5.7 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 9.0 mm; implant space ≈ 4.8 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 18.9 mm; implant space ≈ 9.9 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 14.4 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 13.0 mm; implant space ≈ 9.3 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0145", "images": ["images/placeholder_0145.png"], "question": "Planning for sinus-related complaints. Brief history/status: Omeprazole, Esomeprazole, Insulin glargine, Betolvex, Duroferon, Bufomix Easyhaler, Calcichew-D3. Desired treatment: Measure crest-to-canal distances mandibularly in 35–45, and implant feasibility maxillary 16–26.", "answer": "Review of CBCT volume dated 250125. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 18: bone height ≈ 15.8 mm; implant space ≈ 13.7 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 11.6 mm; implant space ≈ 7.7 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 6.6 mm; implant space ≈ 1.8 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 19.2 mm; implant space ≈ 14.3 mm; nearest critical structure: mental foramen. Region 37: bone height ≈ 7.1 mm; implant space ≈ 5.0 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 12.1 mm; implant space ≈ 6.0 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 16.5 mm; implant space ≈ 10.5 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 7.8 mm; implant space ≈ 0.7 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 14.1 mm; implant space ≈ 10.7 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 11.7 mm; implant space ≈ 6.3 mm; nearest critical structure: mandibular canal. Periapical radiolucency near 11; lamina dura loss noted. Smaller radiolucency at 27. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0146", "images": ["images/placeholder_0146.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Bufomix Easyhaler, Levaxin, Bricanyl, Amlodipine, Betolvex. Desired treatment: Check the bone healing and trabecular fill post extraction sites 36–46.", "answer": "Review of CBCT volume dated 200508. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 28: bone height ≈ 21.6 mm; implant space ≈ 15.1 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 10.6 mm; implant space ≈ 8.9 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 21.9 mm; implant space ≈ 15.0 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 21.5 mm; implant space ≈ 14.9 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 17.9 mm; implant space ≈ 10.0 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 16.2 mm; implant space ≈ 12.4 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 8.1 mm; implant space ≈ 3.8 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 11.1 mm; implant space ≈ 4.3 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 11.9 mm; implant space ≈ 6.8 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 11.1 mm; implant space ≈ 8.6 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 13; lamina dura loss noted. Smaller radiolucency at 16. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0147", "images": ["images/placeholder_0147.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Atorvastatin, Levaxin, Losartan, Betolvex, Amlodipine, Duloxetine, Omeprazole, Trulicity. Desired treatment: Provide measurements relevant to guided surgery stent planning for 35–45 and 16–26.", "answer": "Review of CBCT volume dated 240504. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 18: bone height ≈ 12.0 mm; implant space ≈ 7.7 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 18.9 mm; implant space ≈ 9.9 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 6.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 15.9 mm; implant space ≈ 10.5 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 12.1 mm; implant space ≈ 8.2 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 18.2 mm; implant space ≈ 10.7 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 12.5 mm; implant space ≈ 8.1 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 6.8 mm; implant space ≈ 2.6 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 12.1 mm; implant space ≈ 4.1 mm; nearest critical structure: mental foramen. Periapical radiolucency near 18; lamina dura loss noted. Smaller radiolucency at 15. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Impaction of third molar in quadrant 4 with mesioangular inclination."}
{"id": "case_0148", "images": ["images/placeholder_0148.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Betolvex, Metoprolol, Duloxetine, Levaxin, Amlodipine, Atorvastatin, Bufomix Easyhaler. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 250522. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 13: bone height ≈ 19.2 mm; implant space ≈ 16.3 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 18.0 mm; implant space ≈ 10.6 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 20.1 mm; implant space ≈ 14.4 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 11.7 mm; implant space ≈ 9.2 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 11.9 mm; implant space ≈ 7.5 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 20.8 mm; implant space ≈ 16.5 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 10.5 mm; implant space ≈ 5.7 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 7.4 mm; implant space ≈ 2.5 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 10.2 mm; implant space ≈ 3.2 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 19.2 mm; implant space ≈ 16.1 mm; nearest critical structure: nasal floor. Periapical radiolucency near 16; lamina dura loss noted. Smaller radiolucency at 32. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0149", "images": ["images/placeholder_0149.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Insulin glargine, Omeprazole, Calcichew-D3, Metoprolol, Amlodipine, Bufomix Easyhaler, Esomeprazole, Duloxetine, Duroferon. Desired treatment: Measure crest-to-canal distances mandibularly in 37–47, and implant feasibility maxillary 35–45.", "answer": "Review of CBCT volume dated 210402. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 11: bone height ≈ 10.9 mm; implant space ≈ 6.7 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 11.5 mm; implant space ≈ 7.4 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 15.4 mm; implant space ≈ 6.7 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 9.2 mm; implant space ≈ 2.3 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 11.3 mm; implant space ≈ 3.0 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 14.7 mm; implant space ≈ 12.7 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 6.4 mm; implant space ≈ 1.3 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 4.2 mm; implant space ≈ 2.4 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 20.1 mm; implant space ≈ 12.3 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 21.0 mm; implant space ≈ 17.5 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Findings consistent with chronic apical periodontitis at 41 and 32."}
{"id": "case_0150", "images": ["images/placeholder_0150.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Calcichew-D3, Duroferon, Esomeprazole, Metoprolol, Betolvex, Bricanyl. Desired treatment: Please report bone height and available implant space for regions 35–45 and 17–27.", "answer": "Review of CBCT volume dated 240411. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 14: bone height ≈ 17.5 mm; implant space ≈ 13.1 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 14.8 mm; implant space ≈ 9.6 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 7.5 mm; implant space ≈ 1.9 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 21.9 mm; implant space ≈ 18.5 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 14.8 mm; implant space ≈ 7.7 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 15.7 mm; implant space ≈ 10.3 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 4.2 mm; implant space ≈ 0.7 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 17.3 mm; implant space ≈ 15.7 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 20.8 mm; implant space ≈ 16.2 mm; nearest critical structure: mandibular canal. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0151", "images": ["images/placeholder_0151.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Calcichew-D3, Omeprazole, Levaxin, Betolvex, Losartan, Esomeprazole, Trulicity. Desired treatment: Check the bone healing and trabecular fill post extraction sites 15–25.", "answer": "Review of CBCT volume dated 230824. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 21: bone height ≈ 9.0 mm; implant space ≈ 3.8 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 9.1 mm; implant space ≈ 0.8 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 15.5 mm; implant space ≈ 7.6 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 12.2 mm; implant space ≈ 3.3 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 7.1 mm; implant space ≈ 4.6 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 14.9 mm; implant space ≈ 6.1 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 17.6 mm; implant space ≈ 14.8 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 14.7 mm; implant space ≈ 9.5 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 8.9 mm; implant space ≈ 2.7 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 14.6 mm; implant space ≈ 9.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 46; lamina dura loss noted. Smaller radiolucency at 34. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Peri-implant bone loss at 23 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0152", "images": ["images/placeholder_0152.png"], "question": "Planning for sinus-related complaints. Brief history/status: Betolvex, Atorvastatin, Trulicity, Amlodipine, Omeprazole, Esomeprazole, Duroferon, Levaxin. Desired treatment: Check the bone healing and trabecular fill post extraction sites 15–25.", "answer": "Review of CBCT volume dated 230408. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 48: bone height ≈ 18.1 mm; implant space ≈ 11.7 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 15.0 mm; implant space ≈ 10.3 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 4.8 mm; implant space ≈ 2.4 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 10.8 mm; implant space ≈ 8.7 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 14.9 mm; implant space ≈ 10.7 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 18.8 mm; implant space ≈ 16.7 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 14.7 mm; implant space ≈ 8.7 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 16.6 mm; implant space ≈ 12.8 mm; nearest critical structure: mandibular canal. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Peri-implant bone loss at 45 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0153", "images": ["images/placeholder_0153.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Amlodipine, Trulicity, Losartan, Levaxin, Metoprolol, Duloxetine, Insulin glargine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 17–27.", "answer": "Review of CBCT volume dated 230526. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 14: bone height ≈ 20.2 mm; implant space ≈ 18.3 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 7.7 mm; implant space ≈ 3.9 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 7.1 mm; implant space ≈ 5.2 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 13.4 mm; implant space ≈ 7.5 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 19.1 mm; implant space ≈ 12.4 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 17.7 mm; implant space ≈ 14.1 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 12.1 mm; implant space ≈ 3.5 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 9.5 mm; implant space ≈ 7.9 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 15.5 mm; implant space ≈ 11.5 mm; nearest critical structure: mental foramen. Impression: Peri-implant bone loss at 34 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0154", "images": ["images/placeholder_0154.png"], "question": "Planning for full-arch restoration. Brief history/status: Calcichew-D3, Betolvex, Esomeprazole, Omeprazole, Atorvastatin, Trulicity, Metoprolol, Duloxetine. Desired treatment: Please report bone height and available implant space for regions 36–46 and 16–26.", "answer": "Review of CBCT volume dated 200624. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 32: bone height ≈ 6.2 mm; implant space ≈ 2.1 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 11.0 mm; implant space ≈ 2.8 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 8.9 mm; implant space ≈ 2.6 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 4.6 mm; implant space ≈ 0.6 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 21.0 mm; implant space ≈ 15.1 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 8.8 mm; implant space ≈ 6.3 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 10.6 mm; implant space ≈ 2.0 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 17.6 mm; implant space ≈ 15.0 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 21.4 mm; implant space ≈ 12.8 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 10.8 mm; implant space ≈ 6.5 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 27; lamina dura loss noted. Smaller radiolucency at 32. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination."}
{"id": "case_0155", "images": ["images/placeholder_0155.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Esomeprazole, Duloxetine, Amlodipine, Metoprolol, Calcichew-D3, Duroferon, Levaxin, Atorvastatin, Bufomix Easyhaler. Desired treatment: Provide measurements relevant to guided surgery stent planning for 36–46 and 37–47.", "answer": "Review of CBCT volume dated 250815. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 13: bone height ≈ 4.2 mm; implant space ≈ 2.1 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 20.0 mm; implant space ≈ 15.0 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 16.0 mm; implant space ≈ 11.1 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 8.1 mm; implant space ≈ 1.5 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 21.0 mm; implant space ≈ 12.3 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 20.8 mm; implant space ≈ 15.5 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 16.1 mm; implant space ≈ 9.7 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 20.2 mm; implant space ≈ 17.6 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 15.4 mm; implant space ≈ 9.8 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 20.2 mm; implant space ≈ 11.6 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0156", "images": ["images/placeholder_0156.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Metoprolol, Betolvex, Calcichew-D3, Duroferon, Trulicity. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 17–27.", "answer": "Review of CBCT volume dated 210217. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 26: bone height ≈ 15.3 mm; implant space ≈ 9.0 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 7.7 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 18.8 mm; implant space ≈ 14.4 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 10.0 mm; implant space ≈ 4.4 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 16.5 mm; implant space ≈ 14.9 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 10.9 mm; implant space ≈ 6.2 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 17.3 mm; implant space ≈ 12.7 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 17.8 mm; implant space ≈ 14.5 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 5.8 mm; implant space ≈ 3.0 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 15.2 mm; implant space ≈ 8.5 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0157", "images": ["images/placeholder_0157.png"], "question": "Planning for sinus-related complaints. Brief history/status: Duloxetine, Insulin glargine, Trulicity, Esomeprazole, Amlodipine, Duroferon, Losartan, Levaxin, Calcichew-D3. Desired treatment: Provide measurements relevant to guided surgery stent planning for 37–47 and 36–46.", "answer": "Review of CBCT volume dated 200503. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 15: bone height ≈ 15.7 mm; implant space ≈ 8.8 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 14.9 mm; implant space ≈ 13.3 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 15.3 mm; implant space ≈ 11.9 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 21.4 mm; implant space ≈ 15.3 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 18.1 mm; implant space ≈ 10.6 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 13.6 mm; implant space ≈ 6.2 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 18.7 mm; implant space ≈ 12.4 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 14.0 mm; implant space ≈ 5.7 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 11.9 mm; implant space ≈ 3.5 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 20.9 mm; implant space ≈ 15.8 mm; nearest critical structure: mandibular canal. Periapical radiolucency near 35; lamina dura loss noted. Smaller radiolucency at 34. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0158", "images": ["images/placeholder_0158.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Levaxin, Bufomix Easyhaler, Betolvex, Losartan, Atorvastatin, Duroferon, Trulicity, Amlodipine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 16–26.", "answer": "Review of CBCT volume dated 250928. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 44: bone height ≈ 20.5 mm; implant space ≈ 14.7 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 11.6 mm; implant space ≈ 3.3 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 16.2 mm; implant space ≈ 13.2 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 9.5 mm; implant space ≈ 1.7 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 16.4 mm; implant space ≈ 8.0 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 13.8 mm; implant space ≈ 8.3 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 19.1 mm; implant space ≈ 11.3 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 17.3 mm; implant space ≈ 8.5 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 16.6 mm; implant space ≈ 14.8 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 21.5 mm; implant space ≈ 18.4 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 35; lamina dura loss noted. Smaller radiolucency at 48. Impression: Vertical root fracture suspected at 33; recommend clinical correlation."}
{"id": "case_0159", "images": ["images/placeholder_0159.png"], "question": "Planning for implant planning evaluation. Brief history/status: Insulin glargine, Duloxetine, Amlodipine, Betolvex, Omeprazole, Bricanyl, Calcichew-D3. Desired treatment: Measure crest-to-canal distances mandibularly in 36–46, and implant feasibility maxillary 15–25.", "answer": "Review of CBCT volume dated 201123. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 28: bone height ≈ 7.8 mm; implant space ≈ 2.4 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 6.8 mm; implant space ≈ 5.2 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 16.7 mm; implant space ≈ 10.9 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 9.1 mm; implant space ≈ 6.6 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 19.9 mm; implant space ≈ 16.3 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 20.1 mm; implant space ≈ 15.3 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 19.6 mm; implant space ≈ 17.9 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 6.3 mm; implant space ≈ 2.4 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 16.5 mm; implant space ≈ 13.1 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 16.9 mm; implant space ≈ 11.8 mm; nearest critical structure: incisive canal. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0160", "images": ["images/placeholder_0160.png"], "question": "Planning for implant planning evaluation. Brief history/status: Insulin glargine, Trulicity, Betolvex, Bufomix Easyhaler, Metoprolol, Duroferon, Atorvastatin. Desired treatment: Evaluate periapical status of teeth 23, 13, and 28, and overall sinus condition.", "answer": "Review of CBCT volume dated 221217. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 31: bone height ≈ 20.4 mm; implant space ≈ 15.9 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 20.0 mm; implant space ≈ 13.5 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 6.3 mm; implant space ≈ 3.2 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 6.9 mm; implant space ≈ 3.8 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 6.8 mm; implant space ≈ 3.1 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 20.0 mm; implant space ≈ 13.3 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 8.3 mm; implant space ≈ 4.4 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 21.7 mm; implant space ≈ 16.3 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 20.3 mm; implant space ≈ 17.0 mm; nearest critical structure: mandibular canal. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0161", "images": ["images/placeholder_0161.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Bufomix Easyhaler, Trulicity, Omeprazole, Atorvastatin, Amlodipine. Desired treatment: Measure crest-to-canal distances mandibularly in 16–26, and implant feasibility maxillary 16–26.", "answer": "Review of CBCT volume dated 251019. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 15: bone height ≈ 15.3 mm; implant space ≈ 10.7 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 22.0 mm; implant space ≈ 17.9 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 9.3 mm; implant space ≈ 6.8 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 18.1 mm; implant space ≈ 11.8 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 4.1 mm; implant space ≈ 0.8 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 12.3 mm; implant space ≈ 3.6 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 10.2 mm; implant space ≈ 5.7 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 10.9 mm; implant space ≈ 7.5 mm; nearest critical structure: mental foramen. Region 27: bone height ≈ 8.4 mm; implant space ≈ 3.0 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 6.1 mm; implant space ≈ 4.3 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0162", "images": ["images/placeholder_0162.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Calcichew-D3, Insulin glargine, Metoprolol, Duloxetine, Trulicity, Amlodipine. Desired treatment: Check the bone healing and trabecular fill post extraction sites 35–45.", "answer": "Review of CBCT volume dated 220211. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 18: bone height ≈ 18.8 mm; implant space ≈ 12.2 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 16.6 mm; implant space ≈ 7.8 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 13.4 mm; implant space ≈ 11.2 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 12.1 mm; implant space ≈ 3.9 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 14.2 mm; implant space ≈ 7.5 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 17.0 mm; implant space ≈ 13.7 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 21.6 mm; implant space ≈ 17.4 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 7.4 mm; implant space ≈ 4.5 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 10.9 mm; implant space ≈ 7.3 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 6.8 mm; implant space ≈ 2.2 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0163", "images": ["images/placeholder_0163.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Betolvex, Calcichew-D3, Duroferon, Metoprolol, Atorvastatin, Levaxin, Insulin glargine, Bufomix Easyhaler. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 17–27.", "answer": "Review of CBCT volume dated 250925. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 23: bone height ≈ 14.5 mm; implant space ≈ 5.7 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 13.7 mm; implant space ≈ 5.0 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 10.3 mm; implant space ≈ 6.3 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 7.8 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 15.8 mm; implant space ≈ 10.2 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 7.0 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 11.7 mm; implant space ≈ 5.4 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 13.2 mm; implant space ≈ 7.6 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 9.0 mm; implant space ≈ 2.7 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 18; lamina dura loss noted. Smaller radiolucency at 46. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0164", "images": ["images/placeholder_0164.png"], "question": "Planning for sinus-related complaints. Brief history/status: Bricanyl, Betolvex, Amlodipine, Atorvastatin, Calcichew-D3, Levaxin, Duloxetine. Desired treatment: Please report bone height and available implant space for regions 35–45 and 36–46.", "answer": "Review of CBCT volume dated 220807. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 38: bone height ≈ 18.2 mm; implant space ≈ 9.4 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 13.0 mm; implant space ≈ 8.4 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 6.1 mm; implant space ≈ 0.1 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 8.1 mm; implant space ≈ 4.5 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 18.1 mm; implant space ≈ 13.7 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 18.6 mm; implant space ≈ 12.3 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 4.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 17.1 mm; implant space ≈ 12.7 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 18.5 mm; implant space ≈ 15.3 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 46; lamina dura loss noted. Smaller radiolucency at 28. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0165", "images": ["images/placeholder_0165.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Bufomix Easyhaler, Levaxin, Losartan, Bricanyl, Amlodipine, Calcichew-D3, Betolvex, Trulicity. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 17–27.", "answer": "Review of CBCT volume dated 220212. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 14: bone height ≈ 12.3 mm; implant space ≈ 6.1 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 7.6 mm; implant space ≈ 1.9 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 20.5 mm; implant space ≈ 18.5 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 8.6 mm; implant space ≈ 6.6 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 20.7 mm; implant space ≈ 15.2 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 17.2 mm; implant space ≈ 13.0 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 13.4 mm; implant space ≈ 7.4 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 7.6 mm; implant space ≈ 3.0 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 5.3 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Peri-implant bone loss at 11 within the coronal third, suggestive of peri-implantitis."}
{"id": "case_0166", "images": ["images/placeholder_0166.png"], "question": "Planning for review of post-implant healing. Brief history/status: Esomeprazole, Calcichew-D3, Bricanyl, Trulicity, Duloxetine, Insulin glargine, Metoprolol. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 200509. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 17: bone height ≈ 18.7 mm; implant space ≈ 13.8 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 8.3 mm; implant space ≈ 1.3 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 10.7 mm; implant space ≈ 4.1 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 9.5 mm; implant space ≈ 2.6 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 20.4 mm; implant space ≈ 18.8 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 21.3 mm; implant space ≈ 15.2 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 9.7 mm; implant space ≈ 5.5 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 7.5 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 16.6 mm; implant space ≈ 14.4 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 10.6 mm; implant space ≈ 2.1 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0167", "images": ["images/placeholder_0167.png"], "question": "Planning for implant planning evaluation. Brief history/status: Bufomix Easyhaler, Bricanyl, Insulin glargine, Esomeprazole, Duroferon, Levaxin, Calcichew-D3. Desired treatment: Quantify vertical bone loss around implants in 17–27 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 230914. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 18: bone height ≈ 21.3 mm; implant space ≈ 13.1 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 11.7 mm; implant space ≈ 4.5 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 15.2 mm; implant space ≈ 6.7 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 21.4 mm; implant space ≈ 14.4 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 7.9 mm; implant space ≈ 4.9 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 10.9 mm; implant space ≈ 4.7 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 21.3 mm; implant space ≈ 19.6 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 13.8 mm; implant space ≈ 7.8 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 20.5 mm; implant space ≈ 16.9 mm; nearest critical structure: mandibular canal. Impression: Impaction of third molar in quadrant 4 with mesioangular inclination."}
{"id": "case_0168", "images": ["images/placeholder_0168.png"], "question": "Planning for follow-up after extraction. Brief history/status: Atorvastatin, Insulin glargine, Calcichew-D3, Duroferon, Duloxetine, Esomeprazole, Metoprolol, Amlodipine. Desired treatment: Assess mandibular canal course and distance to apices in 15–25.", "answer": "Review of CBCT volume dated 250202. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 32: bone height ≈ 17.6 mm; implant space ≈ 12.6 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 6.5 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 12.7 mm; implant space ≈ 6.1 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 15.4 mm; implant space ≈ 7.3 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 12.1 mm; implant space ≈ 4.1 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 10.7 mm; implant space ≈ 1.9 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 9.8 mm; implant space ≈ 4.1 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 16.4 mm; implant space ≈ 13.0 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 20.4 mm; implant space ≈ 18.2 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 17.2 mm; implant space ≈ 11.7 mm; nearest critical structure: incisive canal. Periapical radiolucency near 46; lamina dura loss noted. Smaller radiolucency at 45. Impression: Cyst-like well-defined radiolucency near 28, likely radicular cyst."}
{"id": "case_0169", "images": ["images/placeholder_0169.png"], "question": "Planning for delayed healing post endodontic therapy. Brief history/status: Bricanyl, Bufomix Easyhaler, Trulicity, Atorvastatin, Amlodipine, Levaxin, Duroferon, Omeprazole. Desired treatment: Quantify vertical bone loss around implants in 37–47 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 210110. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 17: bone height ≈ 13.7 mm; implant space ≈ 8.9 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 10.0 mm; implant space ≈ 4.8 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 16.5 mm; implant space ≈ 8.5 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 7.6 mm; implant space ≈ 5.1 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 15.4 mm; implant space ≈ 10.9 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 10.2 mm; implant space ≈ 8.3 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 13.2 mm; implant space ≈ 8.4 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 12.7 mm; implant space ≈ 9.1 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 10.2 mm; implant space ≈ 3.3 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 12.9 mm; implant space ≈ 6.9 mm; nearest critical structure: anterior loop. Impression: Vertical root fracture suspected at 47; recommend clinical correlation."}
{"id": "case_0170", "images": ["images/placeholder_0170.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Omeprazole, Amlodipine, Esomeprazole, Atorvastatin, Bricanyl, Duloxetine. Desired treatment: Assess mandibular canal course and distance to apices in 15–25.", "answer": "Review of CBCT volume dated 220621. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 12: bone height ≈ 18.1 mm; implant space ≈ 9.2 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 6.2 mm; implant space ≈ 3.1 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 5.2 mm; implant space ≈ 0.4 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 13.2 mm; implant space ≈ 4.9 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 17.7 mm; implant space ≈ 13.3 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 14.4 mm; implant space ≈ 11.1 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 8.9 mm; implant space ≈ 5.2 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 9.4 mm; implant space ≈ 0.5 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 19.8 mm; implant space ≈ 15.4 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 21.7 mm; implant space ≈ 17.9 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 26; lamina dura loss noted. Smaller radiolucency at 14. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0171", "images": ["images/placeholder_0171.png"], "question": "Planning for implant planning evaluation. Brief history/status: Duloxetine, Losartan, Levaxin, Bufomix Easyhaler, Metoprolol, Atorvastatin, Betolvex, Esomeprazole, Insulin glargine. Desired treatment: Assess mandibular canal course and distance to apices in 36–46.", "answer": "Review of CBCT volume dated 211223. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 33: bone height ≈ 12.4 mm; implant space ≈ 3.6 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 19.9 mm; implant space ≈ 11.9 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 13.9 mm; implant space ≈ 10.8 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 17.9 mm; implant space ≈ 13.4 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 15.2 mm; implant space ≈ 11.1 mm; nearest critical structure: sinus floor. Region 45: bone height ≈ 21.6 mm; implant space ≈ 18.4 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 17.8 mm; implant space ≈ 11.6 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 20.8 mm; implant space ≈ 14.5 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 5.7 mm; implant space ≈ 2.5 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 21; lamina dura loss noted. Smaller radiolucency at 11. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Findings consistent with chronic apical periodontitis at 13 and 46."}
{"id": "case_0172", "images": ["images/placeholder_0172.png"], "question": "Planning for sinus-related complaints. Brief history/status: Calcichew-D3, Levaxin, Insulin glargine, Betolvex, Metoprolol, Esomeprazole, Losartan, Bufomix Easyhaler. Desired treatment: Provide measurements relevant to guided surgery stent planning for 36–46 and 16–26.", "answer": "Review of CBCT volume dated 220120. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 46: bone height ≈ 14.7 mm; implant space ≈ 12.0 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 13.5 mm; implant space ≈ 8.8 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 12.9 mm; implant space ≈ 9.5 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 19.3 mm; implant space ≈ 11.3 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 6.6 mm; implant space ≈ 4.5 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 16.3 mm; implant space ≈ 10.5 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 11.7 mm; implant space ≈ 7.9 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 18.5 mm; implant space ≈ 16.7 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 9.9 mm; implant space ≈ 7.5 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 15.0 mm; implant space ≈ 9.5 mm; nearest critical structure: incisive canal. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0173", "images": ["images/placeholder_0173.png"], "question": "Planning for implant planning evaluation. Brief history/status: Atorvastatin, Bricanyl, Duroferon, Trulicity, Insulin glargine. Desired treatment: Please report bone height and available implant space for regions 17–27 and 37–47.", "answer": "Review of CBCT volume dated 210428. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 36: bone height ≈ 21.7 mm; implant space ≈ 19.8 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 9.6 mm; implant space ≈ 1.7 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 21: bone height ≈ 7.2 mm; implant space ≈ 0.9 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 14.5 mm; implant space ≈ 7.7 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 21.1 mm; implant space ≈ 17.5 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 10.5 mm; implant space ≈ 6.8 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 9.6 mm; implant space ≈ 4.1 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 12.0 mm; implant space ≈ 5.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 16; lamina dura loss noted. Smaller radiolucency at 32. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0174", "images": ["images/placeholder_0174.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Betolvex, Trulicity, Metoprolol, Bricanyl, Insulin glargine, Amlodipine, Atorvastatin, Losartan, Calcichew-D3. Desired treatment: Review the sinus floor elevation and ridge thickness for 35–45.", "answer": "Review of CBCT volume dated 230102. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 41: bone height ≈ 13.2 mm; implant space ≈ 8.7 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 9.2 mm; implant space ≈ 3.8 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 21.7 mm; implant space ≈ 19.9 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 4.1 mm; implant space ≈ 0.4 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 21.7 mm; implant space ≈ 16.1 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 10.9 mm; implant space ≈ 7.3 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 11.3 mm; implant space ≈ 8.9 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 11.1 mm; implant space ≈ 9.2 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 7.9 mm; implant space ≈ 4.8 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 20.0 mm; implant space ≈ 12.6 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0175", "images": ["images/placeholder_0175.png"], "question": "Planning for review of post-implant healing. Brief history/status: Trulicity, Omeprazole, Duloxetine, Insulin glargine, Metoprolol, Bricanyl, Esomeprazole, Calcichew-D3. Desired treatment: Evaluate periapical status of teeth 14, 48, and 37, and overall sinus condition.", "answer": "Review of CBCT volume dated 230214. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 43: bone height ≈ 6.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 12.2 mm; implant space ≈ 6.5 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 17.4 mm; implant space ≈ 15.1 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 14.7 mm; implant space ≈ 7.4 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 4.4 mm; implant space ≈ 0.9 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 10.6 mm; implant space ≈ 8.6 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 11.7 mm; implant space ≈ 8.3 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 10.1 mm; implant space ≈ 8.4 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 8.9 mm; implant space ≈ 7.1 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 36; lamina dura loss noted. Smaller radiolucency at 46. Impression: Cyst-like well-defined radiolucency near 13, likely radicular cyst."}
{"id": "case_0176", "images": ["images/placeholder_0176.png"], "question": "Planning for follow-up after extraction. Brief history/status: Metoprolol, Bufomix Easyhaler, Betolvex, Esomeprazole, Amlodipine, Duroferon, Losartan, Bricanyl. Desired treatment: Check the bone healing and trabecular fill post extraction sites 37–47.", "answer": "Review of CBCT volume dated 250214. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 11: bone height ≈ 11.5 mm; implant space ≈ 3.4 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 7.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 9.6 mm; implant space ≈ 4.2 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 17.9 mm; implant space ≈ 9.4 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 13.1 mm; implant space ≈ 8.1 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 19.4 mm; implant space ≈ 11.3 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 13.8 mm; implant space ≈ 12.2 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 13.1 mm; implant space ≈ 10.0 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 10.0 mm; implant space ≈ 6.7 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 5.4 mm; implant space ≈ 2.1 mm; nearest critical structure: incisive canal. Periapical radiolucency near 42; lamina dura loss noted. Smaller radiolucency at 18. Impression: Vertical root fracture suspected at 41; recommend clinical correlation."}
{"id": "case_0177", "images": ["images/placeholder_0177.png"], "question": "Planning for implant planning evaluation. Brief history/status: Bufomix Easyhaler, Atorvastatin, Insulin glargine, Duloxetine, Omeprazole. Desired treatment: Evaluate periapical status of teeth 23, 16, and 22, and overall sinus condition.", "answer": "Review of CBCT volume dated 221023. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 35: bone height ≈ 16.8 mm; implant space ≈ 13.9 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 4.4 mm; implant space ≈ 2.4 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 9.0 mm; implant space ≈ 6.2 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 21.6 mm; implant space ≈ 18.9 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 19.5 mm; implant space ≈ 15.2 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 9.3 mm; implant space ≈ 1.5 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 6.3 mm; implant space ≈ 4.0 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 15.1 mm; implant space ≈ 6.3 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 11.3 mm; implant space ≈ 3.5 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 6.9 mm; implant space ≈ 0.3 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 34; lamina dura loss noted. Smaller radiolucency at 12. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Cyst-like well-defined radiolucency near 37, likely radicular cyst."}
{"id": "case_0178", "images": ["images/placeholder_0178.png"], "question": "Planning for full-arch restoration. Brief history/status: Levaxin, Esomeprazole, Metoprolol, Atorvastatin, Bufomix Easyhaler. Desired treatment: Assess mandibular canal course and distance to apices in 16–26.", "answer": "Review of CBCT volume dated 230408. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 25: bone height ≈ 16.2 mm; implant space ≈ 12.6 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 18.5 mm; implant space ≈ 17.0 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 21.4 mm; implant space ≈ 15.8 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 9.2 mm; implant space ≈ 1.8 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 6.6 mm; implant space ≈ 0.5 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 9.8 mm; implant space ≈ 1.2 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 21.9 mm; implant space ≈ 16.8 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 21.8 mm; implant space ≈ 13.7 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 20.5 mm; implant space ≈ 18.7 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 13.6 mm; implant space ≈ 6.0 mm; nearest critical structure: incisive canal. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0179", "images": ["images/placeholder_0179.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Omeprazole, Bufomix Easyhaler, Trulicity, Losartan, Bricanyl, Metoprolol, Amlodipine, Calcichew-D3, Betolvex. Desired treatment: Please report bone height and available implant space for regions 15–25 and 35–45.", "answer": "Review of CBCT volume dated 201118. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 45: bone height ≈ 18.3 mm; implant space ≈ 12.2 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 18.4 mm; implant space ≈ 11.7 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 20.9 mm; implant space ≈ 15.8 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 5.9 mm; implant space ≈ 0.7 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 8.9 mm; implant space ≈ 4.5 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 20.7 mm; implant space ≈ 12.6 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 5.4 mm; implant space ≈ 2.0 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 20.9 mm; implant space ≈ 14.8 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 12.7 mm; implant space ≈ 6.3 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 11.9 mm; implant space ≈ 5.4 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0180", "images": ["images/placeholder_0180.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Atorvastatin, Levaxin, Bufomix Easyhaler, Metoprolol, Trulicity. Desired treatment: Measure crest-to-canal distances mandibularly in 16–26, and implant feasibility maxillary 37–47.", "answer": "Review of CBCT volume dated 230421. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 17: bone height ≈ 21.0 mm; implant space ≈ 15.5 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 14.1 mm; implant space ≈ 11.1 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 9.0 mm; implant space ≈ 3.1 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 11.5 mm; implant space ≈ 9.9 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 18.4 mm; implant space ≈ 15.7 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 20.4 mm; implant space ≈ 17.5 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 8.1 mm; implant space ≈ 5.8 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 10.6 mm; implant space ≈ 7.8 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 21.4 mm; implant space ≈ 12.5 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 18.0 mm; implant space ≈ 13.2 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 44; lamina dura loss noted. Smaller radiolucency at 36. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination."}
{"id": "case_0181", "images": ["images/placeholder_0181.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Bricanyl, Losartan, Esomeprazole, Metoprolol, Omeprazole. Desired treatment: Report any signs of peri-implantitis and root resorption in 17–27.", "answer": "Review of CBCT volume dated 250508. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 48: bone height ≈ 8.4 mm; implant space ≈ 2.2 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 18.7 mm; implant space ≈ 11.6 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 17.9 mm; implant space ≈ 16.1 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 13.7 mm; implant space ≈ 9.5 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 14.4 mm; implant space ≈ 6.8 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 8.5 mm; implant space ≈ 2.9 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 9.7 mm; implant space ≈ 3.8 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 21.3 mm; implant space ≈ 19.7 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 8.6 mm; implant space ≈ 5.4 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 15.2 mm; implant space ≈ 13.0 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 22; lamina dura loss noted. Smaller radiolucency at 35. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0182", "images": ["images/placeholder_0182.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Insulin glargine, Calcichew-D3, Metoprolol, Omeprazole, Losartan, Bufomix Easyhaler, Amlodipine. Desired treatment: Please report bone height and available implant space for regions 16–26 and 16–26.", "answer": "Review of CBCT volume dated 241110. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 38: bone height ≈ 10.6 mm; implant space ≈ 4.1 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 20.0 mm; implant space ≈ 18.3 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 14.7 mm; implant space ≈ 6.7 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 4.2 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 18.4 mm; implant space ≈ 12.1 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 5.6 mm; implant space ≈ 1.4 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 6.5 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 6.4 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 7.4 mm; implant space ≈ 4.2 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 11.5 mm; implant space ≈ 9.5 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Vertical root fracture suspected at 34; recommend clinical correlation."}
{"id": "case_0183", "images": ["images/placeholder_0183.png"], "question": "Planning for implant planning evaluation. Brief history/status: Esomeprazole, Amlodipine, Metoprolol, Duroferon, Bufomix Easyhaler, Losartan, Insulin glargine, Duloxetine, Bricanyl. Desired treatment: Check the bone healing and trabecular fill post extraction sites 16–26.", "answer": "Review of CBCT volume dated 210217. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 44: bone height ≈ 18.2 mm; implant space ≈ 11.7 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 9.0 mm; implant space ≈ 2.8 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 8.1 mm; implant space ≈ 3.1 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 10.0 mm; implant space ≈ 8.1 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 10.8 mm; implant space ≈ 6.2 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 19.1 mm; implant space ≈ 16.1 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 8.8 mm; implant space ≈ 5.8 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 13.7 mm; implant space ≈ 5.2 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 18.3 mm; implant space ≈ 11.7 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 14.9 mm; implant space ≈ 7.8 mm; nearest critical structure: nasal floor. Periapical radiolucency near 43; lamina dura loss noted. Smaller radiolucency at 27. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0184", "images": ["images/placeholder_0184.png"], "question": "Planning for review of post-implant healing. Brief history/status: Calcichew-D3, Insulin glargine, Trulicity, Bufomix Easyhaler, Duroferon, Atorvastatin, Esomeprazole, Metoprolol, Bricanyl. Desired treatment: Provide measurements relevant to guided surgery stent planning for 37–47 and 37–47.", "answer": "Review of CBCT volume dated 250503. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 24: bone height ≈ 6.6 mm; implant space ≈ 0.1 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 12.0 mm; implant space ≈ 6.3 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 13.1 mm; implant space ≈ 10.6 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 20.8 mm; implant space ≈ 16.4 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 11.6 mm; implant space ≈ 4.8 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 14.3 mm; implant space ≈ 10.9 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 21.1 mm; implant space ≈ 12.3 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 6.2 mm; implant space ≈ 3.6 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 18.8 mm; implant space ≈ 12.1 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 12.9 mm; implant space ≈ 5.3 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0185", "images": ["images/placeholder_0185.png"], "question": "Planning for implant site evaluation. Brief history/status: Losartan, Omeprazole, Metoprolol, Betolvex, Esomeprazole. Desired treatment: Report any signs of peri-implantitis and root resorption in 36–46.", "answer": "Review of CBCT volume dated 250512. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 16: bone height ≈ 5.9 mm; implant space ≈ 3.5 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 4.1 mm; implant space ≈ 1.6 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 18.2 mm; implant space ≈ 14.3 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 11.4 mm; implant space ≈ 2.8 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 6.8 mm; implant space ≈ 5.1 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 19.3 mm; implant space ≈ 13.7 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 15.5 mm; implant space ≈ 12.1 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 20.9 mm; implant space ≈ 18.6 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 7.5 mm; implant space ≈ 0.1 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 17; lamina dura loss noted. Smaller radiolucency at 34. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Cyst-like well-defined radiolucency near 12, likely radicular cyst."}
{"id": "case_0186", "images": ["images/placeholder_0186.png"], "question": "Planning for full-arch restoration. Brief history/status: Levaxin, Bufomix Easyhaler, Betolvex, Esomeprazole, Metoprolol, Duroferon, Insulin glargine. Desired treatment: Assess mandibular canal course and distance to apices in 15–25.", "answer": "Review of CBCT volume dated 220604. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 26: bone height ≈ 15.8 mm; implant space ≈ 12.0 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 13.3 mm; implant space ≈ 4.4 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 10.8 mm; implant space ≈ 7.4 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 12.6 mm; implant space ≈ 6.6 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 16.7 mm; implant space ≈ 12.0 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 10.9 mm; implant space ≈ 3.5 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 15.9 mm; implant space ≈ 14.2 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 11.0 mm; implant space ≈ 4.1 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 21.8 mm; implant space ≈ 20.0 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 8.9 mm; implant space ≈ 6.5 mm; nearest critical structure: sinus floor. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Findings consistent with chronic apical periodontitis at 46 and 38."}
{"id": "case_0187", "images": ["images/placeholder_0187.png"], "question": "Planning for implant planning evaluation. Brief history/status: Atorvastatin, Insulin glargine, Calcichew-D3, Trulicity, Betolvex, Bufomix Easyhaler, Duroferon, Amlodipine, Levaxin. Desired treatment: Measure crest-to-canal distances mandibularly in 36–46, and implant feasibility maxillary 35–45.", "answer": "Review of CBCT volume dated 200724. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 26: bone height ≈ 17.7 mm; implant space ≈ 12.1 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 10.1 mm; implant space ≈ 2.8 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 12.4 mm; implant space ≈ 5.8 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 20.9 mm; implant space ≈ 18.3 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 8.8 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 18.7 mm; implant space ≈ 13.0 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 12.8 mm; implant space ≈ 10.7 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 10.9 mm; implant space ≈ 4.0 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 5.0 mm; implant space ≈ 0.9 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 9.8 mm; implant space ≈ 1.3 mm; nearest critical structure: sinus floor. Periapical radiolucency near 11; lamina dura loss noted. Smaller radiolucency at 16. Impression: Impaction of third molar in quadrant 4 with mesioangular inclination."}
{"id": "case_0188", "images": ["images/placeholder_0188.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Calcichew-D3, Bricanyl, Insulin glargine, Esomeprazole, Duroferon, Betolvex, Losartan. Desired treatment: Review the sinus floor elevation and ridge thickness for 15–25.", "answer": "Review of CBCT volume dated 230628. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 15: bone height ≈ 11.8 mm; implant space ≈ 6.7 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 15.9 mm; implant space ≈ 11.2 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 21.3 mm; implant space ≈ 13.5 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 19.9 mm; implant space ≈ 11.2 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 10.6 mm; implant space ≈ 6.2 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 4.5 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 21.1 mm; implant space ≈ 15.2 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 12.1 mm; implant space ≈ 5.9 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 13.8 mm; implant space ≈ 9.5 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0189", "images": ["images/placeholder_0189.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Insulin glargine, Calcichew-D3, Metoprolol, Bufomix Easyhaler, Levaxin, Betolvex. Desired treatment: Review the sinus floor elevation and ridge thickness for 36–46.", "answer": "Review of CBCT volume dated 250505. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 22: bone height ≈ 8.1 mm; implant space ≈ 3.1 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 13.4 mm; implant space ≈ 11.3 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 9.9 mm; implant space ≈ 1.2 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 11.0 mm; implant space ≈ 9.3 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 7.2 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 8.9 mm; implant space ≈ 3.1 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 13.2 mm; implant space ≈ 6.5 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 21.5 mm; implant space ≈ 15.7 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 18.4 mm; implant space ≈ 10.4 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 9.5 mm; implant space ≈ 0.5 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0190", "images": ["images/placeholder_0190.png"], "question": "Planning for pre-surgical bone mapping. Brief history/status: Levaxin, Insulin glargine, Bricanyl, Losartan, Amlodipine, Atorvastatin, Esomeprazole, Omeprazole. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.", "answer": "Review of CBCT volume dated 220719. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 28: bone height ≈ 13.5 mm; implant space ≈ 5.9 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 4.5 mm; implant space ≈ 2.8 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 12.2 mm; implant space ≈ 8.4 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 19.7 mm; implant space ≈ 15.2 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 20.3 mm; implant space ≈ 14.9 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 15.9 mm; implant space ≈ 9.1 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 15.1 mm; implant space ≈ 9.7 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 16.2 mm; implant space ≈ 7.6 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 16.4 mm; implant space ≈ 12.1 mm; nearest critical structure: incisive canal. Region 21: bone height ≈ 20.4 mm; implant space ≈ 17.9 mm; nearest critical structure: incisive canal. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0191", "images": ["images/placeholder_0191.png"], "question": "Planning for assessment for guided surgery. Brief history/status: Levaxin, Atorvastatin, Duloxetine, Bufomix Easyhaler, Amlodipine, Calcichew-D3, Duroferon, Bricanyl. Desired treatment: Review the sinus floor elevation and ridge thickness for 17–27.", "answer": "Review of CBCT volume dated 240122. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 14: bone height ≈ 19.5 mm; implant space ≈ 16.5 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 5.9 mm; implant space ≈ 2.8 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 19.4 mm; implant space ≈ 15.7 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 6.4 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 8.7 mm; implant space ≈ 0.1 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 15.5 mm; implant space ≈ 13.6 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 9.0 mm; implant space ≈ 7.2 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 6.6 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 18.8 mm; implant space ≈ 14.9 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 10.4 mm; implant space ≈ 8.2 mm; nearest critical structure: mandibular canal. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated."}
{"id": "case_0192", "images": ["images/placeholder_0192.png"], "question": "Planning for review of post-implant healing. Brief history/status: Bufomix Easyhaler, Duloxetine, Atorvastatin, Losartan, Calcichew-D3. Desired treatment: Please report bone height and available implant space for regions 37–47 and 17–27.", "answer": "Review of CBCT volume dated 200621. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 33: bone height ≈ 21.3 mm; implant space ≈ 17.9 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 6.3 mm; implant space ≈ 1.9 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 6.1 mm; implant space ≈ 4.3 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 20.6 mm; implant space ≈ 12.9 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 18.8 mm; implant space ≈ 11.3 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 21.0 mm; implant space ≈ 13.0 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 16.9 mm; implant space ≈ 9.0 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 13.7 mm; implant space ≈ 12.1 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Vertical root fracture suspected at 11; recommend clinical correlation."}
{"id": "case_0193", "images": ["images/placeholder_0193.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Trulicity, Betolvex, Amlodipine, Omeprazole, Bufomix Easyhaler. Desired treatment: Please report bone height and available implant space for regions 37–47 and 15–25.", "answer": "Review of CBCT volume dated 240301. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 46: bone height ≈ 6.3 mm; implant space ≈ 0.4 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 15.9 mm; implant space ≈ 12.7 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 5.0 mm; implant space ≈ 3.1 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 15.6 mm; implant space ≈ 6.8 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 17.3 mm; implant space ≈ 8.8 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 5.5 mm; implant space ≈ 1.9 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 10.3 mm; implant space ≈ 1.5 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 9.1 mm; implant space ≈ 5.3 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 20.2 mm; implant space ≈ 16.7 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 7.0 mm; implant space ≈ 1.2 mm; nearest critical structure: anterior loop. Periapical radiolucency near 13; lamina dura loss noted. Smaller radiolucency at 34. Impression: No acute pathology identified; anatomy within expected limits for planned procedures."}
{"id": "case_0194", "images": ["images/placeholder_0194.png"], "question": "Planning for review of post-implant healing. Brief history/status: Levaxin, Trulicity, Duloxetine, Omeprazole, Bufomix Easyhaler. Desired treatment: Evaluate periapical status of teeth 46, 34, and 32, and overall sinus condition.", "answer": "Review of CBCT volume dated 230505. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 13: bone height ≈ 5.0 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 10.4 mm; implant space ≈ 6.0 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 5.6 mm; implant space ≈ 1.7 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 17.5 mm; implant space ≈ 12.3 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 12.9 mm; implant space ≈ 9.0 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 12.2 mm; implant space ≈ 4.1 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 16.2 mm; implant space ≈ 10.3 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 16.1 mm; implant space ≈ 13.0 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 5.7 mm; implant space ≈ 2.8 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 17.4 mm; implant space ≈ 13.9 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0195", "images": ["images/placeholder_0195.png"], "question": "Planning for evaluation for bone graft placement. Brief history/status: Insulin glargine, Omeprazole, Atorvastatin, Trulicity, Bufomix Easyhaler, Levaxin, Betolvex, Amlodipine. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 15–25.", "answer": "Review of CBCT volume dated 250817. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 13: bone height ≈ 12.8 mm; implant space ≈ 5.9 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 15.3 mm; implant space ≈ 11.3 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 6.0 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 8.6 mm; implant space ≈ 4.1 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 4.5 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 4.6 mm; implant space ≈ 2.9 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 11.7 mm; implant space ≈ 5.0 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 10.8 mm; implant space ≈ 5.1 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 21.8 mm; implant space ≈ 14.6 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 5.3 mm; implant space ≈ 2.6 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 45; lamina dura loss noted. Smaller radiolucency at 41. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses."}
{"id": "case_0196", "images": ["images/placeholder_0196.png"], "question": "Planning for persistent pain on mastication. Brief history/status: Metoprolol, Esomeprazole, Bufomix Easyhaler, Betolvex, Omeprazole, Insulin glargine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 15–25.", "answer": "Review of CBCT volume dated 250219. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 37: bone height ≈ 7.7 mm; implant space ≈ 3.8 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 8.3 mm; implant space ≈ 6.2 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 15.1 mm; implant space ≈ 9.6 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 16.5 mm; implant space ≈ 10.8 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 21.9 mm; implant space ≈ 18.6 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 12.5 mm; implant space ≈ 8.6 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 7.0 mm; implant space ≈ 2.7 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 17.3 mm; implant space ≈ 13.3 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 18.7 mm; implant space ≈ 12.1 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 5.3 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Periapical radiolucency near 14; lamina dura loss noted. Smaller radiolucency at 41. Impression: Local infection resolved; no residual periapical radiolucency detected."}
{"id": "case_0197", "images": ["images/placeholder_0197.png"], "question": "Planning for sinus-related complaints. Brief history/status: Trulicity, Atorvastatin, Calcichew-D3, Betolvex, Amlodipine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 36–46 and 16–26.", "answer": "Review of CBCT volume dated 200921. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 11: bone height ≈ 19.3 mm; implant space ≈ 13.5 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 19.5 mm; implant space ≈ 10.8 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 9.4 mm; implant space ≈ 5.7 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 6.2 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 21: bone height ≈ 21.7 mm; implant space ≈ 14.8 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 20.2 mm; implant space ≈ 16.7 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 9.9 mm; implant space ≈ 5.5 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 10.9 mm; implant space ≈ 4.4 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 17.6 mm; implant space ≈ 15.8 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 10.4 mm; implant space ≈ 3.5 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0198", "images": ["images/placeholder_0198.png"], "question": "Planning for follow-up after extraction. Brief history/status: Bufomix Easyhaler, Atorvastatin, Esomeprazole, Metoprolol, Losartan. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 221108. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 26: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 14.2 mm; implant space ≈ 11.3 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 12.2 mm; implant space ≈ 5.4 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 8.6 mm; implant space ≈ 2.9 mm; nearest critical structure: mental foramen. Region 37: bone height ≈ 21.8 mm; implant space ≈ 18.3 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 10.0 mm; implant space ≈ 6.2 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 14.6 mm; implant space ≈ 12.3 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 14.0 mm; implant space ≈ 6.3 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 9.5 mm; implant space ≈ 1.1 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 9.0 mm; implant space ≈ 2.8 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Metallic restorations cause localized streak artifacts, slightly limiting detail. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0199", "images": ["images/placeholder_0199.png"], "question": "Planning for sinus-related complaints. Brief history/status: Omeprazole, Bufomix Easyhaler, Metoprolol, Amlodipine, Calcichew-D3, Insulin glargine. Desired treatment: Evaluate periapical status of teeth 16, 18, and 28, and overall sinus condition.", "answer": "Review of CBCT volume dated 200923. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 46: bone height ≈ 5.4 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 8.9 mm; implant space ≈ 6.9 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 10.1 mm; implant space ≈ 8.0 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 7.0 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 6.2 mm; implant space ≈ 0.6 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 9.7 mm; implant space ≈ 7.3 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 21.3 mm; implant space ≈ 18.1 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 12.5 mm; implant space ≈ 5.7 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 14.7 mm; implant space ≈ 12.9 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 11.6 mm; implant space ≈ 3.3 mm; nearest critical structure: mandibular canal. Periapical radiolucency near 34; lamina dura loss noted. Smaller radiolucency at 28. Impression: Normal bone density throughout; suitable for implant placement."}
{"id": "case_0200", "images": ["images/placeholder_0200.png"], "question": "Planning for pre-orthodontic assessment. Brief history/status: Bufomix Easyhaler, Esomeprazole, Losartan, Amlodipine, Duloxetine, Calcichew-D3, Levaxin, Atorvastatin, Omeprazole. Desired treatment: Quantify vertical bone loss around implants in 36–46 and assess anterior maxillary density.", "answer": "Review of CBCT volume dated 250825. Bone quality ranges from ordinary to reduced in posterior segments. Implant space referenced from 5 mm minimal bone width threshold. Region 24: bone height ≈ 10.1 mm; implant space ≈ 3.0 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 17.3 mm; implant space ≈ 8.7 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 14.4 mm; implant space ≈ 11.9 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 16.6 mm; implant space ≈ 8.6 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 21.9 mm; implant space ≈ 13.8 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 16.1 mm; implant space ≈ 7.8 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 12.8 mm; implant space ≈ 7.1 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 10.8 mm; implant space ≈ 8.7 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 11.8 mm; implant space ≈ 9.2 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 17.7 mm; implant space ≈ 14.1 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency near 48; lamina dura loss noted. Smaller radiolucency at 41. Impression: Vertical root fracture suspected at 43; recommend clinical correlation."}
{"id": "case_0001", "images": ["images/placeholder_0001.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Levaxin, Trulicity, Insulin glargine, Atorvastatin, Betolvex, Omeprazole, Esomeprazole. Desired treatment: Assess healing of extraction sockets and bone regeneration at 36–46.", "answer": "Review of CBCT dated 211008. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 14: bone height ≈ 5.5 mm; implant space ≈ 0 mm; nearby sinus floor. Region 18: bone height ≈ 8.8 mm; implant space ≈ 3.8 mm; nearby nasal floor. Region 24: bone height ≈ 17.0 mm; implant space ≈ 13.5 mm; nearby mental foramen. Region 11: bone height ≈ 13.3 mm; implant space ≈ 5.6 mm; nearby mandibular canal. Region 46: bone height ≈ 19.3 mm; implant space ≈ 16.8 mm; nearby anterior loop. Region 33: bone height ≈ 8.0 mm; implant space ≈ 4.7 mm; nearby sinus floor. Region 15: bone height ≈ 11.4 mm; implant space ≈ 7.2 mm; nearby mandibular canal. Region 31: bone height ≈ 7.5 mm; implant space ≈ 2.0 mm; nearby incisive canal. Region 47: bone height ≈ 21.6 mm; implant space ≈ 14.5 mm; nearby sinus floor. Region 25: bone height ≈ 6.1 mm; implant space ≈ 2.7 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Impression: Impacted molar in quadrant 3 associated with mild follicular space widening."}
{"id": "case_0002", "images": ["images/placeholder_0002.png"], "question": "Planning for prosthetic design planning. Brief history/status: Bricanyl, Levaxin, Betolvex, Atorvastatin, Losartan, Duloxetine, Insulin glargine. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 33–43 and 16–26.", "answer": "Review of CBCT dated 230414. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 22: bone height ≈ 18.9 mm; implant space ≈ 11.3 mm; nearby nasal floor. Region 25: bone height ≈ 6.6 mm; implant space ≈ 0 mm; nearby mental foramen. Region 38: bone height ≈ 20.4 mm; implant space ≈ 17.4 mm; nearby nasal floor. Region 34: bone height ≈ 10.1 mm; implant space ≈ 2.3 mm; nearby incisive canal. Region 32: bone height ≈ 13.2 mm; implant space ≈ 7.5 mm; nearby anterior loop. Region 42: bone height ≈ 20.7 mm; implant space ≈ 14.4 mm; nearby incisive canal. Region 21: bone height ≈ 5.3 mm; implant space ≈ 1.7 mm; nearby nasal floor. Region 48: bone height ≈ 16.9 mm; implant space ≈ 12.8 mm; nearby mental foramen. Region 33: bone height ≈ 5.0 mm; implant space ≈ 1.1 mm; nearby incisive canal. Region 15: bone height ≈ 16.9 mm; implant space ≈ 15.8 mm; nearby mandibular canal. Impression: Peri-implantitis changes evident at 43; marginal bone loss noted."}
{"id": "case_0003", "images": ["images/placeholder_0003.png"], "question": "Planning for bone graft planning. Brief history/status: Bricanyl, Metoprolol, Insulin glargine, Levaxin, Trulicity. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 33–43 and 16–26.", "answer": "Review of CBCT dated 240602. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 44: bone height ≈ 10.9 mm; implant space ≈ 7.3 mm; nearby sinus floor. Region 14: bone height ≈ 18.5 mm; implant space ≈ 11.8 mm; nearby nasal floor. Region 21: bone height ≈ 6.6 mm; implant space ≈ 0 mm; nearby anterior loop. Region 17: bone height ≈ 16.6 mm; implant space ≈ 13.7 mm; nearby anterior loop. Region 27: bone height ≈ 8.4 mm; implant space ≈ 1.5 mm; nearby sinus floor. Region 18: bone height ≈ 6.5 mm; implant space ≈ 5.0 mm; nearby sinus floor. Region 41: bone height ≈ 7.3 mm; implant space ≈ 4.5 mm; nearby sinus floor. Region 23: bone height ≈ 8.0 mm; implant space ≈ 5.6 mm; nearby incisive canal. Region 45: bone height ≈ 9.0 mm; implant space ≈ 5.9 mm; nearby nasal floor. Region 22: bone height ≈ 15.2 mm; implant space ≈ 12.2 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 11; minor sclerosis near 42. Image artifacts due to metallic restorations reduce detail locally. Impression: Impacted molar in quadrant 3 associated with mild follicular space widening."}
{"id": "case_0004", "images": ["images/placeholder_0004.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Trulicity, Insulin glargine, Bricanyl, Omeprazole, Losartan, Esomeprazole, Bufomix Easyhaler. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 33–43.", "answer": "Review of CBCT dated 210119. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 18: bone height ≈ 18.9 mm; implant space ≈ 14.9 mm; nearby nasal floor. Region 26: bone height ≈ 21.8 mm; implant space ≈ 20.7 mm; nearby mental foramen. Region 43: bone height ≈ 19.6 mm; implant space ≈ 13.0 mm; nearby mandibular canal. Region 13: bone height ≈ 5.6 mm; implant space ≈ 0 mm; nearby incisive canal. Region 44: bone height ≈ 15.4 mm; implant space ≈ 7.9 mm; nearby anterior loop. Region 17: bone height ≈ 19.0 mm; implant space ≈ 15.7 mm; nearby nasal floor. Region 42: bone height ≈ 16.2 mm; implant space ≈ 8.4 mm; nearby incisive canal. Region 38: bone height ≈ 19.7 mm; implant space ≈ 15.4 mm; nearby nasal floor. Region 34: bone height ≈ 10.5 mm; implant space ≈ 3.6 mm; nearby anterior loop. Region 25: bone height ≈ 5.3 mm; implant space ≈ 3.7 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Impacted molar in quadrant 3 associated with mild follicular space widening."}
{"id": "case_0005", "images": ["images/placeholder_0005.png"], "question": "Planning for bone graft planning. Brief history/status: Trulicity, Atorvastatin, Metoprolol, Calcichew-D3, Omeprazole. Desired treatment: Review periapical status and note any signs of infection in regions 38, 36, 27.", "answer": "Review of CBCT dated 231221. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 32: bone height ≈ 6.9 mm; implant space ≈ 4.0 mm; nearby sinus floor. Region 37: bone height ≈ 22.0 mm; implant space ≈ 16.9 mm; nearby anterior loop. Region 13: bone height ≈ 17.4 mm; implant space ≈ 16.1 mm; nearby sinus floor. Region 46: bone height ≈ 18.3 mm; implant space ≈ 12.7 mm; nearby sinus floor. Region 44: bone height ≈ 7.4 mm; implant space ≈ 3.3 mm; nearby mental foramen. Region 28: bone height ≈ 10.0 mm; implant space ≈ 6.8 mm; nearby sinus floor. Region 24: bone height ≈ 20.5 mm; implant space ≈ 19.1 mm; nearby incisive canal. Region 42: bone height ≈ 7.2 mm; implant space ≈ 0.9 mm; nearby mental foramen. Region 17: bone height ≈ 13.0 mm; implant space ≈ 10.9 mm; nearby anterior loop. Region 48: bone height ≈ 19.8 mm; implant space ≈ 18.5 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 27; minor sclerosis near 16. Impression: Peri-implantitis changes evident at 21; marginal bone loss noted."}
{"id": "case_0006", "images": ["images/placeholder_0006.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Betolvex, Trulicity, Esomeprazole, Bricanyl, Levaxin, Omeprazole, Amlodipine. Desired treatment: Review periapical status and note any signs of infection in regions 37, 16, 28.", "answer": "Review of CBCT dated 210326. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 33: bone height ≈ 15.8 mm; implant space ≈ 11.6 mm; nearby incisive canal. Region 18: bone height ≈ 12.1 mm; implant space ≈ 9.6 mm; nearby mental foramen. Region 37: bone height ≈ 14.2 mm; implant space ≈ 7.3 mm; nearby nasal floor. Region 14: bone height ≈ 14.7 mm; implant space ≈ 13.2 mm; nearby mandibular canal. Region 23: bone height ≈ 19.7 mm; implant space ≈ 15.2 mm; nearby mandibular canal. Region 47: bone height ≈ 11.4 mm; implant space ≈ 6.1 mm; nearby sinus floor. Region 35: bone height ≈ 5.4 mm; implant space ≈ 0 mm; nearby mental foramen. Region 25: bone height ≈ 7.1 mm; implant space ≈ 2.6 mm; nearby anterior loop. Region 28: bone height ≈ 7.6 mm; implant space ≈ 0.8 mm; nearby mandibular canal. Region 13: bone height ≈ 18.1 mm; implant space ≈ 12.6 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Impacted molar in quadrant 3 associated with mild follicular space widening."}
{"id": "case_0007", "images": ["images/placeholder_0007.png"], "question": "Planning for prosthetic design planning. Brief history/status: Duloxetine, Amlodipine, Betolvex, Esomeprazole, Levaxin, Bufomix Easyhaler. Desired treatment: Assess healing of extraction sockets and bone regeneration at 14–24.", "answer": "Review of CBCT dated 240324. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 24: bone height ≈ 12.2 mm; implant space ≈ 4.4 mm; nearby mandibular canal. Region 46: bone height ≈ 13.1 mm; implant space ≈ 9.8 mm; nearby mandibular canal. Region 18: bone height ≈ 19.2 mm; implant space ≈ 17.3 mm; nearby anterior loop. Region 23: bone height ≈ 9.0 mm; implant space ≈ 1.8 mm; nearby mental foramen. Region 13: bone height ≈ 18.4 mm; implant space ≈ 16.8 mm; nearby anterior loop. Region 35: bone height ≈ 19.9 mm; implant space ≈ 18.3 mm; nearby nasal floor. Region 14: bone height ≈ 16.6 mm; implant space ≈ 13.7 mm; nearby nasal floor. Region 16: bone height ≈ 9.1 mm; implant space ≈ 6.2 mm; nearby anterior loop. Region 47: bone height ≈ 20.0 mm; implant space ≈ 16.5 mm; nearby mental foramen. Region 15: bone height ≈ 5.7 mm; implant space ≈ 0 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 16; minor sclerosis near 35. Impression: Vertical root fracture suspected at 34, extending coronally."}
{"id": "case_0008", "images": ["images/placeholder_0008.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Losartan, Amlodipine, Calcichew-D3, Bufomix Easyhaler, Levaxin. Desired treatment: Check for cortical bone thinning or fenestrations near 13–23.", "answer": "Review of CBCT dated 210703. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 42: bone height ≈ 7.0 mm; implant space ≈ 0.9 mm; nearby anterior loop. Region 33: bone height ≈ 15.3 mm; implant space ≈ 12.4 mm; nearby nasal floor. Region 24: bone height ≈ 17.1 mm; implant space ≈ 14.2 mm; nearby incisive canal. Region 11: bone height ≈ 11.3 mm; implant space ≈ 7.8 mm; nearby sinus floor. Region 28: bone height ≈ 15.6 mm; implant space ≈ 10.5 mm; nearby mental foramen. Region 12: bone height ≈ 12.1 mm; implant space ≈ 8.8 mm; nearby incisive canal. Region 38: bone height ≈ 18.6 mm; implant space ≈ 12.4 mm; nearby sinus floor. Region 25: bone height ≈ 6.0 mm; implant space ≈ 0 mm; nearby incisive canal. Region 45: bone height ≈ 6.2 mm; implant space ≈ 0 mm; nearby anterior loop. Region 21: bone height ≈ 17.6 mm; implant space ≈ 16.0 mm; nearby nasal floor. Periapical radiolucency observed near 45; minor sclerosis near 25. Impression: Vertical root fracture suspected at 17, extending coronally."}
{"id": "case_0009", "images": ["images/placeholder_0009.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Bufomix Easyhaler, Trulicity, Omeprazole, Atorvastatin, Esomeprazole, Amlodipine, Levaxin, Duloxetine. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 36–46 and 34–44.", "answer": "Review of CBCT dated 250811. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 11: bone height ≈ 8.9 mm; implant space ≈ 5.1 mm; nearby nasal floor. Region 12: bone height ≈ 6.3 mm; implant space ≈ 1.4 mm; nearby mental foramen. Region 42: bone height ≈ 11.6 mm; implant space ≈ 5.1 mm; nearby anterior loop. Region 44: bone height ≈ 11.5 mm; implant space ≈ 7.8 mm; nearby nasal floor. Region 31: bone height ≈ 12.5 mm; implant space ≈ 10.9 mm; nearby incisive canal. Region 35: bone height ≈ 16.7 mm; implant space ≈ 9.5 mm; nearby nasal floor. Region 43: bone height ≈ 5.5 mm; implant space ≈ 0.2 mm; nearby sinus floor. Region 33: bone height ≈ 13.3 mm; implant space ≈ 9.4 mm; nearby sinus floor. Region 37: bone height ≈ 9.0 mm; implant space ≈ 6.6 mm; nearby nasal floor. Region 24: bone height ≈ 4.7 mm; implant space ≈ 1.8 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 15, extending coronally."}
{"id": "case_0010", "images": ["images/placeholder_0010.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Bufomix Easyhaler, Betolvex, Amlodipine, Trulicity, Calcichew-D3. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 33–43.", "answer": "Review of CBCT dated 211120. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 13: bone height ≈ 7.5 mm; implant space ≈ 4.8 mm; nearby sinus floor. Region 41: bone height ≈ 9.6 mm; implant space ≈ 3.1 mm; nearby incisive canal. Region 42: bone height ≈ 6.0 mm; implant space ≈ 3.0 mm; nearby nasal floor. Region 43: bone height ≈ 16.1 mm; implant space ≈ 13.9 mm; nearby incisive canal. Region 46: bone height ≈ 18.7 mm; implant space ≈ 15.6 mm; nearby mental foramen. Region 48: bone height ≈ 13.7 mm; implant space ≈ 6.5 mm; nearby nasal floor. Region 15: bone height ≈ 4.2 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 17: bone height ≈ 9.9 mm; implant space ≈ 6.0 mm; nearby mandibular canal. Region 14: bone height ≈ 8.6 mm; implant space ≈ 3.9 mm; nearby nasal floor. Region 18: bone height ≈ 21.1 mm; implant space ≈ 15.7 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 11; minor sclerosis near 24. Image artifacts due to metallic restorations reduce detail locally. Impression: Peri-implantitis changes evident at 32; marginal bone loss noted."}
{"id": "case_0011", "images": ["images/placeholder_0011.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Duloxetine, Bufomix Easyhaler, Trulicity, Betolvex, Amlodipine. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 33–43.", "answer": "Review of CBCT dated 210207. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 14: bone height ≈ 13.9 mm; implant space ≈ 9.1 mm; nearby incisive canal. Region 16: bone height ≈ 11.5 mm; implant space ≈ 10.4 mm; nearby nasal floor. Region 34: bone height ≈ 4.5 mm; implant space ≈ 0 mm; nearby sinus floor. Region 33: bone height ≈ 6.5 mm; implant space ≈ 0.4 mm; nearby anterior loop. Region 36: bone height ≈ 12.2 mm; implant space ≈ 6.9 mm; nearby sinus floor. Region 13: bone height ≈ 8.5 mm; implant space ≈ 7.0 mm; nearby nasal floor. Region 42: bone height ≈ 14.9 mm; implant space ≈ 10.7 mm; nearby incisive canal. Region 31: bone height ≈ 5.0 mm; implant space ≈ 0.2 mm; nearby nasal floor. Region 38: bone height ≈ 17.5 mm; implant space ≈ 15.1 mm; nearby anterior loop. Region 35: bone height ≈ 4.3 mm; implant space ≈ 0 mm; nearby sinus floor. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0012", "images": ["images/placeholder_0012.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Metoprolol, Atorvastatin, Levaxin, Betolvex, Omeprazole, Amlodipine, Trulicity, Bufomix Easyhaler. Desired treatment: Provide measurements for alveolar ridge width and height at 13–23.", "answer": "Review of CBCT dated 200110. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 18: bone height ≈ 6.9 mm; implant space ≈ 0.6 mm; nearby incisive canal. Region 23: bone height ≈ 11.3 mm; implant space ≈ 6.6 mm; nearby incisive canal. Region 15: bone height ≈ 8.7 mm; implant space ≈ 6.5 mm; nearby sinus floor. Region 33: bone height ≈ 8.3 mm; implant space ≈ 0.7 mm; nearby anterior loop. Region 46: bone height ≈ 20.9 mm; implant space ≈ 17.0 mm; nearby sinus floor. Region 41: bone height ≈ 7.5 mm; implant space ≈ 6.0 mm; nearby mental foramen. Region 43: bone height ≈ 5.6 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 17: bone height ≈ 15.0 mm; implant space ≈ 10.6 mm; nearby mandibular canal. Region 16: bone height ≈ 22.0 mm; implant space ≈ 19.3 mm; nearby sinus floor. Region 34: bone height ≈ 10.0 mm; implant space ≈ 4.1 mm; nearby anterior loop. Periapical radiolucency observed near 38; minor sclerosis near 13. Image artifacts due to metallic restorations reduce detail locally. Impression: Radiolucent lesion at 48 consistent with radicular cyst; recommend correlation."}
{"id": "case_0013", "images": ["images/placeholder_0013.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Duroferon, Omeprazole, Trulicity, Bricanyl, Bufomix Easyhaler. Desired treatment: Review periapical status and note any signs of infection in regions 36, 33, 14.", "answer": "Review of CBCT dated 211025. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 15: bone height ≈ 8.8 mm; implant space ≈ 3.1 mm; nearby anterior loop. Region 42: bone height ≈ 6.2 mm; implant space ≈ 0 mm; nearby incisive canal. Region 38: bone height ≈ 5.4 mm; implant space ≈ 2.2 mm; nearby mental foramen. Region 12: bone height ≈ 15.9 mm; implant space ≈ 9.7 mm; nearby anterior loop. Region 21: bone height ≈ 15.9 mm; implant space ≈ 9.9 mm; nearby mental foramen. Region 13: bone height ≈ 11.6 mm; implant space ≈ 9.7 mm; nearby mandibular canal. Region 33: bone height ≈ 16.4 mm; implant space ≈ 10.2 mm; nearby nasal floor. Region 26: bone height ≈ 14.3 mm; implant space ≈ 12.2 mm; nearby mental foramen. Region 11: bone height ≈ 16.9 mm; implant space ≈ 15.2 mm; nearby nasal floor. Region 48: bone height ≈ 11.0 mm; implant space ≈ 3.9 mm; nearby mandibular canal. Periapical radiolucency observed near 31; minor sclerosis near 43. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0014", "images": ["images/placeholder_0014.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Bufomix Easyhaler, Betolvex, Amlodipine, Insulin glargine, Levaxin. Desired treatment: Provide measurements for alveolar ridge width and height at 14–24.", "answer": "Review of CBCT dated 230109. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 21: bone height ≈ 12.8 mm; implant space ≈ 11.7 mm; nearby mandibular canal. Region 33: bone height ≈ 7.5 mm; implant space ≈ 3.1 mm; nearby anterior loop. Region 46: bone height ≈ 18.3 mm; implant space ≈ 11.1 mm; nearby mental foramen. Region 27: bone height ≈ 16.5 mm; implant space ≈ 8.8 mm; nearby nasal floor. Region 25: bone height ≈ 12.9 mm; implant space ≈ 11.1 mm; nearby mandibular canal. Region 35: bone height ≈ 18.3 mm; implant space ≈ 13.2 mm; nearby incisive canal. Region 34: bone height ≈ 6.5 mm; implant space ≈ 3.5 mm; nearby anterior loop. Region 26: bone height ≈ 4.5 mm; implant space ≈ 2.6 mm; nearby anterior loop. Region 44: bone height ≈ 21.5 mm; implant space ≈ 15.4 mm; nearby mandibular canal. Region 15: bone height ≈ 4.9 mm; implant space ≈ 1.3 mm; nearby nasal floor. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0015", "images": ["images/placeholder_0015.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Losartan, Bricanyl, Betolvex, Amlodipine, Bufomix Easyhaler, Metoprolol. Desired treatment: Check for cortical bone thinning or fenestrations near 16–26.", "answer": "Review of CBCT dated 250921. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 23: bone height ≈ 12.4 mm; implant space ≈ 4.9 mm; nearby incisive canal. Region 28: bone height ≈ 19.0 mm; implant space ≈ 14.1 mm; nearby anterior loop. Region 47: bone height ≈ 8.6 mm; implant space ≈ 0.8 mm; nearby anterior loop. Region 45: bone height ≈ 13.9 mm; implant space ≈ 10.2 mm; nearby mental foramen. Region 46: bone height ≈ 8.3 mm; implant space ≈ 6.0 mm; nearby nasal floor. Region 44: bone height ≈ 22.0 mm; implant space ≈ 20.2 mm; nearby sinus floor. Region 48: bone height ≈ 8.4 mm; implant space ≈ 1.6 mm; nearby mental foramen. Region 21: bone height ≈ 17.5 mm; implant space ≈ 15.8 mm; nearby mental foramen. Region 42: bone height ≈ 9.7 mm; implant space ≈ 3.0 mm; nearby mental foramen. Region 41: bone height ≈ 15.0 mm; implant space ≈ 11.8 mm; nearby incisive canal. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 18, extending coronally."}
{"id": "case_0016", "images": ["images/placeholder_0016.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Bufomix Easyhaler, Calcichew-D3, Losartan, Duloxetine, Metoprolol, Atorvastatin, Esomeprazole. Desired treatment: Assess proximity to mandibular canal and sinus floor for 33–43 and 34–44.", "answer": "Review of CBCT dated 221008. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 23: bone height ≈ 20.1 mm; implant space ≈ 15.3 mm; nearby mental foramen. Region 41: bone height ≈ 20.4 mm; implant space ≈ 16.2 mm; nearby nasal floor. Region 47: bone height ≈ 6.2 mm; implant space ≈ 0 mm; nearby nasal floor. Region 33: bone height ≈ 7.6 mm; implant space ≈ 2.2 mm; nearby nasal floor. Region 46: bone height ≈ 13.9 mm; implant space ≈ 9.4 mm; nearby sinus floor. Region 37: bone height ≈ 19.3 mm; implant space ≈ 12.6 mm; nearby incisive canal. Region 22: bone height ≈ 19.9 mm; implant space ≈ 13.4 mm; nearby sinus floor. Region 27: bone height ≈ 8.1 mm; implant space ≈ 3.3 mm; nearby incisive canal. Region 21: bone height ≈ 15.7 mm; implant space ≈ 12.3 mm; nearby mental foramen. Region 11: bone height ≈ 21.0 mm; implant space ≈ 17.0 mm; nearby incisive canal. Periapical radiolucency observed near 25; minor sclerosis near 12. Impression: Vertical root fracture suspected at 41, extending coronally."}
{"id": "case_0017", "images": ["images/placeholder_0017.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Bufomix Easyhaler, Duroferon, Betolvex, Amlodipine, Duloxetine, Bricanyl. Desired treatment: Assess healing of extraction sockets and bone regeneration at 36–46.", "answer": "Review of CBCT dated 200804. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 32: bone height ≈ 21.7 mm; implant space ≈ 17.3 mm; nearby anterior loop. Region 41: bone height ≈ 12.9 mm; implant space ≈ 7.0 mm; nearby nasal floor. Region 13: bone height ≈ 7.3 mm; implant space ≈ 0 mm; nearby sinus floor. Region 25: bone height ≈ 15.9 mm; implant space ≈ 10.6 mm; nearby anterior loop. Region 12: bone height ≈ 20.8 mm; implant space ≈ 14.9 mm; nearby sinus floor. Region 33: bone height ≈ 12.8 mm; implant space ≈ 9.6 mm; nearby anterior loop. Region 46: bone height ≈ 18.9 mm; implant space ≈ 17.7 mm; nearby nasal floor. Region 23: bone height ≈ 17.7 mm; implant space ≈ 12.3 mm; nearby anterior loop. Region 11: bone height ≈ 19.8 mm; implant space ≈ 13.7 mm; nearby incisive canal. Region 44: bone height ≈ 5.7 mm; implant space ≈ 2.5 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 41; minor sclerosis near 15. Image artifacts due to metallic restorations reduce detail locally. Impression: Findings consistent with apical periodontitis near 14 and 32."}
{"id": "case_0018", "images": ["images/placeholder_0018.png"], "question": "Planning for prosthetic design planning. Brief history/status: Levaxin, Losartan, Betolvex, Metoprolol, Calcichew-D3, Duloxetine. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 36–46.", "answer": "Review of CBCT dated 211201. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 17: bone height ≈ 6.8 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 31: bone height ≈ 11.5 mm; implant space ≈ 6.2 mm; nearby incisive canal. Region 26: bone height ≈ 14.2 mm; implant space ≈ 13.0 mm; nearby mental foramen. Region 16: bone height ≈ 6.3 mm; implant space ≈ 0.4 mm; nearby incisive canal. Region 13: bone height ≈ 17.2 mm; implant space ≈ 9.8 mm; nearby mental foramen. Region 28: bone height ≈ 5.6 mm; implant space ≈ 0.9 mm; nearby sinus floor. Region 18: bone height ≈ 9.2 mm; implant space ≈ 5.3 mm; nearby incisive canal. Region 43: bone height ≈ 12.2 mm; implant space ≈ 11.0 mm; nearby incisive canal. Region 36: bone height ≈ 12.5 mm; implant space ≈ 7.2 mm; nearby mental foramen. Region 44: bone height ≈ 18.8 mm; implant space ≈ 17.0 mm; nearby incisive canal. Impression: Signs of early osseointegration failure at 12; consider clinical review."}
{"id": "case_0019", "images": ["images/placeholder_0019.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Losartan, Insulin glargine, Omeprazole, Duloxetine, Bricanyl. Desired treatment: Measure ridge augmentation volume required at 36–46 and 36–46.", "answer": "Review of CBCT dated 220424. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 46: bone height ≈ 5.7 mm; implant space ≈ 4.6 mm; nearby mental foramen. Region 43: bone height ≈ 7.6 mm; implant space ≈ 3.1 mm; nearby nasal floor. Region 14: bone height ≈ 16.8 mm; implant space ≈ 10.1 mm; nearby anterior loop. Region 37: bone height ≈ 10.8 mm; implant space ≈ 8.9 mm; nearby nasal floor. Region 32: bone height ≈ 8.7 mm; implant space ≈ 0.8 mm; nearby sinus floor. Region 36: bone height ≈ 10.6 mm; implant space ≈ 6.2 mm; nearby anterior loop. Region 15: bone height ≈ 20.3 mm; implant space ≈ 13.9 mm; nearby sinus floor. Region 31: bone height ≈ 6.5 mm; implant space ≈ 3.3 mm; nearby mental foramen. Region 35: bone height ≈ 14.1 mm; implant space ≈ 8.4 mm; nearby incisive canal. Region 47: bone height ≈ 14.3 mm; implant space ≈ 6.8 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 47; minor sclerosis near 26. Impression: Radiolucent lesion at 42 consistent with radicular cyst; recommend correlation."}
{"id": "case_0020", "images": ["images/placeholder_0020.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Duloxetine, Bufomix Easyhaler, Atorvastatin, Bricanyl, Duroferon, Trulicity. Desired treatment: Check for cortical bone thinning or fenestrations near 16–26.", "answer": "Review of CBCT dated 240201. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 15: bone height ≈ 4.9 mm; implant space ≈ 0.1 mm; nearby nasal floor. Region 44: bone height ≈ 14.1 mm; implant space ≈ 6.9 mm; nearby nasal floor. Region 35: bone height ≈ 17.8 mm; implant space ≈ 10.7 mm; nearby mandibular canal. Region 33: bone height ≈ 5.1 mm; implant space ≈ 3.3 mm; nearby nasal floor. Region 34: bone height ≈ 18.4 mm; implant space ≈ 11.9 mm; nearby nasal floor. Region 32: bone height ≈ 15.1 mm; implant space ≈ 7.4 mm; nearby mandibular canal. Region 13: bone height ≈ 7.8 mm; implant space ≈ 2.6 mm; nearby nasal floor. Region 36: bone height ≈ 17.7 mm; implant space ≈ 15.2 mm; nearby mental foramen. Region 14: bone height ≈ 17.8 mm; implant space ≈ 11.9 mm; nearby anterior loop. Region 26: bone height ≈ 15.2 mm; implant space ≈ 8.3 mm; nearby anterior loop. Image artifacts due to metallic restorations reduce detail locally. Impression: Findings consistent with apical periodontitis near 37 and 14."}
{"id": "case_0021", "images": ["images/placeholder_0021.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Losartan, Insulin glargine, Betolvex, Omeprazole, Calcichew-D3, Trulicity, Amlodipine, Duloxetine. Desired treatment: Provide measurements for alveolar ridge width and height at 13–23.", "answer": "Review of CBCT dated 200519. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 23: bone height ≈ 10.9 mm; implant space ≈ 6.5 mm; nearby anterior loop. Region 46: bone height ≈ 19.8 mm; implant space ≈ 14.8 mm; nearby incisive canal. Region 26: bone height ≈ 21.3 mm; implant space ≈ 13.6 mm; nearby anterior loop. Region 21: bone height ≈ 12.0 mm; implant space ≈ 11.0 mm; nearby nasal floor. Region 12: bone height ≈ 6.5 mm; implant space ≈ 1.1 mm; nearby incisive canal. Region 34: bone height ≈ 18.5 mm; implant space ≈ 12.9 mm; nearby sinus floor. Region 17: bone height ≈ 14.9 mm; implant space ≈ 13.3 mm; nearby anterior loop. Region 42: bone height ≈ 6.4 mm; implant space ≈ 0.4 mm; nearby nasal floor. Region 31: bone height ≈ 8.5 mm; implant space ≈ 7.5 mm; nearby mandibular canal. Region 33: bone height ≈ 20.1 mm; implant space ≈ 16.9 mm; nearby anterior loop. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0022", "images": ["images/placeholder_0022.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Bricanyl, Bufomix Easyhaler, Calcichew-D3, Omeprazole, Trulicity, Metoprolol. Desired treatment: Measure ridge augmentation volume required at 36–46 and 16–26.", "answer": "Review of CBCT dated 251205. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 47: bone height ≈ 21.9 mm; implant space ≈ 18.7 mm; nearby incisive canal. Region 16: bone height ≈ 16.2 mm; implant space ≈ 10.3 mm; nearby anterior loop. Region 17: bone height ≈ 4.1 mm; implant space ≈ 0 mm; nearby anterior loop. Region 21: bone height ≈ 21.3 mm; implant space ≈ 15.3 mm; nearby sinus floor. Region 31: bone height ≈ 12.1 mm; implant space ≈ 5.1 mm; nearby anterior loop. Region 28: bone height ≈ 7.8 mm; implant space ≈ 5.0 mm; nearby mental foramen. Region 48: bone height ≈ 18.3 mm; implant space ≈ 14.5 mm; nearby nasal floor. Region 24: bone height ≈ 21.7 mm; implant space ≈ 14.5 mm; nearby incisive canal. Region 45: bone height ≈ 4.9 mm; implant space ≈ 0.8 mm; nearby mandibular canal. Region 12: bone height ≈ 16.3 mm; implant space ≈ 10.6 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 32; minor sclerosis near 16. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0023", "images": ["images/placeholder_0023.png"], "question": "Planning for bone graft planning. Brief history/status: Omeprazole, Amlodipine, Duroferon, Bufomix Easyhaler, Levaxin, Bricanyl. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 34–44.", "answer": "Review of CBCT dated 251102. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 32: bone height ≈ 12.4 mm; implant space ≈ 11.4 mm; nearby anterior loop. Region 18: bone height ≈ 8.7 mm; implant space ≈ 1.9 mm; nearby incisive canal. Region 41: bone height ≈ 19.3 mm; implant space ≈ 14.6 mm; nearby mandibular canal. Region 15: bone height ≈ 9.4 mm; implant space ≈ 7.9 mm; nearby mental foramen. Region 28: bone height ≈ 17.5 mm; implant space ≈ 11.9 mm; nearby mental foramen. Region 44: bone height ≈ 20.0 mm; implant space ≈ 18.2 mm; nearby nasal floor. Region 26: bone height ≈ 8.0 mm; implant space ≈ 2.8 mm; nearby mandibular canal. Region 34: bone height ≈ 14.0 mm; implant space ≈ 11.8 mm; nearby sinus floor. Region 23: bone height ≈ 17.1 mm; implant space ≈ 12.1 mm; nearby sinus floor. Region 35: bone height ≈ 16.4 mm; implant space ≈ 10.0 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Impression: Vertical root fracture suspected at 17, extending coronally."}
{"id": "case_0024", "images": ["images/placeholder_0024.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Levaxin, Duroferon, Losartan, Bricanyl, Metoprolol. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 16–26 and 16–26.", "answer": "Review of CBCT dated 251115. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 11: bone height ≈ 9.8 mm; implant space ≈ 6.2 mm; nearby incisive canal. Region 26: bone height ≈ 19.1 mm; implant space ≈ 16.0 mm; nearby nasal floor. Region 38: bone height ≈ 9.2 mm; implant space ≈ 4.3 mm; nearby anterior loop. Region 45: bone height ≈ 14.9 mm; implant space ≈ 10.3 mm; nearby mandibular canal. Region 34: bone height ≈ 19.0 mm; implant space ≈ 11.2 mm; nearby mental foramen. Region 48: bone height ≈ 6.9 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 17: bone height ≈ 13.5 mm; implant space ≈ 5.6 mm; nearby incisive canal. Region 47: bone height ≈ 19.9 mm; implant space ≈ 14.7 mm; nearby nasal floor. Region 24: bone height ≈ 17.8 mm; implant space ≈ 13.3 mm; nearby nasal floor. Region 25: bone height ≈ 14.6 mm; implant space ≈ 11.6 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Impression: Signs of early osseointegration failure at 25; consider clinical review."}
{"id": "case_0025", "images": ["images/placeholder_0025.png"], "question": "Planning for pathology review. Brief history/status: Losartan, Betolvex, Trulicity, Amlodipine, Esomeprazole. Desired treatment: Assess proximity to mandibular canal and sinus floor for 13–23 and 34–44.", "answer": "Review of CBCT dated 230221. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 45: bone height ≈ 13.4 mm; implant space ≈ 6.5 mm; nearby mental foramen. Region 41: bone height ≈ 15.4 mm; implant space ≈ 12.7 mm; nearby mandibular canal. Region 35: bone height ≈ 4.8 mm; implant space ≈ 0 mm; nearby mental foramen. Region 21: bone height ≈ 10.0 mm; implant space ≈ 2.0 mm; nearby mental foramen. Region 47: bone height ≈ 18.3 mm; implant space ≈ 13.0 mm; nearby mandibular canal. Region 34: bone height ≈ 18.3 mm; implant space ≈ 14.7 mm; nearby anterior loop. Region 14: bone height ≈ 22.0 mm; implant space ≈ 18.6 mm; nearby sinus floor. Region 48: bone height ≈ 18.7 mm; implant space ≈ 13.2 mm; nearby incisive canal. Region 32: bone height ≈ 20.6 mm; implant space ≈ 13.9 mm; nearby mental foramen. Region 46: bone height ≈ 14.7 mm; implant space ≈ 8.4 mm; nearby sinus floor. Periapical radiolucency observed near 33; minor sclerosis near 43. Impression: Impacted molar in quadrant 1 associated with mild follicular space widening."}
{"id": "case_0026", "images": ["images/placeholder_0026.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Trulicity, Duroferon, Esomeprazole, Amlodipine, Omeprazole, Metoprolol, Bufomix Easyhaler, Insulin glargine. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 220924. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 33: bone height ≈ 9.5 mm; implant space ≈ 3.3 mm; nearby anterior loop. Region 44: bone height ≈ 21.8 mm; implant space ≈ 17.1 mm; nearby mental foramen. Region 47: bone height ≈ 13.1 mm; implant space ≈ 6.1 mm; nearby mandibular canal. Region 42: bone height ≈ 15.1 mm; implant space ≈ 10.6 mm; nearby nasal floor. Region 48: bone height ≈ 20.1 mm; implant space ≈ 14.4 mm; nearby nasal floor. Region 21: bone height ≈ 4.2 mm; implant space ≈ 0 mm; nearby sinus floor. Region 13: bone height ≈ 15.6 mm; implant space ≈ 9.0 mm; nearby mental foramen. Region 16: bone height ≈ 15.0 mm; implant space ≈ 7.9 mm; nearby nasal floor. Region 35: bone height ≈ 10.7 mm; implant space ≈ 5.3 mm; nearby mandibular canal. Region 14: bone height ≈ 18.4 mm; implant space ≈ 10.6 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Impression: Findings consistent with apical periodontitis near 21 and 11."}
{"id": "case_0027", "images": ["images/placeholder_0027.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Levaxin, Calcichew-D3, Insulin glargine, Bricanyl, Duloxetine. Desired treatment: Assess proximity to mandibular canal and sinus floor for 16–26 and 13–23.", "answer": "Review of CBCT dated 210915. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 35: bone height ≈ 10.9 mm; implant space ≈ 3.1 mm; nearby nasal floor. Region 24: bone height ≈ 11.2 mm; implant space ≈ 7.9 mm; nearby mandibular canal. Region 45: bone height ≈ 4.9 mm; implant space ≈ 0.9 mm; nearby mandibular canal. Region 41: bone height ≈ 12.8 mm; implant space ≈ 6.0 mm; nearby anterior loop. Region 32: bone height ≈ 17.0 mm; implant space ≈ 11.8 mm; nearby anterior loop. Region 27: bone height ≈ 7.3 mm; implant space ≈ 4.7 mm; nearby nasal floor. Region 12: bone height ≈ 8.6 mm; implant space ≈ 7.4 mm; nearby mandibular canal. Region 18: bone height ≈ 16.3 mm; implant space ≈ 13.5 mm; nearby sinus floor. Region 22: bone height ≈ 7.7 mm; implant space ≈ 5.9 mm; nearby mental foramen. Region 46: bone height ≈ 6.9 mm; implant space ≈ 2.4 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 11; minor sclerosis near 24. Impression: Radiolucent lesion at 48 consistent with radicular cyst; recommend correlation."}
{"id": "case_0028", "images": ["images/placeholder_0028.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Bricanyl, Insulin glargine, Betolvex, Calcichew-D3, Duloxetine, Duroferon, Metoprolol, Omeprazole. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 34–44.", "answer": "Review of CBCT dated 210216. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 45: bone height ≈ 21.8 mm; implant space ≈ 16.0 mm; nearby incisive canal. Region 48: bone height ≈ 8.0 mm; implant space ≈ 2.8 mm; nearby anterior loop. Region 15: bone height ≈ 21.1 mm; implant space ≈ 15.7 mm; nearby mandibular canal. Region 44: bone height ≈ 13.1 mm; implant space ≈ 6.5 mm; nearby nasal floor. Region 23: bone height ≈ 8.3 mm; implant space ≈ 6.3 mm; nearby sinus floor. Region 33: bone height ≈ 15.0 mm; implant space ≈ 12.7 mm; nearby mandibular canal. Region 35: bone height ≈ 6.4 mm; implant space ≈ 0.9 mm; nearby sinus floor. Region 41: bone height ≈ 9.2 mm; implant space ≈ 4.2 mm; nearby anterior loop. Region 34: bone height ≈ 15.6 mm; implant space ≈ 10.0 mm; nearby incisive canal. Region 22: bone height ≈ 15.3 mm; implant space ≈ 8.4 mm; nearby anterior loop. Image artifacts due to metallic restorations reduce detail locally. Impression: Radiolucent lesion at 47 consistent with radicular cyst; recommend correlation."}
{"id": "case_0029", "images": ["images/placeholder_0029.png"], "question": "Planning for prosthetic design planning. Brief history/status: Omeprazole, Calcichew-D3, Duroferon, Insulin glargine, Bricanyl, Betolvex. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 36–46.", "answer": "Review of CBCT dated 200222. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 14: bone height ≈ 16.3 mm; implant space ≈ 8.4 mm; nearby incisive canal. Region 36: bone height ≈ 8.4 mm; implant space ≈ 5.6 mm; nearby incisive canal. Region 47: bone height ≈ 21.9 mm; implant space ≈ 17.9 mm; nearby incisive canal. Region 31: bone height ≈ 5.8 mm; implant space ≈ 4.6 mm; nearby mandibular canal. Region 24: bone height ≈ 12.7 mm; implant space ≈ 7.3 mm; nearby nasal floor. Region 26: bone height ≈ 22.0 mm; implant space ≈ 16.2 mm; nearby anterior loop. Region 11: bone height ≈ 15.7 mm; implant space ≈ 12.2 mm; nearby mental foramen. Region 15: bone height ≈ 14.2 mm; implant space ≈ 10.2 mm; nearby anterior loop. Region 16: bone height ≈ 17.9 mm; implant space ≈ 10.1 mm; nearby mental foramen. Region 41: bone height ≈ 10.2 mm; implant space ≈ 6.4 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0030", "images": ["images/placeholder_0030.png"], "question": "Planning for implant planning. Brief history/status: Levaxin, Bufomix Easyhaler, Duloxetine, Losartan, Trulicity, Betolvex, Bricanyl. Desired treatment: Assess proximity to mandibular canal and sinus floor for 36–46 and 34–44.", "answer": "Review of CBCT dated 201104. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 45: bone height ≈ 8.1 mm; implant space ≈ 3.2 mm; nearby mental foramen. Region 26: bone height ≈ 21.8 mm; implant space ≈ 19.1 mm; nearby mandibular canal. Region 34: bone height ≈ 11.8 mm; implant space ≈ 8.3 mm; nearby incisive canal. Region 15: bone height ≈ 5.6 mm; implant space ≈ 0.7 mm; nearby mandibular canal. Region 44: bone height ≈ 16.2 mm; implant space ≈ 11.2 mm; nearby sinus floor. Region 37: bone height ≈ 10.1 mm; implant space ≈ 8.1 mm; nearby mandibular canal. Region 31: bone height ≈ 19.8 mm; implant space ≈ 15.1 mm; nearby nasal floor. Region 23: bone height ≈ 10.7 mm; implant space ≈ 5.7 mm; nearby mental foramen. Region 13: bone height ≈ 11.4 mm; implant space ≈ 9.9 mm; nearby mandibular canal. Region 36: bone height ≈ 8.8 mm; implant space ≈ 2.4 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 34; minor sclerosis near 25. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0031", "images": ["images/placeholder_0031.png"], "question": "Planning for implant planning. Brief history/status: Insulin glargine, Losartan, Esomeprazole, Bufomix Easyhaler, Omeprazole. Desired treatment: Check for cortical bone thinning or fenestrations near 13–23.", "answer": "Review of CBCT dated 230417. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 11: bone height ≈ 20.0 mm; implant space ≈ 17.0 mm; nearby sinus floor. Region 15: bone height ≈ 17.5 mm; implant space ≈ 12.7 mm; nearby mandibular canal. Region 17: bone height ≈ 20.6 mm; implant space ≈ 16.2 mm; nearby incisive canal. Region 25: bone height ≈ 8.7 mm; implant space ≈ 3.4 mm; nearby mandibular canal. Region 21: bone height ≈ 11.7 mm; implant space ≈ 10.1 mm; nearby mandibular canal. Region 28: bone height ≈ 11.7 mm; implant space ≈ 6.7 mm; nearby incisive canal. Region 41: bone height ≈ 10.7 mm; implant space ≈ 4.9 mm; nearby mandibular canal. Region 38: bone height ≈ 9.3 mm; implant space ≈ 2.3 mm; nearby anterior loop. Region 26: bone height ≈ 9.4 mm; implant space ≈ 7.0 mm; nearby anterior loop. Region 18: bone height ≈ 11.5 mm; implant space ≈ 4.8 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Impression: Impacted molar in quadrant 4 associated with mild follicular space widening."}
{"id": "case_0032", "images": ["images/placeholder_0032.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Atorvastatin, Losartan, Bufomix Easyhaler, Duroferon, Metoprolol, Insulin glargine, Betolvex. Desired treatment: Provide measurements for alveolar ridge width and height at 14–24.", "answer": "Review of CBCT dated 201212. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 17: bone height ≈ 18.5 mm; implant space ≈ 14.5 mm; nearby anterior loop. Region 35: bone height ≈ 15.6 mm; implant space ≈ 8.9 mm; nearby incisive canal. Region 34: bone height ≈ 21.2 mm; implant space ≈ 20.1 mm; nearby nasal floor. Region 44: bone height ≈ 8.9 mm; implant space ≈ 3.0 mm; nearby nasal floor. Region 45: bone height ≈ 18.2 mm; implant space ≈ 12.0 mm; nearby mental foramen. Region 11: bone height ≈ 15.9 mm; implant space ≈ 13.2 mm; nearby mandibular canal. Region 46: bone height ≈ 17.5 mm; implant space ≈ 14.5 mm; nearby mental foramen. Region 21: bone height ≈ 9.4 mm; implant space ≈ 2.8 mm; nearby nasal floor. Region 31: bone height ≈ 14.7 mm; implant space ≈ 9.7 mm; nearby incisive canal. Region 27: bone height ≈ 19.2 mm; implant space ≈ 15.2 mm; nearby anterior loop. Periapical radiolucency observed near 32; minor sclerosis near 45. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0033", "images": ["images/placeholder_0033.png"], "question": "Planning for bone graft planning. Brief history/status: Levaxin, Bufomix Easyhaler, Trulicity, Omeprazole, Esomeprazole, Amlodipine. Desired treatment: Review periapical status and note any signs of infection in regions 48, 13, 27.", "answer": "Review of CBCT dated 240503. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 38: bone height ≈ 5.2 mm; implant space ≈ 0 mm; nearby sinus floor. Region 26: bone height ≈ 13.8 mm; implant space ≈ 12.1 mm; nearby incisive canal. Region 21: bone height ≈ 5.2 mm; implant space ≈ 1.5 mm; nearby nasal floor. Region 11: bone height ≈ 20.6 mm; implant space ≈ 15.1 mm; nearby mental foramen. Region 14: bone height ≈ 18.8 mm; implant space ≈ 14.4 mm; nearby nasal floor. Region 22: bone height ≈ 7.9 mm; implant space ≈ 3.7 mm; nearby mental foramen. Region 46: bone height ≈ 9.3 mm; implant space ≈ 4.1 mm; nearby sinus floor. Region 37: bone height ≈ 9.0 mm; implant space ≈ 3.0 mm; nearby sinus floor. Region 16: bone height ≈ 17.7 mm; implant space ≈ 16.5 mm; nearby mandibular canal. Region 33: bone height ≈ 12.5 mm; implant space ≈ 6.6 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Findings consistent with apical periodontitis near 21 and 44."}
{"id": "case_0034", "images": ["images/placeholder_0034.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Esomeprazole, Bricanyl, Calcichew-D3, Amlodipine, Levaxin, Duroferon, Insulin glargine. Desired treatment: Assess proximity to mandibular canal and sinus floor for 13–23 and 14–24.", "answer": "Review of CBCT dated 230902. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 27: bone height ≈ 18.8 mm; implant space ≈ 11.5 mm; nearby anterior loop. Region 25: bone height ≈ 14.6 mm; implant space ≈ 10.5 mm; nearby mandibular canal. Region 31: bone height ≈ 4.5 mm; implant space ≈ 0 mm; nearby anterior loop. Region 42: bone height ≈ 17.6 mm; implant space ≈ 9.8 mm; nearby mental foramen. Region 17: bone height ≈ 11.7 mm; implant space ≈ 5.3 mm; nearby incisive canal. Region 38: bone height ≈ 7.2 mm; implant space ≈ 0.2 mm; nearby anterior loop. Region 48: bone height ≈ 5.7 mm; implant space ≈ 4.7 mm; nearby mandibular canal. Region 34: bone height ≈ 17.9 mm; implant space ≈ 11.3 mm; nearby mandibular canal. Region 37: bone height ≈ 11.5 mm; implant space ≈ 8.7 mm; nearby incisive canal. Region 23: bone height ≈ 12.2 mm; implant space ≈ 6.8 mm; nearby nasal floor. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0035", "images": ["images/placeholder_0035.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Duloxetine, Bufomix Easyhaler, Atorvastatin, Trulicity, Duroferon. Desired treatment: Assess healing of extraction sockets and bone regeneration at 16–26.", "answer": "Review of CBCT dated 200707. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 17: bone height ≈ 11.5 mm; implant space ≈ 8.3 mm; nearby nasal floor. Region 26: bone height ≈ 5.8 mm; implant space ≈ 1.9 mm; nearby sinus floor. Region 23: bone height ≈ 11.0 mm; implant space ≈ 8.7 mm; nearby anterior loop. Region 36: bone height ≈ 5.8 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 11: bone height ≈ 14.1 mm; implant space ≈ 8.9 mm; nearby incisive canal. Region 34: bone height ≈ 13.9 mm; implant space ≈ 8.1 mm; nearby nasal floor. Region 16: bone height ≈ 5.8 mm; implant space ≈ 0 mm; nearby sinus floor. Region 37: bone height ≈ 20.0 mm; implant space ≈ 14.1 mm; nearby sinus floor. Region 45: bone height ≈ 13.1 mm; implant space ≈ 6.6 mm; nearby incisive canal. Region 27: bone height ≈ 10.2 mm; implant space ≈ 4.8 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0036", "images": ["images/placeholder_0036.png"], "question": "Planning for pathology review. Brief history/status: Calcichew-D3, Omeprazole, Levaxin, Bricanyl, Metoprolol, Duloxetine. Desired treatment: Assess proximity to mandibular canal and sinus floor for 33–43 and 16–26.", "answer": "Review of CBCT dated 200119. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 28: bone height ≈ 19.4 mm; implant space ≈ 15.3 mm; nearby incisive canal. Region 41: bone height ≈ 20.0 mm; implant space ≈ 17.0 mm; nearby nasal floor. Region 45: bone height ≈ 13.9 mm; implant space ≈ 11.7 mm; nearby mental foramen. Region 21: bone height ≈ 7.2 mm; implant space ≈ 6.1 mm; nearby anterior loop. Region 26: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby mental foramen. Region 32: bone height ≈ 8.8 mm; implant space ≈ 2.0 mm; nearby anterior loop. Region 16: bone height ≈ 21.0 mm; implant space ≈ 18.9 mm; nearby mandibular canal. Region 34: bone height ≈ 20.6 mm; implant space ≈ 19.0 mm; nearby anterior loop. Region 31: bone height ≈ 8.1 mm; implant space ≈ 1.4 mm; nearby nasal floor. Region 33: bone height ≈ 9.0 mm; implant space ≈ 2.1 mm; nearby mental foramen. Periapical radiolucency observed near 22; minor sclerosis near 32. Impression: Impacted molar in quadrant 1 associated with mild follicular space widening."}
{"id": "case_0037", "images": ["images/placeholder_0037.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Atorvastatin, Bufomix Easyhaler, Losartan, Duroferon, Esomeprazole. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 33–43 and 36–46.", "answer": "Review of CBCT dated 231221. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 43: bone height ≈ 6.5 mm; implant space ≈ 3.8 mm; nearby incisive canal. Region 23: bone height ≈ 14.5 mm; implant space ≈ 11.8 mm; nearby mandibular canal. Region 31: bone height ≈ 8.9 mm; implant space ≈ 3.5 mm; nearby sinus floor. Region 27: bone height ≈ 20.0 mm; implant space ≈ 15.3 mm; nearby nasal floor. Region 25: bone height ≈ 19.7 mm; implant space ≈ 15.0 mm; nearby incisive canal. Region 12: bone height ≈ 9.5 mm; implant space ≈ 6.1 mm; nearby nasal floor. Region 47: bone height ≈ 19.8 mm; implant space ≈ 13.9 mm; nearby anterior loop. Region 15: bone height ≈ 7.8 mm; implant space ≈ 6.7 mm; nearby nasal floor. Region 34: bone height ≈ 4.7 mm; implant space ≈ 3.2 mm; nearby nasal floor. Region 17: bone height ≈ 17.6 mm; implant space ≈ 13.5 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 44; minor sclerosis near 47. Impression: Peri-implantitis changes evident at 22; marginal bone loss noted."}
{"id": "case_0038", "images": ["images/placeholder_0038.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Duroferon, Metoprolol, Bufomix Easyhaler, Insulin glargine, Omeprazole, Duloxetine. Desired treatment: Assess healing of extraction sockets and bone regeneration at 14–24.", "answer": "Review of CBCT dated 230404. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 18: bone height ≈ 9.0 mm; implant space ≈ 2.4 mm; nearby nasal floor. Region 38: bone height ≈ 7.3 mm; implant space ≈ 3.8 mm; nearby anterior loop. Region 41: bone height ≈ 21.4 mm; implant space ≈ 14.1 mm; nearby mental foramen. Region 21: bone height ≈ 11.6 mm; implant space ≈ 8.4 mm; nearby mandibular canal. Region 44: bone height ≈ 11.8 mm; implant space ≈ 9.8 mm; nearby incisive canal. Region 36: bone height ≈ 12.5 mm; implant space ≈ 8.9 mm; nearby mental foramen. Region 16: bone height ≈ 15.2 mm; implant space ≈ 13.3 mm; nearby nasal floor. Region 25: bone height ≈ 15.6 mm; implant space ≈ 9.9 mm; nearby sinus floor. Region 24: bone height ≈ 8.8 mm; implant space ≈ 6.0 mm; nearby nasal floor. Region 45: bone height ≈ 21.3 mm; implant space ≈ 19.1 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 12; minor sclerosis near 38. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0039", "images": ["images/placeholder_0039.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Bufomix Easyhaler, Trulicity, Betolvex, Duloxetine, Omeprazole, Levaxin, Bricanyl, Amlodipine. Desired treatment: Review periapical status and note any signs of infection in regions 42, 47, 33.", "answer": "Review of CBCT dated 241228. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 42: bone height ≈ 5.2 mm; implant space ≈ 2.3 mm; nearby sinus floor. Region 21: bone height ≈ 21.2 mm; implant space ≈ 13.4 mm; nearby anterior loop. Region 24: bone height ≈ 13.8 mm; implant space ≈ 5.8 mm; nearby mandibular canal. Region 14: bone height ≈ 18.5 mm; implant space ≈ 12.8 mm; nearby nasal floor. Region 23: bone height ≈ 11.5 mm; implant space ≈ 5.6 mm; nearby mental foramen. Region 25: bone height ≈ 13.6 mm; implant space ≈ 6.4 mm; nearby mandibular canal. Region 38: bone height ≈ 5.9 mm; implant space ≈ 0.7 mm; nearby mandibular canal. Region 46: bone height ≈ 20.0 mm; implant space ≈ 18.3 mm; nearby mental foramen. Region 32: bone height ≈ 12.4 mm; implant space ≈ 8.4 mm; nearby nasal floor. Region 36: bone height ≈ 6.2 mm; implant space ≈ 0 mm; nearby anterior loop. Periapical radiolucency observed near 18; minor sclerosis near 16. Impression: Signs of early osseointegration failure at 36; consider clinical review."}
{"id": "case_0040", "images": ["images/placeholder_0040.png"], "question": "Planning for pathology review. Brief history/status: Calcichew-D3, Duloxetine, Trulicity, Esomeprazole, Duroferon, Insulin glargine, Levaxin. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 16–26.", "answer": "Review of CBCT dated 251127. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 46: bone height ≈ 6.8 mm; implant space ≈ 2.0 mm; nearby nasal floor. Region 24: bone height ≈ 21.8 mm; implant space ≈ 20.1 mm; nearby mandibular canal. Region 27: bone height ≈ 8.2 mm; implant space ≈ 1.0 mm; nearby mandibular canal. Region 32: bone height ≈ 11.0 mm; implant space ≈ 8.8 mm; nearby sinus floor. Region 43: bone height ≈ 12.4 mm; implant space ≈ 10.5 mm; nearby anterior loop. Region 44: bone height ≈ 9.6 mm; implant space ≈ 8.0 mm; nearby mandibular canal. Region 48: bone height ≈ 14.1 mm; implant space ≈ 7.3 mm; nearby nasal floor. Region 38: bone height ≈ 4.3 mm; implant space ≈ 0.6 mm; nearby anterior loop. Region 37: bone height ≈ 13.3 mm; implant space ≈ 7.6 mm; nearby incisive canal. Region 14: bone height ≈ 14.2 mm; implant space ≈ 10.4 mm; nearby mandibular canal. Periapical radiolucency observed near 23; minor sclerosis near 11. Impression: Radiolucent lesion at 28 consistent with radicular cyst; recommend correlation."}
{"id": "case_0041", "images": ["images/placeholder_0041.png"], "question": "Planning for bone graft planning. Brief history/status: Calcichew-D3, Amlodipine, Duroferon, Trulicity, Omeprazole, Bufomix Easyhaler, Insulin glargine. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 34–44.", "answer": "Review of CBCT dated 250323. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 41: bone height ≈ 4.4 mm; implant space ≈ 3.1 mm; nearby mandibular canal. Region 27: bone height ≈ 14.6 mm; implant space ≈ 9.4 mm; nearby sinus floor. Region 23: bone height ≈ 12.2 mm; implant space ≈ 4.4 mm; nearby mandibular canal. Region 24: bone height ≈ 13.2 mm; implant space ≈ 8.8 mm; nearby incisive canal. Region 31: bone height ≈ 12.3 mm; implant space ≈ 11.1 mm; nearby mandibular canal. Region 12: bone height ≈ 17.9 mm; implant space ≈ 13.8 mm; nearby mental foramen. Region 45: bone height ≈ 8.8 mm; implant space ≈ 0.8 mm; nearby sinus floor. Region 35: bone height ≈ 10.7 mm; implant space ≈ 6.9 mm; nearby anterior loop. Region 15: bone height ≈ 20.8 mm; implant space ≈ 16.1 mm; nearby nasal floor. Region 13: bone height ≈ 12.4 mm; implant space ≈ 5.8 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Impression: Signs of early osseointegration failure at 34; consider clinical review."}
{"id": "case_0042", "images": ["images/placeholder_0042.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Esomeprazole, Duloxetine, Bricanyl, Trulicity, Metoprolol, Bufomix Easyhaler, Amlodipine, Losartan. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 34–44.", "answer": "Review of CBCT dated 221004. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 34: bone height ≈ 18.4 mm; implant space ≈ 13.8 mm; nearby mental foramen. Region 28: bone height ≈ 14.6 mm; implant space ≈ 9.3 mm; nearby mandibular canal. Region 23: bone height ≈ 8.1 mm; implant space ≈ 0.6 mm; nearby anterior loop. Region 33: bone height ≈ 18.4 mm; implant space ≈ 16.8 mm; nearby incisive canal. Region 47: bone height ≈ 11.8 mm; implant space ≈ 10.6 mm; nearby anterior loop. Region 27: bone height ≈ 5.9 mm; implant space ≈ 2.7 mm; nearby mandibular canal. Region 12: bone height ≈ 13.1 mm; implant space ≈ 8.9 mm; nearby mental foramen. Region 41: bone height ≈ 9.8 mm; implant space ≈ 4.1 mm; nearby mental foramen. Region 37: bone height ≈ 13.6 mm; implant space ≈ 6.8 mm; nearby mandibular canal. Region 24: bone height ≈ 21.0 mm; implant space ≈ 17.7 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 27; minor sclerosis near 21. Impression: Vertical root fracture suspected at 17, extending coronally."}
{"id": "case_0043", "images": ["images/placeholder_0043.png"], "question": "Planning for pathology review. Brief history/status: Amlodipine, Insulin glargine, Duloxetine, Levaxin, Esomeprazole. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 200322. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 44: bone height ≈ 14.5 mm; implant space ≈ 11.3 mm; nearby nasal floor. Region 47: bone height ≈ 14.4 mm; implant space ≈ 11.4 mm; nearby anterior loop. Region 18: bone height ≈ 9.5 mm; implant space ≈ 7.4 mm; nearby mandibular canal. Region 46: bone height ≈ 17.1 mm; implant space ≈ 10.3 mm; nearby anterior loop. Region 11: bone height ≈ 17.0 mm; implant space ≈ 9.6 mm; nearby incisive canal. Region 48: bone height ≈ 7.3 mm; implant space ≈ 4.7 mm; nearby incisive canal. Region 37: bone height ≈ 14.4 mm; implant space ≈ 10.7 mm; nearby nasal floor. Region 33: bone height ≈ 11.7 mm; implant space ≈ 7.2 mm; nearby mental foramen. Region 14: bone height ≈ 14.3 mm; implant space ≈ 10.8 mm; nearby mental foramen. Region 26: bone height ≈ 17.7 mm; implant space ≈ 15.8 mm; nearby nasal floor. Periapical radiolucency observed near 15; minor sclerosis near 42. Impression: Peri-implantitis changes evident at 22; marginal bone loss noted."}
{"id": "case_0044", "images": ["images/placeholder_0044.png"], "question": "Planning for prosthetic design planning. Brief history/status: Metoprolol, Bufomix Easyhaler, Levaxin, Betolvex, Calcichew-D3, Atorvastatin, Insulin glargine. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 200922. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 35: bone height ≈ 12.7 mm; implant space ≈ 10.5 mm; nearby mandibular canal. Region 31: bone height ≈ 21.7 mm; implant space ≈ 19.5 mm; nearby mental foramen. Region 32: bone height ≈ 12.4 mm; implant space ≈ 5.3 mm; nearby incisive canal. Region 23: bone height ≈ 11.9 mm; implant space ≈ 7.6 mm; nearby anterior loop. Region 38: bone height ≈ 14.7 mm; implant space ≈ 12.4 mm; nearby incisive canal. Region 44: bone height ≈ 8.3 mm; implant space ≈ 3.2 mm; nearby anterior loop. Region 12: bone height ≈ 20.4 mm; implant space ≈ 16.5 mm; nearby mandibular canal. Region 13: bone height ≈ 11.0 mm; implant space ≈ 4.2 mm; nearby mental foramen. Region 43: bone height ≈ 14.1 mm; implant space ≈ 8.8 mm; nearby sinus floor. Region 48: bone height ≈ 16.4 mm; implant space ≈ 14.3 mm; nearby mandibular canal. Periapical radiolucency observed near 38; minor sclerosis near 21. Image artifacts due to metallic restorations reduce detail locally. Impression: Impacted molar in quadrant 4 associated with mild follicular space widening."}
{"id": "case_0045", "images": ["images/placeholder_0045.png"], "question": "Planning for implant planning. Brief history/status: Levaxin, Metoprolol, Esomeprazole, Losartan, Bufomix Easyhaler, Insulin glargine. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 16–26 and 13–23.", "answer": "Review of CBCT dated 250316. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 12: bone height ≈ 16.0 mm; implant space ≈ 13.7 mm; nearby sinus floor. Region 14: bone height ≈ 17.6 mm; implant space ≈ 12.8 mm; nearby mental foramen. Region 37: bone height ≈ 14.9 mm; implant space ≈ 8.7 mm; nearby anterior loop. Region 32: bone height ≈ 12.1 mm; implant space ≈ 4.3 mm; nearby anterior loop. Region 21: bone height ≈ 20.2 mm; implant space ≈ 18.8 mm; nearby mandibular canal. Region 26: bone height ≈ 10.2 mm; implant space ≈ 8.9 mm; nearby nasal floor. Region 16: bone height ≈ 21.5 mm; implant space ≈ 17.6 mm; nearby nasal floor. Region 25: bone height ≈ 14.3 mm; implant space ≈ 7.2 mm; nearby anterior loop. Region 31: bone height ≈ 13.1 mm; implant space ≈ 8.7 mm; nearby anterior loop. Region 44: bone height ≈ 15.7 mm; implant space ≈ 8.5 mm; nearby nasal floor. Periapical radiolucency observed near 47; minor sclerosis near 36. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 27, extending coronally."}
{"id": "case_0046", "images": ["images/placeholder_0046.png"], "question": "Planning for prosthetic design planning. Brief history/status: Duloxetine, Esomeprazole, Bricanyl, Losartan, Metoprolol, Calcichew-D3. Desired treatment: Measure ridge augmentation volume required at 34–44 and 33–43.", "answer": "Review of CBCT dated 251103. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 22: bone height ≈ 13.2 mm; implant space ≈ 6.5 mm; nearby incisive canal. Region 21: bone height ≈ 6.2 mm; implant space ≈ 4.0 mm; nearby incisive canal. Region 45: bone height ≈ 11.8 mm; implant space ≈ 6.7 mm; nearby sinus floor. Region 28: bone height ≈ 17.8 mm; implant space ≈ 15.6 mm; nearby mandibular canal. Region 27: bone height ≈ 14.9 mm; implant space ≈ 9.2 mm; nearby sinus floor. Region 36: bone height ≈ 11.1 mm; implant space ≈ 6.7 mm; nearby mandibular canal. Region 18: bone height ≈ 12.0 mm; implant space ≈ 9.0 mm; nearby anterior loop. Region 42: bone height ≈ 16.6 mm; implant space ≈ 13.4 mm; nearby mandibular canal. Region 24: bone height ≈ 5.6 mm; implant space ≈ 3.8 mm; nearby mandibular canal. Region 41: bone height ≈ 13.5 mm; implant space ≈ 11.7 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0047", "images": ["images/placeholder_0047.png"], "question": "Planning for prosthetic design planning. Brief history/status: Metoprolol, Betolvex, Omeprazole, Bufomix Easyhaler, Calcichew-D3, Levaxin. Desired treatment: Assess healing of extraction sockets and bone regeneration at 16–26.", "answer": "Review of CBCT dated 200605. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 12: bone height ≈ 17.9 mm; implant space ≈ 11.7 mm; nearby mandibular canal. Region 43: bone height ≈ 5.7 mm; implant space ≈ 1.5 mm; nearby mental foramen. Region 48: bone height ≈ 10.9 mm; implant space ≈ 4.9 mm; nearby sinus floor. Region 31: bone height ≈ 13.3 mm; implant space ≈ 7.8 mm; nearby anterior loop. Region 25: bone height ≈ 5.6 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 47: bone height ≈ 6.9 mm; implant space ≈ 1.9 mm; nearby anterior loop. Region 18: bone height ≈ 21.0 mm; implant space ≈ 19.0 mm; nearby sinus floor. Region 45: bone height ≈ 7.7 mm; implant space ≈ 4.9 mm; nearby mandibular canal. Region 27: bone height ≈ 15.0 mm; implant space ≈ 8.7 mm; nearby nasal floor. Region 23: bone height ≈ 8.6 mm; implant space ≈ 3.6 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Findings consistent with apical periodontitis near 34 and 28."}
{"id": "case_0048", "images": ["images/placeholder_0048.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Atorvastatin, Insulin glargine, Calcichew-D3, Duloxetine, Losartan, Trulicity, Duroferon, Esomeprazole. Desired treatment: Review periapical status and note any signs of infection in regions 13, 28, 37.", "answer": "Review of CBCT dated 240310. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 42: bone height ≈ 20.6 mm; implant space ≈ 12.9 mm; nearby mental foramen. Region 11: bone height ≈ 10.6 mm; implant space ≈ 3.3 mm; nearby mandibular canal. Region 34: bone height ≈ 12.3 mm; implant space ≈ 4.4 mm; nearby anterior loop. Region 41: bone height ≈ 8.4 mm; implant space ≈ 1.2 mm; nearby sinus floor. Region 43: bone height ≈ 15.0 mm; implant space ≈ 12.0 mm; nearby mandibular canal. Region 18: bone height ≈ 21.6 mm; implant space ≈ 16.4 mm; nearby incisive canal. Region 28: bone height ≈ 8.5 mm; implant space ≈ 4.7 mm; nearby mandibular canal. Region 44: bone height ≈ 20.9 mm; implant space ≈ 17.9 mm; nearby nasal floor. Region 24: bone height ≈ 7.4 mm; implant space ≈ 4.6 mm; nearby sinus floor. Region 13: bone height ≈ 17.6 mm; implant space ≈ 14.4 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 34; minor sclerosis near 48. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 33, extending coronally."}
{"id": "case_0049", "images": ["images/placeholder_0049.png"], "question": "Planning for pathology review. Brief history/status: Metoprolol, Betolvex, Trulicity, Calcichew-D3, Atorvastatin, Bricanyl, Losartan, Duroferon. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 13–23.", "answer": "Review of CBCT dated 231212. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 48: bone height ≈ 7.7 mm; implant space ≈ 0.5 mm; nearby incisive canal. Region 27: bone height ≈ 19.7 mm; implant space ≈ 13.8 mm; nearby incisive canal. Region 37: bone height ≈ 8.8 mm; implant space ≈ 1.5 mm; nearby anterior loop. Region 45: bone height ≈ 9.7 mm; implant space ≈ 7.5 mm; nearby mandibular canal. Region 15: bone height ≈ 5.5 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 46: bone height ≈ 10.8 mm; implant space ≈ 8.3 mm; nearby mandibular canal. Region 34: bone height ≈ 5.5 mm; implant space ≈ 0 mm; nearby nasal floor. Region 35: bone height ≈ 10.4 mm; implant space ≈ 9.1 mm; nearby sinus floor. Region 47: bone height ≈ 12.3 mm; implant space ≈ 6.4 mm; nearby nasal floor. Region 23: bone height ≈ 6.1 mm; implant space ≈ 2.8 mm; nearby incisive canal. Periapical radiolucency observed near 42; minor sclerosis near 48. Image artifacts due to metallic restorations reduce detail locally. Impression: Signs of early osseointegration failure at 42; consider clinical review."}
{"id": "case_0050", "images": ["images/placeholder_0050.png"], "question": "Planning for prosthetic design planning. Brief history/status: Metoprolol, Esomeprazole, Calcichew-D3, Insulin glargine, Trulicity, Betolvex, Duroferon, Bricanyl. Desired treatment: Provide measurements for alveolar ridge width and height at 13–23.", "answer": "Review of CBCT dated 200315. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 33: bone height ≈ 16.9 mm; implant space ≈ 9.5 mm; nearby sinus floor. Region 21: bone height ≈ 7.7 mm; implant space ≈ 6.3 mm; nearby anterior loop. Region 47: bone height ≈ 4.9 mm; implant space ≈ 0 mm; nearby anterior loop. Region 12: bone height ≈ 8.8 mm; implant space ≈ 1.5 mm; nearby mental foramen. Region 17: bone height ≈ 7.7 mm; implant space ≈ 3.5 mm; nearby incisive canal. Region 22: bone height ≈ 15.4 mm; implant space ≈ 7.8 mm; nearby mandibular canal. Region 16: bone height ≈ 4.2 mm; implant space ≈ 0 mm; nearby mental foramen. Region 27: bone height ≈ 19.6 mm; implant space ≈ 11.9 mm; nearby mandibular canal. Region 24: bone height ≈ 21.1 mm; implant space ≈ 18.2 mm; nearby mandibular canal. Region 41: bone height ≈ 11.9 mm; implant space ≈ 6.4 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 12; minor sclerosis near 23. Impression: Peri-implantitis changes evident at 41; marginal bone loss noted."}
{"id": "case_0051", "images": ["images/placeholder_0051.png"], "question": "Planning for implant planning. Brief history/status: Calcichew-D3, Bricanyl, Atorvastatin, Duloxetine, Losartan, Esomeprazole, Betolvex. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 13–23 and 36–46.", "answer": "Review of CBCT dated 240118. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 42: bone height ≈ 14.7 mm; implant space ≈ 10.3 mm; nearby sinus floor. Region 36: bone height ≈ 14.7 mm; implant space ≈ 10.7 mm; nearby incisive canal. Region 11: bone height ≈ 5.7 mm; implant space ≈ 0.5 mm; nearby mandibular canal. Region 26: bone height ≈ 16.3 mm; implant space ≈ 10.2 mm; nearby anterior loop. Region 14: bone height ≈ 10.3 mm; implant space ≈ 6.0 mm; nearby mental foramen. Region 32: bone height ≈ 21.3 mm; implant space ≈ 14.8 mm; nearby sinus floor. Region 44: bone height ≈ 19.4 mm; implant space ≈ 15.3 mm; nearby mandibular canal. Region 22: bone height ≈ 6.8 mm; implant space ≈ 5.3 mm; nearby mandibular canal. Region 31: bone height ≈ 7.8 mm; implant space ≈ 6.1 mm; nearby sinus floor. Region 21: bone height ≈ 10.0 mm; implant space ≈ 7.7 mm; nearby anterior loop. Periapical radiolucency observed near 34; minor sclerosis near 11. Impression: Findings consistent with apical periodontitis near 22 and 27."}
{"id": "case_0052", "images": ["images/placeholder_0052.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Atorvastatin, Calcichew-D3, Levaxin, Bufomix Easyhaler, Esomeprazole, Trulicity, Losartan. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 201126. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 42: bone height ≈ 14.5 mm; implant space ≈ 8.8 mm; nearby sinus floor. Region 46: bone height ≈ 11.2 mm; implant space ≈ 4.2 mm; nearby anterior loop. Region 21: bone height ≈ 11.6 mm; implant space ≈ 9.2 mm; nearby sinus floor. Region 38: bone height ≈ 12.1 mm; implant space ≈ 8.3 mm; nearby anterior loop. Region 14: bone height ≈ 9.2 mm; implant space ≈ 1.7 mm; nearby mental foramen. Region 25: bone height ≈ 7.2 mm; implant space ≈ 2.1 mm; nearby incisive canal. Region 36: bone height ≈ 14.4 mm; implant space ≈ 12.7 mm; nearby anterior loop. Region 23: bone height ≈ 20.8 mm; implant space ≈ 18.2 mm; nearby mental foramen. Region 48: bone height ≈ 19.4 mm; implant space ≈ 15.8 mm; nearby mental foramen. Region 11: bone height ≈ 18.4 mm; implant space ≈ 14.7 mm; nearby mental foramen. Periapical radiolucency observed near 32; minor sclerosis near 38. Impression: Vertical root fracture suspected at 12, extending coronally."}
{"id": "case_0053", "images": ["images/placeholder_0053.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Calcichew-D3, Duloxetine, Losartan, Levaxin, Insulin glargine, Betolvex. Desired treatment: Check for cortical bone thinning or fenestrations near 13–23.", "answer": "Review of CBCT dated 231202. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 15: bone height ≈ 21.6 mm; implant space ≈ 17.9 mm; nearby sinus floor. Region 22: bone height ≈ 15.0 mm; implant space ≈ 12.5 mm; nearby mandibular canal. Region 24: bone height ≈ 6.1 mm; implant space ≈ 0.8 mm; nearby sinus floor. Region 26: bone height ≈ 7.5 mm; implant space ≈ 5.9 mm; nearby anterior loop. Region 48: bone height ≈ 17.0 mm; implant space ≈ 13.9 mm; nearby anterior loop. Region 12: bone height ≈ 12.6 mm; implant space ≈ 9.3 mm; nearby sinus floor. Region 14: bone height ≈ 17.0 mm; implant space ≈ 9.2 mm; nearby mental foramen. Region 18: bone height ≈ 5.5 mm; implant space ≈ 0 mm; nearby anterior loop. Region 37: bone height ≈ 13.3 mm; implant space ≈ 11.3 mm; nearby anterior loop. Region 38: bone height ≈ 21.3 mm; implant space ≈ 19.7 mm; nearby mandibular canal. Impression: Adequate bone volume present for standard implant placement."}
{"id": "case_0054", "images": ["images/placeholder_0054.png"], "question": "Planning for implant planning. Brief history/status: Levaxin, Betolvex, Metoprolol, Amlodipine, Calcichew-D3, Esomeprazole. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 14–24 and 33–43.", "answer": "Review of CBCT dated 240115. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 41: bone height ≈ 16.8 mm; implant space ≈ 12.7 mm; nearby incisive canal. Region 24: bone height ≈ 6.4 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 13: bone height ≈ 21.7 mm; implant space ≈ 17.4 mm; nearby incisive canal. Region 15: bone height ≈ 13.1 mm; implant space ≈ 10.0 mm; nearby mental foramen. Region 42: bone height ≈ 12.4 mm; implant space ≈ 9.2 mm; nearby nasal floor. Region 46: bone height ≈ 4.7 mm; implant space ≈ 3.2 mm; nearby nasal floor. Region 22: bone height ≈ 18.3 mm; implant space ≈ 11.5 mm; nearby anterior loop. Region 47: bone height ≈ 17.7 mm; implant space ≈ 16.7 mm; nearby mental foramen. Region 12: bone height ≈ 13.8 mm; implant space ≈ 10.3 mm; nearby nasal floor. Region 18: bone height ≈ 21.8 mm; implant space ≈ 14.5 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 32; minor sclerosis near 24. Image artifacts due to metallic restorations reduce detail locally. Impression: Peri-implantitis changes evident at 24; marginal bone loss noted."}
{"id": "case_0055", "images": ["images/placeholder_0055.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Duloxetine, Atorvastatin, Bufomix Easyhaler, Duroferon, Trulicity. Desired treatment: Assess healing of extraction sockets and bone regeneration at 34–44.", "answer": "Review of CBCT dated 210714. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 21: bone height ≈ 14.3 mm; implant space ≈ 10.2 mm; nearby mental foramen. Region 38: bone height ≈ 5.1 mm; implant space ≈ 1.1 mm; nearby incisive canal. Region 12: bone height ≈ 10.4 mm; implant space ≈ 8.7 mm; nearby nasal floor. Region 14: bone height ≈ 8.9 mm; implant space ≈ 4.5 mm; nearby sinus floor. Region 27: bone height ≈ 11.5 mm; implant space ≈ 9.5 mm; nearby sinus floor. Region 34: bone height ≈ 8.8 mm; implant space ≈ 2.0 mm; nearby nasal floor. Region 23: bone height ≈ 18.3 mm; implant space ≈ 12.5 mm; nearby nasal floor. Region 46: bone height ≈ 21.9 mm; implant space ≈ 19.0 mm; nearby incisive canal. Region 43: bone height ≈ 4.3 mm; implant space ≈ 0.3 mm; nearby nasal floor. Region 41: bone height ≈ 4.7 mm; implant space ≈ 0 mm; nearby mandibular canal. Impression: Radiolucent lesion at 44 consistent with radicular cyst; recommend correlation."}
{"id": "case_0056", "images": ["images/placeholder_0056.png"], "question": "Planning for bone graft planning. Brief history/status: Calcichew-D3, Insulin glargine, Levaxin, Esomeprazole, Losartan, Atorvastatin. Desired treatment: Check for cortical bone thinning or fenestrations near 13–23.", "answer": "Review of CBCT dated 230120. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 15: bone height ≈ 6.4 mm; implant space ≈ 0 mm; nearby mental foramen. Region 47: bone height ≈ 13.1 mm; implant space ≈ 9.8 mm; nearby mandibular canal. Region 28: bone height ≈ 10.9 mm; implant space ≈ 5.7 mm; nearby mental foramen. Region 25: bone height ≈ 6.8 mm; implant space ≈ 1.1 mm; nearby mental foramen. Region 41: bone height ≈ 19.8 mm; implant space ≈ 12.5 mm; nearby mandibular canal. Region 48: bone height ≈ 5.4 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 22: bone height ≈ 20.9 mm; implant space ≈ 13.2 mm; nearby nasal floor. Region 43: bone height ≈ 5.3 mm; implant space ≈ 4.2 mm; nearby mental foramen. Region 21: bone height ≈ 11.7 mm; implant space ≈ 4.2 mm; nearby mental foramen. Region 31: bone height ≈ 13.1 mm; implant space ≈ 7.4 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 41; minor sclerosis near 15. Impression: Peri-implantitis changes evident at 48; marginal bone loss noted."}
{"id": "case_0057", "images": ["images/placeholder_0057.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Bricanyl, Duroferon, Amlodipine, Atorvastatin, Betolvex, Levaxin. Desired treatment: Assess proximity to mandibular canal and sinus floor for 13–23 and 36–46.", "answer": "Review of CBCT dated 230605. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 38: bone height ≈ 15.4 mm; implant space ≈ 7.8 mm; nearby incisive canal. Region 32: bone height ≈ 5.1 mm; implant space ≈ 2.2 mm; nearby mental foramen. Region 15: bone height ≈ 14.3 mm; implant space ≈ 9.2 mm; nearby incisive canal. Region 46: bone height ≈ 13.6 mm; implant space ≈ 11.3 mm; nearby mandibular canal. Region 42: bone height ≈ 20.2 mm; implant space ≈ 13.2 mm; nearby nasal floor. Region 14: bone height ≈ 16.6 mm; implant space ≈ 14.6 mm; nearby sinus floor. Region 25: bone height ≈ 17.8 mm; implant space ≈ 16.1 mm; nearby nasal floor. Region 34: bone height ≈ 10.3 mm; implant space ≈ 6.6 mm; nearby mental foramen. Region 12: bone height ≈ 18.7 mm; implant space ≈ 15.4 mm; nearby anterior loop. Region 28: bone height ≈ 12.4 mm; implant space ≈ 6.5 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 48; minor sclerosis near 27. Image artifacts due to metallic restorations reduce detail locally. Impression: Peri-implantitis changes evident at 26; marginal bone loss noted."}
{"id": "case_0058", "images": ["images/placeholder_0058.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Losartan, Trulicity, Duloxetine, Amlodipine, Esomeprazole, Atorvastatin, Bufomix Easyhaler, Metoprolol. Desired treatment: Provide measurements for alveolar ridge width and height at 13–23.", "answer": "Review of CBCT dated 230204. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 25: bone height ≈ 13.2 mm; implant space ≈ 10.2 mm; nearby sinus floor. Region 46: bone height ≈ 7.6 mm; implant space ≈ 2.0 mm; nearby nasal floor. Region 12: bone height ≈ 17.9 mm; implant space ≈ 16.1 mm; nearby anterior loop. Region 21: bone height ≈ 9.2 mm; implant space ≈ 2.1 mm; nearby sinus floor. Region 28: bone height ≈ 21.1 mm; implant space ≈ 18.4 mm; nearby incisive canal. Region 24: bone height ≈ 13.6 mm; implant space ≈ 8.1 mm; nearby mental foramen. Region 42: bone height ≈ 18.3 mm; implant space ≈ 17.3 mm; nearby incisive canal. Region 23: bone height ≈ 21.3 mm; implant space ≈ 14.7 mm; nearby anterior loop. Region 35: bone height ≈ 7.7 mm; implant space ≈ 3.9 mm; nearby mandibular canal. Region 14: bone height ≈ 11.6 mm; implant space ≈ 9.4 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0059", "images": ["images/placeholder_0059.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Bufomix Easyhaler, Esomeprazole, Metoprolol, Amlodipine, Losartan, Duloxetine. Desired treatment: Assess healing of extraction sockets and bone regeneration at 33–43.", "answer": "Review of CBCT dated 240911. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 14: bone height ≈ 9.9 mm; implant space ≈ 7.5 mm; nearby incisive canal. Region 45: bone height ≈ 11.6 mm; implant space ≈ 8.7 mm; nearby mental foramen. Region 25: bone height ≈ 16.9 mm; implant space ≈ 10.7 mm; nearby mental foramen. Region 32: bone height ≈ 13.9 mm; implant space ≈ 7.5 mm; nearby anterior loop. Region 24: bone height ≈ 18.3 mm; implant space ≈ 13.0 mm; nearby nasal floor. Region 42: bone height ≈ 21.7 mm; implant space ≈ 15.3 mm; nearby incisive canal. Region 34: bone height ≈ 16.0 mm; implant space ≈ 11.6 mm; nearby nasal floor. Region 44: bone height ≈ 8.3 mm; implant space ≈ 1.0 mm; nearby incisive canal. Region 47: bone height ≈ 11.4 mm; implant space ≈ 7.3 mm; nearby mandibular canal. Region 37: bone height ≈ 10.5 mm; implant space ≈ 9.2 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 24, extending coronally."}
{"id": "case_0060", "images": ["images/placeholder_0060.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Metoprolol, Losartan, Bricanyl, Duloxetine, Atorvastatin, Omeprazole, Esomeprazole. Desired treatment: Check for cortical bone thinning or fenestrations near 14–24.", "answer": "Review of CBCT dated 250416. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 25: bone height ≈ 6.5 mm; implant space ≈ 5.4 mm; nearby mandibular canal. Region 15: bone height ≈ 7.5 mm; implant space ≈ 4.4 mm; nearby anterior loop. Region 26: bone height ≈ 9.9 mm; implant space ≈ 3.5 mm; nearby anterior loop. Region 41: bone height ≈ 16.2 mm; implant space ≈ 12.3 mm; nearby anterior loop. Region 43: bone height ≈ 7.9 mm; implant space ≈ 0.6 mm; nearby sinus floor. Region 13: bone height ≈ 7.9 mm; implant space ≈ 3.4 mm; nearby anterior loop. Region 22: bone height ≈ 4.9 mm; implant space ≈ 0.6 mm; nearby mandibular canal. Region 11: bone height ≈ 19.4 mm; implant space ≈ 12.3 mm; nearby mandibular canal. Region 42: bone height ≈ 15.9 mm; implant space ≈ 8.7 mm; nearby anterior loop. Region 31: bone height ≈ 14.5 mm; implant space ≈ 12.6 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 34; minor sclerosis near 33. Impression: Vertical root fracture suspected at 45, extending coronally."}
{"id": "case_0061", "images": ["images/placeholder_0061.png"], "question": "Planning for prosthetic design planning. Brief history/status: Duloxetine, Bricanyl, Amlodipine, Levaxin, Esomeprazole, Bufomix Easyhaler, Losartan, Atorvastatin. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 16–26.", "answer": "Review of CBCT dated 220623. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 43: bone height ≈ 5.6 mm; implant space ≈ 0 mm; nearby nasal floor. Region 44: bone height ≈ 11.5 mm; implant space ≈ 9.4 mm; nearby sinus floor. Region 28: bone height ≈ 19.4 mm; implant space ≈ 16.6 mm; nearby mandibular canal. Region 27: bone height ≈ 18.0 mm; implant space ≈ 14.5 mm; nearby anterior loop. Region 47: bone height ≈ 18.0 mm; implant space ≈ 16.0 mm; nearby incisive canal. Region 13: bone height ≈ 19.7 mm; implant space ≈ 14.5 mm; nearby incisive canal. Region 46: bone height ≈ 10.2 mm; implant space ≈ 4.1 mm; nearby mandibular canal. Region 45: bone height ≈ 15.0 mm; implant space ≈ 12.6 mm; nearby sinus floor. Region 31: bone height ≈ 20.9 mm; implant space ≈ 15.8 mm; nearby nasal floor. Region 37: bone height ≈ 11.1 mm; implant space ≈ 8.5 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 38; minor sclerosis near 12. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0062", "images": ["images/placeholder_0062.png"], "question": "Planning for implant planning. Brief history/status: Metoprolol, Duroferon, Amlodipine, Levaxin, Insulin glargine. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 36–46.", "answer": "Review of CBCT dated 201123. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 36: bone height ≈ 21.3 mm; implant space ≈ 16.0 mm; nearby incisive canal. Region 32: bone height ≈ 16.9 mm; implant space ≈ 15.8 mm; nearby sinus floor. Region 47: bone height ≈ 20.7 mm; implant space ≈ 19.0 mm; nearby anterior loop. Region 46: bone height ≈ 4.6 mm; implant space ≈ 2.9 mm; nearby anterior loop. Region 25: bone height ≈ 16.1 mm; implant space ≈ 9.4 mm; nearby mandibular canal. Region 23: bone height ≈ 18.0 mm; implant space ≈ 13.2 mm; nearby nasal floor. Region 48: bone height ≈ 21.4 mm; implant space ≈ 15.0 mm; nearby nasal floor. Region 31: bone height ≈ 9.2 mm; implant space ≈ 4.2 mm; nearby mental foramen. Region 38: bone height ≈ 20.3 mm; implant space ≈ 15.2 mm; nearby mental foramen. Region 26: bone height ≈ 11.1 mm; implant space ≈ 7.4 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Impression: Radiolucent lesion at 15 consistent with radicular cyst; recommend correlation."}
{"id": "case_0063", "images": ["images/placeholder_0063.png"], "question": "Planning for prosthetic design planning. Brief history/status: Bricanyl, Bufomix Easyhaler, Duloxetine, Duroferon, Betolvex. Desired treatment: Assess healing of extraction sockets and bone regeneration at 16–26.", "answer": "Review of CBCT dated 241120. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 26: bone height ≈ 16.8 mm; implant space ≈ 11.2 mm; nearby mental foramen. Region 18: bone height ≈ 18.6 mm; implant space ≈ 14.0 mm; nearby incisive canal. Region 25: bone height ≈ 20.6 mm; implant space ≈ 15.2 mm; nearby anterior loop. Region 43: bone height ≈ 17.0 mm; implant space ≈ 10.5 mm; nearby mandibular canal. Region 45: bone height ≈ 15.6 mm; implant space ≈ 7.9 mm; nearby incisive canal. Region 27: bone height ≈ 20.2 mm; implant space ≈ 17.5 mm; nearby mental foramen. Region 12: bone height ≈ 10.6 mm; implant space ≈ 8.3 mm; nearby sinus floor. Region 14: bone height ≈ 9.1 mm; implant space ≈ 3.7 mm; nearby anterior loop. Region 34: bone height ≈ 13.1 mm; implant space ≈ 9.7 mm; nearby incisive canal. Region 44: bone height ≈ 6.3 mm; implant space ≈ 0 mm; nearby sinus floor. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0064", "images": ["images/placeholder_0064.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Duroferon, Esomeprazole, Trulicity, Insulin glargine, Duloxetine, Bricanyl. Desired treatment: Check for cortical bone thinning or fenestrations near 34–44.", "answer": "Review of CBCT dated 251117. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 17: bone height ≈ 5.4 mm; implant space ≈ 3.6 mm; nearby mandibular canal. Region 12: bone height ≈ 14.5 mm; implant space ≈ 9.8 mm; nearby mandibular canal. Region 23: bone height ≈ 10.8 mm; implant space ≈ 4.9 mm; nearby incisive canal. Region 44: bone height ≈ 18.1 mm; implant space ≈ 11.3 mm; nearby nasal floor. Region 38: bone height ≈ 19.1 mm; implant space ≈ 16.0 mm; nearby mandibular canal. Region 31: bone height ≈ 4.7 mm; implant space ≈ 0 mm; nearby incisive canal. Region 14: bone height ≈ 10.0 mm; implant space ≈ 6.9 mm; nearby incisive canal. Region 25: bone height ≈ 6.5 mm; implant space ≈ 5.2 mm; nearby anterior loop. Region 27: bone height ≈ 17.6 mm; implant space ≈ 13.5 mm; nearby mental foramen. Region 45: bone height ≈ 18.5 mm; implant space ≈ 15.3 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Signs of early osseointegration failure at 15; consider clinical review."}
{"id": "case_0065", "images": ["images/placeholder_0065.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Bricanyl, Losartan, Esomeprazole, Bufomix Easyhaler, Calcichew-D3, Omeprazole, Trulicity. Desired treatment: Assess healing of extraction sockets and bone regeneration at 14–24.", "answer": "Review of CBCT dated 231028. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 48: bone height ≈ 20.4 mm; implant space ≈ 14.8 mm; nearby anterior loop. Region 34: bone height ≈ 7.2 mm; implant space ≈ 2.7 mm; nearby sinus floor. Region 42: bone height ≈ 14.9 mm; implant space ≈ 13.6 mm; nearby sinus floor. Region 35: bone height ≈ 12.6 mm; implant space ≈ 7.0 mm; nearby anterior loop. Region 41: bone height ≈ 9.0 mm; implant space ≈ 7.0 mm; nearby mental foramen. Region 25: bone height ≈ 8.9 mm; implant space ≈ 2.4 mm; nearby mandibular canal. Region 13: bone height ≈ 17.6 mm; implant space ≈ 11.5 mm; nearby mandibular canal. Region 22: bone height ≈ 8.2 mm; implant space ≈ 5.1 mm; nearby mental foramen. Region 33: bone height ≈ 18.2 mm; implant space ≈ 12.1 mm; nearby anterior loop. Region 36: bone height ≈ 18.8 mm; implant space ≈ 14.9 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 44; minor sclerosis near 48. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0066", "images": ["images/placeholder_0066.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Esomeprazole, Calcichew-D3, Trulicity, Levaxin, Duloxetine, Atorvastatin, Bricanyl, Losartan. Desired treatment: Assess healing of extraction sockets and bone regeneration at 33–43.", "answer": "Review of CBCT dated 200106. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 37: bone height ≈ 20.6 mm; implant space ≈ 15.1 mm; nearby mandibular canal. Region 17: bone height ≈ 4.8 mm; implant space ≈ 0 mm; nearby sinus floor. Region 38: bone height ≈ 8.9 mm; implant space ≈ 3.0 mm; nearby sinus floor. Region 12: bone height ≈ 20.3 mm; implant space ≈ 15.8 mm; nearby anterior loop. Region 13: bone height ≈ 16.3 mm; implant space ≈ 11.2 mm; nearby incisive canal. Region 21: bone height ≈ 13.6 mm; implant space ≈ 9.4 mm; nearby incisive canal. Region 41: bone height ≈ 14.9 mm; implant space ≈ 11.6 mm; nearby mandibular canal. Region 36: bone height ≈ 17.3 mm; implant space ≈ 13.0 mm; nearby anterior loop. Region 18: bone height ≈ 18.4 mm; implant space ≈ 17.4 mm; nearby mandibular canal. Region 24: bone height ≈ 5.8 mm; implant space ≈ 3.9 mm; nearby incisive canal. Periapical radiolucency observed near 17; minor sclerosis near 42. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 43, extending coronally."}
{"id": "case_0067", "images": ["images/placeholder_0067.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Esomeprazole, Betolvex, Levaxin, Omeprazole, Calcichew-D3, Duloxetine, Bricanyl, Metoprolol. Desired treatment: Review periapical status and note any signs of infection in regions 41, 27, 12.", "answer": "Review of CBCT dated 240317. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 24: bone height ≈ 18.6 mm; implant space ≈ 14.4 mm; nearby nasal floor. Region 21: bone height ≈ 7.4 mm; implant space ≈ 1.3 mm; nearby mental foramen. Region 38: bone height ≈ 18.4 mm; implant space ≈ 13.4 mm; nearby incisive canal. Region 17: bone height ≈ 20.2 mm; implant space ≈ 15.9 mm; nearby nasal floor. Region 26: bone height ≈ 11.3 mm; implant space ≈ 9.6 mm; nearby mental foramen. Region 47: bone height ≈ 6.5 mm; implant space ≈ 0 mm; nearby sinus floor. Region 22: bone height ≈ 7.3 mm; implant space ≈ 4.8 mm; nearby sinus floor. Region 14: bone height ≈ 7.1 mm; implant space ≈ 1.3 mm; nearby anterior loop. Region 25: bone height ≈ 19.5 mm; implant space ≈ 16.1 mm; nearby mental foramen. Region 44: bone height ≈ 16.8 mm; implant space ≈ 12.4 mm; nearby mandibular canal. Impression: Findings consistent with apical periodontitis near 32 and 46."}
{"id": "case_0068", "images": ["images/placeholder_0068.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Insulin glargine, Amlodipine, Bricanyl, Esomeprazole, Atorvastatin, Metoprolol, Betolvex, Omeprazole. Desired treatment: Assess healing of extraction sockets and bone regeneration at 34–44.", "answer": "Review of CBCT dated 201127. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 15: bone height ≈ 9.4 mm; implant space ≈ 4.4 mm; nearby nasal floor. Region 31: bone height ≈ 19.7 mm; implant space ≈ 15.5 mm; nearby anterior loop. Region 27: bone height ≈ 10.3 mm; implant space ≈ 2.4 mm; nearby sinus floor. Region 18: bone height ≈ 21.0 mm; implant space ≈ 15.5 mm; nearby incisive canal. Region 45: bone height ≈ 11.0 mm; implant space ≈ 5.3 mm; nearby sinus floor. Region 25: bone height ≈ 13.6 mm; implant space ≈ 8.4 mm; nearby mandibular canal. Region 43: bone height ≈ 16.2 mm; implant space ≈ 10.7 mm; nearby anterior loop. Region 47: bone height ≈ 6.5 mm; implant space ≈ 1.7 mm; nearby mental foramen. Region 35: bone height ≈ 13.6 mm; implant space ≈ 9.6 mm; nearby nasal floor. Region 34: bone height ≈ 9.4 mm; implant space ≈ 5.7 mm; nearby sinus floor. Periapical radiolucency observed near 36; minor sclerosis near 45. Impression: Signs of early osseointegration failure at 31; consider clinical review."}
{"id": "case_0069", "images": ["images/placeholder_0069.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Betolvex, Esomeprazole, Levaxin, Amlodipine, Bufomix Easyhaler, Metoprolol. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 33–43 and 13–23.", "answer": "Review of CBCT dated 251218. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 46: bone height ≈ 11.5 mm; implant space ≈ 7.2 mm; nearby mandibular canal. Region 22: bone height ≈ 20.2 mm; implant space ≈ 18.4 mm; nearby mandibular canal. Region 32: bone height ≈ 18.8 mm; implant space ≈ 11.7 mm; nearby sinus floor. Region 28: bone height ≈ 18.3 mm; implant space ≈ 14.5 mm; nearby incisive canal. Region 23: bone height ≈ 19.6 mm; implant space ≈ 17.2 mm; nearby incisive canal. Region 34: bone height ≈ 8.2 mm; implant space ≈ 2.7 mm; nearby anterior loop. Region 44: bone height ≈ 4.1 mm; implant space ≈ 2.0 mm; nearby mental foramen. Region 43: bone height ≈ 10.7 mm; implant space ≈ 8.8 mm; nearby incisive canal. Region 36: bone height ≈ 20.0 mm; implant space ≈ 12.4 mm; nearby sinus floor. Region 27: bone height ≈ 16.5 mm; implant space ≈ 14.3 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 21; minor sclerosis near 28. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0070", "images": ["images/placeholder_0070.png"], "question": "Planning for prosthetic design planning. Brief history/status: Levaxin, Duloxetine, Insulin glargine, Atorvastatin, Bufomix Easyhaler, Duroferon. Desired treatment: Review periapical status and note any signs of infection in regions 21, 27, 26.", "answer": "Review of CBCT dated 230125. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 12: bone height ≈ 9.4 mm; implant space ≈ 8.1 mm; nearby nasal floor. Region 16: bone height ≈ 14.8 mm; implant space ≈ 9.9 mm; nearby nasal floor. Region 41: bone height ≈ 4.5 mm; implant space ≈ 0 mm; nearby mental foramen. Region 14: bone height ≈ 18.9 mm; implant space ≈ 17.5 mm; nearby mental foramen. Region 28: bone height ≈ 7.4 mm; implant space ≈ 6.2 mm; nearby mandibular canal. Region 17: bone height ≈ 4.5 mm; implant space ≈ 0.7 mm; nearby sinus floor. Region 46: bone height ≈ 5.1 mm; implant space ≈ 0 mm; nearby mental foramen. Region 38: bone height ≈ 10.0 mm; implant space ≈ 7.4 mm; nearby mandibular canal. Region 23: bone height ≈ 10.6 mm; implant space ≈ 9.5 mm; nearby incisive canal. Region 13: bone height ≈ 21.1 mm; implant space ≈ 18.9 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Impression: Findings consistent with apical periodontitis near 18 and 23."}
{"id": "case_0071", "images": ["images/placeholder_0071.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Losartan, Bricanyl, Betolvex, Omeprazole, Bufomix Easyhaler, Duroferon, Esomeprazole, Amlodipine. Desired treatment: Check for cortical bone thinning or fenestrations near 36–46.", "answer": "Review of CBCT dated 220527. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 41: bone height ≈ 8.3 mm; implant space ≈ 6.6 mm; nearby mental foramen. Region 35: bone height ≈ 14.4 mm; implant space ≈ 10.3 mm; nearby nasal floor. Region 21: bone height ≈ 16.1 mm; implant space ≈ 12.6 mm; nearby mental foramen. Region 27: bone height ≈ 10.3 mm; implant space ≈ 8.0 mm; nearby mandibular canal. Region 36: bone height ≈ 12.1 mm; implant space ≈ 8.8 mm; nearby anterior loop. Region 45: bone height ≈ 10.3 mm; implant space ≈ 9.1 mm; nearby anterior loop. Region 23: bone height ≈ 13.4 mm; implant space ≈ 7.5 mm; nearby anterior loop. Region 26: bone height ≈ 20.7 mm; implant space ≈ 17.8 mm; nearby nasal floor. Region 37: bone height ≈ 18.0 mm; implant space ≈ 16.9 mm; nearby anterior loop. Region 12: bone height ≈ 9.2 mm; implant space ≈ 6.5 mm; nearby nasal floor. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 17, extending coronally."}
{"id": "case_0072", "images": ["images/placeholder_0072.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Amlodipine, Levaxin, Atorvastatin, Trulicity, Duroferon. Desired treatment: Assess healing of extraction sockets and bone regeneration at 36–46.", "answer": "Review of CBCT dated 200225. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 13: bone height ≈ 18.0 mm; implant space ≈ 14.5 mm; nearby mandibular canal. Region 24: bone height ≈ 22.0 mm; implant space ≈ 16.3 mm; nearby mandibular canal. Region 35: bone height ≈ 16.4 mm; implant space ≈ 8.7 mm; nearby mandibular canal. Region 26: bone height ≈ 8.4 mm; implant space ≈ 4.3 mm; nearby sinus floor. Region 11: bone height ≈ 21.8 mm; implant space ≈ 18.3 mm; nearby mental foramen. Region 34: bone height ≈ 20.6 mm; implant space ≈ 13.0 mm; nearby nasal floor. Region 48: bone height ≈ 20.1 mm; implant space ≈ 15.9 mm; nearby anterior loop. Region 38: bone height ≈ 12.0 mm; implant space ≈ 9.3 mm; nearby nasal floor. Region 32: bone height ≈ 12.2 mm; implant space ≈ 6.2 mm; nearby sinus floor. Region 14: bone height ≈ 11.5 mm; implant space ≈ 9.3 mm; nearby incisive canal. Periapical radiolucency observed near 27; minor sclerosis near 16. Impression: Peri-implantitis changes evident at 43; marginal bone loss noted."}
{"id": "case_0073", "images": ["images/placeholder_0073.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Amlodipine, Trulicity, Levaxin, Insulin glargine, Duloxetine, Metoprolol, Esomeprazole. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 240507. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 48: bone height ≈ 10.6 mm; implant space ≈ 3.9 mm; nearby incisive canal. Region 22: bone height ≈ 12.0 mm; implant space ≈ 7.3 mm; nearby incisive canal. Region 47: bone height ≈ 9.0 mm; implant space ≈ 6.2 mm; nearby mental foramen. Region 42: bone height ≈ 16.1 mm; implant space ≈ 12.5 mm; nearby anterior loop. Region 26: bone height ≈ 20.5 mm; implant space ≈ 13.1 mm; nearby anterior loop. Region 31: bone height ≈ 6.5 mm; implant space ≈ 3.9 mm; nearby anterior loop. Region 34: bone height ≈ 13.5 mm; implant space ≈ 12.0 mm; nearby incisive canal. Region 16: bone height ≈ 15.3 mm; implant space ≈ 9.6 mm; nearby sinus floor. Region 11: bone height ≈ 19.8 mm; implant space ≈ 18.3 mm; nearby mandibular canal. Region 14: bone height ≈ 20.5 mm; implant space ≈ 18.6 mm; nearby anterior loop. Impression: Adequate bone volume present for standard implant placement."}
{"id": "case_0074", "images": ["images/placeholder_0074.png"], "question": "Planning for pathology review. Brief history/status: Losartan, Trulicity, Duloxetine, Betolvex, Esomeprazole, Insulin glargine, Duroferon, Metoprolol. Desired treatment: Measure ridge augmentation volume required at 36–46 and 36–46.", "answer": "Review of CBCT dated 250303. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 11: bone height ≈ 12.0 mm; implant space ≈ 6.1 mm; nearby mental foramen. Region 44: bone height ≈ 7.4 mm; implant space ≈ 4.0 mm; nearby nasal floor. Region 26: bone height ≈ 20.4 mm; implant space ≈ 16.3 mm; nearby mandibular canal. Region 17: bone height ≈ 21.8 mm; implant space ≈ 19.3 mm; nearby incisive canal. Region 37: bone height ≈ 20.9 mm; implant space ≈ 13.2 mm; nearby mental foramen. Region 14: bone height ≈ 8.1 mm; implant space ≈ 1.9 mm; nearby mental foramen. Region 28: bone height ≈ 12.7 mm; implant space ≈ 7.9 mm; nearby incisive canal. Region 22: bone height ≈ 12.2 mm; implant space ≈ 10.1 mm; nearby incisive canal. Region 38: bone height ≈ 14.8 mm; implant space ≈ 13.1 mm; nearby mandibular canal. Region 12: bone height ≈ 5.1 mm; implant space ≈ 3.5 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 14; minor sclerosis near 15. Image artifacts due to metallic restorations reduce detail locally. Impression: Peri-implantitis changes evident at 35; marginal bone loss noted."}
{"id": "case_0075", "images": ["images/placeholder_0075.png"], "question": "Planning for prosthetic design planning. Brief history/status: Duloxetine, Betolvex, Amlodipine, Losartan, Calcichew-D3, Trulicity, Bricanyl, Atorvastatin. Desired treatment: Review periapical status and note any signs of infection in regions 44, 33, 16.", "answer": "Review of CBCT dated 210223. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 26: bone height ≈ 6.9 mm; implant space ≈ 1.9 mm; nearby anterior loop. Region 47: bone height ≈ 14.6 mm; implant space ≈ 7.0 mm; nearby nasal floor. Region 43: bone height ≈ 17.9 mm; implant space ≈ 13.6 mm; nearby mandibular canal. Region 17: bone height ≈ 12.2 mm; implant space ≈ 7.8 mm; nearby mental foramen. Region 38: bone height ≈ 15.4 mm; implant space ≈ 13.7 mm; nearby sinus floor. Region 24: bone height ≈ 8.7 mm; implant space ≈ 1.1 mm; nearby incisive canal. Region 22: bone height ≈ 10.9 mm; implant space ≈ 8.1 mm; nearby anterior loop. Region 27: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby sinus floor. Region 28: bone height ≈ 10.9 mm; implant space ≈ 9.1 mm; nearby mandibular canal. Region 15: bone height ≈ 7.7 mm; implant space ≈ 6.7 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0076", "images": ["images/placeholder_0076.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Duroferon, Bricanyl, Calcichew-D3, Insulin glargine, Esomeprazole. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 13–23.", "answer": "Review of CBCT dated 200804. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 22: bone height ≈ 14.0 mm; implant space ≈ 7.5 mm; nearby anterior loop. Region 43: bone height ≈ 4.7 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 46: bone height ≈ 11.5 mm; implant space ≈ 5.5 mm; nearby mandibular canal. Region 47: bone height ≈ 21.1 mm; implant space ≈ 13.5 mm; nearby mental foramen. Region 25: bone height ≈ 21.6 mm; implant space ≈ 16.0 mm; nearby anterior loop. Region 34: bone height ≈ 7.5 mm; implant space ≈ 0.5 mm; nearby sinus floor. Region 15: bone height ≈ 18.8 mm; implant space ≈ 13.7 mm; nearby mental foramen. Region 12: bone height ≈ 7.7 mm; implant space ≈ 4.5 mm; nearby mental foramen. Region 26: bone height ≈ 20.2 mm; implant space ≈ 17.9 mm; nearby incisive canal. Region 41: bone height ≈ 12.2 mm; implant space ≈ 4.6 mm; nearby anterior loop. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0077", "images": ["images/placeholder_0077.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Duloxetine, Omeprazole, Atorvastatin, Insulin glargine, Esomeprazole, Trulicity, Levaxin. Desired treatment: Check for cortical bone thinning or fenestrations near 33–43.", "answer": "Review of CBCT dated 251214. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 31: bone height ≈ 18.6 mm; implant space ≈ 15.5 mm; nearby mental foramen. Region 22: bone height ≈ 19.0 mm; implant space ≈ 16.4 mm; nearby anterior loop. Region 17: bone height ≈ 7.0 mm; implant space ≈ 3.6 mm; nearby anterior loop. Region 21: bone height ≈ 7.9 mm; implant space ≈ 5.6 mm; nearby sinus floor. Region 28: bone height ≈ 5.4 mm; implant space ≈ 0 mm; nearby nasal floor. Region 15: bone height ≈ 10.8 mm; implant space ≈ 3.2 mm; nearby incisive canal. Region 26: bone height ≈ 5.4 mm; implant space ≈ 4.1 mm; nearby sinus floor. Region 41: bone height ≈ 4.7 mm; implant space ≈ 0 mm; nearby sinus floor. Region 43: bone height ≈ 21.4 mm; implant space ≈ 16.4 mm; nearby mandibular canal. Region 35: bone height ≈ 20.1 mm; implant space ≈ 16.4 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 47; minor sclerosis near 24. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0078", "images": ["images/placeholder_0078.png"], "question": "Planning for pathology review. Brief history/status: Duloxetine, Bricanyl, Amlodipine, Omeprazole, Bufomix Easyhaler, Betolvex, Trulicity. Desired treatment: Check for cortical bone thinning or fenestrations near 34–44.", "answer": "Review of CBCT dated 200327. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 45: bone height ≈ 10.9 mm; implant space ≈ 4.3 mm; nearby nasal floor. Region 37: bone height ≈ 13.1 mm; implant space ≈ 8.1 mm; nearby incisive canal. Region 33: bone height ≈ 14.8 mm; implant space ≈ 13.7 mm; nearby mental foramen. Region 32: bone height ≈ 21.6 mm; implant space ≈ 13.9 mm; nearby nasal floor. Region 24: bone height ≈ 11.4 mm; implant space ≈ 9.5 mm; nearby nasal floor. Region 13: bone height ≈ 7.3 mm; implant space ≈ 6.1 mm; nearby nasal floor. Region 21: bone height ≈ 14.9 mm; implant space ≈ 9.2 mm; nearby incisive canal. Region 11: bone height ≈ 21.2 mm; implant space ≈ 16.2 mm; nearby mandibular canal. Region 23: bone height ≈ 11.9 mm; implant space ≈ 9.7 mm; nearby incisive canal. Region 14: bone height ≈ 7.7 mm; implant space ≈ 3.8 mm; nearby sinus floor. Periapical radiolucency observed near 48; minor sclerosis near 46. Impression: Adequate bone volume present for standard implant placement."}
{"id": "case_0079", "images": ["images/placeholder_0079.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Bufomix Easyhaler, Metoprolol, Esomeprazole, Atorvastatin, Levaxin. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 14–24.", "answer": "Review of CBCT dated 200321. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 13: bone height ≈ 16.4 mm; implant space ≈ 12.7 mm; nearby incisive canal. Region 28: bone height ≈ 20.7 mm; implant space ≈ 17.6 mm; nearby incisive canal. Region 22: bone height ≈ 7.1 mm; implant space ≈ 0 mm; nearby sinus floor. Region 26: bone height ≈ 15.6 mm; implant space ≈ 10.4 mm; nearby anterior loop. Region 12: bone height ≈ 6.2 mm; implant space ≈ 3.2 mm; nearby sinus floor. Region 27: bone height ≈ 5.6 mm; implant space ≈ 4.3 mm; nearby sinus floor. Region 35: bone height ≈ 8.7 mm; implant space ≈ 2.2 mm; nearby sinus floor. Region 37: bone height ≈ 21.4 mm; implant space ≈ 16.8 mm; nearby nasal floor. Region 17: bone height ≈ 6.1 mm; implant space ≈ 0.3 mm; nearby mental foramen. Region 33: bone height ≈ 20.0 mm; implant space ≈ 12.3 mm; nearby mental foramen. Image artifacts due to metallic restorations reduce detail locally. Impression: Radiolucent lesion at 17 consistent with radicular cyst; recommend correlation."}
{"id": "case_0080", "images": ["images/placeholder_0080.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Esomeprazole, Duloxetine, Losartan, Duroferon, Levaxin, Trulicity, Insulin glargine. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 36–46 and 16–26.", "answer": "Review of CBCT dated 250709. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 31: bone height ≈ 17.0 mm; implant space ≈ 15.2 mm; nearby nasal floor. Region 26: bone height ≈ 7.3 mm; implant space ≈ 4.4 mm; nearby anterior loop. Region 18: bone height ≈ 10.4 mm; implant space ≈ 5.0 mm; nearby mental foramen. Region 33: bone height ≈ 18.3 mm; implant space ≈ 11.4 mm; nearby anterior loop. Region 48: bone height ≈ 15.6 mm; implant space ≈ 10.8 mm; nearby mandibular canal. Region 24: bone height ≈ 20.6 mm; implant space ≈ 19.2 mm; nearby incisive canal. Region 22: bone height ≈ 11.7 mm; implant space ≈ 4.9 mm; nearby mental foramen. Region 16: bone height ≈ 16.5 mm; implant space ≈ 13.2 mm; nearby incisive canal. Region 15: bone height ≈ 6.3 mm; implant space ≈ 1.7 mm; nearby sinus floor. Region 36: bone height ≈ 20.1 mm; implant space ≈ 14.0 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Impression: Radiolucent lesion at 23 consistent with radicular cyst; recommend correlation."}
{"id": "case_0081", "images": ["images/placeholder_0081.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Levaxin, Amlodipine, Duroferon, Esomeprazole, Omeprazole, Insulin glargine, Bricanyl, Duloxetine. Desired treatment: Assess proximity to mandibular canal and sinus floor for 13–23 and 14–24.", "answer": "Review of CBCT dated 250823. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 21: bone height ≈ 20.3 mm; implant space ≈ 19.2 mm; nearby sinus floor. Region 32: bone height ≈ 4.6 mm; implant space ≈ 3.2 mm; nearby mental foramen. Region 26: bone height ≈ 13.4 mm; implant space ≈ 7.5 mm; nearby mental foramen. Region 18: bone height ≈ 10.6 mm; implant space ≈ 5.5 mm; nearby incisive canal. Region 46: bone height ≈ 13.1 mm; implant space ≈ 8.1 mm; nearby incisive canal. Region 36: bone height ≈ 7.1 mm; implant space ≈ 1.8 mm; nearby mental foramen. Region 25: bone height ≈ 6.8 mm; implant space ≈ 5.0 mm; nearby mandibular canal. Region 47: bone height ≈ 13.5 mm; implant space ≈ 6.4 mm; nearby incisive canal. Region 17: bone height ≈ 14.9 mm; implant space ≈ 7.8 mm; nearby mandibular canal. Region 41: bone height ≈ 7.2 mm; implant space ≈ 0 mm; nearby mental foramen. Periapical radiolucency observed near 18; minor sclerosis near 17. Image artifacts due to metallic restorations reduce detail locally. Impression: Findings consistent with apical periodontitis near 12 and 41."}
{"id": "case_0082", "images": ["images/placeholder_0082.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Atorvastatin, Trulicity, Bufomix Easyhaler, Levaxin, Betolvex, Insulin glargine, Amlodipine. Desired treatment: Check for cortical bone thinning or fenestrations near 33–43.", "answer": "Review of CBCT dated 220121. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 27: bone height ≈ 5.6 mm; implant space ≈ 4.2 mm; nearby anterior loop. Region 42: bone height ≈ 7.3 mm; implant space ≈ 6.2 mm; nearby mandibular canal. Region 13: bone height ≈ 14.3 mm; implant space ≈ 10.7 mm; nearby nasal floor. Region 41: bone height ≈ 15.2 mm; implant space ≈ 9.2 mm; nearby mental foramen. Region 28: bone height ≈ 15.2 mm; implant space ≈ 10.2 mm; nearby sinus floor. Region 14: bone height ≈ 4.9 mm; implant space ≈ 2.7 mm; nearby nasal floor. Region 11: bone height ≈ 16.6 mm; implant space ≈ 9.6 mm; nearby incisive canal. Region 18: bone height ≈ 6.6 mm; implant space ≈ 0 mm; nearby incisive canal. Region 45: bone height ≈ 18.1 mm; implant space ≈ 12.7 mm; nearby nasal floor. Region 24: bone height ≈ 7.3 mm; implant space ≈ 1.4 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 22; minor sclerosis near 13. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0083", "images": ["images/placeholder_0083.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Esomeprazole, Bufomix Easyhaler, Bricanyl, Insulin glargine, Trulicity, Betolvex, Atorvastatin, Metoprolol. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 210812. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 31: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby anterior loop. Region 26: bone height ≈ 15.0 mm; implant space ≈ 8.2 mm; nearby mandibular canal. Region 33: bone height ≈ 11.8 mm; implant space ≈ 4.0 mm; nearby nasal floor. Region 43: bone height ≈ 16.0 mm; implant space ≈ 10.7 mm; nearby anterior loop. Region 24: bone height ≈ 20.8 mm; implant space ≈ 17.7 mm; nearby sinus floor. Region 36: bone height ≈ 7.6 mm; implant space ≈ 0.5 mm; nearby nasal floor. Region 25: bone height ≈ 11.5 mm; implant space ≈ 6.8 mm; nearby nasal floor. Region 27: bone height ≈ 6.1 mm; implant space ≈ 0 mm; nearby anterior loop. Region 35: bone height ≈ 13.3 mm; implant space ≈ 8.4 mm; nearby anterior loop. Region 22: bone height ≈ 12.3 mm; implant space ≈ 6.0 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 44; minor sclerosis near 14. Impression: Vertical root fracture suspected at 26, extending coronally."}
{"id": "case_0084", "images": ["images/placeholder_0084.png"], "question": "Planning for bone graft planning. Brief history/status: Bufomix Easyhaler, Calcichew-D3, Omeprazole, Levaxin, Metoprolol, Betolvex, Amlodipine, Losartan. Desired treatment: Check for cortical bone thinning or fenestrations near 16–26.", "answer": "Review of CBCT dated 230103. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 32: bone height ≈ 21.4 mm; implant space ≈ 15.8 mm; nearby mandibular canal. Region 26: bone height ≈ 8.6 mm; implant space ≈ 7.1 mm; nearby mandibular canal. Region 38: bone height ≈ 5.5 mm; implant space ≈ 0 mm; nearby mental foramen. Region 12: bone height ≈ 11.7 mm; implant space ≈ 8.9 mm; nearby incisive canal. Region 15: bone height ≈ 12.0 mm; implant space ≈ 4.5 mm; nearby sinus floor. Region 13: bone height ≈ 14.8 mm; implant space ≈ 10.2 mm; nearby mandibular canal. Region 21: bone height ≈ 4.7 mm; implant space ≈ 0 mm; nearby mental foramen. Region 46: bone height ≈ 14.3 mm; implant space ≈ 8.6 mm; nearby sinus floor. Region 42: bone height ≈ 16.1 mm; implant space ≈ 12.9 mm; nearby incisive canal. Region 11: bone height ≈ 4.5 mm; implant space ≈ 0 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 44; minor sclerosis near 23. Impression: Radiolucent lesion at 32 consistent with radicular cyst; recommend correlation."}
{"id": "case_0085", "images": ["images/placeholder_0085.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Esomeprazole, Bricanyl, Bufomix Easyhaler, Atorvastatin, Losartan, Insulin glargine, Omeprazole. Desired treatment: Measure ridge augmentation volume required at 13–23 and 36–46.", "answer": "Review of CBCT dated 250128. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 15: bone height ≈ 17.4 mm; implant space ≈ 10.9 mm; nearby mandibular canal. Region 16: bone height ≈ 19.1 mm; implant space ≈ 18.1 mm; nearby mental foramen. Region 22: bone height ≈ 14.1 mm; implant space ≈ 6.4 mm; nearby nasal floor. Region 21: bone height ≈ 10.8 mm; implant space ≈ 5.4 mm; nearby mandibular canal. Region 28: bone height ≈ 11.1 mm; implant space ≈ 8.2 mm; nearby sinus floor. Region 45: bone height ≈ 9.0 mm; implant space ≈ 2.5 mm; nearby sinus floor. Region 37: bone height ≈ 6.1 mm; implant space ≈ 0 mm; nearby anterior loop. Region 14: bone height ≈ 20.6 mm; implant space ≈ 17.4 mm; nearby sinus floor. Region 17: bone height ≈ 16.0 mm; implant space ≈ 12.9 mm; nearby mental foramen. Region 31: bone height ≈ 4.5 mm; implant space ≈ 1.0 mm; nearby nasal floor. Periapical radiolucency observed near 23; minor sclerosis near 41. Impression: Impacted molar in quadrant 3 associated with mild follicular space widening."}
{"id": "case_0086", "images": ["images/placeholder_0086.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Metoprolol, Losartan, Atorvastatin, Bricanyl, Omeprazole, Duroferon, Amlodipine. Desired treatment: Review periapical status and note any signs of infection in regions 34, 33, 44.", "answer": "Review of CBCT dated 220922. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 44: bone height ≈ 9.5 mm; implant space ≈ 6.4 mm; nearby mental foramen. Region 25: bone height ≈ 19.2 mm; implant space ≈ 12.7 mm; nearby mandibular canal. Region 36: bone height ≈ 11.9 mm; implant space ≈ 10.8 mm; nearby sinus floor. Region 24: bone height ≈ 7.3 mm; implant space ≈ 5.7 mm; nearby incisive canal. Region 15: bone height ≈ 9.2 mm; implant space ≈ 2.0 mm; nearby anterior loop. Region 27: bone height ≈ 15.3 mm; implant space ≈ 7.6 mm; nearby mental foramen. Region 32: bone height ≈ 20.8 mm; implant space ≈ 19.6 mm; nearby nasal floor. Region 35: bone height ≈ 13.0 mm; implant space ≈ 7.7 mm; nearby mandibular canal. Region 47: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby anterior loop. Region 11: bone height ≈ 15.5 mm; implant space ≈ 9.5 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Impression: Radiolucent lesion at 43 consistent with radicular cyst; recommend correlation."}
{"id": "case_0087", "images": ["images/placeholder_0087.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Amlodipine, Trulicity, Duroferon, Bricanyl, Calcichew-D3, Levaxin. Desired treatment: Review periapical status and note any signs of infection in regions 36, 21, 38.", "answer": "Review of CBCT dated 211118. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 18: bone height ≈ 17.7 mm; implant space ≈ 14.3 mm; nearby mental foramen. Region 31: bone height ≈ 10.7 mm; implant space ≈ 3.6 mm; nearby nasal floor. Region 24: bone height ≈ 10.2 mm; implant space ≈ 6.2 mm; nearby mental foramen. Region 46: bone height ≈ 12.5 mm; implant space ≈ 10.8 mm; nearby mandibular canal. Region 14: bone height ≈ 21.8 mm; implant space ≈ 14.7 mm; nearby anterior loop. Region 27: bone height ≈ 12.3 mm; implant space ≈ 8.4 mm; nearby sinus floor. Region 36: bone height ≈ 20.8 mm; implant space ≈ 15.0 mm; nearby nasal floor. Region 25: bone height ≈ 9.6 mm; implant space ≈ 2.3 mm; nearby mental foramen. Region 34: bone height ≈ 13.8 mm; implant space ≈ 11.4 mm; nearby sinus floor. Region 12: bone height ≈ 5.6 mm; implant space ≈ 2.2 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 21; minor sclerosis near 42. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0088", "images": ["images/placeholder_0088.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Omeprazole, Insulin glargine, Amlodipine, Levaxin, Atorvastatin. Desired treatment: Provide measurements for alveolar ridge width and height at 13–23.", "answer": "Review of CBCT dated 240808. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 31: bone height ≈ 18.9 mm; implant space ≈ 17.7 mm; nearby nasal floor. Region 34: bone height ≈ 8.5 mm; implant space ≈ 1.5 mm; nearby anterior loop. Region 38: bone height ≈ 17.1 mm; implant space ≈ 9.6 mm; nearby anterior loop. Region 14: bone height ≈ 13.9 mm; implant space ≈ 8.7 mm; nearby anterior loop. Region 28: bone height ≈ 10.9 mm; implant space ≈ 3.6 mm; nearby anterior loop. Region 42: bone height ≈ 10.0 mm; implant space ≈ 5.1 mm; nearby mandibular canal. Region 11: bone height ≈ 16.6 mm; implant space ≈ 12.7 mm; nearby incisive canal. Region 32: bone height ≈ 16.1 mm; implant space ≈ 15.1 mm; nearby mandibular canal. Region 17: bone height ≈ 7.1 mm; implant space ≈ 0 mm; nearby nasal floor. Region 33: bone height ≈ 14.4 mm; implant space ≈ 13.2 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 28; minor sclerosis near 12. Impression: Vertical root fracture suspected at 41, extending coronally."}
{"id": "case_0089", "images": ["images/placeholder_0089.png"], "question": "Planning for pathology review. Brief history/status: Betolvex, Calcichew-D3, Losartan, Trulicity, Amlodipine, Duloxetine, Bufomix Easyhaler, Bricanyl. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 210408. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 41: bone height ≈ 17.5 mm; implant space ≈ 15.2 mm; nearby nasal floor. Region 15: bone height ≈ 10.5 mm; implant space ≈ 7.9 mm; nearby mandibular canal. Region 45: bone height ≈ 18.5 mm; implant space ≈ 11.2 mm; nearby anterior loop. Region 13: bone height ≈ 11.6 mm; implant space ≈ 8.6 mm; nearby mandibular canal. Region 43: bone height ≈ 9.2 mm; implant space ≈ 4.4 mm; nearby mental foramen. Region 14: bone height ≈ 6.2 mm; implant space ≈ 1.0 mm; nearby nasal floor. Region 23: bone height ≈ 8.9 mm; implant space ≈ 5.1 mm; nearby mandibular canal. Region 24: bone height ≈ 9.3 mm; implant space ≈ 7.9 mm; nearby incisive canal. Region 38: bone height ≈ 10.9 mm; implant space ≈ 6.8 mm; nearby anterior loop. Region 11: bone height ≈ 16.2 mm; implant space ≈ 14.0 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 46; minor sclerosis near 33. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0090", "images": ["images/placeholder_0090.png"], "question": "Planning for bone graft planning. Brief history/status: Atorvastatin, Levaxin, Metoprolol, Duloxetine, Omeprazole, Trulicity, Amlodipine. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 231205. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 37: bone height ≈ 18.8 mm; implant space ≈ 17.0 mm; nearby sinus floor. Region 13: bone height ≈ 19.1 mm; implant space ≈ 14.4 mm; nearby incisive canal. Region 34: bone height ≈ 19.8 mm; implant space ≈ 14.4 mm; nearby anterior loop. Region 36: bone height ≈ 14.2 mm; implant space ≈ 11.3 mm; nearby mental foramen. Region 38: bone height ≈ 4.8 mm; implant space ≈ 0.3 mm; nearby mental foramen. Region 26: bone height ≈ 7.8 mm; implant space ≈ 2.3 mm; nearby nasal floor. Region 22: bone height ≈ 14.8 mm; implant space ≈ 13.6 mm; nearby incisive canal. Region 41: bone height ≈ 14.6 mm; implant space ≈ 8.4 mm; nearby anterior loop. Region 25: bone height ≈ 17.7 mm; implant space ≈ 15.7 mm; nearby mandibular canal. Region 12: bone height ≈ 18.0 mm; implant space ≈ 10.3 mm; nearby anterior loop. Impression: Findings consistent with apical periodontitis near 46 and 17."}
{"id": "case_0091", "images": ["images/placeholder_0091.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Amlodipine, Losartan, Levaxin, Omeprazole, Duroferon, Trulicity, Betolvex, Calcichew-D3. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 33–43 and 34–44.", "answer": "Review of CBCT dated 200615. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 46: bone height ≈ 17.9 mm; implant space ≈ 11.7 mm; nearby mental foramen. Region 38: bone height ≈ 12.4 mm; implant space ≈ 4.8 mm; nearby mandibular canal. Region 15: bone height ≈ 12.6 mm; implant space ≈ 5.1 mm; nearby sinus floor. Region 14: bone height ≈ 13.1 mm; implant space ≈ 11.5 mm; nearby nasal floor. Region 28: bone height ≈ 20.2 mm; implant space ≈ 12.7 mm; nearby anterior loop. Region 34: bone height ≈ 7.6 mm; implant space ≈ 6.1 mm; nearby mental foramen. Region 11: bone height ≈ 8.1 mm; implant space ≈ 3.6 mm; nearby incisive canal. Region 48: bone height ≈ 21.0 mm; implant space ≈ 16.5 mm; nearby nasal floor. Region 43: bone height ≈ 13.5 mm; implant space ≈ 8.3 mm; nearby sinus floor. Region 23: bone height ≈ 15.2 mm; implant space ≈ 7.2 mm; nearby nasal floor. Image artifacts due to metallic restorations reduce detail locally. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0092", "images": ["images/placeholder_0092.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Losartan, Trulicity, Insulin glargine, Levaxin, Atorvastatin. Desired treatment: Assess proximity to mandibular canal and sinus floor for 36–46 and 36–46.", "answer": "Review of CBCT dated 210721. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 43: bone height ≈ 20.8 mm; implant space ≈ 16.4 mm; nearby sinus floor. Region 46: bone height ≈ 19.5 mm; implant space ≈ 14.6 mm; nearby sinus floor. Region 32: bone height ≈ 11.4 mm; implant space ≈ 6.2 mm; nearby mental foramen. Region 47: bone height ≈ 13.0 mm; implant space ≈ 7.1 mm; nearby anterior loop. Region 17: bone height ≈ 4.7 mm; implant space ≈ 3.4 mm; nearby incisive canal. Region 48: bone height ≈ 21.4 mm; implant space ≈ 13.6 mm; nearby sinus floor. Region 42: bone height ≈ 16.4 mm; implant space ≈ 11.8 mm; nearby sinus floor. Region 18: bone height ≈ 9.3 mm; implant space ≈ 3.2 mm; nearby sinus floor. Region 41: bone height ≈ 21.9 mm; implant space ≈ 17.5 mm; nearby incisive canal. Region 12: bone height ≈ 11.4 mm; implant space ≈ 6.9 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0093", "images": ["images/placeholder_0093.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Bricanyl, Esomeprazole, Losartan, Omeprazole, Bufomix Easyhaler, Trulicity, Metoprolol. Desired treatment: Assess proximity to mandibular canal and sinus floor for 14–24 and 13–23.", "answer": "Review of CBCT dated 250110. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 17: bone height ≈ 8.4 mm; implant space ≈ 5.7 mm; nearby anterior loop. Region 44: bone height ≈ 11.7 mm; implant space ≈ 8.2 mm; nearby mental foramen. Region 37: bone height ≈ 15.5 mm; implant space ≈ 8.6 mm; nearby incisive canal. Region 26: bone height ≈ 18.7 mm; implant space ≈ 12.1 mm; nearby mandibular canal. Region 25: bone height ≈ 7.7 mm; implant space ≈ 1.1 mm; nearby nasal floor. Region 28: bone height ≈ 11.4 mm; implant space ≈ 5.0 mm; nearby mental foramen. Region 43: bone height ≈ 15.9 mm; implant space ≈ 9.4 mm; nearby mental foramen. Region 47: bone height ≈ 20.0 mm; implant space ≈ 15.2 mm; nearby incisive canal. Region 24: bone height ≈ 15.4 mm; implant space ≈ 9.0 mm; nearby mental foramen. Region 32: bone height ≈ 14.9 mm; implant space ≈ 12.1 mm; nearby mental foramen. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0094", "images": ["images/placeholder_0094.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Levaxin, Calcichew-D3, Losartan, Duloxetine, Insulin glargine, Atorvastatin, Bufomix Easyhaler. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 16–26.", "answer": "Review of CBCT dated 240113. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 34: bone height ≈ 8.4 mm; implant space ≈ 7.4 mm; nearby nasal floor. Region 15: bone height ≈ 13.3 mm; implant space ≈ 5.7 mm; nearby anterior loop. Region 17: bone height ≈ 15.0 mm; implant space ≈ 11.7 mm; nearby anterior loop. Region 18: bone height ≈ 13.4 mm; implant space ≈ 11.6 mm; nearby mental foramen. Region 42: bone height ≈ 10.7 mm; implant space ≈ 4.2 mm; nearby nasal floor. Region 31: bone height ≈ 15.1 mm; implant space ≈ 8.0 mm; nearby mandibular canal. Region 22: bone height ≈ 13.4 mm; implant space ≈ 9.1 mm; nearby mandibular canal. Region 21: bone height ≈ 19.1 mm; implant space ≈ 16.4 mm; nearby nasal floor. Region 43: bone height ≈ 18.3 mm; implant space ≈ 10.4 mm; nearby anterior loop. Region 12: bone height ≈ 8.4 mm; implant space ≈ 2.4 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0095", "images": ["images/placeholder_0095.png"], "question": "Planning for pathology review. Brief history/status: Metoprolol, Bricanyl, Bufomix Easyhaler, Atorvastatin, Calcichew-D3. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 34–44 and 36–46.", "answer": "Review of CBCT dated 210818. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 34: bone height ≈ 4.5 mm; implant space ≈ 0 mm; nearby nasal floor. Region 12: bone height ≈ 21.7 mm; implant space ≈ 16.4 mm; nearby nasal floor. Region 16: bone height ≈ 9.7 mm; implant space ≈ 2.8 mm; nearby incisive canal. Region 35: bone height ≈ 20.5 mm; implant space ≈ 14.8 mm; nearby nasal floor. Region 23: bone height ≈ 13.7 mm; implant space ≈ 10.3 mm; nearby sinus floor. Region 42: bone height ≈ 17.8 mm; implant space ≈ 16.5 mm; nearby mandibular canal. Region 47: bone height ≈ 19.9 mm; implant space ≈ 15.5 mm; nearby sinus floor. Region 36: bone height ≈ 4.2 mm; implant space ≈ 0 mm; nearby anterior loop. Region 11: bone height ≈ 14.7 mm; implant space ≈ 12.5 mm; nearby mandibular canal. Region 17: bone height ≈ 13.7 mm; implant space ≈ 9.5 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Peri-implantitis changes evident at 25; marginal bone loss noted."}
{"id": "case_0096", "images": ["images/placeholder_0096.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Esomeprazole, Duloxetine, Calcichew-D3, Bufomix Easyhaler, Omeprazole. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 200110. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 34: bone height ≈ 12.7 mm; implant space ≈ 6.1 mm; nearby nasal floor. Region 43: bone height ≈ 17.8 mm; implant space ≈ 14.4 mm; nearby mandibular canal. Region 42: bone height ≈ 6.8 mm; implant space ≈ 2.0 mm; nearby mental foramen. Region 45: bone height ≈ 8.5 mm; implant space ≈ 6.7 mm; nearby sinus floor. Region 35: bone height ≈ 4.0 mm; implant space ≈ 0 mm; nearby mental foramen. Region 32: bone height ≈ 19.3 mm; implant space ≈ 12.7 mm; nearby mandibular canal. Region 48: bone height ≈ 21.8 mm; implant space ≈ 15.2 mm; nearby mandibular canal. Region 38: bone height ≈ 9.0 mm; implant space ≈ 3.7 mm; nearby incisive canal. Region 44: bone height ≈ 20.3 mm; implant space ≈ 18.4 mm; nearby anterior loop. Region 27: bone height ≈ 20.4 mm; implant space ≈ 14.3 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 18; minor sclerosis near 48. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0097", "images": ["images/placeholder_0097.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Metoprolol, Insulin glargine, Levaxin, Atorvastatin, Esomeprazole. Desired treatment: Check for cortical bone thinning or fenestrations near 36–46.", "answer": "Review of CBCT dated 250926. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 33: bone height ≈ 13.3 mm; implant space ≈ 6.6 mm; nearby mandibular canal. Region 45: bone height ≈ 15.3 mm; implant space ≈ 8.8 mm; nearby incisive canal. Region 21: bone height ≈ 21.4 mm; implant space ≈ 17.3 mm; nearby nasal floor. Region 47: bone height ≈ 20.0 mm; implant space ≈ 12.7 mm; nearby nasal floor. Region 37: bone height ≈ 18.2 mm; implant space ≈ 15.4 mm; nearby incisive canal. Region 42: bone height ≈ 20.2 mm; implant space ≈ 17.2 mm; nearby mandibular canal. Region 31: bone height ≈ 20.7 mm; implant space ≈ 18.4 mm; nearby anterior loop. Region 27: bone height ≈ 11.3 mm; implant space ≈ 5.5 mm; nearby mandibular canal. Region 24: bone height ≈ 11.0 mm; implant space ≈ 3.1 mm; nearby nasal floor. Region 16: bone height ≈ 16.5 mm; implant space ≈ 11.5 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Impression: Findings consistent with apical periodontitis near 32 and 24."}
{"id": "case_0098", "images": ["images/placeholder_0098.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Levaxin, Atorvastatin, Metoprolol, Losartan, Trulicity, Insulin glargine, Betolvex, Amlodipine. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 33–43 and 36–46.", "answer": "Review of CBCT dated 220827. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 18: bone height ≈ 4.2 mm; implant space ≈ 0 mm; nearby incisive canal. Region 38: bone height ≈ 10.3 mm; implant space ≈ 5.2 mm; nearby mental foramen. Region 45: bone height ≈ 4.2 mm; implant space ≈ 0 mm; nearby mental foramen. Region 26: bone height ≈ 21.3 mm; implant space ≈ 14.5 mm; nearby sinus floor. Region 46: bone height ≈ 11.5 mm; implant space ≈ 5.5 mm; nearby anterior loop. Region 12: bone height ≈ 17.7 mm; implant space ≈ 12.7 mm; nearby incisive canal. Region 31: bone height ≈ 8.6 mm; implant space ≈ 2.4 mm; nearby mental foramen. Region 24: bone height ≈ 14.8 mm; implant space ≈ 7.7 mm; nearby mandibular canal. Region 44: bone height ≈ 6.4 mm; implant space ≈ 0 mm; nearby sinus floor. Region 23: bone height ≈ 7.1 mm; implant space ≈ 5.6 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 14; minor sclerosis near 44. Impression: Peri-implantitis changes evident at 21; marginal bone loss noted."}
{"id": "case_0099", "images": ["images/placeholder_0099.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Duloxetine, Losartan, Bufomix Easyhaler, Bricanyl, Atorvastatin. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 200118. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 45: bone height ≈ 4.4 mm; implant space ≈ 2.9 mm; nearby nasal floor. Region 26: bone height ≈ 20.6 mm; implant space ≈ 15.3 mm; nearby sinus floor. Region 33: bone height ≈ 20.1 mm; implant space ≈ 17.9 mm; nearby mental foramen. Region 23: bone height ≈ 9.0 mm; implant space ≈ 2.9 mm; nearby sinus floor. Region 14: bone height ≈ 4.5 mm; implant space ≈ 1.3 mm; nearby nasal floor. Region 43: bone height ≈ 8.8 mm; implant space ≈ 4.2 mm; nearby mandibular canal. Region 35: bone height ≈ 21.2 mm; implant space ≈ 19.0 mm; nearby nasal floor. Region 25: bone height ≈ 19.0 mm; implant space ≈ 12.6 mm; nearby mandibular canal. Region 31: bone height ≈ 11.4 mm; implant space ≈ 8.5 mm; nearby sinus floor. Region 32: bone height ≈ 5.8 mm; implant space ≈ 2.1 mm; nearby nasal floor. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 43, extending coronally."}
{"id": "case_0100", "images": ["images/placeholder_0100.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Insulin glargine, Omeprazole, Amlodipine, Duloxetine, Losartan, Esomeprazole, Duroferon, Trulicity. Desired treatment: Review periapical status and note any signs of infection in regions 43, 26, 11.", "answer": "Review of CBCT dated 240617. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 25: bone height ≈ 10.9 mm; implant space ≈ 8.3 mm; nearby anterior loop. Region 23: bone height ≈ 6.2 mm; implant space ≈ 3.0 mm; nearby incisive canal. Region 13: bone height ≈ 20.9 mm; implant space ≈ 19.3 mm; nearby nasal floor. Region 42: bone height ≈ 11.7 mm; implant space ≈ 9.8 mm; nearby sinus floor. Region 22: bone height ≈ 16.4 mm; implant space ≈ 13.2 mm; nearby mental foramen. Region 43: bone height ≈ 10.6 mm; implant space ≈ 6.2 mm; nearby incisive canal. Region 12: bone height ≈ 16.6 mm; implant space ≈ 12.4 mm; nearby anterior loop. Region 14: bone height ≈ 10.3 mm; implant space ≈ 7.3 mm; nearby mental foramen. Region 18: bone height ≈ 13.9 mm; implant space ≈ 11.5 mm; nearby nasal floor. Region 15: bone height ≈ 18.1 mm; implant space ≈ 16.9 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 26; minor sclerosis near 42. Impression: Radiolucent lesion at 42 consistent with radicular cyst; recommend correlation."}
{"id": "case_0101", "images": ["images/placeholder_0101.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Calcichew-D3, Amlodipine, Losartan, Bricanyl, Insulin glargine, Trulicity, Metoprolol. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 33–43.", "answer": "Review of CBCT dated 200321. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 16: bone height ≈ 21.7 mm; implant space ≈ 20.6 mm; nearby nasal floor. Region 41: bone height ≈ 16.7 mm; implant space ≈ 11.6 mm; nearby anterior loop. Region 32: bone height ≈ 20.4 mm; implant space ≈ 12.6 mm; nearby anterior loop. Region 24: bone height ≈ 14.3 mm; implant space ≈ 12.4 mm; nearby mental foramen. Region 22: bone height ≈ 8.0 mm; implant space ≈ 2.3 mm; nearby mental foramen. Region 38: bone height ≈ 7.9 mm; implant space ≈ 1.1 mm; nearby sinus floor. Region 27: bone height ≈ 17.8 mm; implant space ≈ 11.2 mm; nearby mandibular canal. Region 18: bone height ≈ 8.4 mm; implant space ≈ 5.1 mm; nearby mandibular canal. Region 15: bone height ≈ 18.2 mm; implant space ≈ 11.8 mm; nearby sinus floor. Region 25: bone height ≈ 8.4 mm; implant space ≈ 3.6 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 16; minor sclerosis near 45. Impression: Peri-implantitis changes evident at 12; marginal bone loss noted."}
{"id": "case_0102", "images": ["images/placeholder_0102.png"], "question": "Planning for prosthetic design planning. Brief history/status: Metoprolol, Trulicity, Bricanyl, Calcichew-D3, Omeprazole, Betolvex, Bufomix Easyhaler, Losartan. Desired treatment: Provide measurements for alveolar ridge width and height at 14–24.", "answer": "Review of CBCT dated 210607. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 16: bone height ≈ 14.4 mm; implant space ≈ 8.1 mm; nearby anterior loop. Region 13: bone height ≈ 10.9 mm; implant space ≈ 6.0 mm; nearby mental foramen. Region 28: bone height ≈ 8.8 mm; implant space ≈ 7.3 mm; nearby mental foramen. Region 46: bone height ≈ 9.5 mm; implant space ≈ 2.1 mm; nearby incisive canal. Region 21: bone height ≈ 21.3 mm; implant space ≈ 17.5 mm; nearby nasal floor. Region 33: bone height ≈ 17.3 mm; implant space ≈ 15.7 mm; nearby mandibular canal. Region 38: bone height ≈ 21.7 mm; implant space ≈ 14.2 mm; nearby incisive canal. Region 48: bone height ≈ 15.8 mm; implant space ≈ 13.0 mm; nearby mandibular canal. Region 31: bone height ≈ 16.1 mm; implant space ≈ 11.7 mm; nearby incisive canal. Region 47: bone height ≈ 13.6 mm; implant space ≈ 7.6 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Impression: Signs of early osseointegration failure at 33; consider clinical review."}
{"id": "case_0103", "images": ["images/placeholder_0103.png"], "question": "Planning for bone graft planning. Brief history/status: Insulin glargine, Bufomix Easyhaler, Duloxetine, Calcichew-D3, Losartan, Duroferon, Omeprazole. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 230328. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 43: bone height ≈ 6.2 mm; implant space ≈ 3.2 mm; nearby nasal floor. Region 41: bone height ≈ 20.9 mm; implant space ≈ 14.0 mm; nearby mental foramen. Region 22: bone height ≈ 7.0 mm; implant space ≈ 1.5 mm; nearby mandibular canal. Region 11: bone height ≈ 7.6 mm; implant space ≈ 1.6 mm; nearby mental foramen. Region 47: bone height ≈ 6.8 mm; implant space ≈ 0 mm; nearby mental foramen. Region 24: bone height ≈ 21.7 mm; implant space ≈ 19.5 mm; nearby sinus floor. Region 12: bone height ≈ 10.6 mm; implant space ≈ 6.1 mm; nearby mandibular canal. Region 27: bone height ≈ 12.1 mm; implant space ≈ 9.1 mm; nearby nasal floor. Region 33: bone height ≈ 18.3 mm; implant space ≈ 13.6 mm; nearby anterior loop. Region 46: bone height ≈ 20.1 mm; implant space ≈ 17.8 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 48; minor sclerosis near 33. Impression: Vertical root fracture suspected at 33, extending coronally."}
{"id": "case_0104", "images": ["images/placeholder_0104.png"], "question": "Planning for prosthetic design planning. Brief history/status: Duloxetine, Trulicity, Omeprazole, Esomeprazole, Calcichew-D3. Desired treatment: Assess proximity to mandibular canal and sinus floor for 34–44 and 34–44.", "answer": "Review of CBCT dated 210918. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 18: bone height ≈ 7.7 mm; implant space ≈ 2.5 mm; nearby anterior loop. Region 42: bone height ≈ 20.0 mm; implant space ≈ 16.3 mm; nearby mental foramen. Region 45: bone height ≈ 21.6 mm; implant space ≈ 19.6 mm; nearby mandibular canal. Region 33: bone height ≈ 17.5 mm; implant space ≈ 13.3 mm; nearby incisive canal. Region 17: bone height ≈ 17.1 mm; implant space ≈ 12.5 mm; nearby anterior loop. Region 32: bone height ≈ 20.8 mm; implant space ≈ 13.3 mm; nearby mental foramen. Region 43: bone height ≈ 13.6 mm; implant space ≈ 7.7 mm; nearby mandibular canal. Region 21: bone height ≈ 20.8 mm; implant space ≈ 15.3 mm; nearby anterior loop. Region 12: bone height ≈ 13.7 mm; implant space ≈ 9.8 mm; nearby sinus floor. Region 31: bone height ≈ 8.1 mm; implant space ≈ 1.4 mm; nearby mental foramen. Periapical radiolucency observed near 44; minor sclerosis near 25. Image artifacts due to metallic restorations reduce detail locally. Impression: Radiolucent lesion at 13 consistent with radicular cyst; recommend correlation."}
{"id": "case_0105", "images": ["images/placeholder_0105.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Amlodipine, Losartan, Duloxetine, Omeprazole, Levaxin, Bufomix Easyhaler, Duroferon, Trulicity. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 13–23.", "answer": "Review of CBCT dated 250701. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 35: bone height ≈ 16.7 mm; implant space ≈ 14.5 mm; nearby anterior loop. Region 46: bone height ≈ 6.4 mm; implant space ≈ 3.1 mm; nearby anterior loop. Region 13: bone height ≈ 14.7 mm; implant space ≈ 12.3 mm; nearby incisive canal. Region 21: bone height ≈ 14.1 mm; implant space ≈ 9.8 mm; nearby mandibular canal. Region 27: bone height ≈ 15.8 mm; implant space ≈ 10.6 mm; nearby anterior loop. Region 23: bone height ≈ 13.7 mm; implant space ≈ 10.5 mm; nearby anterior loop. Region 22: bone height ≈ 14.4 mm; implant space ≈ 13.3 mm; nearby anterior loop. Region 28: bone height ≈ 6.0 mm; implant space ≈ 4.8 mm; nearby sinus floor. Region 32: bone height ≈ 7.2 mm; implant space ≈ 6.2 mm; nearby anterior loop. Region 31: bone height ≈ 17.4 mm; implant space ≈ 11.7 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 18; minor sclerosis near 31. Image artifacts due to metallic restorations reduce detail locally. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0106", "images": ["images/placeholder_0106.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Betolvex, Duroferon, Duloxetine, Omeprazole, Levaxin, Metoprolol, Bufomix Easyhaler, Insulin glargine. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 230221. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 28: bone height ≈ 15.1 mm; implant space ≈ 12.8 mm; nearby incisive canal. Region 43: bone height ≈ 15.4 mm; implant space ≈ 7.8 mm; nearby sinus floor. Region 41: bone height ≈ 12.3 mm; implant space ≈ 11.2 mm; nearby anterior loop. Region 18: bone height ≈ 5.5 mm; implant space ≈ 1.7 mm; nearby nasal floor. Region 38: bone height ≈ 15.8 mm; implant space ≈ 12.5 mm; nearby mandibular canal. Region 46: bone height ≈ 10.1 mm; implant space ≈ 8.3 mm; nearby sinus floor. Region 14: bone height ≈ 8.1 mm; implant space ≈ 4.6 mm; nearby nasal floor. Region 26: bone height ≈ 20.9 mm; implant space ≈ 16.1 mm; nearby mental foramen. Region 32: bone height ≈ 18.8 mm; implant space ≈ 13.9 mm; nearby mandibular canal. Region 21: bone height ≈ 8.9 mm; implant space ≈ 4.9 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0107", "images": ["images/placeholder_0107.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Esomeprazole, Insulin glargine, Metoprolol, Duloxetine, Trulicity, Calcichew-D3. Desired treatment: Assess proximity to mandibular canal and sinus floor for 16–26 and 14–24.", "answer": "Review of CBCT dated 240814. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 28: bone height ≈ 5.7 mm; implant space ≈ 2.1 mm; nearby nasal floor. Region 15: bone height ≈ 6.8 mm; implant space ≈ 4.7 mm; nearby mandibular canal. Region 36: bone height ≈ 5.7 mm; implant space ≈ 1.7 mm; nearby nasal floor. Region 23: bone height ≈ 6.2 mm; implant space ≈ 4.2 mm; nearby sinus floor. Region 44: bone height ≈ 4.8 mm; implant space ≈ 1.5 mm; nearby sinus floor. Region 45: bone height ≈ 5.8 mm; implant space ≈ 1.6 mm; nearby nasal floor. Region 16: bone height ≈ 10.7 mm; implant space ≈ 7.8 mm; nearby anterior loop. Region 11: bone height ≈ 5.0 mm; implant space ≈ 0 mm; nearby anterior loop. Region 12: bone height ≈ 20.0 mm; implant space ≈ 13.7 mm; nearby nasal floor. Region 38: bone height ≈ 4.3 mm; implant space ≈ 0 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 36; minor sclerosis near 43. Image artifacts due to metallic restorations reduce detail locally. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0108", "images": ["images/placeholder_0108.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Omeprazole, Levaxin, Bufomix Easyhaler, Calcichew-D3, Amlodipine, Trulicity, Atorvastatin. Desired treatment: Assess healing of extraction sockets and bone regeneration at 16–26.", "answer": "Review of CBCT dated 220408. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 46: bone height ≈ 12.2 mm; implant space ≈ 6.1 mm; nearby mental foramen. Region 36: bone height ≈ 20.4 mm; implant space ≈ 13.7 mm; nearby nasal floor. Region 31: bone height ≈ 16.7 mm; implant space ≈ 14.4 mm; nearby anterior loop. Region 11: bone height ≈ 21.5 mm; implant space ≈ 19.3 mm; nearby incisive canal. Region 26: bone height ≈ 11.0 mm; implant space ≈ 3.9 mm; nearby incisive canal. Region 23: bone height ≈ 4.3 mm; implant space ≈ 1.6 mm; nearby incisive canal. Region 32: bone height ≈ 11.9 mm; implant space ≈ 10.9 mm; nearby nasal floor. Region 17: bone height ≈ 10.7 mm; implant space ≈ 8.8 mm; nearby incisive canal. Region 16: bone height ≈ 9.0 mm; implant space ≈ 5.9 mm; nearby anterior loop. Region 27: bone height ≈ 9.5 mm; implant space ≈ 4.0 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 33; minor sclerosis near 31. Impression: Findings consistent with apical periodontitis near 31 and 34."}
{"id": "case_0109", "images": ["images/placeholder_0109.png"], "question": "Planning for implant planning. Brief history/status: Duloxetine, Esomeprazole, Bricanyl, Trulicity, Insulin glargine, Metoprolol, Atorvastatin. Desired treatment: Assess proximity to mandibular canal and sinus floor for 33–43 and 13–23.", "answer": "Review of CBCT dated 210512. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 45: bone height ≈ 4.5 mm; implant space ≈ 0 mm; nearby sinus floor. Region 11: bone height ≈ 17.3 mm; implant space ≈ 16.2 mm; nearby mental foramen. Region 17: bone height ≈ 11.7 mm; implant space ≈ 6.6 mm; nearby mandibular canal. Region 18: bone height ≈ 5.2 mm; implant space ≈ 3.0 mm; nearby mandibular canal. Region 15: bone height ≈ 10.6 mm; implant space ≈ 2.6 mm; nearby incisive canal. Region 44: bone height ≈ 21.6 mm; implant space ≈ 20.4 mm; nearby sinus floor. Region 46: bone height ≈ 14.8 mm; implant space ≈ 7.4 mm; nearby incisive canal. Region 41: bone height ≈ 14.5 mm; implant space ≈ 11.1 mm; nearby anterior loop. Region 26: bone height ≈ 12.0 mm; implant space ≈ 10.1 mm; nearby nasal floor. Region 23: bone height ≈ 9.1 mm; implant space ≈ 3.0 mm; nearby mandibular canal. Periapical radiolucency observed near 27; minor sclerosis near 38. Impression: Radiolucent lesion at 48 consistent with radicular cyst; recommend correlation."}
{"id": "case_0110", "images": ["images/placeholder_0110.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Duloxetine, Losartan, Levaxin, Calcichew-D3, Betolvex, Amlodipine. Desired treatment: Review periapical status and note any signs of infection in regions 18, 42, 37.", "answer": "Review of CBCT dated 210208. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 32: bone height ≈ 15.6 mm; implant space ≈ 9.9 mm; nearby anterior loop. Region 38: bone height ≈ 13.4 mm; implant space ≈ 8.2 mm; nearby mental foramen. Region 22: bone height ≈ 18.4 mm; implant space ≈ 16.1 mm; nearby mental foramen. Region 17: bone height ≈ 15.1 mm; implant space ≈ 13.4 mm; nearby anterior loop. Region 46: bone height ≈ 21.5 mm; implant space ≈ 20.2 mm; nearby nasal floor. Region 42: bone height ≈ 7.8 mm; implant space ≈ 6.4 mm; nearby sinus floor. Region 33: bone height ≈ 19.4 mm; implant space ≈ 14.0 mm; nearby nasal floor. Region 47: bone height ≈ 8.1 mm; implant space ≈ 7.0 mm; nearby nasal floor. Region 15: bone height ≈ 14.8 mm; implant space ≈ 8.2 mm; nearby anterior loop. Region 41: bone height ≈ 6.3 mm; implant space ≈ 2.0 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 28; minor sclerosis near 11. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0111", "images": ["images/placeholder_0111.png"], "question": "Planning for prosthetic design planning. Brief history/status: Metoprolol, Omeprazole, Esomeprazole, Atorvastatin, Trulicity, Duroferon, Bricanyl, Duloxetine. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 251210. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 27: bone height ≈ 12.0 mm; implant space ≈ 9.0 mm; nearby anterior loop. Region 25: bone height ≈ 18.5 mm; implant space ≈ 14.6 mm; nearby nasal floor. Region 16: bone height ≈ 12.8 mm; implant space ≈ 4.9 mm; nearby incisive canal. Region 23: bone height ≈ 20.7 mm; implant space ≈ 14.0 mm; nearby anterior loop. Region 14: bone height ≈ 18.3 mm; implant space ≈ 14.1 mm; nearby nasal floor. Region 31: bone height ≈ 21.3 mm; implant space ≈ 14.2 mm; nearby mental foramen. Region 15: bone height ≈ 9.2 mm; implant space ≈ 5.8 mm; nearby sinus floor. Region 21: bone height ≈ 6.8 mm; implant space ≈ 5.6 mm; nearby nasal floor. Region 36: bone height ≈ 17.4 mm; implant space ≈ 11.5 mm; nearby sinus floor. Region 34: bone height ≈ 18.5 mm; implant space ≈ 13.5 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 41; minor sclerosis near 35. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0112", "images": ["images/placeholder_0112.png"], "question": "Planning for pathology review. Brief history/status: Insulin glargine, Bufomix Easyhaler, Bricanyl, Omeprazole, Trulicity, Amlodipine. Desired treatment: Check for cortical bone thinning or fenestrations near 34–44.", "answer": "Review of CBCT dated 220127. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 18: bone height ≈ 21.6 mm; implant space ≈ 17.7 mm; nearby incisive canal. Region 13: bone height ≈ 8.2 mm; implant space ≈ 7.2 mm; nearby nasal floor. Region 31: bone height ≈ 7.4 mm; implant space ≈ 6.2 mm; nearby sinus floor. Region 35: bone height ≈ 5.8 mm; implant space ≈ 0 mm; nearby nasal floor. Region 26: bone height ≈ 21.5 mm; implant space ≈ 14.9 mm; nearby mental foramen. Region 17: bone height ≈ 22.0 mm; implant space ≈ 17.6 mm; nearby mandibular canal. Region 28: bone height ≈ 21.2 mm; implant space ≈ 14.7 mm; nearby nasal floor. Region 47: bone height ≈ 6.9 mm; implant space ≈ 2.6 mm; nearby sinus floor. Region 32: bone height ≈ 11.5 mm; implant space ≈ 5.3 mm; nearby sinus floor. Region 14: bone height ≈ 19.3 mm; implant space ≈ 12.5 mm; nearby mental foramen. Periapical radiolucency observed near 12; minor sclerosis near 15. Impression: Radiolucent lesion at 11 consistent with radicular cyst; recommend correlation."}
{"id": "case_0113", "images": ["images/placeholder_0113.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Bufomix Easyhaler, Duloxetine, Trulicity, Duroferon, Bricanyl. Desired treatment: Review periapical status and note any signs of infection in regions 32, 36, 25.", "answer": "Review of CBCT dated 250411. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 48: bone height ≈ 15.0 mm; implant space ≈ 9.9 mm; nearby nasal floor. Region 36: bone height ≈ 12.1 mm; implant space ≈ 5.8 mm; nearby mandibular canal. Region 13: bone height ≈ 16.7 mm; implant space ≈ 10.8 mm; nearby sinus floor. Region 46: bone height ≈ 7.1 mm; implant space ≈ 0.2 mm; nearby anterior loop. Region 24: bone height ≈ 18.4 mm; implant space ≈ 15.0 mm; nearby sinus floor. Region 22: bone height ≈ 14.2 mm; implant space ≈ 13.1 mm; nearby mental foramen. Region 21: bone height ≈ 17.3 mm; implant space ≈ 16.2 mm; nearby incisive canal. Region 42: bone height ≈ 16.5 mm; implant space ≈ 12.4 mm; nearby sinus floor. Region 15: bone height ≈ 5.6 mm; implant space ≈ 1.6 mm; nearby anterior loop. Region 43: bone height ≈ 9.0 mm; implant space ≈ 7.2 mm; nearby incisive canal. Periapical radiolucency observed near 25; minor sclerosis near 42. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0114", "images": ["images/placeholder_0114.png"], "question": "Planning for bone graft planning. Brief history/status: Calcichew-D3, Bricanyl, Bufomix Easyhaler, Amlodipine, Omeprazole, Losartan. Desired treatment: Measure ridge augmentation volume required at 33–43 and 13–23.", "answer": "Review of CBCT dated 220709. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 14: bone height ≈ 16.5 mm; implant space ≈ 14.2 mm; nearby anterior loop. Region 35: bone height ≈ 5.6 mm; implant space ≈ 3.3 mm; nearby anterior loop. Region 27: bone height ≈ 21.4 mm; implant space ≈ 18.9 mm; nearby mandibular canal. Region 11: bone height ≈ 20.0 mm; implant space ≈ 15.3 mm; nearby mental foramen. Region 36: bone height ≈ 13.6 mm; implant space ≈ 11.1 mm; nearby sinus floor. Region 32: bone height ≈ 6.5 mm; implant space ≈ 0.6 mm; nearby anterior loop. Region 18: bone height ≈ 12.7 mm; implant space ≈ 5.1 mm; nearby mandibular canal. Region 34: bone height ≈ 16.0 mm; implant space ≈ 11.7 mm; nearby mandibular canal. Region 26: bone height ≈ 11.7 mm; implant space ≈ 4.3 mm; nearby incisive canal. Region 15: bone height ≈ 21.3 mm; implant space ≈ 15.2 mm; nearby nasal floor. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0115", "images": ["images/placeholder_0115.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Omeprazole, Bufomix Easyhaler, Betolvex, Trulicity, Duloxetine, Losartan, Duroferon, Bricanyl. Desired treatment: Check for cortical bone thinning or fenestrations near 34–44.", "answer": "Review of CBCT dated 250506. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 13: bone height ≈ 7.7 mm; implant space ≈ 4.4 mm; nearby anterior loop. Region 17: bone height ≈ 9.9 mm; implant space ≈ 7.8 mm; nearby anterior loop. Region 15: bone height ≈ 9.3 mm; implant space ≈ 4.9 mm; nearby mandibular canal. Region 45: bone height ≈ 9.4 mm; implant space ≈ 5.3 mm; nearby mandibular canal. Region 28: bone height ≈ 11.2 mm; implant space ≈ 4.3 mm; nearby incisive canal. Region 14: bone height ≈ 14.0 mm; implant space ≈ 8.4 mm; nearby nasal floor. Region 44: bone height ≈ 21.6 mm; implant space ≈ 16.2 mm; nearby anterior loop. Region 27: bone height ≈ 12.9 mm; implant space ≈ 8.3 mm; nearby nasal floor. Region 31: bone height ≈ 17.4 mm; implant space ≈ 12.4 mm; nearby anterior loop. Region 21: bone height ≈ 4.7 mm; implant space ≈ 1.4 mm; nearby mental foramen. Image artifacts due to metallic restorations reduce detail locally. Impression: Signs of early osseointegration failure at 45; consider clinical review."}
{"id": "case_0116", "images": ["images/placeholder_0116.png"], "question": "Planning for implant planning. Brief history/status: Trulicity, Insulin glargine, Calcichew-D3, Bricanyl, Betolvex, Bufomix Easyhaler, Amlodipine, Esomeprazole. Desired treatment: Assess healing of extraction sockets and bone regeneration at 34–44.", "answer": "Review of CBCT dated 251206. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 31: bone height ≈ 19.6 mm; implant space ≈ 13.7 mm; nearby sinus floor. Region 41: bone height ≈ 12.5 mm; implant space ≈ 11.2 mm; nearby mandibular canal. Region 45: bone height ≈ 19.7 mm; implant space ≈ 16.4 mm; nearby anterior loop. Region 16: bone height ≈ 8.3 mm; implant space ≈ 3.3 mm; nearby sinus floor. Region 33: bone height ≈ 18.2 mm; implant space ≈ 12.6 mm; nearby sinus floor. Region 28: bone height ≈ 16.5 mm; implant space ≈ 12.8 mm; nearby anterior loop. Region 43: bone height ≈ 7.9 mm; implant space ≈ 0 mm; nearby nasal floor. Region 36: bone height ≈ 14.2 mm; implant space ≈ 7.7 mm; nearby mandibular canal. Region 24: bone height ≈ 12.0 mm; implant space ≈ 7.1 mm; nearby sinus floor. Region 27: bone height ≈ 13.0 mm; implant space ≈ 7.5 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 44; minor sclerosis near 12. Image artifacts due to metallic restorations reduce detail locally. Impression: Findings consistent with apical periodontitis near 35 and 21."}
{"id": "case_0117", "images": ["images/placeholder_0117.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Insulin glargine, Esomeprazole, Omeprazole, Duroferon, Metoprolol. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 13–23 and 36–46.", "answer": "Review of CBCT dated 220806. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 17: bone height ≈ 19.2 mm; implant space ≈ 15.7 mm; nearby anterior loop. Region 22: bone height ≈ 17.9 mm; implant space ≈ 10.8 mm; nearby incisive canal. Region 13: bone height ≈ 10.1 mm; implant space ≈ 4.2 mm; nearby mental foramen. Region 32: bone height ≈ 17.1 mm; implant space ≈ 16.1 mm; nearby mental foramen. Region 33: bone height ≈ 5.8 mm; implant space ≈ 0.7 mm; nearby sinus floor. Region 15: bone height ≈ 17.2 mm; implant space ≈ 9.8 mm; nearby mental foramen. Region 44: bone height ≈ 7.9 mm; implant space ≈ 5.9 mm; nearby anterior loop. Region 25: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby mental foramen. Region 11: bone height ≈ 10.7 mm; implant space ≈ 3.3 mm; nearby mental foramen. Region 36: bone height ≈ 20.0 mm; implant space ≈ 15.1 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Radiolucent lesion at 13 consistent with radicular cyst; recommend correlation."}
{"id": "case_0118", "images": ["images/placeholder_0118.png"], "question": "Planning for prosthetic design planning. Brief history/status: Bricanyl, Losartan, Trulicity, Metoprolol, Bufomix Easyhaler, Amlodipine, Insulin glargine, Betolvex. Desired treatment: Assess healing of extraction sockets and bone regeneration at 13–23.", "answer": "Review of CBCT dated 210808. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 36: bone height ≈ 20.9 mm; implant space ≈ 16.8 mm; nearby incisive canal. Region 37: bone height ≈ 5.6 mm; implant space ≈ 0 mm; nearby incisive canal. Region 47: bone height ≈ 12.2 mm; implant space ≈ 7.7 mm; nearby anterior loop. Region 43: bone height ≈ 15.3 mm; implant space ≈ 10.0 mm; nearby mental foramen. Region 18: bone height ≈ 12.5 mm; implant space ≈ 4.5 mm; nearby mental foramen. Region 35: bone height ≈ 5.6 mm; implant space ≈ 4.0 mm; nearby anterior loop. Region 45: bone height ≈ 15.8 mm; implant space ≈ 9.5 mm; nearby nasal floor. Region 12: bone height ≈ 14.3 mm; implant space ≈ 11.6 mm; nearby mental foramen. Region 25: bone height ≈ 15.3 mm; implant space ≈ 8.6 mm; nearby sinus floor. Region 24: bone height ≈ 19.0 mm; implant space ≈ 12.5 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0119", "images": ["images/placeholder_0119.png"], "question": "Planning for implant planning. Brief history/status: Bufomix Easyhaler, Duroferon, Amlodipine, Omeprazole, Levaxin, Atorvastatin, Duloxetine, Losartan. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 240420. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 34: bone height ≈ 17.7 mm; implant space ≈ 11.7 mm; nearby mental foramen. Region 47: bone height ≈ 21.1 mm; implant space ≈ 17.0 mm; nearby sinus floor. Region 31: bone height ≈ 16.3 mm; implant space ≈ 9.4 mm; nearby mental foramen. Region 46: bone height ≈ 19.9 mm; implant space ≈ 18.0 mm; nearby nasal floor. Region 13: bone height ≈ 14.3 mm; implant space ≈ 12.9 mm; nearby incisive canal. Region 41: bone height ≈ 13.7 mm; implant space ≈ 11.9 mm; nearby nasal floor. Region 38: bone height ≈ 21.8 mm; implant space ≈ 20.5 mm; nearby mandibular canal. Region 32: bone height ≈ 5.1 mm; implant space ≈ 0.8 mm; nearby sinus floor. Region 21: bone height ≈ 20.7 mm; implant space ≈ 16.8 mm; nearby sinus floor. Region 28: bone height ≈ 12.2 mm; implant space ≈ 5.9 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Impression: Radiolucent lesion at 44 consistent with radicular cyst; recommend correlation."}
{"id": "case_0120", "images": ["images/placeholder_0120.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Amlodipine, Metoprolol, Duroferon, Losartan, Esomeprazole. Desired treatment: Review periapical status and note any signs of infection in regions 16, 44, 24.", "answer": "Review of CBCT dated 210811. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 16: bone height ≈ 12.7 mm; implant space ≈ 11.0 mm; nearby mandibular canal. Region 21: bone height ≈ 15.6 mm; implant space ≈ 9.4 mm; nearby anterior loop. Region 14: bone height ≈ 21.8 mm; implant space ≈ 14.8 mm; nearby nasal floor. Region 46: bone height ≈ 7.3 mm; implant space ≈ 0.7 mm; nearby sinus floor. Region 36: bone height ≈ 17.5 mm; implant space ≈ 13.4 mm; nearby mental foramen. Region 37: bone height ≈ 19.8 mm; implant space ≈ 14.8 mm; nearby incisive canal. Region 44: bone height ≈ 17.9 mm; implant space ≈ 16.6 mm; nearby mandibular canal. Region 41: bone height ≈ 4.2 mm; implant space ≈ 1.1 mm; nearby mandibular canal. Region 32: bone height ≈ 21.3 mm; implant space ≈ 18.3 mm; nearby nasal floor. Region 22: bone height ≈ 10.4 mm; implant space ≈ 3.1 mm; nearby incisive canal. Impression: Vertical root fracture suspected at 21, extending coronally."}
{"id": "case_0121", "images": ["images/placeholder_0121.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Bricanyl, Levaxin, Duloxetine, Duroferon, Losartan. Desired treatment: Review periapical status and note any signs of infection in regions 16, 34, 27.", "answer": "Review of CBCT dated 211209. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 38: bone height ≈ 16.7 mm; implant space ≈ 13.4 mm; nearby anterior loop. Region 47: bone height ≈ 10.0 mm; implant space ≈ 3.2 mm; nearby incisive canal. Region 42: bone height ≈ 5.2 mm; implant space ≈ 1.9 mm; nearby mandibular canal. Region 28: bone height ≈ 19.3 mm; implant space ≈ 14.9 mm; nearby anterior loop. Region 45: bone height ≈ 12.1 mm; implant space ≈ 9.6 mm; nearby sinus floor. Region 14: bone height ≈ 15.4 mm; implant space ≈ 12.9 mm; nearby nasal floor. Region 41: bone height ≈ 5.7 mm; implant space ≈ 0.8 mm; nearby mandibular canal. Region 34: bone height ≈ 18.9 mm; implant space ≈ 14.9 mm; nearby incisive canal. Region 22: bone height ≈ 16.4 mm; implant space ≈ 13.6 mm; nearby mandibular canal. Region 26: bone height ≈ 4.8 mm; implant space ≈ 3.5 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 15; minor sclerosis near 16. Impression: Impacted molar in quadrant 1 associated with mild follicular space widening."}
{"id": "case_0122", "images": ["images/placeholder_0122.png"], "question": "Planning for pathology review. Brief history/status: Bufomix Easyhaler, Betolvex, Duroferon, Losartan, Bricanyl, Trulicity, Metoprolol. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 16–26.", "answer": "Review of CBCT dated 241206. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 26: bone height ≈ 18.5 mm; implant space ≈ 11.3 mm; nearby mental foramen. Region 35: bone height ≈ 19.4 mm; implant space ≈ 15.6 mm; nearby anterior loop. Region 13: bone height ≈ 20.4 mm; implant space ≈ 13.7 mm; nearby mandibular canal. Region 18: bone height ≈ 15.0 mm; implant space ≈ 11.5 mm; nearby mandibular canal. Region 34: bone height ≈ 7.3 mm; implant space ≈ 3.9 mm; nearby incisive canal. Region 32: bone height ≈ 11.9 mm; implant space ≈ 7.5 mm; nearby nasal floor. Region 11: bone height ≈ 8.8 mm; implant space ≈ 6.6 mm; nearby nasal floor. Region 33: bone height ≈ 14.8 mm; implant space ≈ 11.1 mm; nearby anterior loop. Region 44: bone height ≈ 18.7 mm; implant space ≈ 10.8 mm; nearby incisive canal. Region 15: bone height ≈ 14.1 mm; implant space ≈ 11.9 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 17; minor sclerosis near 48. Impression: Peri-implantitis changes evident at 22; marginal bone loss noted."}
{"id": "case_0123", "images": ["images/placeholder_0123.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Omeprazole, Insulin glargine, Levaxin, Duroferon, Bricanyl, Amlodipine, Esomeprazole. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 33–43 and 36–46.", "answer": "Review of CBCT dated 220620. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 46: bone height ≈ 6.0 mm; implant space ≈ 3.4 mm; nearby mandibular canal. Region 42: bone height ≈ 5.0 mm; implant space ≈ 2.0 mm; nearby mental foramen. Region 11: bone height ≈ 18.7 mm; implant space ≈ 15.9 mm; nearby incisive canal. Region 24: bone height ≈ 18.1 mm; implant space ≈ 11.3 mm; nearby incisive canal. Region 48: bone height ≈ 18.3 mm; implant space ≈ 17.0 mm; nearby incisive canal. Region 26: bone height ≈ 7.5 mm; implant space ≈ 0.8 mm; nearby incisive canal. Region 13: bone height ≈ 12.3 mm; implant space ≈ 8.3 mm; nearby nasal floor. Region 32: bone height ≈ 15.3 mm; implant space ≈ 11.9 mm; nearby mental foramen. Region 47: bone height ≈ 16.1 mm; implant space ≈ 14.2 mm; nearby mental foramen. Region 43: bone height ≈ 8.4 mm; implant space ≈ 5.7 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 31; minor sclerosis near 47. Impression: Signs of early osseointegration failure at 24; consider clinical review."}
{"id": "case_0124", "images": ["images/placeholder_0124.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Esomeprazole, Omeprazole, Bricanyl, Insulin glargine, Duroferon, Bufomix Easyhaler. Desired treatment: Provide measurements for alveolar ridge width and height at 14–24.", "answer": "Review of CBCT dated 200723. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 34: bone height ≈ 5.5 mm; implant space ≈ 4.4 mm; nearby nasal floor. Region 22: bone height ≈ 7.8 mm; implant space ≈ 5.4 mm; nearby incisive canal. Region 15: bone height ≈ 17.1 mm; implant space ≈ 12.7 mm; nearby incisive canal. Region 27: bone height ≈ 15.4 mm; implant space ≈ 11.2 mm; nearby sinus floor. Region 14: bone height ≈ 14.5 mm; implant space ≈ 7.8 mm; nearby nasal floor. Region 13: bone height ≈ 10.5 mm; implant space ≈ 3.7 mm; nearby mandibular canal. Region 37: bone height ≈ 16.6 mm; implant space ≈ 13.3 mm; nearby nasal floor. Region 48: bone height ≈ 19.5 mm; implant space ≈ 15.9 mm; nearby sinus floor. Region 23: bone height ≈ 6.0 mm; implant space ≈ 0 mm; nearby mental foramen. Region 31: bone height ≈ 15.3 mm; implant space ≈ 8.6 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 17; minor sclerosis near 38. Image artifacts due to metallic restorations reduce detail locally. Impression: Findings consistent with apical periodontitis near 17 and 48."}
{"id": "case_0125", "images": ["images/placeholder_0125.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Bricanyl, Losartan, Metoprolol, Calcichew-D3, Duloxetine, Duroferon, Esomeprazole. Desired treatment: Review periapical status and note any signs of infection in regions 46, 45, 44.", "answer": "Review of CBCT dated 200502. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 32: bone height ≈ 9.5 mm; implant space ≈ 3.7 mm; nearby nasal floor. Region 47: bone height ≈ 15.9 mm; implant space ≈ 11.3 mm; nearby mental foramen. Region 31: bone height ≈ 4.1 mm; implant space ≈ 0 mm; nearby mental foramen. Region 26: bone height ≈ 12.6 mm; implant space ≈ 9.4 mm; nearby anterior loop. Region 45: bone height ≈ 9.9 mm; implant space ≈ 3.9 mm; nearby anterior loop. Region 38: bone height ≈ 14.7 mm; implant space ≈ 12.4 mm; nearby anterior loop. Region 28: bone height ≈ 15.1 mm; implant space ≈ 12.0 mm; nearby anterior loop. Region 37: bone height ≈ 8.1 mm; implant space ≈ 5.9 mm; nearby mandibular canal. Region 24: bone height ≈ 17.2 mm; implant space ≈ 11.5 mm; nearby mental foramen. Region 18: bone height ≈ 20.7 mm; implant space ≈ 14.2 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Impression: Vertical root fracture suspected at 36, extending coronally."}
{"id": "case_0126", "images": ["images/placeholder_0126.png"], "question": "Planning for implant planning. Brief history/status: Bricanyl, Insulin glargine, Levaxin, Esomeprazole, Amlodipine, Betolvex, Atorvastatin, Duroferon. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 33–43 and 14–24.", "answer": "Review of CBCT dated 250204. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 45: bone height ≈ 17.9 mm; implant space ≈ 14.7 mm; nearby nasal floor. Region 26: bone height ≈ 20.7 mm; implant space ≈ 18.4 mm; nearby incisive canal. Region 33: bone height ≈ 8.1 mm; implant space ≈ 1.4 mm; nearby anterior loop. Region 47: bone height ≈ 10.8 mm; implant space ≈ 4.8 mm; nearby mental foramen. Region 46: bone height ≈ 15.5 mm; implant space ≈ 13.6 mm; nearby mandibular canal. Region 14: bone height ≈ 10.4 mm; implant space ≈ 7.2 mm; nearby anterior loop. Region 12: bone height ≈ 17.5 mm; implant space ≈ 16.4 mm; nearby sinus floor. Region 38: bone height ≈ 4.8 mm; implant space ≈ 0 mm; nearby nasal floor. Region 13: bone height ≈ 4.3 mm; implant space ≈ 0 mm; nearby sinus floor. Region 44: bone height ≈ 17.0 mm; implant space ≈ 11.5 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 44; minor sclerosis near 14. Impression: Signs of early osseointegration failure at 37; consider clinical review."}
{"id": "case_0127", "images": ["images/placeholder_0127.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Duloxetine, Trulicity, Levaxin, Calcichew-D3, Metoprolol. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 14–24.", "answer": "Review of CBCT dated 220511. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 41: bone height ≈ 4.3 mm; implant space ≈ 0.6 mm; nearby anterior loop. Region 25: bone height ≈ 18.9 mm; implant space ≈ 11.2 mm; nearby mandibular canal. Region 12: bone height ≈ 13.4 mm; implant space ≈ 9.7 mm; nearby nasal floor. Region 48: bone height ≈ 10.5 mm; implant space ≈ 8.9 mm; nearby anterior loop. Region 27: bone height ≈ 13.8 mm; implant space ≈ 9.8 mm; nearby incisive canal. Region 37: bone height ≈ 7.3 mm; implant space ≈ 0.3 mm; nearby nasal floor. Region 17: bone height ≈ 21.2 mm; implant space ≈ 15.9 mm; nearby anterior loop. Region 38: bone height ≈ 22.0 mm; implant space ≈ 17.4 mm; nearby sinus floor. Region 46: bone height ≈ 5.6 mm; implant space ≈ 3.5 mm; nearby mandibular canal. Region 31: bone height ≈ 5.2 mm; implant space ≈ 0 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0128", "images": ["images/placeholder_0128.png"], "question": "Planning for pathology review. Brief history/status: Amlodipine, Losartan, Levaxin, Duroferon, Insulin glargine, Bricanyl, Metoprolol. Desired treatment: Review periapical status and note any signs of infection in regions 11, 37, 17.", "answer": "Review of CBCT dated 200604. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 26: bone height ≈ 13.1 mm; implant space ≈ 12.0 mm; nearby nasal floor. Region 38: bone height ≈ 4.3 mm; implant space ≈ 0 mm; nearby sinus floor. Region 27: bone height ≈ 4.8 mm; implant space ≈ 2.0 mm; nearby nasal floor. Region 43: bone height ≈ 8.8 mm; implant space ≈ 7.6 mm; nearby nasal floor. Region 22: bone height ≈ 17.9 mm; implant space ≈ 16.4 mm; nearby nasal floor. Region 13: bone height ≈ 13.3 mm; implant space ≈ 7.9 mm; nearby nasal floor. Region 17: bone height ≈ 18.0 mm; implant space ≈ 12.3 mm; nearby nasal floor. Region 21: bone height ≈ 8.1 mm; implant space ≈ 1.1 mm; nearby incisive canal. Region 32: bone height ≈ 5.4 mm; implant space ≈ 0 mm; nearby anterior loop. Region 25: bone height ≈ 8.4 mm; implant space ≈ 5.5 mm; nearby anterior loop. Periapical radiolucency observed near 28; minor sclerosis near 36. Image artifacts due to metallic restorations reduce detail locally. Impression: Radiolucent lesion at 14 consistent with radicular cyst; recommend correlation."}
{"id": "case_0129", "images": ["images/placeholder_0129.png"], "question": "Planning for implant planning. Brief history/status: Duloxetine, Betolvex, Insulin glargine, Atorvastatin, Esomeprazole, Levaxin, Calcichew-D3, Trulicity. Desired treatment: Assess healing of extraction sockets and bone regeneration at 16–26.", "answer": "Review of CBCT dated 250415. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 22: bone height ≈ 19.1 mm; implant space ≈ 18.0 mm; nearby nasal floor. Region 36: bone height ≈ 20.9 mm; implant space ≈ 17.8 mm; nearby mental foramen. Region 38: bone height ≈ 7.6 mm; implant space ≈ 6.0 mm; nearby anterior loop. Region 25: bone height ≈ 14.3 mm; implant space ≈ 8.7 mm; nearby anterior loop. Region 21: bone height ≈ 19.5 mm; implant space ≈ 12.0 mm; nearby incisive canal. Region 44: bone height ≈ 5.9 mm; implant space ≈ 4.1 mm; nearby mental foramen. Region 12: bone height ≈ 5.0 mm; implant space ≈ 0 mm; nearby anterior loop. Region 35: bone height ≈ 21.4 mm; implant space ≈ 15.1 mm; nearby mandibular canal. Region 24: bone height ≈ 17.4 mm; implant space ≈ 10.6 mm; nearby anterior loop. Region 18: bone height ≈ 19.6 mm; implant space ≈ 12.0 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 46; minor sclerosis near 15. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0130", "images": ["images/placeholder_0130.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Bricanyl, Trulicity, Levaxin, Bufomix Easyhaler, Omeprazole. Desired treatment: Provide measurements for alveolar ridge width and height at 33–43.", "answer": "Review of CBCT dated 241105. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 21: bone height ≈ 7.7 mm; implant space ≈ 6.5 mm; nearby incisive canal. Region 26: bone height ≈ 16.9 mm; implant space ≈ 9.8 mm; nearby mandibular canal. Region 12: bone height ≈ 16.8 mm; implant space ≈ 12.2 mm; nearby anterior loop. Region 25: bone height ≈ 15.5 mm; implant space ≈ 13.6 mm; nearby sinus floor. Region 18: bone height ≈ 12.6 mm; implant space ≈ 5.2 mm; nearby mandibular canal. Region 22: bone height ≈ 13.3 mm; implant space ≈ 7.3 mm; nearby mandibular canal. Region 16: bone height ≈ 6.6 mm; implant space ≈ 4.3 mm; nearby sinus floor. Region 45: bone height ≈ 13.0 mm; implant space ≈ 9.6 mm; nearby incisive canal. Region 33: bone height ≈ 7.6 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 14: bone height ≈ 18.9 mm; implant space ≈ 17.6 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 24; minor sclerosis near 37. Image artifacts due to metallic restorations reduce detail locally. Impression: Radiolucent lesion at 42 consistent with radicular cyst; recommend correlation."}
{"id": "case_0131", "images": ["images/placeholder_0131.png"], "question": "Planning for bone graft planning. Brief history/status: Duloxetine, Bufomix Easyhaler, Bricanyl, Duroferon, Levaxin, Losartan, Metoprolol, Calcichew-D3. Desired treatment: Assess healing of extraction sockets and bone regeneration at 16–26.", "answer": "Review of CBCT dated 230405. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 36: bone height ≈ 18.6 mm; implant space ≈ 13.9 mm; nearby mental foramen. Region 44: bone height ≈ 21.8 mm; implant space ≈ 19.9 mm; nearby anterior loop. Region 28: bone height ≈ 5.9 mm; implant space ≈ 1.3 mm; nearby sinus floor. Region 18: bone height ≈ 17.3 mm; implant space ≈ 14.2 mm; nearby anterior loop. Region 31: bone height ≈ 17.5 mm; implant space ≈ 11.2 mm; nearby incisive canal. Region 24: bone height ≈ 20.2 mm; implant space ≈ 12.3 mm; nearby incisive canal. Region 16: bone height ≈ 20.7 mm; implant space ≈ 18.3 mm; nearby nasal floor. Region 48: bone height ≈ 12.9 mm; implant space ≈ 7.5 mm; nearby incisive canal. Region 46: bone height ≈ 20.7 mm; implant space ≈ 18.8 mm; nearby nasal floor. Region 26: bone height ≈ 14.1 mm; implant space ≈ 6.8 mm; nearby nasal floor. Periapical radiolucency observed near 16; minor sclerosis near 28. Image artifacts due to metallic restorations reduce detail locally. Impression: Impacted molar in quadrant 2 associated with mild follicular space widening."}
{"id": "case_0132", "images": ["images/placeholder_0132.png"], "question": "Planning for bone graft planning. Brief history/status: Duroferon, Bricanyl, Insulin glargine, Omeprazole, Bufomix Easyhaler, Duloxetine. Desired treatment: Assess healing of extraction sockets and bone regeneration at 13–23.", "answer": "Review of CBCT dated 220420. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 37: bone height ≈ 9.0 mm; implant space ≈ 7.5 mm; nearby sinus floor. Region 25: bone height ≈ 12.9 mm; implant space ≈ 8.2 mm; nearby nasal floor. Region 35: bone height ≈ 8.5 mm; implant space ≈ 6.7 mm; nearby nasal floor. Region 17: bone height ≈ 16.9 mm; implant space ≈ 14.7 mm; nearby mandibular canal. Region 26: bone height ≈ 8.0 mm; implant space ≈ 6.0 mm; nearby incisive canal. Region 16: bone height ≈ 16.9 mm; implant space ≈ 14.2 mm; nearby mental foramen. Region 31: bone height ≈ 20.7 mm; implant space ≈ 13.9 mm; nearby sinus floor. Region 18: bone height ≈ 10.1 mm; implant space ≈ 3.7 mm; nearby sinus floor. Region 34: bone height ≈ 9.6 mm; implant space ≈ 6.9 mm; nearby incisive canal. Region 33: bone height ≈ 6.0 mm; implant space ≈ 4.2 mm; nearby sinus floor. Impression: Findings consistent with apical periodontitis near 26 and 23."}
{"id": "case_0133", "images": ["images/placeholder_0133.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Insulin glargine, Levaxin, Betolvex, Atorvastatin, Bricanyl, Esomeprazole, Metoprolol, Amlodipine. Desired treatment: Measure ridge augmentation volume required at 34–44 and 36–46.", "answer": "Review of CBCT dated 241124. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 24: bone height ≈ 19.8 mm; implant space ≈ 15.9 mm; nearby incisive canal. Region 33: bone height ≈ 17.4 mm; implant space ≈ 15.0 mm; nearby sinus floor. Region 41: bone height ≈ 21.9 mm; implant space ≈ 16.1 mm; nearby mandibular canal. Region 34: bone height ≈ 5.7 mm; implant space ≈ 1.3 mm; nearby sinus floor. Region 45: bone height ≈ 15.6 mm; implant space ≈ 13.1 mm; nearby sinus floor. Region 43: bone height ≈ 9.0 mm; implant space ≈ 1.8 mm; nearby incisive canal. Region 18: bone height ≈ 19.8 mm; implant space ≈ 15.9 mm; nearby mental foramen. Region 22: bone height ≈ 21.4 mm; implant space ≈ 13.6 mm; nearby mental foramen. Region 26: bone height ≈ 16.5 mm; implant space ≈ 9.4 mm; nearby mandibular canal. Region 44: bone height ≈ 8.6 mm; implant space ≈ 3.9 mm; nearby nasal floor. Impression: Peri-implantitis changes evident at 16; marginal bone loss noted."}
{"id": "case_0134", "images": ["images/placeholder_0134.png"], "question": "Planning for implant planning. Brief history/status: Trulicity, Metoprolol, Amlodipine, Duroferon, Atorvastatin, Bricanyl. Desired treatment: Check for cortical bone thinning or fenestrations near 14–24.", "answer": "Review of CBCT dated 200422. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 43: bone height ≈ 21.0 mm; implant space ≈ 16.5 mm; nearby nasal floor. Region 46: bone height ≈ 20.1 mm; implant space ≈ 13.4 mm; nearby nasal floor. Region 14: bone height ≈ 18.1 mm; implant space ≈ 14.2 mm; nearby nasal floor. Region 31: bone height ≈ 16.8 mm; implant space ≈ 10.7 mm; nearby anterior loop. Region 44: bone height ≈ 13.5 mm; implant space ≈ 10.0 mm; nearby mandibular canal. Region 22: bone height ≈ 17.7 mm; implant space ≈ 10.0 mm; nearby incisive canal. Region 47: bone height ≈ 21.4 mm; implant space ≈ 13.6 mm; nearby mandibular canal. Region 26: bone height ≈ 7.5 mm; implant space ≈ 4.1 mm; nearby anterior loop. Region 24: bone height ≈ 19.8 mm; implant space ≈ 13.0 mm; nearby sinus floor. Region 16: bone height ≈ 8.6 mm; implant space ≈ 1.7 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0135", "images": ["images/placeholder_0135.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Bricanyl, Insulin glargine, Duloxetine, Bufomix Easyhaler, Calcichew-D3, Esomeprazole. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 240525. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 44: bone height ≈ 14.5 mm; implant space ≈ 8.8 mm; nearby sinus floor. Region 35: bone height ≈ 11.0 mm; implant space ≈ 7.3 mm; nearby sinus floor. Region 23: bone height ≈ 11.9 mm; implant space ≈ 8.4 mm; nearby nasal floor. Region 12: bone height ≈ 16.3 mm; implant space ≈ 14.5 mm; nearby nasal floor. Region 38: bone height ≈ 13.8 mm; implant space ≈ 10.5 mm; nearby mental foramen. Region 34: bone height ≈ 20.5 mm; implant space ≈ 19.2 mm; nearby incisive canal. Region 45: bone height ≈ 21.9 mm; implant space ≈ 19.5 mm; nearby incisive canal. Region 16: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 32: bone height ≈ 14.3 mm; implant space ≈ 10.5 mm; nearby mandibular canal. Region 24: bone height ≈ 10.4 mm; implant space ≈ 6.8 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Impression: Adequate bone volume present for standard implant placement."}
{"id": "case_0136", "images": ["images/placeholder_0136.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Omeprazole, Duroferon, Insulin glargine, Calcichew-D3, Betolvex, Metoprolol, Losartan, Levaxin. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 33–43.", "answer": "Review of CBCT dated 231012. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 46: bone height ≈ 14.4 mm; implant space ≈ 7.6 mm; nearby mandibular canal. Region 27: bone height ≈ 6.3 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 36: bone height ≈ 8.2 mm; implant space ≈ 6.6 mm; nearby nasal floor. Region 16: bone height ≈ 12.6 mm; implant space ≈ 6.2 mm; nearby sinus floor. Region 41: bone height ≈ 11.5 mm; implant space ≈ 7.0 mm; nearby incisive canal. Region 42: bone height ≈ 10.8 mm; implant space ≈ 4.0 mm; nearby mental foramen. Region 45: bone height ≈ 12.1 mm; implant space ≈ 10.4 mm; nearby anterior loop. Region 11: bone height ≈ 5.1 mm; implant space ≈ 0 mm; nearby anterior loop. Region 17: bone height ≈ 10.8 mm; implant space ≈ 3.3 mm; nearby incisive canal. Region 35: bone height ≈ 18.6 mm; implant space ≈ 11.5 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 26; minor sclerosis near 38. Image artifacts due to metallic restorations reduce detail locally. Impression: Peri-implantitis changes evident at 17; marginal bone loss noted."}
{"id": "case_0137", "images": ["images/placeholder_0137.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Amlodipine, Trulicity, Calcichew-D3, Betolvex, Metoprolol. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 220116. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 33: bone height ≈ 19.6 mm; implant space ≈ 18.6 mm; nearby incisive canal. Region 38: bone height ≈ 12.5 mm; implant space ≈ 9.4 mm; nearby anterior loop. Region 35: bone height ≈ 8.9 mm; implant space ≈ 4.8 mm; nearby mandibular canal. Region 48: bone height ≈ 17.3 mm; implant space ≈ 10.8 mm; nearby nasal floor. Region 31: bone height ≈ 5.7 mm; implant space ≈ 0 mm; nearby sinus floor. Region 26: bone height ≈ 8.3 mm; implant space ≈ 5.6 mm; nearby sinus floor. Region 23: bone height ≈ 18.6 mm; implant space ≈ 15.8 mm; nearby mandibular canal. Region 18: bone height ≈ 17.7 mm; implant space ≈ 12.9 mm; nearby anterior loop. Region 32: bone height ≈ 6.0 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 47: bone height ≈ 5.4 mm; implant space ≈ 3.8 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0138", "images": ["images/placeholder_0138.png"], "question": "Planning for bone graft planning. Brief history/status: Bricanyl, Betolvex, Levaxin, Esomeprazole, Insulin glargine, Bufomix Easyhaler, Atorvastatin, Calcichew-D3. Desired treatment: Measure ridge augmentation volume required at 34–44 and 36–46.", "answer": "Review of CBCT dated 250715. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 34: bone height ≈ 11.7 mm; implant space ≈ 10.7 mm; nearby incisive canal. Region 15: bone height ≈ 5.5 mm; implant space ≈ 0 mm; nearby incisive canal. Region 21: bone height ≈ 5.0 mm; implant space ≈ 0 mm; nearby sinus floor. Region 17: bone height ≈ 19.3 mm; implant space ≈ 15.5 mm; nearby anterior loop. Region 37: bone height ≈ 18.4 mm; implant space ≈ 15.0 mm; nearby anterior loop. Region 38: bone height ≈ 17.3 mm; implant space ≈ 14.2 mm; nearby mandibular canal. Region 22: bone height ≈ 4.4 mm; implant space ≈ 0 mm; nearby nasal floor. Region 46: bone height ≈ 11.5 mm; implant space ≈ 7.7 mm; nearby nasal floor. Region 41: bone height ≈ 8.9 mm; implant space ≈ 4.6 mm; nearby incisive canal. Region 35: bone height ≈ 12.5 mm; implant space ≈ 11.3 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 36; minor sclerosis near 37. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0139", "images": ["images/placeholder_0139.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Insulin glargine, Betolvex, Omeprazole, Duloxetine, Atorvastatin, Levaxin, Esomeprazole, Bricanyl. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 33–43 and 14–24.", "answer": "Review of CBCT dated 211228. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 38: bone height ≈ 19.2 mm; implant space ≈ 17.5 mm; nearby nasal floor. Region 11: bone height ≈ 7.7 mm; implant space ≈ 3.5 mm; nearby mental foramen. Region 45: bone height ≈ 11.1 mm; implant space ≈ 6.9 mm; nearby mandibular canal. Region 18: bone height ≈ 15.1 mm; implant space ≈ 13.1 mm; nearby mental foramen. Region 48: bone height ≈ 16.4 mm; implant space ≈ 13.0 mm; nearby mandibular canal. Region 44: bone height ≈ 12.2 mm; implant space ≈ 10.5 mm; nearby mandibular canal. Region 28: bone height ≈ 5.1 mm; implant space ≈ 0 mm; nearby incisive canal. Region 41: bone height ≈ 17.1 mm; implant space ≈ 9.8 mm; nearby anterior loop. Region 15: bone height ≈ 5.7 mm; implant space ≈ 0 mm; nearby mental foramen. Region 37: bone height ≈ 6.1 mm; implant space ≈ 0.5 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 34; minor sclerosis near 35. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0140", "images": ["images/placeholder_0140.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Calcichew-D3, Insulin glargine, Amlodipine, Esomeprazole, Omeprazole. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 16–26 and 36–46.", "answer": "Review of CBCT dated 220109. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 12: bone height ≈ 8.7 mm; implant space ≈ 7.5 mm; nearby mental foramen. Region 38: bone height ≈ 19.8 mm; implant space ≈ 13.0 mm; nearby anterior loop. Region 22: bone height ≈ 8.1 mm; implant space ≈ 5.4 mm; nearby anterior loop. Region 35: bone height ≈ 17.3 mm; implant space ≈ 10.0 mm; nearby anterior loop. Region 32: bone height ≈ 21.0 mm; implant space ≈ 15.7 mm; nearby mental foramen. Region 48: bone height ≈ 21.4 mm; implant space ≈ 13.6 mm; nearby anterior loop. Region 15: bone height ≈ 18.7 mm; implant space ≈ 11.1 mm; nearby mental foramen. Region 21: bone height ≈ 20.0 mm; implant space ≈ 18.7 mm; nearby incisive canal. Region 43: bone height ≈ 15.0 mm; implant space ≈ 13.2 mm; nearby sinus floor. Region 26: bone height ≈ 6.4 mm; implant space ≈ 1.0 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Impacted molar in quadrant 3 associated with mild follicular space widening."}
{"id": "case_0141", "images": ["images/placeholder_0141.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Bufomix Easyhaler, Bricanyl, Atorvastatin, Insulin glargine, Losartan, Duroferon, Trulicity, Amlodipine. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 14–24 and 33–43.", "answer": "Review of CBCT dated 240314. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 28: bone height ≈ 5.1 mm; implant space ≈ 1.8 mm; nearby sinus floor. Region 46: bone height ≈ 21.8 mm; implant space ≈ 15.9 mm; nearby incisive canal. Region 45: bone height ≈ 8.7 mm; implant space ≈ 4.4 mm; nearby nasal floor. Region 32: bone height ≈ 9.5 mm; implant space ≈ 7.8 mm; nearby nasal floor. Region 18: bone height ≈ 11.9 mm; implant space ≈ 7.4 mm; nearby nasal floor. Region 12: bone height ≈ 13.7 mm; implant space ≈ 11.9 mm; nearby mandibular canal. Region 14: bone height ≈ 11.7 mm; implant space ≈ 8.2 mm; nearby nasal floor. Region 41: bone height ≈ 11.8 mm; implant space ≈ 9.4 mm; nearby anterior loop. Region 15: bone height ≈ 6.6 mm; implant space ≈ 3.7 mm; nearby anterior loop. Region 47: bone height ≈ 10.2 mm; implant space ≈ 9.1 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Impression: Signs of early osseointegration failure at 45; consider clinical review."}
{"id": "case_0142", "images": ["images/placeholder_0142.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Bricanyl, Omeprazole, Trulicity, Losartan, Atorvastatin, Esomeprazole, Metoprolol, Calcichew-D3. Desired treatment: Provide measurements for alveolar ridge width and height at 34–44.", "answer": "Review of CBCT dated 230102. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 36: bone height ≈ 11.5 mm; implant space ≈ 8.6 mm; nearby nasal floor. Region 37: bone height ≈ 7.8 mm; implant space ≈ 3.9 mm; nearby nasal floor. Region 21: bone height ≈ 9.4 mm; implant space ≈ 7.3 mm; nearby nasal floor. Region 16: bone height ≈ 5.4 mm; implant space ≈ 1.2 mm; nearby nasal floor. Region 35: bone height ≈ 19.2 mm; implant space ≈ 11.6 mm; nearby sinus floor. Region 33: bone height ≈ 5.1 mm; implant space ≈ 0 mm; nearby sinus floor. Region 34: bone height ≈ 4.3 mm; implant space ≈ 0 mm; nearby sinus floor. Region 12: bone height ≈ 21.3 mm; implant space ≈ 16.4 mm; nearby incisive canal. Region 41: bone height ≈ 14.8 mm; implant space ≈ 11.7 mm; nearby sinus floor. Region 47: bone height ≈ 18.7 mm; implant space ≈ 15.4 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 41; minor sclerosis near 44. Impression: Findings consistent with apical periodontitis near 43 and 21."}
{"id": "case_0143", "images": ["images/placeholder_0143.png"], "question": "Planning for bone graft planning. Brief history/status: Metoprolol, Atorvastatin, Bufomix Easyhaler, Duloxetine, Betolvex. Desired treatment: Assess healing of extraction sockets and bone regeneration at 33–43.", "answer": "Review of CBCT dated 251106. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 11: bone height ≈ 14.7 mm; implant space ≈ 12.8 mm; nearby sinus floor. Region 26: bone height ≈ 11.7 mm; implant space ≈ 3.9 mm; nearby anterior loop. Region 28: bone height ≈ 4.1 mm; implant space ≈ 0 mm; nearby incisive canal. Region 24: bone height ≈ 20.0 mm; implant space ≈ 16.0 mm; nearby mental foramen. Region 33: bone height ≈ 8.2 mm; implant space ≈ 4.6 mm; nearby nasal floor. Region 12: bone height ≈ 7.7 mm; implant space ≈ 3.4 mm; nearby nasal floor. Region 47: bone height ≈ 4.3 mm; implant space ≈ 0 mm; nearby nasal floor. Region 44: bone height ≈ 14.2 mm; implant space ≈ 11.5 mm; nearby anterior loop. Region 22: bone height ≈ 10.7 mm; implant space ≈ 8.6 mm; nearby sinus floor. Region 42: bone height ≈ 18.4 mm; implant space ≈ 11.2 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Radiolucent lesion at 28 consistent with radicular cyst; recommend correlation."}
{"id": "case_0144", "images": ["images/placeholder_0144.png"], "question": "Planning for pathology review. Brief history/status: Trulicity, Bricanyl, Losartan, Esomeprazole, Betolvex, Calcichew-D3. Desired treatment: Measure ridge augmentation volume required at 14–24 and 13–23.", "answer": "Review of CBCT dated 250524. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 32: bone height ≈ 17.3 mm; implant space ≈ 11.5 mm; nearby mandibular canal. Region 22: bone height ≈ 16.6 mm; implant space ≈ 9.1 mm; nearby nasal floor. Region 41: bone height ≈ 13.5 mm; implant space ≈ 12.4 mm; nearby incisive canal. Region 37: bone height ≈ 21.9 mm; implant space ≈ 17.1 mm; nearby nasal floor. Region 27: bone height ≈ 5.4 mm; implant space ≈ 0 mm; nearby incisive canal. Region 47: bone height ≈ 19.9 mm; implant space ≈ 15.5 mm; nearby sinus floor. Region 33: bone height ≈ 19.3 mm; implant space ≈ 18.0 mm; nearby anterior loop. Region 31: bone height ≈ 15.4 mm; implant space ≈ 11.6 mm; nearby incisive canal. Region 38: bone height ≈ 16.8 mm; implant space ≈ 13.9 mm; nearby mental foramen. Region 25: bone height ≈ 20.5 mm; implant space ≈ 17.9 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Impression: Signs of early osseointegration failure at 46; consider clinical review."}
{"id": "case_0145", "images": ["images/placeholder_0145.png"], "question": "Planning for bone graft planning. Brief history/status: Losartan, Calcichew-D3, Levaxin, Esomeprazole, Metoprolol. Desired treatment: Provide measurements for alveolar ridge width and height at 16–26.", "answer": "Review of CBCT dated 231127. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 25: bone height ≈ 15.5 mm; implant space ≈ 8.2 mm; nearby incisive canal. Region 46: bone height ≈ 13.0 mm; implant space ≈ 8.5 mm; nearby mandibular canal. Region 24: bone height ≈ 17.0 mm; implant space ≈ 15.2 mm; nearby sinus floor. Region 18: bone height ≈ 8.6 mm; implant space ≈ 4.5 mm; nearby nasal floor. Region 45: bone height ≈ 4.5 mm; implant space ≈ 0 mm; nearby sinus floor. Region 27: bone height ≈ 11.0 mm; implant space ≈ 8.6 mm; nearby sinus floor. Region 32: bone height ≈ 4.9 mm; implant space ≈ 0 mm; nearby mental foramen. Region 38: bone height ≈ 14.7 mm; implant space ≈ 7.6 mm; nearby incisive canal. Region 42: bone height ≈ 4.1 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 12: bone height ≈ 13.4 mm; implant space ≈ 6.4 mm; nearby sinus floor. Periapical radiolucency observed near 21; minor sclerosis near 45. Image artifacts due to metallic restorations reduce detail locally. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0146", "images": ["images/placeholder_0146.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Losartan, Insulin glargine, Amlodipine, Bufomix Easyhaler, Trulicity, Betolvex, Omeprazole. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 16–26.", "answer": "Review of CBCT dated 211214. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 26: bone height ≈ 7.3 mm; implant space ≈ 0 mm; nearby anterior loop. Region 23: bone height ≈ 15.8 mm; implant space ≈ 9.3 mm; nearby sinus floor. Region 27: bone height ≈ 5.2 mm; implant space ≈ 3.9 mm; nearby incisive canal. Region 16: bone height ≈ 9.7 mm; implant space ≈ 6.7 mm; nearby mandibular canal. Region 25: bone height ≈ 9.3 mm; implant space ≈ 6.1 mm; nearby anterior loop. Region 28: bone height ≈ 11.3 mm; implant space ≈ 9.9 mm; nearby anterior loop. Region 22: bone height ≈ 13.6 mm; implant space ≈ 11.1 mm; nearby mandibular canal. Region 13: bone height ≈ 6.7 mm; implant space ≈ 5.3 mm; nearby mental foramen. Region 48: bone height ≈ 9.1 mm; implant space ≈ 1.7 mm; nearby mandibular canal. Region 14: bone height ≈ 5.5 mm; implant space ≈ 2.5 mm; nearby nasal floor. Periapical radiolucency observed near 24; minor sclerosis near 41. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0147", "images": ["images/placeholder_0147.png"], "question": "Planning for bone graft planning. Brief history/status: Bufomix Easyhaler, Amlodipine, Losartan, Insulin glargine, Metoprolol, Levaxin, Duroferon, Betolvex. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 13–23.", "answer": "Review of CBCT dated 250312. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 23: bone height ≈ 9.8 mm; implant space ≈ 6.3 mm; nearby incisive canal. Region 42: bone height ≈ 20.0 mm; implant space ≈ 16.1 mm; nearby sinus floor. Region 16: bone height ≈ 11.8 mm; implant space ≈ 7.2 mm; nearby sinus floor. Region 37: bone height ≈ 20.2 mm; implant space ≈ 19.1 mm; nearby sinus floor. Region 48: bone height ≈ 14.2 mm; implant space ≈ 10.7 mm; nearby nasal floor. Region 12: bone height ≈ 11.1 mm; implant space ≈ 3.8 mm; nearby mandibular canal. Region 43: bone height ≈ 15.5 mm; implant space ≈ 13.5 mm; nearby mental foramen. Region 21: bone height ≈ 12.9 mm; implant space ≈ 10.2 mm; nearby anterior loop. Region 13: bone height ≈ 13.9 mm; implant space ≈ 11.9 mm; nearby nasal floor. Region 38: bone height ≈ 21.3 mm; implant space ≈ 16.1 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 48; minor sclerosis near 37. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0148", "images": ["images/placeholder_0148.png"], "question": "Planning for implant planning. Brief history/status: Bricanyl, Trulicity, Metoprolol, Esomeprazole, Amlodipine, Losartan, Insulin glargine, Omeprazole. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 240725. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 43: bone height ≈ 11.3 mm; implant space ≈ 5.5 mm; nearby anterior loop. Region 28: bone height ≈ 19.0 mm; implant space ≈ 14.1 mm; nearby sinus floor. Region 32: bone height ≈ 10.3 mm; implant space ≈ 4.4 mm; nearby sinus floor. Region 27: bone height ≈ 13.1 mm; implant space ≈ 5.2 mm; nearby sinus floor. Region 24: bone height ≈ 8.3 mm; implant space ≈ 6.7 mm; nearby sinus floor. Region 11: bone height ≈ 9.0 mm; implant space ≈ 1.2 mm; nearby anterior loop. Region 15: bone height ≈ 6.7 mm; implant space ≈ 5.5 mm; nearby mental foramen. Region 25: bone height ≈ 20.0 mm; implant space ≈ 16.7 mm; nearby nasal floor. Region 38: bone height ≈ 5.7 mm; implant space ≈ 1.8 mm; nearby anterior loop. Region 26: bone height ≈ 19.4 mm; implant space ≈ 14.3 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 18; minor sclerosis near 35. Impression: Impacted molar in quadrant 3 associated with mild follicular space widening."}
{"id": "case_0149", "images": ["images/placeholder_0149.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Betolvex, Atorvastatin, Losartan, Omeprazole, Duloxetine, Bricanyl, Amlodipine. Desired treatment: Measure ridge augmentation volume required at 36–46 and 34–44.", "answer": "Review of CBCT dated 220822. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 38: bone height ≈ 11.5 mm; implant space ≈ 7.4 mm; nearby mandibular canal. Region 22: bone height ≈ 14.9 mm; implant space ≈ 12.4 mm; nearby incisive canal. Region 18: bone height ≈ 18.5 mm; implant space ≈ 14.0 mm; nearby anterior loop. Region 42: bone height ≈ 9.3 mm; implant space ≈ 6.4 mm; nearby mandibular canal. Region 14: bone height ≈ 10.1 mm; implant space ≈ 3.7 mm; nearby mental foramen. Region 43: bone height ≈ 15.2 mm; implant space ≈ 12.8 mm; nearby nasal floor. Region 26: bone height ≈ 7.3 mm; implant space ≈ 4.7 mm; nearby incisive canal. Region 25: bone height ≈ 8.6 mm; implant space ≈ 1.5 mm; nearby incisive canal. Region 11: bone height ≈ 10.0 mm; implant space ≈ 2.0 mm; nearby mental foramen. Region 41: bone height ≈ 13.0 mm; implant space ≈ 9.7 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0150", "images": ["images/placeholder_0150.png"], "question": "Planning for pathology review. Brief history/status: Betolvex, Omeprazole, Levaxin, Losartan, Duloxetine, Metoprolol, Duroferon, Calcichew-D3. Desired treatment: Review periapical status and note any signs of infection in regions 41, 28, 24.", "answer": "Review of CBCT dated 220612. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 38: bone height ≈ 8.8 mm; implant space ≈ 2.8 mm; nearby incisive canal. Region 18: bone height ≈ 11.0 mm; implant space ≈ 5.2 mm; nearby mandibular canal. Region 42: bone height ≈ 7.6 mm; implant space ≈ 0.8 mm; nearby incisive canal. Region 32: bone height ≈ 14.6 mm; implant space ≈ 7.7 mm; nearby mandibular canal. Region 36: bone height ≈ 6.4 mm; implant space ≈ 3.1 mm; nearby sinus floor. Region 26: bone height ≈ 10.3 mm; implant space ≈ 9.2 mm; nearby incisive canal. Region 46: bone height ≈ 5.3 mm; implant space ≈ 3.5 mm; nearby mental foramen. Region 15: bone height ≈ 20.9 mm; implant space ≈ 14.5 mm; nearby mandibular canal. Region 44: bone height ≈ 6.6 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 33: bone height ≈ 5.6 mm; implant space ≈ 2.5 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 48; minor sclerosis near 11. Image artifacts due to metallic restorations reduce detail locally. Impression: Peri-implantitis changes evident at 44; marginal bone loss noted."}
{"id": "case_0151", "images": ["images/placeholder_0151.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Bricanyl, Omeprazole, Metoprolol, Amlodipine, Duloxetine, Trulicity, Betolvex, Insulin glargine. Desired treatment: Assess healing of extraction sockets and bone regeneration at 14–24.", "answer": "Review of CBCT dated 211222. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 32: bone height ≈ 15.2 mm; implant space ≈ 7.9 mm; nearby mandibular canal. Region 27: bone height ≈ 18.3 mm; implant space ≈ 13.1 mm; nearby nasal floor. Region 46: bone height ≈ 8.9 mm; implant space ≈ 5.9 mm; nearby anterior loop. Region 48: bone height ≈ 5.7 mm; implant space ≈ 2.3 mm; nearby nasal floor. Region 15: bone height ≈ 6.8 mm; implant space ≈ 1.8 mm; nearby incisive canal. Region 11: bone height ≈ 8.1 mm; implant space ≈ 4.7 mm; nearby anterior loop. Region 35: bone height ≈ 20.8 mm; implant space ≈ 12.8 mm; nearby nasal floor. Region 34: bone height ≈ 15.9 mm; implant space ≈ 12.5 mm; nearby mandibular canal. Region 24: bone height ≈ 5.3 mm; implant space ≈ 3.8 mm; nearby mental foramen. Region 13: bone height ≈ 17.9 mm; implant space ≈ 15.0 mm; nearby nasal floor. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0152", "images": ["images/placeholder_0152.png"], "question": "Planning for prosthetic design planning. Brief history/status: Bricanyl, Omeprazole, Losartan, Trulicity, Betolvex, Amlodipine, Duloxetine. Desired treatment: Check for cortical bone thinning or fenestrations near 16–26.", "answer": "Review of CBCT dated 210305. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 27: bone height ≈ 21.3 mm; implant space ≈ 17.4 mm; nearby mandibular canal. Region 18: bone height ≈ 5.8 mm; implant space ≈ 0 mm; nearby anterior loop. Region 33: bone height ≈ 7.9 mm; implant space ≈ 0.1 mm; nearby anterior loop. Region 34: bone height ≈ 9.3 mm; implant space ≈ 2.3 mm; nearby incisive canal. Region 42: bone height ≈ 14.6 mm; implant space ≈ 7.5 mm; nearby incisive canal. Region 23: bone height ≈ 8.1 mm; implant space ≈ 3.8 mm; nearby mandibular canal. Region 28: bone height ≈ 14.2 mm; implant space ≈ 11.8 mm; nearby mental foramen. Region 41: bone height ≈ 21.4 mm; implant space ≈ 16.4 mm; nearby incisive canal. Region 13: bone height ≈ 17.8 mm; implant space ≈ 13.6 mm; nearby nasal floor. Region 43: bone height ≈ 20.2 mm; implant space ≈ 18.5 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 14; minor sclerosis near 15. Impression: Radiolucent lesion at 43 consistent with radicular cyst; recommend correlation."}
{"id": "case_0153", "images": ["images/placeholder_0153.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Bricanyl, Omeprazole, Trulicity, Amlodipine, Duroferon. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 33–43.", "answer": "Review of CBCT dated 200428. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 42: bone height ≈ 18.4 mm; implant space ≈ 14.9 mm; nearby sinus floor. Region 37: bone height ≈ 8.6 mm; implant space ≈ 3.0 mm; nearby sinus floor. Region 31: bone height ≈ 7.6 mm; implant space ≈ 0 mm; nearby sinus floor. Region 24: bone height ≈ 15.5 mm; implant space ≈ 12.6 mm; nearby mental foramen. Region 34: bone height ≈ 7.8 mm; implant space ≈ 4.0 mm; nearby anterior loop. Region 18: bone height ≈ 13.3 mm; implant space ≈ 8.3 mm; nearby incisive canal. Region 46: bone height ≈ 20.0 mm; implant space ≈ 16.1 mm; nearby mental foramen. Region 17: bone height ≈ 17.4 mm; implant space ≈ 9.8 mm; nearby mental foramen. Region 13: bone height ≈ 4.7 mm; implant space ≈ 1.2 mm; nearby nasal floor. Region 32: bone height ≈ 20.7 mm; implant space ≈ 18.6 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 24; minor sclerosis near 45. Impression: Findings consistent with apical periodontitis near 26 and 42."}
{"id": "case_0154", "images": ["images/placeholder_0154.png"], "question": "Planning for implant planning. Brief history/status: Trulicity, Duloxetine, Insulin glargine, Calcichew-D3, Atorvastatin, Metoprolol, Esomeprazole, Duroferon. Desired treatment: Review periapical status and note any signs of infection in regions 23, 41, 12.", "answer": "Review of CBCT dated 211014. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 28: bone height ≈ 8.9 mm; implant space ≈ 5.1 mm; nearby incisive canal. Region 31: bone height ≈ 16.7 mm; implant space ≈ 11.0 mm; nearby mandibular canal. Region 37: bone height ≈ 17.8 mm; implant space ≈ 16.4 mm; nearby sinus floor. Region 25: bone height ≈ 6.1 mm; implant space ≈ 1.7 mm; nearby mental foramen. Region 45: bone height ≈ 17.8 mm; implant space ≈ 10.9 mm; nearby sinus floor. Region 24: bone height ≈ 11.1 mm; implant space ≈ 7.3 mm; nearby incisive canal. Region 13: bone height ≈ 16.1 mm; implant space ≈ 11.2 mm; nearby mandibular canal. Region 34: bone height ≈ 6.2 mm; implant space ≈ 3.7 mm; nearby incisive canal. Region 38: bone height ≈ 21.3 mm; implant space ≈ 13.8 mm; nearby anterior loop. Region 26: bone height ≈ 6.0 mm; implant space ≈ 0 mm; nearby sinus floor. Impression: Adequate bone volume present for standard implant placement."}
{"id": "case_0155", "images": ["images/placeholder_0155.png"], "question": "Planning for prosthetic design planning. Brief history/status: Bufomix Easyhaler, Amlodipine, Metoprolol, Bricanyl, Duloxetine, Betolvex, Esomeprazole, Levaxin. Desired treatment: Assess healing of extraction sockets and bone regeneration at 36–46.", "answer": "Review of CBCT dated 210214. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 47: bone height ≈ 22.0 mm; implant space ≈ 18.1 mm; nearby anterior loop. Region 16: bone height ≈ 19.5 mm; implant space ≈ 14.3 mm; nearby mental foramen. Region 28: bone height ≈ 14.9 mm; implant space ≈ 10.2 mm; nearby anterior loop. Region 15: bone height ≈ 20.1 mm; implant space ≈ 15.8 mm; nearby mandibular canal. Region 14: bone height ≈ 22.0 mm; implant space ≈ 19.7 mm; nearby nasal floor. Region 36: bone height ≈ 10.8 mm; implant space ≈ 9.2 mm; nearby sinus floor. Region 33: bone height ≈ 13.3 mm; implant space ≈ 5.5 mm; nearby nasal floor. Region 18: bone height ≈ 12.7 mm; implant space ≈ 7.3 mm; nearby sinus floor. Region 27: bone height ≈ 12.3 mm; implant space ≈ 11.1 mm; nearby mental foramen. Region 48: bone height ≈ 19.1 mm; implant space ≈ 12.9 mm; nearby mental foramen. Periapical radiolucency observed near 15; minor sclerosis near 11. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0156", "images": ["images/placeholder_0156.png"], "question": "Planning for prosthetic design planning. Brief history/status: Losartan, Omeprazole, Levaxin, Esomeprazole, Betolvex. Desired treatment: Check for cortical bone thinning or fenestrations near 36–46.", "answer": "Review of CBCT dated 251126. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 47: bone height ≈ 21.8 mm; implant space ≈ 19.7 mm; nearby mental foramen. Region 33: bone height ≈ 6.2 mm; implant space ≈ 0.1 mm; nearby mental foramen. Region 36: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby anterior loop. Region 48: bone height ≈ 19.1 mm; implant space ≈ 15.9 mm; nearby incisive canal. Region 24: bone height ≈ 12.6 mm; implant space ≈ 10.8 mm; nearby mandibular canal. Region 16: bone height ≈ 20.2 mm; implant space ≈ 14.7 mm; nearby mental foramen. Region 45: bone height ≈ 14.1 mm; implant space ≈ 8.0 mm; nearby mandibular canal. Region 42: bone height ≈ 5.0 mm; implant space ≈ 0 mm; nearby incisive canal. Region 37: bone height ≈ 20.0 mm; implant space ≈ 14.0 mm; nearby anterior loop. Region 28: bone height ≈ 10.6 mm; implant space ≈ 8.5 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 48; minor sclerosis near 16. Image artifacts due to metallic restorations reduce detail locally. Impression: Peri-implantitis changes evident at 22; marginal bone loss noted."}
{"id": "case_0157", "images": ["images/placeholder_0157.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Duroferon, Calcichew-D3, Atorvastatin, Bricanyl, Amlodipine. Desired treatment: Assess proximity to mandibular canal and sinus floor for 34–44 and 16–26.", "answer": "Review of CBCT dated 220828. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 36: bone height ≈ 10.4 mm; implant space ≈ 7.3 mm; nearby incisive canal. Region 42: bone height ≈ 10.0 mm; implant space ≈ 4.2 mm; nearby sinus floor. Region 37: bone height ≈ 21.4 mm; implant space ≈ 14.0 mm; nearby nasal floor. Region 38: bone height ≈ 17.1 mm; implant space ≈ 10.1 mm; nearby incisive canal. Region 33: bone height ≈ 7.4 mm; implant space ≈ 5.7 mm; nearby anterior loop. Region 35: bone height ≈ 9.7 mm; implant space ≈ 4.6 mm; nearby sinus floor. Region 28: bone height ≈ 11.5 mm; implant space ≈ 7.6 mm; nearby nasal floor. Region 27: bone height ≈ 21.1 mm; implant space ≈ 18.9 mm; nearby mandibular canal. Region 31: bone height ≈ 20.7 mm; implant space ≈ 17.9 mm; nearby sinus floor. Region 14: bone height ≈ 20.0 mm; implant space ≈ 14.4 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 47, extending coronally."}
{"id": "case_0158", "images": ["images/placeholder_0158.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Duroferon, Losartan, Duloxetine, Levaxin, Metoprolol. Desired treatment: Assess healing of extraction sockets and bone regeneration at 34–44.", "answer": "Review of CBCT dated 200801. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 33: bone height ≈ 18.5 mm; implant space ≈ 15.9 mm; nearby mental foramen. Region 32: bone height ≈ 5.3 mm; implant space ≈ 3.9 mm; nearby anterior loop. Region 26: bone height ≈ 14.0 mm; implant space ≈ 9.1 mm; nearby mental foramen. Region 13: bone height ≈ 11.6 mm; implant space ≈ 6.4 mm; nearby mandibular canal. Region 16: bone height ≈ 16.9 mm; implant space ≈ 10.3 mm; nearby anterior loop. Region 22: bone height ≈ 9.3 mm; implant space ≈ 4.7 mm; nearby nasal floor. Region 45: bone height ≈ 10.1 mm; implant space ≈ 3.3 mm; nearby mandibular canal. Region 17: bone height ≈ 5.0 mm; implant space ≈ 2.9 mm; nearby sinus floor. Region 28: bone height ≈ 6.3 mm; implant space ≈ 3.6 mm; nearby mental foramen. Region 48: bone height ≈ 6.4 mm; implant space ≈ 4.9 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Impression: Findings consistent with apical periodontitis near 36 and 34."}
{"id": "case_0159", "images": ["images/placeholder_0159.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Esomeprazole, Atorvastatin, Bufomix Easyhaler, Betolvex, Levaxin. Desired treatment: Check for cortical bone thinning or fenestrations near 13–23.", "answer": "Review of CBCT dated 220608. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 31: bone height ≈ 10.7 mm; implant space ≈ 5.1 mm; nearby anterior loop. Region 32: bone height ≈ 19.7 mm; implant space ≈ 16.9 mm; nearby anterior loop. Region 11: bone height ≈ 18.7 mm; implant space ≈ 11.3 mm; nearby nasal floor. Region 18: bone height ≈ 21.1 mm; implant space ≈ 16.4 mm; nearby anterior loop. Region 12: bone height ≈ 9.6 mm; implant space ≈ 5.6 mm; nearby incisive canal. Region 37: bone height ≈ 11.7 mm; implant space ≈ 6.5 mm; nearby mandibular canal. Region 46: bone height ≈ 16.6 mm; implant space ≈ 12.8 mm; nearby anterior loop. Region 45: bone height ≈ 9.3 mm; implant space ≈ 6.2 mm; nearby sinus floor. Region 13: bone height ≈ 6.5 mm; implant space ≈ 3.1 mm; nearby nasal floor. Region 33: bone height ≈ 14.8 mm; implant space ≈ 12.5 mm; nearby mental foramen. Periapical radiolucency observed near 13; minor sclerosis near 43. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0160", "images": ["images/placeholder_0160.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Atorvastatin, Levaxin, Omeprazole, Duloxetine, Losartan, Trulicity, Metoprolol. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 240804. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 28: bone height ≈ 4.8 mm; implant space ≈ 2.0 mm; nearby mandibular canal. Region 18: bone height ≈ 13.2 mm; implant space ≈ 6.4 mm; nearby mental foramen. Region 34: bone height ≈ 21.2 mm; implant space ≈ 13.9 mm; nearby incisive canal. Region 17: bone height ≈ 13.1 mm; implant space ≈ 9.7 mm; nearby mandibular canal. Region 45: bone height ≈ 8.2 mm; implant space ≈ 1.8 mm; nearby incisive canal. Region 23: bone height ≈ 9.9 mm; implant space ≈ 6.3 mm; nearby nasal floor. Region 11: bone height ≈ 13.5 mm; implant space ≈ 8.7 mm; nearby sinus floor. Region 15: bone height ≈ 10.6 mm; implant space ≈ 9.2 mm; nearby sinus floor. Region 33: bone height ≈ 13.2 mm; implant space ≈ 9.8 mm; nearby mental foramen. Region 12: bone height ≈ 9.5 mm; implant space ≈ 6.4 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 36; minor sclerosis near 44. Image artifacts due to metallic restorations reduce detail locally. Impression: Peri-implantitis changes evident at 48; marginal bone loss noted."}
{"id": "case_0161", "images": ["images/placeholder_0161.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Trulicity, Esomeprazole, Bufomix Easyhaler, Duloxetine, Omeprazole, Levaxin, Bricanyl. Desired treatment: Assess proximity to mandibular canal and sinus floor for 36–46 and 13–23.", "answer": "Review of CBCT dated 210417. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 21: bone height ≈ 20.0 mm; implant space ≈ 12.6 mm; nearby nasal floor. Region 41: bone height ≈ 19.0 mm; implant space ≈ 13.4 mm; nearby sinus floor. Region 46: bone height ≈ 8.9 mm; implant space ≈ 4.9 mm; nearby nasal floor. Region 24: bone height ≈ 6.7 mm; implant space ≈ 5.1 mm; nearby anterior loop. Region 48: bone height ≈ 9.9 mm; implant space ≈ 4.2 mm; nearby nasal floor. Region 36: bone height ≈ 15.7 mm; implant space ≈ 11.0 mm; nearby nasal floor. Region 13: bone height ≈ 13.6 mm; implant space ≈ 11.4 mm; nearby sinus floor. Region 33: bone height ≈ 9.5 mm; implant space ≈ 3.2 mm; nearby mental foramen. Region 45: bone height ≈ 6.2 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 25: bone height ≈ 16.8 mm; implant space ≈ 10.4 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 15; minor sclerosis near 47. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 14, extending coronally."}
{"id": "case_0162", "images": ["images/placeholder_0162.png"], "question": "Planning for pathology review. Brief history/status: Trulicity, Levaxin, Metoprolol, Amlodipine, Duroferon, Insulin glargine, Bufomix Easyhaler. Desired treatment: Check for cortical bone thinning or fenestrations near 33–43.", "answer": "Review of CBCT dated 201210. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 11: bone height ≈ 10.9 mm; implant space ≈ 4.1 mm; nearby mental foramen. Region 31: bone height ≈ 9.7 mm; implant space ≈ 4.7 mm; nearby sinus floor. Region 12: bone height ≈ 11.1 mm; implant space ≈ 8.4 mm; nearby anterior loop. Region 15: bone height ≈ 21.9 mm; implant space ≈ 17.1 mm; nearby mandibular canal. Region 36: bone height ≈ 14.5 mm; implant space ≈ 7.5 mm; nearby anterior loop. Region 28: bone height ≈ 16.9 mm; implant space ≈ 14.5 mm; nearby mental foramen. Region 24: bone height ≈ 19.6 mm; implant space ≈ 14.1 mm; nearby nasal floor. Region 34: bone height ≈ 21.7 mm; implant space ≈ 14.3 mm; nearby incisive canal. Region 42: bone height ≈ 13.4 mm; implant space ≈ 10.7 mm; nearby mental foramen. Region 13: bone height ≈ 11.0 mm; implant space ≈ 4.4 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Adequate bone volume present for standard implant placement."}
{"id": "case_0163", "images": ["images/placeholder_0163.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Omeprazole, Esomeprazole, Metoprolol, Calcichew-D3, Levaxin, Atorvastatin, Bufomix Easyhaler. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 13–23.", "answer": "Review of CBCT dated 250601. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 38: bone height ≈ 13.9 mm; implant space ≈ 9.5 mm; nearby sinus floor. Region 44: bone height ≈ 10.7 mm; implant space ≈ 9.5 mm; nearby mandibular canal. Region 35: bone height ≈ 5.6 mm; implant space ≈ 0 mm; nearby mental foramen. Region 43: bone height ≈ 9.7 mm; implant space ≈ 2.6 mm; nearby mental foramen. Region 42: bone height ≈ 21.5 mm; implant space ≈ 19.0 mm; nearby mental foramen. Region 22: bone height ≈ 21.8 mm; implant space ≈ 19.1 mm; nearby mental foramen. Region 45: bone height ≈ 8.4 mm; implant space ≈ 5.8 mm; nearby mandibular canal. Region 12: bone height ≈ 15.4 mm; implant space ≈ 10.7 mm; nearby anterior loop. Region 41: bone height ≈ 6.9 mm; implant space ≈ 1.1 mm; nearby incisive canal. Region 15: bone height ≈ 21.6 mm; implant space ≈ 16.2 mm; nearby sinus floor. Periapical radiolucency observed near 47; minor sclerosis near 18. Image artifacts due to metallic restorations reduce detail locally. Impression: Vertical root fracture suspected at 47, extending coronally."}
{"id": "case_0164", "images": ["images/placeholder_0164.png"], "question": "Planning for implant planning. Brief history/status: Insulin glargine, Esomeprazole, Duloxetine, Losartan, Calcichew-D3. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 251221. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 25: bone height ≈ 7.3 mm; implant space ≈ 0.8 mm; nearby incisive canal. Region 15: bone height ≈ 7.9 mm; implant space ≈ 4.1 mm; nearby mandibular canal. Region 36: bone height ≈ 14.2 mm; implant space ≈ 8.9 mm; nearby nasal floor. Region 28: bone height ≈ 12.3 mm; implant space ≈ 8.9 mm; nearby mental foramen. Region 48: bone height ≈ 19.1 mm; implant space ≈ 12.8 mm; nearby sinus floor. Region 33: bone height ≈ 8.1 mm; implant space ≈ 0.8 mm; nearby nasal floor. Region 37: bone height ≈ 6.1 mm; implant space ≈ 2.9 mm; nearby anterior loop. Region 23: bone height ≈ 7.6 mm; implant space ≈ 2.3 mm; nearby mandibular canal. Region 45: bone height ≈ 13.8 mm; implant space ≈ 7.1 mm; nearby incisive canal. Region 31: bone height ≈ 9.1 mm; implant space ≈ 2.3 mm; nearby mandibular canal. Periapical radiolucency observed near 21; minor sclerosis near 48. Impression: Findings consistent with apical periodontitis near 27 and 11."}
{"id": "case_0165", "images": ["images/placeholder_0165.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Duroferon, Losartan, Trulicity, Levaxin, Betolvex, Insulin glargine, Atorvastatin. Desired treatment: Assess healing of extraction sockets and bone regeneration at 16–26.", "answer": "Review of CBCT dated 250314. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 34: bone height ≈ 6.3 mm; implant space ≈ 0.1 mm; nearby incisive canal. Region 14: bone height ≈ 5.9 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 47: bone height ≈ 13.4 mm; implant space ≈ 9.0 mm; nearby mandibular canal. Region 15: bone height ≈ 7.3 mm; implant space ≈ 0 mm; nearby sinus floor. Region 48: bone height ≈ 15.7 mm; implant space ≈ 12.6 mm; nearby anterior loop. Region 32: bone height ≈ 15.0 mm; implant space ≈ 13.6 mm; nearby nasal floor. Region 37: bone height ≈ 9.0 mm; implant space ≈ 5.0 mm; nearby anterior loop. Region 13: bone height ≈ 8.7 mm; implant space ≈ 6.5 mm; nearby anterior loop. Region 43: bone height ≈ 6.3 mm; implant space ≈ 1.4 mm; nearby mental foramen. Region 45: bone height ≈ 14.8 mm; implant space ≈ 9.2 mm; nearby mandibular canal. Periapical radiolucency observed near 25; minor sclerosis near 12. Impression: Signs of early osseointegration failure at 16; consider clinical review."}
{"id": "case_0166", "images": ["images/placeholder_0166.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Betolvex, Esomeprazole, Duloxetine, Bufomix Easyhaler, Omeprazole, Losartan, Metoprolol. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 240916. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 25: bone height ≈ 10.5 mm; implant space ≈ 5.3 mm; nearby anterior loop. Region 43: bone height ≈ 21.1 mm; implant space ≈ 16.8 mm; nearby sinus floor. Region 33: bone height ≈ 20.3 mm; implant space ≈ 17.0 mm; nearby mandibular canal. Region 44: bone height ≈ 16.0 mm; implant space ≈ 12.9 mm; nearby mental foramen. Region 16: bone height ≈ 13.3 mm; implant space ≈ 10.4 mm; nearby sinus floor. Region 21: bone height ≈ 10.7 mm; implant space ≈ 4.9 mm; nearby anterior loop. Region 35: bone height ≈ 12.5 mm; implant space ≈ 6.2 mm; nearby incisive canal. Region 36: bone height ≈ 13.6 mm; implant space ≈ 10.5 mm; nearby incisive canal. Region 47: bone height ≈ 9.1 mm; implant space ≈ 2.6 mm; nearby nasal floor. Region 13: bone height ≈ 4.7 mm; implant space ≈ 0 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 11; minor sclerosis near 48. Impression: Vertical root fracture suspected at 14, extending coronally."}
{"id": "case_0167", "images": ["images/placeholder_0167.png"], "question": "Planning for implant planning. Brief history/status: Omeprazole, Betolvex, Duroferon, Calcichew-D3, Levaxin, Metoprolol, Duloxetine. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 14–24.", "answer": "Review of CBCT dated 240418. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 15: bone height ≈ 13.3 mm; implant space ≈ 9.8 mm; nearby nasal floor. Region 27: bone height ≈ 20.4 mm; implant space ≈ 18.5 mm; nearby mandibular canal. Region 42: bone height ≈ 9.6 mm; implant space ≈ 6.5 mm; nearby sinus floor. Region 13: bone height ≈ 6.1 mm; implant space ≈ 0.3 mm; nearby incisive canal. Region 22: bone height ≈ 14.8 mm; implant space ≈ 8.8 mm; nearby mental foramen. Region 25: bone height ≈ 4.5 mm; implant space ≈ 0.3 mm; nearby sinus floor. Region 48: bone height ≈ 7.9 mm; implant space ≈ 6.4 mm; nearby mandibular canal. Region 41: bone height ≈ 17.3 mm; implant space ≈ 9.9 mm; nearby incisive canal. Region 36: bone height ≈ 18.3 mm; implant space ≈ 13.4 mm; nearby nasal floor. Region 23: bone height ≈ 4.6 mm; implant space ≈ 3.3 mm; nearby incisive canal. Image artifacts due to metallic restorations reduce detail locally. Impression: Peri-implantitis changes evident at 45; marginal bone loss noted."}
{"id": "case_0168", "images": ["images/placeholder_0168.png"], "question": "Planning for prosthetic design planning. Brief history/status: Betolvex, Insulin glargine, Amlodipine, Duloxetine, Esomeprazole, Losartan. Desired treatment: Assess proximity to mandibular canal and sinus floor for 16–26 and 16–26.", "answer": "Review of CBCT dated 240619. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 12: bone height ≈ 11.2 mm; implant space ≈ 7.0 mm; nearby nasal floor. Region 13: bone height ≈ 15.6 mm; implant space ≈ 14.1 mm; nearby nasal floor. Region 42: bone height ≈ 18.9 mm; implant space ≈ 16.5 mm; nearby incisive canal. Region 17: bone height ≈ 7.6 mm; implant space ≈ 3.6 mm; nearby anterior loop. Region 33: bone height ≈ 13.3 mm; implant space ≈ 5.8 mm; nearby mental foramen. Region 11: bone height ≈ 7.8 mm; implant space ≈ 0 mm; nearby incisive canal. Region 31: bone height ≈ 5.0 mm; implant space ≈ 0 mm; nearby anterior loop. Region 27: bone height ≈ 13.5 mm; implant space ≈ 11.2 mm; nearby mandibular canal. Region 32: bone height ≈ 14.8 mm; implant space ≈ 8.6 mm; nearby nasal floor. Region 15: bone height ≈ 13.6 mm; implant space ≈ 6.0 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0169", "images": ["images/placeholder_0169.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Atorvastatin, Insulin glargine, Duroferon, Duloxetine, Bricanyl. Desired treatment: Review periapical status and note any signs of infection in regions 47, 14, 37.", "answer": "Review of CBCT dated 251107. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 16: bone height ≈ 5.3 mm; implant space ≈ 1.2 mm; nearby sinus floor. Region 38: bone height ≈ 20.2 mm; implant space ≈ 14.7 mm; nearby nasal floor. Region 32: bone height ≈ 12.9 mm; implant space ≈ 9.5 mm; nearby sinus floor. Region 25: bone height ≈ 14.6 mm; implant space ≈ 9.9 mm; nearby mandibular canal. Region 11: bone height ≈ 16.7 mm; implant space ≈ 12.3 mm; nearby anterior loop. Region 18: bone height ≈ 15.6 mm; implant space ≈ 13.2 mm; nearby sinus floor. Region 36: bone height ≈ 18.6 mm; implant space ≈ 12.9 mm; nearby mental foramen. Region 44: bone height ≈ 4.8 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 31: bone height ≈ 20.3 mm; implant space ≈ 16.9 mm; nearby anterior loop. Region 15: bone height ≈ 16.0 mm; implant space ≈ 13.6 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 47; minor sclerosis near 18. Impression: Adequate bone volume present for standard implant placement."}
{"id": "case_0170", "images": ["images/placeholder_0170.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Metoprolol, Trulicity, Insulin glargine, Amlodipine, Omeprazole, Bufomix Easyhaler, Calcichew-D3, Atorvastatin. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 36–46 and 13–23.", "answer": "Review of CBCT dated 200920. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 42: bone height ≈ 20.0 mm; implant space ≈ 13.2 mm; nearby sinus floor. Region 11: bone height ≈ 19.4 mm; implant space ≈ 17.6 mm; nearby mandibular canal. Region 13: bone height ≈ 13.8 mm; implant space ≈ 10.4 mm; nearby nasal floor. Region 28: bone height ≈ 20.8 mm; implant space ≈ 15.2 mm; nearby mental foramen. Region 23: bone height ≈ 18.0 mm; implant space ≈ 11.3 mm; nearby mental foramen. Region 38: bone height ≈ 11.4 mm; implant space ≈ 7.6 mm; nearby mental foramen. Region 22: bone height ≈ 5.4 mm; implant space ≈ 4.1 mm; nearby anterior loop. Region 48: bone height ≈ 17.0 mm; implant space ≈ 13.0 mm; nearby anterior loop. Region 45: bone height ≈ 11.9 mm; implant space ≈ 9.8 mm; nearby mandibular canal. Region 25: bone height ≈ 8.5 mm; implant space ≈ 5.9 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 46; minor sclerosis near 23. Image artifacts due to metallic restorations reduce detail locally. Impression: Adequate bone volume present for standard implant placement."}
{"id": "case_0171", "images": ["images/placeholder_0171.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Trulicity, Esomeprazole, Bufomix Easyhaler, Metoprolol, Insulin glargine, Duloxetine, Omeprazole, Levaxin. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 13–23.", "answer": "Review of CBCT dated 230716. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 48: bone height ≈ 21.7 mm; implant space ≈ 20.4 mm; nearby sinus floor. Region 26: bone height ≈ 14.7 mm; implant space ≈ 9.9 mm; nearby nasal floor. Region 32: bone height ≈ 11.4 mm; implant space ≈ 4.0 mm; nearby incisive canal. Region 44: bone height ≈ 21.5 mm; implant space ≈ 14.8 mm; nearby incisive canal. Region 16: bone height ≈ 12.7 mm; implant space ≈ 6.0 mm; nearby mandibular canal. Region 23: bone height ≈ 6.5 mm; implant space ≈ 2.5 mm; nearby nasal floor. Region 46: bone height ≈ 16.0 mm; implant space ≈ 10.1 mm; nearby incisive canal. Region 47: bone height ≈ 21.6 mm; implant space ≈ 14.2 mm; nearby mandibular canal. Region 27: bone height ≈ 9.4 mm; implant space ≈ 5.8 mm; nearby sinus floor. Region 34: bone height ≈ 8.3 mm; implant space ≈ 6.1 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 45; minor sclerosis near 21. Impression: Peri-implantitis changes evident at 25; marginal bone loss noted."}
{"id": "case_0172", "images": ["images/placeholder_0172.png"], "question": "Planning for orthodontic anchorage evaluation. Brief history/status: Duloxetine, Esomeprazole, Bufomix Easyhaler, Bricanyl, Calcichew-D3, Levaxin, Omeprazole. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 16–26.", "answer": "Review of CBCT dated 201111. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 23: bone height ≈ 10.3 mm; implant space ≈ 5.6 mm; nearby nasal floor. Region 37: bone height ≈ 5.9 mm; implant space ≈ 3.6 mm; nearby mandibular canal. Region 14: bone height ≈ 13.3 mm; implant space ≈ 11.0 mm; nearby nasal floor. Region 47: bone height ≈ 11.0 mm; implant space ≈ 7.1 mm; nearby incisive canal. Region 28: bone height ≈ 9.5 mm; implant space ≈ 2.4 mm; nearby sinus floor. Region 42: bone height ≈ 17.7 mm; implant space ≈ 11.7 mm; nearby anterior loop. Region 24: bone height ≈ 4.4 mm; implant space ≈ 0.2 mm; nearby nasal floor. Region 17: bone height ≈ 16.5 mm; implant space ≈ 10.5 mm; nearby mandibular canal. Region 45: bone height ≈ 7.9 mm; implant space ≈ 1.4 mm; nearby sinus floor. Region 26: bone height ≈ 19.7 mm; implant space ≈ 15.8 mm; nearby nasal floor. Maxillary sinus: mucosal thickening mild on both sides. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0173", "images": ["images/placeholder_0173.png"], "question": "Planning for pathology review. Brief history/status: Duloxetine, Trulicity, Calcichew-D3, Omeprazole, Esomeprazole. Desired treatment: Check for cortical bone thinning or fenestrations near 33–43.", "answer": "Review of CBCT dated 220507. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 24: bone height ≈ 11.7 mm; implant space ≈ 8.4 mm; nearby incisive canal. Region 36: bone height ≈ 9.5 mm; implant space ≈ 2.3 mm; nearby incisive canal. Region 43: bone height ≈ 13.1 mm; implant space ≈ 9.9 mm; nearby mental foramen. Region 37: bone height ≈ 12.9 mm; implant space ≈ 8.8 mm; nearby incisive canal. Region 14: bone height ≈ 17.8 mm; implant space ≈ 10.8 mm; nearby anterior loop. Region 18: bone height ≈ 14.9 mm; implant space ≈ 12.1 mm; nearby mental foramen. Region 33: bone height ≈ 9.2 mm; implant space ≈ 7.6 mm; nearby nasal floor. Region 16: bone height ≈ 11.3 mm; implant space ≈ 7.5 mm; nearby sinus floor. Region 42: bone height ≈ 18.5 mm; implant space ≈ 11.8 mm; nearby nasal floor. Region 48: bone height ≈ 14.8 mm; implant space ≈ 9.8 mm; nearby nasal floor. Impression: Radiolucent lesion at 34 consistent with radicular cyst; recommend correlation."}
{"id": "case_0174", "images": ["images/placeholder_0174.png"], "question": "Planning for prosthetic design planning. Brief history/status: Betolvex, Duloxetine, Losartan, Duroferon, Bricanyl, Amlodipine, Levaxin. Desired treatment: Assess proximity to mandibular canal and sinus floor for 33–43 and 16–26.", "answer": "Review of CBCT dated 240910. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 35: bone height ≈ 17.5 mm; implant space ≈ 14.4 mm; nearby nasal floor. Region 24: bone height ≈ 11.5 mm; implant space ≈ 10.4 mm; nearby anterior loop. Region 42: bone height ≈ 6.6 mm; implant space ≈ 5.2 mm; nearby nasal floor. Region 37: bone height ≈ 11.1 mm; implant space ≈ 9.6 mm; nearby mandibular canal. Region 14: bone height ≈ 21.3 mm; implant space ≈ 18.8 mm; nearby anterior loop. Region 31: bone height ≈ 8.3 mm; implant space ≈ 1.0 mm; nearby mandibular canal. Region 47: bone height ≈ 6.6 mm; implant space ≈ 4.3 mm; nearby mental foramen. Region 48: bone height ≈ 12.4 mm; implant space ≈ 10.1 mm; nearby anterior loop. Region 21: bone height ≈ 10.2 mm; implant space ≈ 4.2 mm; nearby nasal floor. Region 17: bone height ≈ 21.8 mm; implant space ≈ 19.2 mm; nearby nasal floor. Image artifacts due to metallic restorations reduce detail locally. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0175", "images": ["images/placeholder_0175.png"], "question": "Planning for implant planning. Brief history/status: Betolvex, Omeprazole, Insulin glargine, Atorvastatin, Trulicity. Desired treatment: Measure ridge augmentation volume required at 16–26 and 14–24.", "answer": "Review of CBCT dated 240114. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 47: bone height ≈ 14.3 mm; implant space ≈ 8.5 mm; nearby mental foramen. Region 14: bone height ≈ 5.2 mm; implant space ≈ 0 mm; nearby anterior loop. Region 34: bone height ≈ 16.1 mm; implant space ≈ 10.9 mm; nearby mandibular canal. Region 42: bone height ≈ 4.5 mm; implant space ≈ 0 mm; nearby mental foramen. Region 26: bone height ≈ 14.1 mm; implant space ≈ 9.9 mm; nearby mandibular canal. Region 16: bone height ≈ 9.4 mm; implant space ≈ 2.7 mm; nearby sinus floor. Region 45: bone height ≈ 15.0 mm; implant space ≈ 10.4 mm; nearby sinus floor. Region 31: bone height ≈ 15.1 mm; implant space ≈ 12.1 mm; nearby incisive canal. Region 48: bone height ≈ 16.0 mm; implant space ≈ 13.5 mm; nearby mental foramen. Region 23: bone height ≈ 20.8 mm; implant space ≈ 16.2 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Adequate bone volume present for standard implant placement."}
{"id": "case_0176", "images": ["images/placeholder_0176.png"], "question": "Planning for pathology review. Brief history/status: Duloxetine, Metoprolol, Betolvex, Amlodipine, Atorvastatin, Bufomix Easyhaler, Bricanyl. Desired treatment: Assess proximity to mandibular canal and sinus floor for 16–26 and 13–23.", "answer": "Review of CBCT dated 250920. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 45: bone height ≈ 13.3 mm; implant space ≈ 5.7 mm; nearby mental foramen. Region 46: bone height ≈ 11.4 mm; implant space ≈ 7.5 mm; nearby mental foramen. Region 23: bone height ≈ 20.6 mm; implant space ≈ 17.5 mm; nearby incisive canal. Region 37: bone height ≈ 8.9 mm; implant space ≈ 5.9 mm; nearby incisive canal. Region 47: bone height ≈ 11.1 mm; implant space ≈ 10.0 mm; nearby anterior loop. Region 27: bone height ≈ 6.3 mm; implant space ≈ 0 mm; nearby mental foramen. Region 18: bone height ≈ 18.1 mm; implant space ≈ 14.2 mm; nearby mandibular canal. Region 35: bone height ≈ 12.2 mm; implant space ≈ 10.3 mm; nearby anterior loop. Region 44: bone height ≈ 12.8 mm; implant space ≈ 10.5 mm; nearby anterior loop. Region 14: bone height ≈ 14.5 mm; implant space ≈ 9.3 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Impression: Residual ridge height sufficient for short implants; grafting optional."}
{"id": "case_0177", "images": ["images/placeholder_0177.png"], "question": "Planning for bone graft planning. Brief history/status: Atorvastatin, Trulicity, Metoprolol, Insulin glargine, Esomeprazole, Omeprazole, Bricanyl. Desired treatment: Measure ridge augmentation volume required at 36–46 and 33–43.", "answer": "Review of CBCT dated 200302. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 45: bone height ≈ 17.3 mm; implant space ≈ 10.0 mm; nearby incisive canal. Region 11: bone height ≈ 13.6 mm; implant space ≈ 8.6 mm; nearby mandibular canal. Region 35: bone height ≈ 10.1 mm; implant space ≈ 6.4 mm; nearby incisive canal. Region 26: bone height ≈ 7.4 mm; implant space ≈ 0 mm; nearby nasal floor. Region 16: bone height ≈ 13.8 mm; implant space ≈ 11.9 mm; nearby nasal floor. Region 33: bone height ≈ 8.6 mm; implant space ≈ 6.9 mm; nearby anterior loop. Region 37: bone height ≈ 20.3 mm; implant space ≈ 18.7 mm; nearby nasal floor. Region 46: bone height ≈ 17.3 mm; implant space ≈ 11.3 mm; nearby nasal floor. Region 44: bone height ≈ 13.4 mm; implant space ≈ 9.1 mm; nearby mandibular canal. Region 13: bone height ≈ 11.7 mm; implant space ≈ 5.1 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 36; minor sclerosis near 24. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0178", "images": ["images/placeholder_0178.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Duloxetine, Amlodipine, Betolvex, Esomeprazole, Metoprolol. Desired treatment: Check for cortical bone thinning or fenestrations near 34–44.", "answer": "Review of CBCT dated 200101. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 43: bone height ≈ 16.7 mm; implant space ≈ 12.0 mm; nearby anterior loop. Region 18: bone height ≈ 11.3 mm; implant space ≈ 4.6 mm; nearby anterior loop. Region 45: bone height ≈ 13.3 mm; implant space ≈ 5.8 mm; nearby incisive canal. Region 33: bone height ≈ 15.2 mm; implant space ≈ 7.5 mm; nearby anterior loop. Region 44: bone height ≈ 21.6 mm; implant space ≈ 17.4 mm; nearby mandibular canal. Region 34: bone height ≈ 15.2 mm; implant space ≈ 13.5 mm; nearby incisive canal. Region 48: bone height ≈ 20.1 mm; implant space ≈ 13.3 mm; nearby incisive canal. Region 21: bone height ≈ 15.2 mm; implant space ≈ 8.8 mm; nearby mandibular canal. Region 32: bone height ≈ 9.3 mm; implant space ≈ 7.8 mm; nearby sinus floor. Region 17: bone height ≈ 21.8 mm; implant space ≈ 16.5 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 11; minor sclerosis near 16. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0179", "images": ["images/placeholder_0179.png"], "question": "Planning for implant planning. Brief history/status: Esomeprazole, Bufomix Easyhaler, Betolvex, Bricanyl, Duloxetine, Omeprazole, Duroferon. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 251128. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 16: bone height ≈ 7.2 mm; implant space ≈ 1.7 mm; nearby nasal floor. Region 35: bone height ≈ 9.2 mm; implant space ≈ 2.4 mm; nearby anterior loop. Region 18: bone height ≈ 15.4 mm; implant space ≈ 12.6 mm; nearby incisive canal. Region 48: bone height ≈ 5.2 mm; implant space ≈ 0.5 mm; nearby anterior loop. Region 47: bone height ≈ 8.1 mm; implant space ≈ 4.9 mm; nearby sinus floor. Region 27: bone height ≈ 5.9 mm; implant space ≈ 4.8 mm; nearby sinus floor. Region 44: bone height ≈ 16.5 mm; implant space ≈ 8.6 mm; nearby mandibular canal. Region 26: bone height ≈ 10.4 mm; implant space ≈ 5.7 mm; nearby anterior loop. Region 45: bone height ≈ 15.6 mm; implant space ≈ 13.2 mm; nearby incisive canal. Region 28: bone height ≈ 21.5 mm; implant space ≈ 17.1 mm; nearby nasal floor. Periapical radiolucency observed near 18; minor sclerosis near 48. Impression: Vertical root fracture suspected at 36, extending coronally."}
{"id": "case_0180", "images": ["images/placeholder_0180.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Levaxin, Omeprazole, Bufomix Easyhaler, Duroferon, Trulicity. Desired treatment: Provide measurements for alveolar ridge width and height at 34–44.", "answer": "Review of CBCT dated 240304. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 18: bone height ≈ 21.3 mm; implant space ≈ 18.0 mm; nearby mental foramen. Region 27: bone height ≈ 11.5 mm; implant space ≈ 4.5 mm; nearby mental foramen. Region 32: bone height ≈ 18.3 mm; implant space ≈ 15.2 mm; nearby incisive canal. Region 24: bone height ≈ 7.1 mm; implant space ≈ 2.6 mm; nearby anterior loop. Region 34: bone height ≈ 19.4 mm; implant space ≈ 14.7 mm; nearby nasal floor. Region 25: bone height ≈ 5.5 mm; implant space ≈ 3.0 mm; nearby mandibular canal. Region 41: bone height ≈ 15.8 mm; implant space ≈ 9.3 mm; nearby nasal floor. Region 22: bone height ≈ 14.7 mm; implant space ≈ 7.0 mm; nearby incisive canal. Region 28: bone height ≈ 9.8 mm; implant space ≈ 7.3 mm; nearby mental foramen. Region 14: bone height ≈ 7.4 mm; implant space ≈ 4.2 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 14; minor sclerosis near 34. Impression: Signs of early osseointegration failure at 42; consider clinical review."}
{"id": "case_0181", "images": ["images/placeholder_0181.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Esomeprazole, Bufomix Easyhaler, Levaxin, Losartan, Duroferon. Desired treatment: Provide measurements for alveolar ridge width and height at 34–44.", "answer": "Review of CBCT dated 210420. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 15: bone height ≈ 14.2 mm; implant space ≈ 12.7 mm; nearby anterior loop. Region 22: bone height ≈ 16.0 mm; implant space ≈ 14.0 mm; nearby nasal floor. Region 47: bone height ≈ 12.6 mm; implant space ≈ 8.3 mm; nearby nasal floor. Region 16: bone height ≈ 8.1 mm; implant space ≈ 6.5 mm; nearby mental foramen. Region 48: bone height ≈ 14.4 mm; implant space ≈ 6.8 mm; nearby mental foramen. Region 27: bone height ≈ 9.3 mm; implant space ≈ 6.3 mm; nearby nasal floor. Region 14: bone height ≈ 17.4 mm; implant space ≈ 13.1 mm; nearby anterior loop. Region 32: bone height ≈ 16.4 mm; implant space ≈ 15.1 mm; nearby sinus floor. Region 13: bone height ≈ 11.2 mm; implant space ≈ 9.9 mm; nearby mandibular canal. Region 23: bone height ≈ 16.8 mm; implant space ≈ 14.9 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0182", "images": ["images/placeholder_0182.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Bufomix Easyhaler, Atorvastatin, Insulin glargine, Esomeprazole, Amlodipine. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 36–46 and 13–23.", "answer": "Review of CBCT dated 210925. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 24: bone height ≈ 6.1 mm; implant space ≈ 3.9 mm; nearby incisive canal. Region 46: bone height ≈ 4.7 mm; implant space ≈ 3.0 mm; nearby sinus floor. Region 13: bone height ≈ 19.1 mm; implant space ≈ 17.0 mm; nearby mental foramen. Region 31: bone height ≈ 19.1 mm; implant space ≈ 12.7 mm; nearby incisive canal. Region 25: bone height ≈ 9.5 mm; implant space ≈ 3.8 mm; nearby incisive canal. Region 17: bone height ≈ 13.8 mm; implant space ≈ 7.4 mm; nearby sinus floor. Region 27: bone height ≈ 11.2 mm; implant space ≈ 8.6 mm; nearby anterior loop. Region 32: bone height ≈ 19.4 mm; implant space ≈ 13.1 mm; nearby mental foramen. Region 44: bone height ≈ 18.8 mm; implant space ≈ 12.7 mm; nearby sinus floor. Region 36: bone height ≈ 4.7 mm; implant space ≈ 3.5 mm; nearby anterior loop. Periapical radiolucency observed near 26; minor sclerosis near 43. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0183", "images": ["images/placeholder_0183.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Duloxetine, Duroferon, Insulin glargine, Bricanyl, Metoprolol, Bufomix Easyhaler. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 33–43.", "answer": "Review of CBCT dated 200205. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 36: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby incisive canal. Region 22: bone height ≈ 4.3 mm; implant space ≈ 0 mm; nearby mental foramen. Region 42: bone height ≈ 5.6 mm; implant space ≈ 4.3 mm; nearby sinus floor. Region 45: bone height ≈ 15.6 mm; implant space ≈ 12.4 mm; nearby incisive canal. Region 23: bone height ≈ 14.9 mm; implant space ≈ 9.8 mm; nearby mandibular canal. Region 41: bone height ≈ 13.9 mm; implant space ≈ 8.3 mm; nearby sinus floor. Region 14: bone height ≈ 9.3 mm; implant space ≈ 3.2 mm; nearby sinus floor. Region 47: bone height ≈ 8.1 mm; implant space ≈ 1.7 mm; nearby incisive canal. Region 13: bone height ≈ 18.6 mm; implant space ≈ 14.8 mm; nearby anterior loop. Region 15: bone height ≈ 9.6 mm; implant space ≈ 7.4 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 35; minor sclerosis near 41. Image artifacts due to metallic restorations reduce detail locally. Impression: Radiolucent lesion at 26 consistent with radicular cyst; recommend correlation."}
{"id": "case_0184", "images": ["images/placeholder_0184.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Duloxetine, Betolvex, Bricanyl, Esomeprazole, Atorvastatin, Bufomix Easyhaler. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 34–44.", "answer": "Review of CBCT dated 241121. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 18: bone height ≈ 19.5 mm; implant space ≈ 17.5 mm; nearby incisive canal. Region 28: bone height ≈ 17.0 mm; implant space ≈ 13.1 mm; nearby nasal floor. Region 15: bone height ≈ 4.2 mm; implant space ≈ 0 mm; nearby nasal floor. Region 27: bone height ≈ 15.5 mm; implant space ≈ 12.2 mm; nearby mandibular canal. Region 45: bone height ≈ 13.2 mm; implant space ≈ 9.5 mm; nearby mandibular canal. Region 42: bone height ≈ 19.9 mm; implant space ≈ 17.5 mm; nearby mandibular canal. Region 37: bone height ≈ 21.6 mm; implant space ≈ 17.4 mm; nearby incisive canal. Region 14: bone height ≈ 11.1 mm; implant space ≈ 9.6 mm; nearby mandibular canal. Region 33: bone height ≈ 17.3 mm; implant space ≈ 16.1 mm; nearby anterior loop. Region 41: bone height ≈ 18.9 mm; implant space ≈ 12.7 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Impression: Moderate mucosal thickening in sinus floor region bilaterally."}
{"id": "case_0185", "images": ["images/placeholder_0185.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Bricanyl, Losartan, Betolvex, Insulin glargine, Omeprazole, Trulicity. Desired treatment: Quantify vertical bone height reduction and comment on trabecular density.", "answer": "Review of CBCT dated 221109. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 38: bone height ≈ 8.2 mm; implant space ≈ 6.6 mm; nearby anterior loop. Region 23: bone height ≈ 5.6 mm; implant space ≈ 0 mm; nearby incisive canal. Region 31: bone height ≈ 8.3 mm; implant space ≈ 4.6 mm; nearby sinus floor. Region 42: bone height ≈ 20.2 mm; implant space ≈ 19.0 mm; nearby mandibular canal. Region 18: bone height ≈ 5.6 mm; implant space ≈ 1.6 mm; nearby nasal floor. Region 22: bone height ≈ 7.0 mm; implant space ≈ 2.1 mm; nearby mandibular canal. Region 12: bone height ≈ 5.8 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 14: bone height ≈ 18.1 mm; implant space ≈ 11.3 mm; nearby sinus floor. Region 43: bone height ≈ 11.7 mm; implant space ≈ 7.0 mm; nearby anterior loop. Region 34: bone height ≈ 6.3 mm; implant space ≈ 4.7 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 33; minor sclerosis near 38. Impression: Radiolucent lesion at 28 consistent with radicular cyst; recommend correlation."}
{"id": "case_0186", "images": ["images/placeholder_0186.png"], "question": "Planning for bone graft planning. Brief history/status: Losartan, Levaxin, Insulin glargine, Metoprolol, Esomeprazole. Desired treatment: Review periapical status and note any signs of infection in regions 24, 23, 12.", "answer": "Review of CBCT dated 220828. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 44: bone height ≈ 18.6 mm; implant space ≈ 15.9 mm; nearby incisive canal. Region 42: bone height ≈ 4.6 mm; implant space ≈ 0 mm; nearby anterior loop. Region 38: bone height ≈ 6.1 mm; implant space ≈ 1.7 mm; nearby anterior loop. Region 32: bone height ≈ 7.3 mm; implant space ≈ 6.0 mm; nearby sinus floor. Region 23: bone height ≈ 9.0 mm; implant space ≈ 5.6 mm; nearby nasal floor. Region 31: bone height ≈ 21.9 mm; implant space ≈ 16.3 mm; nearby nasal floor. Region 45: bone height ≈ 13.5 mm; implant space ≈ 10.2 mm; nearby sinus floor. Region 12: bone height ≈ 10.8 mm; implant space ≈ 4.7 mm; nearby nasal floor. Region 17: bone height ≈ 13.7 mm; implant space ≈ 8.2 mm; nearby nasal floor. Region 16: bone height ≈ 5.5 mm; implant space ≈ 0.5 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: Findings consistent with apical periodontitis near 21 and 33."}
{"id": "case_0187", "images": ["images/placeholder_0187.png"], "question": "Planning for edentulous ridge mapping. Brief history/status: Amlodipine, Losartan, Insulin glargine, Duloxetine, Bufomix Easyhaler, Calcichew-D3, Betolvex. Desired treatment: Please evaluate bone height, implant space, and anatomical constraints for regions 33–43 and 36–46.", "answer": "Review of CBCT dated 250127. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 42: bone height ≈ 8.0 mm; implant space ≈ 0.2 mm; nearby nasal floor. Region 41: bone height ≈ 9.8 mm; implant space ≈ 4.5 mm; nearby anterior loop. Region 14: bone height ≈ 8.2 mm; implant space ≈ 1.2 mm; nearby incisive canal. Region 21: bone height ≈ 14.9 mm; implant space ≈ 7.6 mm; nearby anterior loop. Region 24: bone height ≈ 20.0 mm; implant space ≈ 14.4 mm; nearby incisive canal. Region 32: bone height ≈ 17.3 mm; implant space ≈ 11.3 mm; nearby anterior loop. Region 36: bone height ≈ 9.9 mm; implant space ≈ 7.4 mm; nearby mandibular canal. Region 37: bone height ≈ 13.0 mm; implant space ≈ 10.5 mm; nearby nasal floor. Region 44: bone height ≈ 15.0 mm; implant space ≈ 10.7 mm; nearby sinus floor. Region 31: bone height ≈ 16.2 mm; implant space ≈ 14.4 mm; nearby mental foramen. Impression: Findings consistent with apical periodontitis near 17 and 47."}
{"id": "case_0188", "images": ["images/placeholder_0188.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Bricanyl, Betolvex, Calcichew-D3, Atorvastatin, Losartan, Omeprazole. Desired treatment: Measure crest-to-canal and crest-to-foramen distances across 33–43.", "answer": "Review of CBCT dated 240401. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 38: bone height ≈ 18.5 mm; implant space ≈ 10.7 mm; nearby mandibular canal. Region 44: bone height ≈ 11.9 mm; implant space ≈ 9.6 mm; nearby sinus floor. Region 24: bone height ≈ 12.2 mm; implant space ≈ 6.9 mm; nearby anterior loop. Region 13: bone height ≈ 10.7 mm; implant space ≈ 2.7 mm; nearby mandibular canal. Region 35: bone height ≈ 21.5 mm; implant space ≈ 14.5 mm; nearby anterior loop. Region 28: bone height ≈ 18.5 mm; implant space ≈ 12.5 mm; nearby sinus floor. Region 31: bone height ≈ 9.5 mm; implant space ≈ 6.4 mm; nearby incisive canal. Region 27: bone height ≈ 10.0 mm; implant space ≈ 7.3 mm; nearby mandibular canal. Region 18: bone height ≈ 10.4 mm; implant space ≈ 2.5 mm; nearby incisive canal. Region 46: bone height ≈ 12.7 mm; implant space ≈ 5.1 mm; nearby incisive canal. Impression: Impacted molar in quadrant 1 associated with mild follicular space widening."}
{"id": "case_0189", "images": ["images/placeholder_0189.png"], "question": "Planning for implant planning. Brief history/status: Calcichew-D3, Esomeprazole, Atorvastatin, Bricanyl, Levaxin, Omeprazole, Bufomix Easyhaler. Desired treatment: Check for cortical bone thinning or fenestrations near 36–46.", "answer": "Review of CBCT dated 230803. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 14: bone height ≈ 8.7 mm; implant space ≈ 1.1 mm; nearby incisive canal. Region 42: bone height ≈ 7.4 mm; implant space ≈ 6.2 mm; nearby nasal floor. Region 18: bone height ≈ 15.8 mm; implant space ≈ 10.0 mm; nearby mental foramen. Region 26: bone height ≈ 19.6 mm; implant space ≈ 15.0 mm; nearby mental foramen. Region 38: bone height ≈ 18.5 mm; implant space ≈ 16.7 mm; nearby sinus floor. Region 25: bone height ≈ 19.8 mm; implant space ≈ 17.1 mm; nearby mandibular canal. Region 36: bone height ≈ 19.9 mm; implant space ≈ 18.2 mm; nearby anterior loop. Region 44: bone height ≈ 18.9 mm; implant space ≈ 17.7 mm; nearby sinus floor. Region 45: bone height ≈ 15.1 mm; implant space ≈ 9.2 mm; nearby anterior loop. Region 34: bone height ≈ 14.7 mm; implant space ≈ 8.5 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 37; minor sclerosis near 41. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0190", "images": ["images/placeholder_0190.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Losartan, Duloxetine, Bufomix Easyhaler, Metoprolol, Esomeprazole, Trulicity, Bricanyl. Desired treatment: Review periapical status and note any signs of infection in regions 17, 41, 45.", "answer": "Review of CBCT dated 251212. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 25: bone height ≈ 12.8 mm; implant space ≈ 8.7 mm; nearby nasal floor. Region 26: bone height ≈ 16.8 mm; implant space ≈ 12.9 mm; nearby nasal floor. Region 17: bone height ≈ 4.3 mm; implant space ≈ 0.2 mm; nearby sinus floor. Region 48: bone height ≈ 18.0 mm; implant space ≈ 14.0 mm; nearby nasal floor. Region 35: bone height ≈ 12.9 mm; implant space ≈ 6.7 mm; nearby mental foramen. Region 21: bone height ≈ 11.8 mm; implant space ≈ 9.7 mm; nearby nasal floor. Region 23: bone height ≈ 4.2 mm; implant space ≈ 0 mm; nearby anterior loop. Region 31: bone height ≈ 16.2 mm; implant space ≈ 14.7 mm; nearby incisive canal. Region 46: bone height ≈ 9.6 mm; implant space ≈ 3.8 mm; nearby mandibular canal. Region 44: bone height ≈ 13.3 mm; implant space ≈ 5.5 mm; nearby sinus floor. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 34; minor sclerosis near 24. Image artifacts due to metallic restorations reduce detail locally. Impression: Adequate bone volume present for standard implant placement."}
{"id": "case_0191", "images": ["images/placeholder_0191.png"], "question": "Planning for evaluation of post-implant healing. Brief history/status: Calcichew-D3, Bufomix Easyhaler, Amlodipine, Betolvex, Levaxin, Losartan. Desired treatment: Check for cortical bone thinning or fenestrations near 13–23.", "answer": "Review of CBCT dated 241121. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 13: bone height ≈ 6.8 mm; implant space ≈ 3.3 mm; nearby anterior loop. Region 12: bone height ≈ 7.2 mm; implant space ≈ 5.2 mm; nearby nasal floor. Region 22: bone height ≈ 12.4 mm; implant space ≈ 5.4 mm; nearby mandibular canal. Region 15: bone height ≈ 9.8 mm; implant space ≈ 5.6 mm; nearby incisive canal. Region 27: bone height ≈ 17.7 mm; implant space ≈ 12.3 mm; nearby sinus floor. Region 23: bone height ≈ 9.8 mm; implant space ≈ 5.7 mm; nearby nasal floor. Region 33: bone height ≈ 18.6 mm; implant space ≈ 16.4 mm; nearby incisive canal. Region 16: bone height ≈ 10.3 mm; implant space ≈ 8.6 mm; nearby mental foramen. Region 41: bone height ≈ 18.0 mm; implant space ≈ 14.3 mm; nearby nasal floor. Region 25: bone height ≈ 20.8 mm; implant space ≈ 14.6 mm; nearby sinus floor. Periapical radiolucency observed near 32; minor sclerosis near 27. Impression: Radiolucent lesion at 41 consistent with radicular cyst; recommend correlation."}
{"id": "case_0192", "images": ["images/placeholder_0192.png"], "question": "Planning for implant planning. Brief history/status: Metoprolol, Esomeprazole, Bricanyl, Duloxetine, Losartan, Duroferon, Amlodipine, Calcichew-D3. Desired treatment: Review periapical status and note any signs of infection in regions 23, 44, 27.", "answer": "Review of CBCT dated 230509. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 41: bone height ≈ 9.7 mm; implant space ≈ 7.1 mm; nearby incisive canal. Region 32: bone height ≈ 16.5 mm; implant space ≈ 14.0 mm; nearby incisive canal. Region 31: bone height ≈ 21.3 mm; implant space ≈ 14.0 mm; nearby incisive canal. Region 34: bone height ≈ 10.0 mm; implant space ≈ 4.5 mm; nearby incisive canal. Region 14: bone height ≈ 15.7 mm; implant space ≈ 11.4 mm; nearby nasal floor. Region 22: bone height ≈ 14.4 mm; implant space ≈ 9.9 mm; nearby sinus floor. Region 17: bone height ≈ 14.2 mm; implant space ≈ 8.1 mm; nearby anterior loop. Region 43: bone height ≈ 15.4 mm; implant space ≈ 12.8 mm; nearby incisive canal. Region 36: bone height ≈ 18.9 mm; implant space ≈ 13.2 mm; nearby mandibular canal. Region 33: bone height ≈ 21.0 mm; implant space ≈ 18.9 mm; nearby anterior loop. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0193", "images": ["images/placeholder_0193.png"], "question": "Planning for full-mouth rehabilitation. Brief history/status: Insulin glargine, Levaxin, Losartan, Esomeprazole, Metoprolol, Bufomix Easyhaler, Omeprazole. Desired treatment: Measure ridge augmentation volume required at 13–23 and 34–44.", "answer": "Review of CBCT dated 250224. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 38: bone height ≈ 18.7 mm; implant space ≈ 16.1 mm; nearby nasal floor. Region 41: bone height ≈ 7.7 mm; implant space ≈ 1.4 mm; nearby anterior loop. Region 44: bone height ≈ 11.3 mm; implant space ≈ 10.2 mm; nearby mental foramen. Region 47: bone height ≈ 5.0 mm; implant space ≈ 1.7 mm; nearby anterior loop. Region 22: bone height ≈ 13.0 mm; implant space ≈ 12.0 mm; nearby anterior loop. Region 24: bone height ≈ 6.5 mm; implant space ≈ 0 mm; nearby incisive canal. Region 27: bone height ≈ 21.0 mm; implant space ≈ 18.7 mm; nearby nasal floor. Region 43: bone height ≈ 14.4 mm; implant space ≈ 7.5 mm; nearby incisive canal. Region 32: bone height ≈ 20.3 mm; implant space ≈ 18.0 mm; nearby mental foramen. Region 48: bone height ≈ 19.4 mm; implant space ≈ 17.1 mm; nearby anterior loop. Periapical radiolucency observed near 42; minor sclerosis near 14. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0194", "images": ["images/placeholder_0194.png"], "question": "Planning for pain and swelling assessment. Brief history/status: Trulicity, Duloxetine, Bufomix Easyhaler, Calcichew-D3, Levaxin. Desired treatment: Provide measurements for alveolar ridge width and height at 13–23.", "answer": "Review of CBCT dated 200609. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 11: bone height ≈ 5.9 mm; implant space ≈ 0 mm; nearby incisive canal. Region 41: bone height ≈ 9.9 mm; implant space ≈ 6.5 mm; nearby incisive canal. Region 35: bone height ≈ 7.9 mm; implant space ≈ 3.2 mm; nearby sinus floor. Region 28: bone height ≈ 21.7 mm; implant space ≈ 16.6 mm; nearby mandibular canal. Region 48: bone height ≈ 5.1 mm; implant space ≈ 1.1 mm; nearby anterior loop. Region 22: bone height ≈ 14.7 mm; implant space ≈ 9.4 mm; nearby sinus floor. Region 44: bone height ≈ 7.2 mm; implant space ≈ 2.9 mm; nearby nasal floor. Region 37: bone height ≈ 5.6 mm; implant space ≈ 2.7 mm; nearby anterior loop. Region 12: bone height ≈ 17.2 mm; implant space ≈ 14.8 mm; nearby mental foramen. Region 45: bone height ≈ 6.3 mm; implant space ≈ 1.1 mm; nearby anterior loop. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 31; minor sclerosis near 28. Image artifacts due to metallic restorations reduce detail locally. Impression: Signs of early osseointegration failure at 43; consider clinical review."}
{"id": "case_0195", "images": ["images/placeholder_0195.png"], "question": "Planning for bone graft planning. Brief history/status: Calcichew-D3, Losartan, Duroferon, Insulin glargine, Amlodipine, Betolvex, Duloxetine. Desired treatment: Assess healing of extraction sockets and bone regeneration at 13–23.", "answer": "Review of CBCT dated 240928. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 36: bone height ≈ 20.2 mm; implant space ≈ 15.4 mm; nearby nasal floor. Region 38: bone height ≈ 19.4 mm; implant space ≈ 12.5 mm; nearby nasal floor. Region 11: bone height ≈ 12.0 mm; implant space ≈ 10.6 mm; nearby anterior loop. Region 32: bone height ≈ 20.7 mm; implant space ≈ 12.7 mm; nearby nasal floor. Region 17: bone height ≈ 14.7 mm; implant space ≈ 11.0 mm; nearby anterior loop. Region 33: bone height ≈ 13.0 mm; implant space ≈ 5.0 mm; nearby sinus floor. Region 22: bone height ≈ 6.0 mm; implant space ≈ 2.5 mm; nearby mandibular canal. Region 15: bone height ≈ 18.6 mm; implant space ≈ 12.6 mm; nearby sinus floor. Region 46: bone height ≈ 5.0 mm; implant space ≈ 0 mm; nearby incisive canal. Region 34: bone height ≈ 5.0 mm; implant space ≈ 0 mm; nearby mandibular canal. Image artifacts due to metallic restorations reduce detail locally. Impression: Radiolucent lesion at 23 consistent with radicular cyst; recommend correlation."}
{"id": "case_0196", "images": ["images/placeholder_0196.png"], "question": "Planning for pathology review. Brief history/status: Metoprolol, Losartan, Duroferon, Insulin glargine, Levaxin, Bufomix Easyhaler, Betolvex. Desired treatment: Assess proximity to mandibular canal and sinus floor for 36–46 and 33–43.", "answer": "Review of CBCT dated 250223. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 37: bone height ≈ 16.3 mm; implant space ≈ 14.3 mm; nearby mental foramen. Region 24: bone height ≈ 15.9 mm; implant space ≈ 10.9 mm; nearby mental foramen. Region 22: bone height ≈ 13.7 mm; implant space ≈ 8.5 mm; nearby anterior loop. Region 41: bone height ≈ 13.2 mm; implant space ≈ 7.2 mm; nearby mandibular canal. Region 45: bone height ≈ 18.7 mm; implant space ≈ 15.1 mm; nearby incisive canal. Region 13: bone height ≈ 10.0 mm; implant space ≈ 4.0 mm; nearby incisive canal. Region 42: bone height ≈ 19.4 mm; implant space ≈ 11.8 mm; nearby nasal floor. Region 12: bone height ≈ 7.2 mm; implant space ≈ 1.9 mm; nearby mandibular canal. Region 44: bone height ≈ 16.2 mm; implant space ≈ 10.0 mm; nearby mandibular canal. Region 43: bone height ≈ 10.4 mm; implant space ≈ 3.9 mm; nearby incisive canal. Maxillary sinus: mucosal thickening mild on both sides. Image artifacts due to metallic restorations reduce detail locally. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0197", "images": ["images/placeholder_0197.png"], "question": "Planning for maxillary sinus evaluation. Brief history/status: Bricanyl, Esomeprazole, Metoprolol, Betolvex, Omeprazole, Calcichew-D3. Desired treatment: Evaluate implant thread exposure and peri-implant bone loss at 13–23.", "answer": "Review of CBCT dated 210223. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 15: bone height ≈ 19.9 mm; implant space ≈ 15.1 mm; nearby incisive canal. Region 31: bone height ≈ 15.5 mm; implant space ≈ 10.1 mm; nearby nasal floor. Region 33: bone height ≈ 16.4 mm; implant space ≈ 15.0 mm; nearby nasal floor. Region 48: bone height ≈ 21.6 mm; implant space ≈ 19.5 mm; nearby mental foramen. Region 24: bone height ≈ 14.5 mm; implant space ≈ 8.1 mm; nearby anterior loop. Region 17: bone height ≈ 14.1 mm; implant space ≈ 8.9 mm; nearby mental foramen. Region 22: bone height ≈ 17.1 mm; implant space ≈ 13.7 mm; nearby nasal floor. Region 45: bone height ≈ 5.9 mm; implant space ≈ 1.5 mm; nearby sinus floor. Region 12: bone height ≈ 5.5 mm; implant space ≈ 0.6 mm; nearby mandibular canal. Region 38: bone height ≈ 10.5 mm; implant space ≈ 3.0 mm; nearby anterior loop. Image artifacts due to metallic restorations reduce detail locally. Impression: Signs of early osseointegration failure at 12; consider clinical review."}
{"id": "case_0198", "images": ["images/placeholder_0198.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Metoprolol, Levaxin, Duroferon, Trulicity, Duloxetine, Bufomix Easyhaler, Bricanyl, Losartan. Desired treatment: Measure ridge augmentation volume required at 13–23 and 14–24.", "answer": "Review of CBCT dated 250326. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 28: bone height ≈ 7.2 mm; implant space ≈ 1.5 mm; nearby mandibular canal. Region 27: bone height ≈ 9.7 mm; implant space ≈ 5.3 mm; nearby anterior loop. Region 11: bone height ≈ 16.8 mm; implant space ≈ 11.6 mm; nearby incisive canal. Region 25: bone height ≈ 18.4 mm; implant space ≈ 12.0 mm; nearby nasal floor. Region 32: bone height ≈ 18.8 mm; implant space ≈ 13.7 mm; nearby mental foramen. Region 42: bone height ≈ 18.6 mm; implant space ≈ 14.0 mm; nearby anterior loop. Region 46: bone height ≈ 13.3 mm; implant space ≈ 9.2 mm; nearby mandibular canal. Region 48: bone height ≈ 15.9 mm; implant space ≈ 8.9 mm; nearby anterior loop. Region 33: bone height ≈ 17.8 mm; implant space ≈ 11.0 mm; nearby mandibular canal. Region 36: bone height ≈ 5.6 mm; implant space ≈ 0 mm; nearby mental foramen. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 18; minor sclerosis near 26. Impression: No evidence of pathological lesions; satisfactory bone remodeling observed."}
{"id": "case_0199", "images": ["images/placeholder_0199.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Esomeprazole, Bricanyl, Levaxin, Bufomix Easyhaler, Duroferon, Duloxetine. Desired treatment: Review periapical status and note any signs of infection in regions 35, 17, 48.", "answer": "Review of CBCT dated 220625. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 12: bone height ≈ 17.4 mm; implant space ≈ 14.7 mm; nearby mandibular canal. Region 25: bone height ≈ 14.5 mm; implant space ≈ 10.0 mm; nearby mandibular canal. Region 46: bone height ≈ 6.5 mm; implant space ≈ 0.4 mm; nearby sinus floor. Region 44: bone height ≈ 8.6 mm; implant space ≈ 6.4 mm; nearby mental foramen. Region 28: bone height ≈ 13.7 mm; implant space ≈ 6.1 mm; nearby incisive canal. Region 27: bone height ≈ 10.0 mm; implant space ≈ 8.5 mm; nearby mental foramen. Region 34: bone height ≈ 9.0 mm; implant space ≈ 2.6 mm; nearby mandibular canal. Region 45: bone height ≈ 10.8 mm; implant space ≈ 5.6 mm; nearby anterior loop. Region 32: bone height ≈ 20.6 mm; implant space ≈ 18.5 mm; nearby anterior loop. Region 11: bone height ≈ 13.8 mm; implant space ≈ 8.8 mm; nearby mental foramen. Periapical radiolucency observed near 48; minor sclerosis near 17. Impression: Radiolucent lesion at 24 consistent with radicular cyst; recommend correlation."}
{"id": "case_0200", "images": ["images/placeholder_0200.png"], "question": "Planning for follow-up after guided surgery. Brief history/status: Omeprazole, Bricanyl, Insulin glargine, Amlodipine, Calcichew-D3. Desired treatment: Review periapical status and note any signs of infection in regions 23, 24, 43.", "answer": "Review of CBCT dated 220204. Overall bone density within expected limits except in posterior maxilla. Implant feasibility evaluated with 5 mm minimal bone width threshold. Region 11: bone height ≈ 4.6 mm; implant space ≈ 0 mm; nearby mandibular canal. Region 25: bone height ≈ 13.3 mm; implant space ≈ 9.8 mm; nearby mental foramen. Region 24: bone height ≈ 17.3 mm; implant space ≈ 10.4 mm; nearby incisive canal. Region 16: bone height ≈ 8.6 mm; implant space ≈ 5.3 mm; nearby incisive canal. Region 28: bone height ≈ 20.8 mm; implant space ≈ 13.0 mm; nearby incisive canal. Region 38: bone height ≈ 19.2 mm; implant space ≈ 17.6 mm; nearby incisive canal. Region 35: bone height ≈ 5.0 mm; implant space ≈ 0 mm; nearby mental foramen. Region 33: bone height ≈ 21.7 mm; implant space ≈ 18.9 mm; nearby sinus floor. Region 43: bone height ≈ 13.6 mm; implant space ≈ 12.5 mm; nearby sinus floor. Region 15: bone height ≈ 13.1 mm; implant space ≈ 7.0 mm; nearby mandibular canal. Maxillary sinus: mucosal thickening mild on both sides. Periapical radiolucency observed near 45; minor sclerosis near 44. Impression: Impacted molar in quadrant 3 associated with mild follicular space widening."}
{"id": "case_0001", "images": ["images/placeholder_0001.png"], "question": "Planning for implant placement verification. Brief history/status: Bricanyl, Metoprolol, Duloxetine, Bufomix Easyhaler, Betolvex, Levaxin. Desired treatment: Review the relationship between alveolar crest and mandibular canal in 13–23.", "answer": "Review of CBCT scan dated 240607. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 37: bone height ≈ 9.7 mm; implant space ≈ 4.8 mm; nearby structure: mental foramen. Region 28: bone height ≈ 21.3 mm; implant space ≈ 20.1 mm; nearby structure: mental foramen. Region 44: bone height ≈ 10.3 mm; implant space ≈ 3.9 mm; nearby structure: mental foramen. Region 27: bone height ≈ 20.5 mm; implant space ≈ 12.7 mm; nearby structure: sinus floor. Region 36: bone height ≈ 11.1 mm; implant space ≈ 3.3 mm; nearby structure: mental foramen. Region 34: bone height ≈ 15.2 mm; implant space ≈ 13.8 mm; nearby structure: mandibular canal. Region 46: bone height ≈ 19.8 mm; implant space ≈ 15.3 mm; nearby structure: sinus floor. Region 48: bone height ≈ 6.1 mm; implant space ≈ 4.9 mm; nearby structure: mandibular canal. Region 15: bone height ≈ 12.7 mm; implant space ≈ 8.1 mm; nearby structure: anterior loop. Region 12: bone height ≈ 18.5 mm; implant space ≈ 17.1 mm; nearby structure: mental foramen. Maxillary sinus shows mild mucosal thickening bilaterally. Periapical radiolucency visible at 22, additional smaller lesion near 36. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Diffuse radiolucency with irregular margin near 45; correlate clinically."}
{"id": "case_0002", "images": ["images/placeholder_0002.png"], "question": "Planning for implant placement verification. Brief history/status: Bufomix Easyhaler, Esomeprazole, Metoprolol, Amlodipine, Duloxetine, Insulin glargine. Desired treatment: Measure available vertical height and ridge width in 33–43 and 16–26.", "answer": "Review of CBCT scan dated 250312. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 25: bone height ≈ 14.7 mm; implant space ≈ 8.6 mm; nearby structure: mandibular canal. Region 31: bone height ≈ 15.7 mm; implant space ≈ 10.8 mm; nearby structure: nasal floor. Region 14: bone height ≈ 15.8 mm; implant space ≈ 14.8 mm; nearby structure: anterior loop. Region 18: bone height ≈ 15.3 mm; implant space ≈ 9.3 mm; nearby structure: nasal floor. Region 44: bone height ≈ 9.4 mm; implant space ≈ 2.4 mm; nearby structure: mental foramen. Region 15: bone height ≈ 13.0 mm; implant space ≈ 7.7 mm; nearby structure: sinus floor. Region 21: bone height ≈ 4.1 mm; implant space ≈ 0 mm; nearby structure: sinus floor. Region 43: bone height ≈ 6.3 mm; implant space ≈ 0 mm; nearby structure: nasal floor. Region 11: bone height ≈ 7.0 mm; implant space ≈ 1.5 mm; nearby structure: anterior loop. Region 35: bone height ≈ 14.3 mm; implant space ≈ 9.1 mm; nearby structure: mandibular canal. Impression: No radiographic evidence of acute infection or pathology detected."}
{"id": "case_0003", "images": ["images/placeholder_0003.png"], "question": "Planning for evaluation for prosthetic design. Brief history/status: Duroferon, Betolvex, Bufomix Easyhaler, Levaxin, Insulin glargine, Losartan, Amlodipine. Desired treatment: Check for apical radiolucency or infection in regions 33, 11, and 42.", "answer": "Review of CBCT scan dated 250913. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 38: bone height ≈ 6.4 mm; implant space ≈ 0 mm; nearby structure: mental foramen. Region 42: bone height ≈ 12.5 mm; implant space ≈ 5.0 mm; nearby structure: anterior loop. Region 17: bone height ≈ 9.7 mm; implant space ≈ 2.0 mm; nearby structure: anterior loop. Region 45: bone height ≈ 9.0 mm; implant space ≈ 2.4 mm; nearby structure: sinus floor. Region 18: bone height ≈ 15.6 mm; implant space ≈ 8.5 mm; nearby structure: nasal floor. Region 28: bone height ≈ 9.1 mm; implant space ≈ 5.1 mm; nearby structure: mandibular canal. Region 11: bone height ≈ 16.1 mm; implant space ≈ 11.9 mm; nearby structure: anterior loop. Region 47: bone height ≈ 20.0 mm; implant space ≈ 17.4 mm; nearby structure: sinus floor. Region 34: bone height ≈ 5.6 mm; implant space ≈ 0 mm; nearby structure: mental foramen. Region 25: bone height ≈ 9.3 mm; implant space ≈ 4.5 mm; nearby structure: nasal floor. Maxillary sinus shows mild mucosal thickening bilaterally. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Mild bone resorption near 16 and 14; stable post-surgical remodeling."}
{"id": "case_0004", "images": ["images/placeholder_0004.png"], "question": "Planning for chronic sinusitis evaluation. Brief history/status: Calcichew-D3, Duloxetine, Trulicity, Amlodipine, Metoprolol. Desired treatment: Provide detailed bone mapping and canal proximity data for 14–24.", "answer": "Review of CBCT scan dated 240418. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 13: bone height ≈ 8.9 mm; implant space ≈ 4.9 mm; nearby structure: anterior loop. Region 47: bone height ≈ 14.7 mm; implant space ≈ 9.8 mm; nearby structure: mandibular canal. Region 48: bone height ≈ 10.3 mm; implant space ≈ 3.4 mm; nearby structure: sinus floor. Region 37: bone height ≈ 16.5 mm; implant space ≈ 10.0 mm; nearby structure: sinus floor. Region 21: bone height ≈ 15.9 mm; implant space ≈ 10.8 mm; nearby structure: nasal floor. Region 27: bone height ≈ 13.2 mm; implant space ≈ 7.7 mm; nearby structure: nasal floor. Region 22: bone height ≈ 9.9 mm; implant space ≈ 3.5 mm; nearby structure: nasal floor. Region 46: bone height ≈ 14.3 mm; implant space ≈ 9.5 mm; nearby structure: anterior loop. Region 26: bone height ≈ 5.2 mm; implant space ≈ 0.4 mm; nearby structure: mental foramen. Region 35: bone height ≈ 15.0 mm; implant space ≈ 11.5 mm; nearby structure: sinus floor. Impression: Findings indicate sufficient bone height with mild sinus mucosal thickening."}
{"id": "case_0005", "images": ["images/placeholder_0005.png"], "question": "Planning for follow-up after implant restoration. Brief history/status: Duloxetine, Insulin glargine, Omeprazole, Bufomix Easyhaler, Metoprolol, Atorvastatin. Desired treatment: Evaluate cortical thickness and spongy bone quality in 13–23.", "answer": "Review of CBCT scan dated 240523. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 23: bone height ≈ 17.5 mm; implant space ≈ 11.8 mm; nearby structure: mental foramen. Region 21: bone height ≈ 20.3 mm; implant space ≈ 13.7 mm; nearby structure: anterior loop. Region 47: bone height ≈ 14.7 mm; implant space ≈ 13.6 mm; nearby structure: nasal floor. Region 28: bone height ≈ 21.1 mm; implant space ≈ 17.8 mm; nearby structure: sinus floor. Region 13: bone height ≈ 12.4 mm; implant space ≈ 9.2 mm; nearby structure: nasal floor. Region 14: bone height ≈ 14.4 mm; implant space ≈ 7.1 mm; nearby structure: sinus floor. Region 36: bone height ≈ 21.1 mm; implant space ≈ 17.2 mm; nearby structure: mental foramen. Region 16: bone height ≈ 7.5 mm; implant space ≈ 5.4 mm; nearby structure: anterior loop. Region 22: bone height ≈ 11.7 mm; implant space ≈ 9.1 mm; nearby structure: anterior loop. Region 46: bone height ≈ 16.3 mm; implant space ≈ 14.4 mm; nearby structure: mandibular canal. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Peri-implant bone loss at 23 consistent with early peri-implantitis."}
{"id": "case_0006", "images": ["images/placeholder_0006.png"], "question": "Planning for implant placement verification. Brief history/status: Levaxin, Betolvex, Bufomix Easyhaler, Duroferon, Losartan, Atorvastatin, Bricanyl. Desired treatment: Assess implant site quality and need for sinus lift or graft in 34–44.", "answer": "Review of CBCT scan dated 231012. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 18: bone height ≈ 12.1 mm; implant space ≈ 8.0 mm; nearby structure: sinus floor. Region 21: bone height ≈ 17.8 mm; implant space ≈ 12.4 mm; nearby structure: sinus floor. Region 47: bone height ≈ 17.1 mm; implant space ≈ 14.9 mm; nearby structure: sinus floor. Region 14: bone height ≈ 15.8 mm; implant space ≈ 12.9 mm; nearby structure: nasal floor. Region 42: bone height ≈ 14.9 mm; implant space ≈ 8.4 mm; nearby structure: sinus floor. Region 25: bone height ≈ 19.0 mm; implant space ≈ 16.4 mm; nearby structure: mental foramen. Region 41: bone height ≈ 17.8 mm; implant space ≈ 11.6 mm; nearby structure: sinus floor. Region 17: bone height ≈ 19.2 mm; implant space ≈ 13.5 mm; nearby structure: nasal floor. Region 11: bone height ≈ 9.1 mm; implant space ≈ 5.0 mm; nearby structure: anterior loop. Region 22: bone height ≈ 10.0 mm; implant space ≈ 5.2 mm; nearby structure: anterior loop. Maxillary sinus shows mild mucosal thickening bilaterally. Periapical radiolucency visible at 26, additional smaller lesion near 45. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Mild bone resorption near 45 and 26; stable post-surgical remodeling."}
{"id": "case_0007", "images": ["images/placeholder_0007.png"], "question": "Planning for radiolucency investigation. Brief history/status: Omeprazole, Esomeprazole, Bricanyl, Atorvastatin, Metoprolol, Duroferon. Desired treatment: Provide detailed bone mapping and canal proximity data for 34–44.", "answer": "Review of CBCT scan dated 251126. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 28: bone height ≈ 11.2 mm; implant space ≈ 4.5 mm; nearby structure: nasal floor. Region 36: bone height ≈ 9.2 mm; implant space ≈ 4.2 mm; nearby structure: mandibular canal. Region 46: bone height ≈ 11.2 mm; implant space ≈ 9.4 mm; nearby structure: sinus floor. Region 44: bone height ≈ 5.9 mm; implant space ≈ 1.0 mm; nearby structure: mental foramen. Region 11: bone height ≈ 18.0 mm; implant space ≈ 13.8 mm; nearby structure: mandibular canal. Region 45: bone height ≈ 7.6 mm; implant space ≈ 2.5 mm; nearby structure: mental foramen. Region 43: bone height ≈ 13.3 mm; implant space ≈ 10.0 mm; nearby structure: sinus floor. Region 15: bone height ≈ 20.7 mm; implant space ≈ 17.0 mm; nearby structure: mandibular canal. Region 16: bone height ≈ 17.2 mm; implant space ≈ 13.6 mm; nearby structure: sinus floor. Region 32: bone height ≈ 18.0 mm; implant space ≈ 15.7 mm; nearby structure: anterior loop. Maxillary sinus shows mild mucosal thickening bilaterally. Impression: Diffuse radiolucency with irregular margin near 17; correlate clinically."}
{"id": "case_0008", "images": ["images/placeholder_0008.png"], "question": "Planning for chronic sinusitis evaluation. Brief history/status: Duloxetine, Bufomix Easyhaler, Betolvex, Amlodipine, Insulin glargine, Metoprolol, Calcichew-D3. Desired treatment: Review the relationship between alveolar crest and mandibular canal in 16–26.", "answer": "Review of CBCT scan dated 210515. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 47: bone height ≈ 9.0 mm; implant space ≈ 3.9 mm; nearby structure: anterior loop. Region 18: bone height ≈ 19.5 mm; implant space ≈ 18.2 mm; nearby structure: mandibular canal. Region 15: bone height ≈ 16.0 mm; implant space ≈ 9.7 mm; nearby structure: mandibular canal. Region 14: bone height ≈ 11.7 mm; implant space ≈ 3.9 mm; nearby structure: sinus floor. Region 35: bone height ≈ 13.7 mm; implant space ≈ 5.9 mm; nearby structure: anterior loop. Region 23: bone height ≈ 21.0 mm; implant space ≈ 13.0 mm; nearby structure: mental foramen. Region 11: bone height ≈ 6.8 mm; implant space ≈ 5.8 mm; nearby structure: nasal floor. Region 34: bone height ≈ 19.4 mm; implant space ≈ 16.5 mm; nearby structure: mental foramen. Region 37: bone height ≈ 10.7 mm; implant space ≈ 3.8 mm; nearby structure: anterior loop. Region 38: bone height ≈ 8.0 mm; implant space ≈ 3.0 mm; nearby structure: mental foramen. Periapical radiolucency visible at 31, additional smaller lesion near 18. Impression: Adequate bone density throughout; implant feasible without augmentation."}
{"id": "case_0009", "images": ["images/placeholder_0009.png"], "question": "Planning for pre-implant radiological mapping. Brief history/status: Trulicity, Metoprolol, Duloxetine, Esomeprazole, Levaxin, Atorvastatin, Calcichew-D3. Desired treatment: Assess implant site quality and need for sinus lift or graft in 14–24.", "answer": "Review of CBCT scan dated 230824. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 13: bone height ≈ 7.1 mm; implant space ≈ 3.0 mm; nearby structure: anterior loop. Region 42: bone height ≈ 19.6 mm; implant space ≈ 11.7 mm; nearby structure: sinus floor. Region 37: bone height ≈ 4.5 mm; implant space ≈ 0.2 mm; nearby structure: nasal floor. Region 24: bone height ≈ 5.1 mm; implant space ≈ 0.4 mm; nearby structure: nasal floor. Region 44: bone height ≈ 5.3 mm; implant space ≈ 3.9 mm; nearby structure: mental foramen. Region 27: bone height ≈ 10.9 mm; implant space ≈ 5.2 mm; nearby structure: sinus floor. Region 12: bone height ≈ 10.1 mm; implant space ≈ 7.5 mm; nearby structure: mandibular canal. Region 14: bone height ≈ 16.2 mm; implant space ≈ 11.7 mm; nearby structure: sinus floor. Region 22: bone height ≈ 13.9 mm; implant space ≈ 10.7 mm; nearby structure: anterior loop. Region 32: bone height ≈ 16.8 mm; implant space ≈ 9.2 mm; nearby structure: sinus floor. Periapical radiolucency visible at 27, additional smaller lesion near 48. Impression: Diffuse radiolucency with irregular margin near 25; correlate clinically."}
{"id": "case_0010", "images": ["images/placeholder_0010.png"], "question": "Planning for assessment of residual ridge. Brief history/status: Duloxetine, Esomeprazole, Levaxin, Bufomix Easyhaler, Metoprolol, Losartan, Bricanyl, Betolvex. Desired treatment: Assess sinus membrane integrity and bone height for implant feasibility in 14–24.", "answer": "Review of CBCT scan dated 240610. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 25: bone height ≈ 17.5 mm; implant space ≈ 13.0 mm; nearby structure: sinus floor. Region 44: bone height ≈ 14.3 mm; implant space ≈ 10.9 mm; nearby structure: mental foramen. Region 12: bone height ≈ 6.9 mm; implant space ≈ 0.9 mm; nearby structure: nasal floor. Region 32: bone height ≈ 5.2 mm; implant space ≈ 0 mm; nearby structure: mental foramen. Region 41: bone height ≈ 8.7 mm; implant space ≈ 1.1 mm; nearby structure: sinus floor. Region 46: bone height ≈ 8.0 mm; implant space ≈ 1.8 mm; nearby structure: mental foramen. Region 33: bone height ≈ 17.8 mm; implant space ≈ 13.9 mm; nearby structure: mandibular canal. Region 38: bone height ≈ 16.3 mm; implant space ≈ 9.1 mm; nearby structure: mental foramen. Region 36: bone height ≈ 11.0 mm; implant space ≈ 9.5 mm; nearby structure: mental foramen. Region 28: bone height ≈ 17.5 mm; implant space ≈ 11.0 mm; nearby structure: sinus floor. Maxillary sinus shows mild mucosal thickening bilaterally. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Mild bone resorption near 35 and 11; stable post-surgical remodeling."}
{"id": "case_0011", "images": ["images/placeholder_0011.png"], "question": "Planning for pre-implant radiological mapping. Brief history/status: Betolvex, Bricanyl, Calcichew-D3, Duroferon, Losartan. Desired treatment: Check for apical radiolucency or infection in regions 46, 37, and 36.", "answer": "Review of CBCT scan dated 241126. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 45: bone height ≈ 7.6 mm; implant space ≈ 3.3 mm; nearby structure: mandibular canal. Region 16: bone height ≈ 12.8 mm; implant space ≈ 8.8 mm; nearby structure: anterior loop. Region 32: bone height ≈ 17.5 mm; implant space ≈ 12.0 mm; nearby structure: anterior loop. Region 11: bone height ≈ 14.4 mm; implant space ≈ 12.0 mm; nearby structure: mandibular canal. Region 38: bone height ≈ 7.3 mm; implant space ≈ 0.2 mm; nearby structure: mental foramen. Region 21: bone height ≈ 10.4 mm; implant space ≈ 7.5 mm; nearby structure: nasal floor. Region 36: bone height ≈ 10.1 mm; implant space ≈ 3.6 mm; nearby structure: anterior loop. Region 22: bone height ≈ 13.9 mm; implant space ≈ 10.9 mm; nearby structure: mandibular canal. Region 35: bone height ≈ 21.0 mm; implant space ≈ 13.2 mm; nearby structure: mandibular canal. Region 17: bone height ≈ 5.7 mm; implant space ≈ 0 mm; nearby structure: mandibular canal. Maxillary sinus shows mild mucosal thickening bilaterally. Periapical radiolucency visible at 25, additional smaller lesion near 11. Impression: Findings indicate sufficient bone height with mild sinus mucosal thickening."}
{"id": "case_0012", "images": ["images/placeholder_0012.png"], "question": "Planning for chronic sinusitis evaluation. Brief history/status: Betolvex, Calcichew-D3, Losartan, Insulin glargine, Metoprolol, Duloxetine, Amlodipine, Atorvastatin. Desired treatment: Provide detailed bone mapping and canal proximity data for 33–43.", "answer": "Review of CBCT scan dated 250311. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 44: bone height ≈ 7.9 mm; implant space ≈ 4.4 mm; nearby structure: mandibular canal. Region 15: bone height ≈ 12.6 mm; implant space ≈ 5.5 mm; nearby structure: sinus floor. Region 26: bone height ≈ 6.9 mm; implant space ≈ 4.4 mm; nearby structure: sinus floor. Region 25: bone height ≈ 20.8 mm; implant space ≈ 16.0 mm; nearby structure: sinus floor. Region 13: bone height ≈ 17.2 mm; implant space ≈ 15.3 mm; nearby structure: anterior loop. Region 48: bone height ≈ 10.9 mm; implant space ≈ 7.4 mm; nearby structure: nasal floor. Region 42: bone height ≈ 8.0 mm; implant space ≈ 3.4 mm; nearby structure: anterior loop. Region 11: bone height ≈ 11.0 mm; implant space ≈ 3.3 mm; nearby structure: mandibular canal. Region 17: bone height ≈ 16.7 mm; implant space ≈ 10.3 mm; nearby structure: mandibular canal. Region 32: bone height ≈ 6.9 mm; implant space ≈ 0.8 mm; nearby structure: nasal floor. Periapical radiolucency visible at 11, additional smaller lesion near 15. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: No radiographic evidence of acute infection or pathology detected."}
{"id": "case_0013", "images": ["images/placeholder_0013.png"], "question": "Planning for implant placement verification. Brief history/status: Omeprazole, Duroferon, Esomeprazole, Metoprolol, Bufomix Easyhaler, Amlodipine. Desired treatment: Provide detailed bone mapping and canal proximity data for 33–43.", "answer": "Review of CBCT scan dated 220508. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 45: bone height ≈ 9.4 mm; implant space ≈ 6.1 mm; nearby structure: mandibular canal. Region 26: bone height ≈ 9.1 mm; implant space ≈ 6.9 mm; nearby structure: mandibular canal. Region 37: bone height ≈ 13.5 mm; implant space ≈ 12.2 mm; nearby structure: mandibular canal. Region 14: bone height ≈ 6.6 mm; implant space ≈ 1.5 mm; nearby structure: mental foramen. Region 12: bone height ≈ 12.3 mm; implant space ≈ 10.7 mm; nearby structure: mandibular canal. Region 17: bone height ≈ 6.2 mm; implant space ≈ 4.7 mm; nearby structure: nasal floor. Region 21: bone height ≈ 7.0 mm; implant space ≈ 4.9 mm; nearby structure: nasal floor. Region 43: bone height ≈ 7.8 mm; implant space ≈ 2.1 mm; nearby structure: anterior loop. Region 23: bone height ≈ 6.2 mm; implant space ≈ 4.9 mm; nearby structure: anterior loop. Region 32: bone height ≈ 19.5 mm; implant space ≈ 16.8 mm; nearby structure: mandibular canal. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Cystic lesion in posterior mandible region 27, likely odontogenic cyst."}
{"id": "case_0014", "images": ["images/placeholder_0014.png"], "question": "Planning for implant placement verification. Brief history/status: Omeprazole, Amlodipine, Losartan, Trulicity, Calcichew-D3, Atorvastatin, Insulin glargine, Levaxin. Desired treatment: Assess sinus membrane integrity and bone height for implant feasibility in 36–46.", "answer": "Review of CBCT scan dated 220528. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 48: bone height ≈ 20.0 mm; implant space ≈ 12.7 mm; nearby structure: mental foramen. Region 42: bone height ≈ 6.3 mm; implant space ≈ 0 mm; nearby structure: nasal floor. Region 26: bone height ≈ 19.1 mm; implant space ≈ 12.9 mm; nearby structure: anterior loop. Region 32: bone height ≈ 12.3 mm; implant space ≈ 4.5 mm; nearby structure: anterior loop. Region 13: bone height ≈ 15.7 mm; implant space ≈ 14.5 mm; nearby structure: anterior loop. Region 24: bone height ≈ 19.3 mm; implant space ≈ 17.3 mm; nearby structure: anterior loop. Region 33: bone height ≈ 17.0 mm; implant space ≈ 10.9 mm; nearby structure: mandibular canal. Region 18: bone height ≈ 18.6 mm; implant space ≈ 13.6 mm; nearby structure: nasal floor. Region 16: bone height ≈ 5.7 mm; implant space ≈ 2.1 mm; nearby structure: nasal floor. Region 35: bone height ≈ 6.6 mm; implant space ≈ 5.1 mm; nearby structure: sinus floor. Periapical radiolucency visible at 35, additional smaller lesion near 14. Impression: Chronic apical periodontitis noted at 13 and 36; recommend endodontic consultation."}
{"id": "case_0015", "images": ["images/placeholder_0015.png"], "question": "Planning for pre-implant radiological mapping. Brief history/status: Losartan, Duroferon, Bricanyl, Bufomix Easyhaler, Esomeprazole, Atorvastatin. Desired treatment: Please analyze bone height, width, and proximity to critical anatomy across 13–23 and 14–24.", "answer": "Review of CBCT scan dated 250422. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 37: bone height ≈ 4.2 mm; implant space ≈ 0 mm; nearby structure: sinus floor. Region 41: bone height ≈ 13.6 mm; implant space ≈ 8.9 mm; nearby structure: mandibular canal. Region 15: bone height ≈ 7.9 mm; implant space ≈ 5.7 mm; nearby structure: sinus floor. Region 45: bone height ≈ 7.6 mm; implant space ≈ 2.1 mm; nearby structure: nasal floor. Region 44: bone height ≈ 12.1 mm; implant space ≈ 4.2 mm; nearby structure: nasal floor. Region 25: bone height ≈ 15.5 mm; implant space ≈ 13.7 mm; nearby structure: nasal floor. Region 32: bone height ≈ 19.8 mm; implant space ≈ 17.1 mm; nearby structure: mental foramen. Region 22: bone height ≈ 17.1 mm; implant space ≈ 12.9 mm; nearby structure: sinus floor. Region 35: bone height ≈ 15.6 mm; implant space ≈ 10.6 mm; nearby structure: nasal floor. Region 36: bone height ≈ 11.7 mm; implant space ≈ 9.7 mm; nearby structure: mandibular canal. Periapical radiolucency visible at 16, additional smaller lesion near 17. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Mild bone resorption near 47 and 43; stable post-surgical remodeling."}
{"id": "case_0016", "images": ["images/placeholder_0016.png"], "question": "Planning for pre-implant radiological mapping. Brief history/status: Bricanyl, Betolvex, Insulin glargine, Esomeprazole, Amlodipine. Desired treatment: Review the relationship between alveolar crest and mandibular canal in 36–46.", "answer": "Review of CBCT scan dated 251008. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 18: bone height ≈ 20.2 mm; implant space ≈ 14.5 mm; nearby structure: anterior loop. Region 44: bone height ≈ 19.8 mm; implant space ≈ 15.9 mm; nearby structure: mandibular canal. Region 33: bone height ≈ 6.6 mm; implant space ≈ 1.1 mm; nearby structure: mental foramen. Region 15: bone height ≈ 13.4 mm; implant space ≈ 7.6 mm; nearby structure: mental foramen. Region 24: bone height ≈ 20.6 mm; implant space ≈ 12.8 mm; nearby structure: mandibular canal. Region 47: bone height ≈ 4.6 mm; implant space ≈ 3.1 mm; nearby structure: mandibular canal. Region 45: bone height ≈ 10.8 mm; implant space ≈ 4.5 mm; nearby structure: sinus floor. Region 23: bone height ≈ 6.7 mm; implant space ≈ 1.2 mm; nearby structure: nasal floor. Region 42: bone height ≈ 7.1 mm; implant space ≈ 1.0 mm; nearby structure: mandibular canal. Region 14: bone height ≈ 18.9 mm; implant space ≈ 12.7 mm; nearby structure: mandibular canal. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Chronic apical periodontitis noted at 22 and 31; recommend endodontic consultation."}
{"id": "case_0017", "images": ["images/placeholder_0017.png"], "question": "Planning for implant planning and sinus evaluation. Brief history/status: Bufomix Easyhaler, Calcichew-D3, Esomeprazole, Betolvex, Insulin glargine, Amlodipine. Desired treatment: Please analyze bone height, width, and proximity to critical anatomy across 33–43 and 34–44.", "answer": "Review of CBCT scan dated 230227. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 32: bone height ≈ 18.4 mm; implant space ≈ 15.1 mm; nearby structure: mandibular canal. Region 36: bone height ≈ 7.8 mm; implant space ≈ 5.3 mm; nearby structure: sinus floor. Region 47: bone height ≈ 8.7 mm; implant space ≈ 2.8 mm; nearby structure: anterior loop. Region 42: bone height ≈ 21.0 mm; implant space ≈ 18.8 mm; nearby structure: nasal floor. Region 24: bone height ≈ 8.6 mm; implant space ≈ 4.6 mm; nearby structure: anterior loop. Region 12: bone height ≈ 18.3 mm; implant space ≈ 13.3 mm; nearby structure: anterior loop. Region 43: bone height ≈ 5.1 mm; implant space ≈ 0.9 mm; nearby structure: nasal floor. Region 18: bone height ≈ 7.5 mm; implant space ≈ 1.9 mm; nearby structure: sinus floor. Region 35: bone height ≈ 12.1 mm; implant space ≈ 7.3 mm; nearby structure: sinus floor. Region 16: bone height ≈ 6.4 mm; implant space ≈ 4.5 mm; nearby structure: sinus floor. Maxillary sinus shows mild mucosal thickening bilaterally. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Diffuse radiolucency with irregular margin near 12; correlate clinically."}
{"id": "case_0018", "images": ["images/placeholder_0018.png"], "question": "Planning for assessment of residual ridge. Brief history/status: Betolvex, Esomeprazole, Amlodipine, Bricanyl, Bufomix Easyhaler. Desired treatment: Please analyze bone height, width, and proximity to critical anatomy across 33–43 and 36–46.", "answer": "Review of CBCT scan dated 250812. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 21: bone height ≈ 19.6 mm; implant space ≈ 12.6 mm; nearby structure: sinus floor. Region 18: bone height ≈ 15.3 mm; implant space ≈ 8.3 mm; nearby structure: mental foramen. Region 28: bone height ≈ 13.5 mm; implant space ≈ 8.7 mm; nearby structure: mandibular canal. Region 41: bone height ≈ 16.7 mm; implant space ≈ 11.4 mm; nearby structure: mental foramen. Region 22: bone height ≈ 4.7 mm; implant space ≈ 0 mm; nearby structure: nasal floor. Region 25: bone height ≈ 8.2 mm; implant space ≈ 4.8 mm; nearby structure: anterior loop. Region 11: bone height ≈ 22.0 mm; implant space ≈ 14.3 mm; nearby structure: nasal floor. Region 43: bone height ≈ 6.0 mm; implant space ≈ 4.3 mm; nearby structure: nasal floor. Region 23: bone height ≈ 18.8 mm; implant space ≈ 15.0 mm; nearby structure: mental foramen. Region 44: bone height ≈ 7.4 mm; implant space ≈ 1.3 mm; nearby structure: mandibular canal. Maxillary sinus shows mild mucosal thickening bilaterally. Periapical radiolucency visible at 26, additional smaller lesion near 16. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Chronic apical periodontitis noted at 36 and 41; recommend endodontic consultation."}
{"id": "case_0019", "images": ["images/placeholder_0019.png"], "question": "Planning for assessment of residual ridge. Brief history/status: Duloxetine, Bufomix Easyhaler, Atorvastatin, Duroferon, Betolvex, Amlodipine, Omeprazole, Trulicity. Desired treatment: Check for apical radiolucency or infection in regions 16, 13, and 41.", "answer": "Review of CBCT scan dated 250403. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 12: bone height ≈ 5.5 mm; implant space ≈ 3.1 mm; nearby structure: mental foramen. Region 37: bone height ≈ 18.1 mm; implant space ≈ 16.0 mm; nearby structure: sinus floor. Region 45: bone height ≈ 14.1 mm; implant space ≈ 9.1 mm; nearby structure: sinus floor. Region 15: bone height ≈ 9.0 mm; implant space ≈ 7.2 mm; nearby structure: mandibular canal. Region 41: bone height ≈ 13.1 mm; implant space ≈ 5.8 mm; nearby structure: nasal floor. Region 34: bone height ≈ 17.9 mm; implant space ≈ 15.2 mm; nearby structure: mandibular canal. Region 47: bone height ≈ 15.5 mm; implant space ≈ 13.1 mm; nearby structure: anterior loop. Region 35: bone height ≈ 5.8 mm; implant space ≈ 0 mm; nearby structure: anterior loop. Region 17: bone height ≈ 20.6 mm; implant space ≈ 13.3 mm; nearby structure: mandibular canal. Region 27: bone height ≈ 4.2 mm; implant space ≈ 2.6 mm; nearby structure: sinus floor. Maxillary sinus shows mild mucosal thickening bilaterally. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Adequate bone density throughout; implant feasible without augmentation."}
{"id": "case_0020", "images": ["images/placeholder_0020.png"], "question": "Planning for follow-up after implant restoration. Brief history/status: Bufomix Easyhaler, Bricanyl, Atorvastatin, Betolvex, Metoprolol. Desired treatment: Assess sinus membrane integrity and bone height for implant feasibility in 16–26.", "answer": "Review of CBCT scan dated 240302. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 28: bone height ≈ 17.4 mm; implant space ≈ 9.4 mm; nearby structure: mandibular canal. Region 44: bone height ≈ 19.5 mm; implant space ≈ 15.6 mm; nearby structure: mandibular canal. Region 22: bone height ≈ 16.0 mm; implant space ≈ 14.0 mm; nearby structure: sinus floor. Region 43: bone height ≈ 10.2 mm; implant space ≈ 8.9 mm; nearby structure: nasal floor. Region 36: bone height ≈ 6.4 mm; implant space ≈ 1.0 mm; nearby structure: mental foramen. Region 23: bone height ≈ 8.3 mm; implant space ≈ 3.3 mm; nearby structure: mandibular canal. Region 41: bone height ≈ 7.0 mm; implant space ≈ 2.6 mm; nearby structure: mental foramen. Region 24: bone height ≈ 15.7 mm; implant space ≈ 12.5 mm; nearby structure: mental foramen. Region 25: bone height ≈ 13.1 mm; implant space ≈ 11.0 mm; nearby structure: sinus floor. Region 37: bone height ≈ 5.9 mm; implant space ≈ 0.7 mm; nearby structure: sinus floor. Maxillary sinus shows mild mucosal thickening bilaterally. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Mild bone resorption near 27 and 36; stable post-surgical remodeling."}
{"id": "case_0021", "images": ["images/placeholder_0021.png"], "question": "Planning for implant placement verification. Brief history/status: Amlodipine, Esomeprazole, Duloxetine, Omeprazole, Metoprolol, Bufomix Easyhaler, Betolvex, Duroferon. Desired treatment: Evaluate cortical thickness and spongy bone quality in 16–26.", "answer": "Review of CBCT scan dated 211025. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 24: bone height ≈ 16.0 mm; implant space ≈ 12.3 mm; nearby structure: sinus floor. Region 38: bone height ≈ 11.9 mm; implant space ≈ 4.0 mm; nearby structure: nasal floor. Region 28: bone height ≈ 13.3 mm; implant space ≈ 8.9 mm; nearby structure: mental foramen. Region 31: bone height ≈ 9.3 mm; implant space ≈ 8.3 mm; nearby structure: sinus floor. Region 34: bone height ≈ 6.0 mm; implant space ≈ 3.6 mm; nearby structure: nasal floor. Region 47: bone height ≈ 8.2 mm; implant space ≈ 2.4 mm; nearby structure: anterior loop. Region 21: bone height ≈ 13.2 mm; implant space ≈ 11.4 mm; nearby structure: sinus floor. Region 42: bone height ≈ 21.9 mm; implant space ≈ 20.8 mm; nearby structure: sinus floor. Region 26: bone height ≈ 13.2 mm; implant space ≈ 5.8 mm; nearby structure: sinus floor. Region 22: bone height ≈ 8.0 mm; implant space ≈ 4.9 mm; nearby structure: anterior loop. Maxillary sinus shows mild mucosal thickening bilaterally. Periapical radiolucency visible at 45, additional smaller lesion near 48. Impression: Mild bone resorption near 17 and 33; stable post-surgical remodeling."}
{"id": "case_0022", "images": ["images/placeholder_0022.png"], "question": "Planning for implant placement verification. Brief history/status: Omeprazole, Duroferon, Trulicity, Insulin glargine, Losartan, Bricanyl. Desired treatment: Review the relationship between alveolar crest and mandibular canal in 36–46.", "answer": "Review of CBCT scan dated 221212. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 11: bone height ≈ 8.9 mm; implant space ≈ 2.4 mm; nearby structure: anterior loop. Region 16: bone height ≈ 18.3 mm; implant space ≈ 10.6 mm; nearby structure: anterior loop. Region 41: bone height ≈ 11.4 mm; implant space ≈ 9.1 mm; nearby structure: anterior loop. Region 37: bone height ≈ 7.9 mm; implant space ≈ 5.8 mm; nearby structure: nasal floor. Region 21: bone height ≈ 17.1 mm; implant space ≈ 15.2 mm; nearby structure: mandibular canal. Region 24: bone height ≈ 12.4 mm; implant space ≈ 5.9 mm; nearby structure: mandibular canal. Region 31: bone height ≈ 18.1 mm; implant space ≈ 16.5 mm; nearby structure: sinus floor. Region 46: bone height ≈ 6.3 mm; implant space ≈ 4.6 mm; nearby structure: mental foramen. Region 12: bone height ≈ 21.0 mm; implant space ≈ 16.7 mm; nearby structure: nasal floor. Region 25: bone height ≈ 12.1 mm; implant space ≈ 10.5 mm; nearby structure: mental foramen. Maxillary sinus shows mild mucosal thickening bilaterally. Impression: Cystic lesion in posterior mandible region 44, likely odontogenic cyst."}
{"id": "case_0023", "images": ["images/placeholder_0023.png"], "question": "Planning for assessment of residual ridge. Brief history/status: Atorvastatin, Esomeprazole, Metoprolol, Duloxetine, Duroferon. Desired treatment: Provide detailed bone mapping and canal proximity data for 34–44.", "answer": "Review of CBCT scan dated 251027. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 42: bone height ≈ 16.7 mm; implant space ≈ 14.4 mm; nearby structure: nasal floor. Region 26: bone height ≈ 17.9 mm; implant space ≈ 12.6 mm; nearby structure: sinus floor. Region 48: bone height ≈ 9.2 mm; implant space ≈ 5.3 mm; nearby structure: mandibular canal. Region 43: bone height ≈ 16.1 mm; implant space ≈ 10.1 mm; nearby structure: mandibular canal. Region 18: bone height ≈ 13.7 mm; implant space ≈ 8.7 mm; nearby structure: sinus floor. Region 15: bone height ≈ 20.2 mm; implant space ≈ 19.0 mm; nearby structure: mental foramen. Region 36: bone height ≈ 4.8 mm; implant space ≈ 0 mm; nearby structure: mental foramen. Region 11: bone height ≈ 20.4 mm; implant space ≈ 17.2 mm; nearby structure: anterior loop. Region 33: bone height ≈ 19.8 mm; implant space ≈ 14.8 mm; nearby structure: mental foramen. Region 21: bone height ≈ 6.3 mm; implant space ≈ 0.2 mm; nearby structure: mental foramen. Maxillary sinus shows mild mucosal thickening bilaterally. Impression: Residual ridge height insufficient in 37; sinus lift recommended."}
{"id": "case_0024", "images": ["images/placeholder_0024.png"], "question": "Planning for bone density and height measurement. Brief history/status: Duroferon, Trulicity, Esomeprazole, Bufomix Easyhaler, Insulin glargine, Amlodipine, Omeprazole. Desired treatment: Assess sinus membrane integrity and bone height for implant feasibility in 33–43.", "answer": "Review of CBCT scan dated 200921. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 24: bone height ≈ 12.6 mm; implant space ≈ 6.4 mm; nearby structure: mental foramen. Region 13: bone height ≈ 4.4 mm; implant space ≈ 3.0 mm; nearby structure: mandibular canal. Region 21: bone height ≈ 10.4 mm; implant space ≈ 7.6 mm; nearby structure: mental foramen. Region 34: bone height ≈ 4.1 mm; implant space ≈ 1.0 mm; nearby structure: mental foramen. Region 44: bone height ≈ 12.7 mm; implant space ≈ 7.0 mm; nearby structure: anterior loop. Region 43: bone height ≈ 13.2 mm; implant space ≈ 11.4 mm; nearby structure: anterior loop. Region 38: bone height ≈ 12.4 mm; implant space ≈ 11.1 mm; nearby structure: mandibular canal. Region 15: bone height ≈ 21.6 mm; implant space ≈ 19.3 mm; nearby structure: sinus floor. Region 12: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby structure: nasal floor. Region 27: bone height ≈ 9.6 mm; implant space ≈ 7.2 mm; nearby structure: mandibular canal. Periapical radiolucency visible at 12, additional smaller lesion near 24. Impression: Cystic lesion in posterior mandible region 28, likely odontogenic cyst."}
{"id": "case_0025", "images": ["images/placeholder_0025.png"], "question": "Planning for assessment of residual ridge. Brief history/status: Trulicity, Bricanyl, Esomeprazole, Duroferon, Levaxin, Betolvex, Amlodipine, Metoprolol. Desired treatment: Assess implant site quality and need for sinus lift or graft in 36–46.", "answer": "Review of CBCT scan dated 241113. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 12: bone height ≈ 4.9 mm; implant space ≈ 3.7 mm; nearby structure: sinus floor. Region 34: bone height ≈ 17.9 mm; implant space ≈ 10.7 mm; nearby structure: mandibular canal. Region 27: bone height ≈ 16.5 mm; implant space ≈ 14.9 mm; nearby structure: sinus floor. Region 44: bone height ≈ 10.0 mm; implant space ≈ 6.8 mm; nearby structure: mental foramen. Region 11: bone height ≈ 17.3 mm; implant space ≈ 13.4 mm; nearby structure: mandibular canal. Region 18: bone height ≈ 18.8 mm; implant space ≈ 12.3 mm; nearby structure: sinus floor. Region 17: bone height ≈ 10.6 mm; implant space ≈ 4.1 mm; nearby structure: sinus floor. Region 25: bone height ≈ 20.8 mm; implant space ≈ 18.6 mm; nearby structure: anterior loop. Region 42: bone height ≈ 5.7 mm; implant space ≈ 4.2 mm; nearby structure: sinus floor. Region 22: bone height ≈ 13.7 mm; implant space ≈ 10.8 mm; nearby structure: nasal floor. Maxillary sinus shows mild mucosal thickening bilaterally. Impression: Peri-implant bone loss at 37 consistent with early peri-implantitis."}
{"id": "case_0026", "images": ["images/placeholder_0026.png"], "question": "Planning for chronic sinusitis evaluation. Brief history/status: Bufomix Easyhaler, Calcichew-D3, Atorvastatin, Trulicity, Metoprolol, Betolvex, Levaxin. Desired treatment: Please analyze bone height, width, and proximity to critical anatomy across 16–26 and 14–24.", "answer": "Review of CBCT scan dated 220410. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 48: bone height ≈ 11.9 mm; implant space ≈ 6.7 mm; nearby structure: mandibular canal. Region 31: bone height ≈ 5.0 mm; implant space ≈ 1.1 mm; nearby structure: nasal floor. Region 37: bone height ≈ 7.0 mm; implant space ≈ 4.8 mm; nearby structure: mandibular canal. Region 44: bone height ≈ 14.0 mm; implant space ≈ 9.2 mm; nearby structure: mental foramen. Region 47: bone height ≈ 13.6 mm; implant space ≈ 6.6 mm; nearby structure: anterior loop. Region 15: bone height ≈ 6.2 mm; implant space ≈ 3.5 mm; nearby structure: sinus floor. Region 21: bone height ≈ 7.4 mm; implant space ≈ 0.9 mm; nearby structure: mental foramen. Region 35: bone height ≈ 19.2 mm; implant space ≈ 12.4 mm; nearby structure: sinus floor. Region 43: bone height ≈ 9.0 mm; implant space ≈ 6.0 mm; nearby structure: mandibular canal. Region 11: bone height ≈ 14.9 mm; implant space ≈ 12.5 mm; nearby structure: mandibular canal. Maxillary sinus shows mild mucosal thickening bilaterally. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Residual ridge height insufficient in 37; sinus lift recommended."}
{"id": "case_0027", "images": ["images/placeholder_0027.png"], "question": "Planning for bone density and height measurement. Brief history/status: Amlodipine, Esomeprazole, Betolvex, Bricanyl, Duroferon, Atorvastatin. Desired treatment: Assess sinus membrane integrity and bone height for implant feasibility in 14–24.", "answer": "Review of CBCT scan dated 230624. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 23: bone height ≈ 6.0 mm; implant space ≈ 3.2 mm; nearby structure: mental foramen. Region 28: bone height ≈ 19.8 mm; implant space ≈ 17.0 mm; nearby structure: nasal floor. Region 22: bone height ≈ 20.6 mm; implant space ≈ 13.5 mm; nearby structure: sinus floor. Region 25: bone height ≈ 13.6 mm; implant space ≈ 7.2 mm; nearby structure: sinus floor. Region 34: bone height ≈ 5.2 mm; implant space ≈ 0.3 mm; nearby structure: mental foramen. Region 16: bone height ≈ 10.3 mm; implant space ≈ 5.8 mm; nearby structure: mandibular canal. Region 36: bone height ≈ 7.8 mm; implant space ≈ 4.9 mm; nearby structure: mandibular canal. Region 32: bone height ≈ 8.3 mm; implant space ≈ 6.3 mm; nearby structure: mandibular canal. Region 38: bone height ≈ 7.3 mm; implant space ≈ 0.8 mm; nearby structure: anterior loop. Region 18: bone height ≈ 14.7 mm; implant space ≈ 13.6 mm; nearby structure: mental foramen. Maxillary sinus shows mild mucosal thickening bilaterally. Impression: Normal trabecular pattern observed; cortical plates intact."}
{"id": "case_0028", "images": ["images/placeholder_0028.png"], "question": "Planning for follow-up after implant restoration. Brief history/status: Amlodipine, Duroferon, Omeprazole, Bufomix Easyhaler, Betolvex, Insulin glargine, Trulicity. Desired treatment: Quantify bone resorption and density changes across 13–23.", "answer": "Review of CBCT scan dated 200809. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 27: bone height ≈ 7.3 mm; implant space ≈ 5.9 mm; nearby structure: mental foramen. Region 47: bone height ≈ 13.5 mm; implant space ≈ 5.7 mm; nearby structure: mandibular canal. Region 11: bone height ≈ 11.5 mm; implant space ≈ 9.2 mm; nearby structure: nasal floor. Region 22: bone height ≈ 20.4 mm; implant space ≈ 15.4 mm; nearby structure: sinus floor. Region 12: bone height ≈ 16.3 mm; implant space ≈ 12.4 mm; nearby structure: anterior loop. Region 16: bone height ≈ 18.4 mm; implant space ≈ 14.2 mm; nearby structure: sinus floor. Region 32: bone height ≈ 20.0 mm; implant space ≈ 13.0 mm; nearby structure: sinus floor. Region 24: bone height ≈ 18.4 mm; implant space ≈ 12.1 mm; nearby structure: nasal floor. Region 48: bone height ≈ 16.9 mm; implant space ≈ 15.7 mm; nearby structure: anterior loop. Region 14: bone height ≈ 16.7 mm; implant space ≈ 11.2 mm; nearby structure: nasal floor. Maxillary sinus shows mild mucosal thickening bilaterally. Periapical radiolucency visible at 43, additional smaller lesion near 25. Impression: Normal trabecular pattern observed; cortical plates intact."}
{"id": "case_0029", "images": ["images/placeholder_0029.png"], "question": "Planning for bone grafting assessment. Brief history/status: Levaxin, Bricanyl, Amlodipine, Esomeprazole, Metoprolol. Desired treatment: Check for apical radiolucency or infection in regions 45, 12, and 27.", "answer": "Review of CBCT scan dated 240804. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 13: bone height ≈ 5.6 mm; implant space ≈ 2.4 mm; nearby structure: mandibular canal. Region 47: bone height ≈ 5.9 mm; implant space ≈ 0 mm; nearby structure: mandibular canal. Region 16: bone height ≈ 14.9 mm; implant space ≈ 12.4 mm; nearby structure: anterior loop. Region 33: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby structure: nasal floor. Region 42: bone height ≈ 21.9 mm; implant space ≈ 19.0 mm; nearby structure: mandibular canal. Region 32: bone height ≈ 15.2 mm; implant space ≈ 10.5 mm; nearby structure: sinus floor. Region 48: bone height ≈ 7.9 mm; implant space ≈ 0.8 mm; nearby structure: sinus floor. Region 41: bone height ≈ 9.3 mm; implant space ≈ 7.3 mm; nearby structure: mental foramen. Region 18: bone height ≈ 12.6 mm; implant space ≈ 5.3 mm; nearby structure: nasal floor. Region 12: bone height ≈ 16.1 mm; implant space ≈ 11.1 mm; nearby structure: mandibular canal. Maxillary sinus shows mild mucosal thickening bilaterally. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Peri-implant bone loss at 36 consistent with early peri-implantitis."}
{"id": "case_0030", "images": ["images/placeholder_0030.png"], "question": "Planning for follow-up after implant restoration. Brief history/status: Losartan, Atorvastatin, Levaxin, Duloxetine, Bricanyl, Betolvex, Amlodipine, Bufomix Easyhaler. Desired treatment: Measure vertical height from alveolar crest to anatomical constraints for 14–24.", "answer": "Review of CBCT scan dated 210907. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 33: bone height ≈ 5.2 mm; implant space ≈ 1.9 mm; nearby structure: sinus floor. Region 15: bone height ≈ 6.8 mm; implant space ≈ 4.4 mm; nearby structure: sinus floor. Region 47: bone height ≈ 16.5 mm; implant space ≈ 9.5 mm; nearby structure: sinus floor. Region 26: bone height ≈ 17.4 mm; implant space ≈ 13.2 mm; nearby structure: mental foramen. Region 31: bone height ≈ 19.7 mm; implant space ≈ 12.6 mm; nearby structure: mandibular canal. Region 36: bone height ≈ 11.9 mm; implant space ≈ 4.0 mm; nearby structure: mental foramen. Region 18: bone height ≈ 7.4 mm; implant space ≈ 5.3 mm; nearby structure: mental foramen. Region 23: bone height ≈ 14.3 mm; implant space ≈ 6.9 mm; nearby structure: anterior loop. Region 44: bone height ≈ 11.9 mm; implant space ≈ 4.6 mm; nearby structure: anterior loop. Region 14: bone height ≈ 10.0 mm; implant space ≈ 4.7 mm; nearby structure: anterior loop. Maxillary sinus shows mild mucosal thickening bilaterally. Impression: Findings indicate sufficient bone height with mild sinus mucosal thickening."}
{"id": "case_0031", "images": ["images/placeholder_0031.png"], "question": "Planning for implant placement verification. Brief history/status: Amlodipine, Duloxetine, Esomeprazole, Calcichew-D3, Trulicity, Levaxin, Atorvastatin. Desired treatment: Check for apical radiolucency or infection in regions 48, 35, and 18.", "answer": "Review of CBCT scan dated 231228. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 36: bone height ≈ 7.4 mm; implant space ≈ 0 mm; nearby structure: anterior loop. Region 42: bone height ≈ 10.2 mm; implant space ≈ 8.5 mm; nearby structure: mandibular canal. Region 32: bone height ≈ 16.3 mm; implant space ≈ 9.0 mm; nearby structure: anterior loop. Region 41: bone height ≈ 17.2 mm; implant space ≈ 10.5 mm; nearby structure: anterior loop. Region 25: bone height ≈ 16.9 mm; implant space ≈ 12.8 mm; nearby structure: sinus floor. Region 23: bone height ≈ 7.0 mm; implant space ≈ 4.2 mm; nearby structure: anterior loop. Region 13: bone height ≈ 17.5 mm; implant space ≈ 16.0 mm; nearby structure: mental foramen. Region 31: bone height ≈ 17.5 mm; implant space ≈ 14.1 mm; nearby structure: mandibular canal. Region 33: bone height ≈ 6.5 mm; implant space ≈ 3.0 mm; nearby structure: sinus floor. Region 12: bone height ≈ 6.0 mm; implant space ≈ 1.7 mm; nearby structure: sinus floor. Maxillary sinus shows mild mucosal thickening bilaterally. Impression: Mild bone resorption near 28 and 38; stable post-surgical remodeling."}
{"id": "case_0032", "images": ["images/placeholder_0032.png"], "question": "Planning for assessment of residual ridge. Brief history/status: Duloxetine, Amlodipine, Bufomix Easyhaler, Duroferon, Insulin glargine, Trulicity, Bricanyl, Calcichew-D3. Desired treatment: Quantify bone resorption and density changes across 36–46.", "answer": "Review of CBCT scan dated 200209. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 16: bone height ≈ 9.7 mm; implant space ≈ 6.6 mm; nearby structure: nasal floor. Region 43: bone height ≈ 4.8 mm; implant space ≈ 0 mm; nearby structure: mandibular canal. Region 46: bone height ≈ 12.8 mm; implant space ≈ 10.3 mm; nearby structure: mandibular canal. Region 15: bone height ≈ 11.6 mm; implant space ≈ 8.5 mm; nearby structure: anterior loop. Region 28: bone height ≈ 19.5 mm; implant space ≈ 16.2 mm; nearby structure: nasal floor. Region 21: bone height ≈ 11.8 mm; implant space ≈ 9.1 mm; nearby structure: sinus floor. Region 35: bone height ≈ 14.3 mm; implant space ≈ 9.7 mm; nearby structure: anterior loop. Region 11: bone height ≈ 21.6 mm; implant space ≈ 16.4 mm; nearby structure: anterior loop. Region 36: bone height ≈ 13.5 mm; implant space ≈ 9.4 mm; nearby structure: sinus floor. Region 41: bone height ≈ 10.9 mm; implant space ≈ 4.7 mm; nearby structure: anterior loop. Periapical radiolucency visible at 14, additional smaller lesion near 12. Impression: Normal trabecular pattern observed; cortical plates intact."}
{"id": "case_0033", "images": ["images/placeholder_0033.png"], "question": "Planning for evaluation for prosthetic design. Brief history/status: Bricanyl, Bufomix Easyhaler, Amlodipine, Duloxetine, Betolvex, Losartan, Calcichew-D3, Trulicity. Desired treatment: Check for apical radiolucency or infection in regions 18, 14, and 38.", "answer": "Review of CBCT scan dated 240823. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 18: bone height ≈ 12.6 mm; implant space ≈ 8.7 mm; nearby structure: mental foramen. Region 38: bone height ≈ 9.6 mm; implant space ≈ 4.0 mm; nearby structure: mental foramen. Region 43: bone height ≈ 9.4 mm; implant space ≈ 4.0 mm; nearby structure: sinus floor. Region 22: bone height ≈ 10.5 mm; implant space ≈ 9.2 mm; nearby structure: sinus floor. Region 45: bone height ≈ 19.9 mm; implant space ≈ 16.8 mm; nearby structure: anterior loop. Region 42: bone height ≈ 18.9 mm; implant space ≈ 14.3 mm; nearby structure: mental foramen. Region 36: bone height ≈ 18.1 mm; implant space ≈ 12.7 mm; nearby structure: nasal floor. Region 24: bone height ≈ 10.1 mm; implant space ≈ 3.2 mm; nearby structure: anterior loop. Region 37: bone height ≈ 11.2 mm; implant space ≈ 9.8 mm; nearby structure: sinus floor. Region 25: bone height ≈ 6.1 mm; implant space ≈ 3.8 mm; nearby structure: anterior loop. Impression: Findings indicate sufficient bone height with mild sinus mucosal thickening."}
{"id": "case_0034", "images": ["images/placeholder_0034.png"], "question": "Planning for bone density and height measurement. Brief history/status: Bricanyl, Losartan, Bufomix Easyhaler, Betolvex, Atorvastatin, Levaxin, Metoprolol, Duloxetine. Desired treatment: Evaluate cortical thickness and spongy bone quality in 36–46.", "answer": "Review of CBCT scan dated 240517. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 47: bone height ≈ 17.1 mm; implant space ≈ 12.1 mm; nearby structure: sinus floor. Region 24: bone height ≈ 7.0 mm; implant space ≈ 2.9 mm; nearby structure: mental foramen. Region 16: bone height ≈ 21.8 mm; implant space ≈ 18.9 mm; nearby structure: mandibular canal. Region 34: bone height ≈ 10.1 mm; implant space ≈ 8.9 mm; nearby structure: mental foramen. Region 23: bone height ≈ 14.4 mm; implant space ≈ 6.7 mm; nearby structure: anterior loop. Region 32: bone height ≈ 16.0 mm; implant space ≈ 14.6 mm; nearby structure: anterior loop. Region 27: bone height ≈ 6.4 mm; implant space ≈ 0 mm; nearby structure: anterior loop. Region 46: bone height ≈ 14.0 mm; implant space ≈ 10.9 mm; nearby structure: mandibular canal. Region 36: bone height ≈ 17.0 mm; implant space ≈ 15.5 mm; nearby structure: nasal floor. Region 38: bone height ≈ 20.9 mm; implant space ≈ 13.6 mm; nearby structure: mandibular canal. Periapical radiolucency visible at 31, additional smaller lesion near 44. Impression: No radiographic evidence of acute infection or pathology detected."}
{"id": "case_0035", "images": ["images/placeholder_0035.png"], "question": "Planning for implant placement verification. Brief history/status: Trulicity, Betolvex, Levaxin, Amlodipine, Omeprazole, Metoprolol. Desired treatment: Measure available vertical height and ridge width in 36–46 and 16–26.", "answer": "Review of CBCT scan dated 200426. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 12: bone height ≈ 17.3 mm; implant space ≈ 12.6 mm; nearby structure: mandibular canal. Region 42: bone height ≈ 18.9 mm; implant space ≈ 11.3 mm; nearby structure: mental foramen. Region 28: bone height ≈ 15.7 mm; implant space ≈ 12.5 mm; nearby structure: sinus floor. Region 38: bone height ≈ 16.4 mm; implant space ≈ 14.6 mm; nearby structure: mental foramen. Region 22: bone height ≈ 4.6 mm; implant space ≈ 0 mm; nearby structure: mental foramen. Region 44: bone height ≈ 16.7 mm; implant space ≈ 11.1 mm; nearby structure: mandibular canal. Region 46: bone height ≈ 18.3 mm; implant space ≈ 15.3 mm; nearby structure: mandibular canal. Region 24: bone height ≈ 5.9 mm; implant space ≈ 0.9 mm; nearby structure: mandibular canal. Region 11: bone height ≈ 19.2 mm; implant space ≈ 12.9 mm; nearby structure: nasal floor. Region 17: bone height ≈ 11.3 mm; implant space ≈ 8.9 mm; nearby structure: nasal floor. Periapical radiolucency visible at 15, additional smaller lesion near 27. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: No radiographic evidence of acute infection or pathology detected."}
{"id": "case_0036", "images": ["images/placeholder_0036.png"], "question": "Planning for pre-implant radiological mapping. Brief history/status: Bricanyl, Calcichew-D3, Bufomix Easyhaler, Duroferon, Amlodipine, Esomeprazole, Losartan, Trulicity. Desired treatment: Review the relationship between alveolar crest and mandibular canal in 36–46.", "answer": "Review of CBCT scan dated 221123. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 14: bone height ≈ 5.3 mm; implant space ≈ 0 mm; nearby structure: sinus floor. Region 15: bone height ≈ 17.7 mm; implant space ≈ 14.9 mm; nearby structure: sinus floor. Region 25: bone height ≈ 13.8 mm; implant space ≈ 12.5 mm; nearby structure: sinus floor. Region 22: bone height ≈ 20.5 mm; implant space ≈ 12.7 mm; nearby structure: mandibular canal. Region 17: bone height ≈ 5.2 mm; implant space ≈ 0 mm; nearby structure: nasal floor. Region 31: bone height ≈ 9.9 mm; implant space ≈ 3.4 mm; nearby structure: nasal floor. Region 42: bone height ≈ 20.4 mm; implant space ≈ 18.5 mm; nearby structure: mandibular canal. Region 18: bone height ≈ 22.0 mm; implant space ≈ 16.8 mm; nearby structure: mandibular canal. Region 27: bone height ≈ 15.0 mm; implant space ≈ 12.7 mm; nearby structure: anterior loop. Region 41: bone height ≈ 4.2 mm; implant space ≈ 0 mm; nearby structure: nasal floor. Periapical radiolucency visible at 31, additional smaller lesion near 18. Impression: Normal trabecular pattern observed; cortical plates intact."}
{"id": "case_0037", "images": ["images/placeholder_0037.png"], "question": "Planning for implant placement verification. Brief history/status: Insulin glargine, Atorvastatin, Duloxetine, Omeprazole, Betolvex. Desired treatment: Review the relationship between alveolar crest and mandibular canal in 16–26.", "answer": "Review of CBCT scan dated 230621. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 45: bone height ≈ 10.2 mm; implant space ≈ 2.8 mm; nearby structure: mental foramen. Region 32: bone height ≈ 10.7 mm; implant space ≈ 3.5 mm; nearby structure: anterior loop. Region 34: bone height ≈ 11.0 mm; implant space ≈ 3.3 mm; nearby structure: sinus floor. Region 18: bone height ≈ 12.1 mm; implant space ≈ 4.1 mm; nearby structure: nasal floor. Region 27: bone height ≈ 6.3 mm; implant space ≈ 0.7 mm; nearby structure: anterior loop. Region 14: bone height ≈ 20.5 mm; implant space ≈ 16.9 mm; nearby structure: anterior loop. Region 23: bone height ≈ 15.0 mm; implant space ≈ 8.3 mm; nearby structure: sinus floor. Region 41: bone height ≈ 10.9 mm; implant space ≈ 6.3 mm; nearby structure: mandibular canal. Region 15: bone height ≈ 19.2 mm; implant space ≈ 14.2 mm; nearby structure: mental foramen. Region 33: bone height ≈ 18.5 mm; implant space ≈ 11.1 mm; nearby structure: nasal floor. Maxillary sinus shows mild mucosal thickening bilaterally. Periapical radiolucency visible at 48, additional smaller lesion near 14. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Residual ridge height insufficient in 11; sinus lift recommended."}
{"id": "case_0038", "images": ["images/placeholder_0038.png"], "question": "Planning for assessment of residual ridge. Brief history/status: Omeprazole, Calcichew-D3, Bufomix Easyhaler, Duroferon, Losartan, Esomeprazole, Duloxetine. Desired treatment: Evaluate cortical thickness and spongy bone quality in 16–26.", "answer": "Review of CBCT scan dated 220203. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 37: bone height ≈ 7.3 mm; implant space ≈ 5.7 mm; nearby structure: nasal floor. Region 31: bone height ≈ 14.9 mm; implant space ≈ 8.5 mm; nearby structure: mandibular canal. Region 46: bone height ≈ 12.5 mm; implant space ≈ 9.6 mm; nearby structure: anterior loop. Region 13: bone height ≈ 13.1 mm; implant space ≈ 8.1 mm; nearby structure: nasal floor. Region 42: bone height ≈ 13.8 mm; implant space ≈ 8.0 mm; nearby structure: sinus floor. Region 18: bone height ≈ 5.2 mm; implant space ≈ 0.9 mm; nearby structure: mandibular canal. Region 45: bone height ≈ 20.6 mm; implant space ≈ 15.8 mm; nearby structure: nasal floor. Region 26: bone height ≈ 15.5 mm; implant space ≈ 13.4 mm; nearby structure: anterior loop. Region 43: bone height ≈ 20.0 mm; implant space ≈ 13.1 mm; nearby structure: mandibular canal. Region 35: bone height ≈ 12.1 mm; implant space ≈ 8.2 mm; nearby structure: mandibular canal. Periapical radiolucency visible at 25, additional smaller lesion near 31. Impression: Chronic apical periodontitis noted at 16 and 32; recommend endodontic consultation."}
{"id": "case_0039", "images": ["images/placeholder_0039.png"], "question": "Planning for bone grafting assessment. Brief history/status: Trulicity, Losartan, Insulin glargine, Bricanyl, Atorvastatin. Desired treatment: Assess sinus membrane integrity and bone height for implant feasibility in 16–26.", "answer": "Review of CBCT scan dated 251019. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 27: bone height ≈ 9.9 mm; implant space ≈ 3.4 mm; nearby structure: anterior loop. Region 22: bone height ≈ 16.8 mm; implant space ≈ 14.7 mm; nearby structure: sinus floor. Region 35: bone height ≈ 20.7 mm; implant space ≈ 17.8 mm; nearby structure: mandibular canal. Region 44: bone height ≈ 19.5 mm; implant space ≈ 16.2 mm; nearby structure: sinus floor. Region 32: bone height ≈ 8.5 mm; implant space ≈ 2.0 mm; nearby structure: anterior loop. Region 13: bone height ≈ 16.4 mm; implant space ≈ 8.4 mm; nearby structure: mandibular canal. Region 36: bone height ≈ 14.9 mm; implant space ≈ 8.6 mm; nearby structure: mental foramen. Region 45: bone height ≈ 20.9 mm; implant space ≈ 17.8 mm; nearby structure: mental foramen. Region 48: bone height ≈ 11.3 mm; implant space ≈ 6.1 mm; nearby structure: sinus floor. Region 37: bone height ≈ 15.9 mm; implant space ≈ 10.5 mm; nearby structure: nasal floor. Maxillary sinus shows mild mucosal thickening bilaterally. Periapical radiolucency visible at 42, additional smaller lesion near 41. Impression: Normal trabecular pattern observed; cortical plates intact."}
{"id": "case_0040", "images": ["images/placeholder_0040.png"], "question": "Planning for radiolucency investigation. Brief history/status: Betolvex, Atorvastatin, Calcichew-D3, Duloxetine, Omeprazole, Metoprolol, Insulin glargine. Desired treatment: Review the relationship between alveolar crest and mandibular canal in 36–46.", "answer": "Review of CBCT scan dated 230528. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 25: bone height ≈ 4.3 mm; implant space ≈ 1.6 mm; nearby structure: mental foramen. Region 11: bone height ≈ 20.6 mm; implant space ≈ 13.8 mm; nearby structure: sinus floor. Region 48: bone height ≈ 6.4 mm; implant space ≈ 2.6 mm; nearby structure: mental foramen. Region 35: bone height ≈ 20.5 mm; implant space ≈ 14.3 mm; nearby structure: mandibular canal. Region 43: bone height ≈ 5.1 mm; implant space ≈ 1.4 mm; nearby structure: mental foramen. Region 31: bone height ≈ 11.4 mm; implant space ≈ 7.5 mm; nearby structure: sinus floor. Region 41: bone height ≈ 15.6 mm; implant space ≈ 14.4 mm; nearby structure: mental foramen. Region 38: bone height ≈ 6.9 mm; implant space ≈ 1.5 mm; nearby structure: nasal floor. Region 24: bone height ≈ 20.1 mm; implant space ≈ 12.6 mm; nearby structure: mental foramen. Region 18: bone height ≈ 15.1 mm; implant space ≈ 13.1 mm; nearby structure: anterior loop. Maxillary sinus shows mild mucosal thickening bilaterally. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Normal trabecular pattern observed; cortical plates intact."}
{"id": "case_0041", "images": ["images/placeholder_0041.png"], "question": "Planning for implant placement verification. Brief history/status: Levaxin, Atorvastatin, Duloxetine, Omeprazole, Bufomix Easyhaler. Desired treatment: Please analyze bone height, width, and proximity to critical anatomy across 34–44 and 34–44.", "answer": "Review of CBCT scan dated 230307. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 46: bone height ≈ 7.8 mm; implant space ≈ 2.8 mm; nearby structure: mental foramen. Region 27: bone height ≈ 14.4 mm; implant space ≈ 10.6 mm; nearby structure: mental foramen. Region 16: bone height ≈ 19.2 mm; implant space ≈ 15.6 mm; nearby structure: nasal floor. Region 23: bone height ≈ 6.0 mm; implant space ≈ 4.3 mm; nearby structure: sinus floor. Region 14: bone height ≈ 21.4 mm; implant space ≈ 20.4 mm; nearby structure: mandibular canal. Region 21: bone height ≈ 16.9 mm; implant space ≈ 10.8 mm; nearby structure: mental foramen. Region 11: bone height ≈ 10.2 mm; implant space ≈ 6.1 mm; nearby structure: sinus floor. Region 42: bone height ≈ 18.0 mm; implant space ≈ 13.6 mm; nearby structure: nasal floor. Region 45: bone height ≈ 14.8 mm; implant space ≈ 9.1 mm; nearby structure: nasal floor. Region 48: bone height ≈ 16.2 mm; implant space ≈ 11.3 mm; nearby structure: mandibular canal. Maxillary sinus shows mild mucosal thickening bilaterally. Periapical radiolucency visible at 15, additional smaller lesion near 31. Impression: Findings indicate sufficient bone height with mild sinus mucosal thickening."}
{"id": "case_0042", "images": ["images/placeholder_0042.png"], "question": "Planning for bone density and height measurement. Brief history/status: Amlodipine, Trulicity, Duroferon, Calcichew-D3, Losartan, Bufomix Easyhaler, Duloxetine. Desired treatment: Assess sinus membrane integrity and bone height for implant feasibility in 16–26.", "answer": "Review of CBCT scan dated 240215. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 21: bone height ≈ 4.1 mm; implant space ≈ 0.3 mm; nearby structure: mental foramen. Region 45: bone height ≈ 10.5 mm; implant space ≈ 7.5 mm; nearby structure: mandibular canal. Region 24: bone height ≈ 7.9 mm; implant space ≈ 0.5 mm; nearby structure: mental foramen. Region 22: bone height ≈ 16.1 mm; implant space ≈ 9.6 mm; nearby structure: mandibular canal. Region 48: bone height ≈ 8.1 mm; implant space ≈ 0.7 mm; nearby structure: mental foramen. Region 43: bone height ≈ 7.0 mm; implant space ≈ 0 mm; nearby structure: sinus floor. Region 31: bone height ≈ 20.1 mm; implant space ≈ 17.2 mm; nearby structure: mandibular canal. Region 16: bone height ≈ 6.0 mm; implant space ≈ 1.5 mm; nearby structure: mandibular canal. Region 26: bone height ≈ 20.5 mm; implant space ≈ 17.7 mm; nearby structure: sinus floor. Region 23: bone height ≈ 5.7 mm; implant space ≈ 1.5 mm; nearby structure: sinus floor. Maxillary sinus shows mild mucosal thickening bilaterally. Impression: Adequate bone density throughout; implant feasible without augmentation."}
{"id": "case_0043", "images": ["images/placeholder_0043.png"], "question": "Planning for implant placement verification. Brief history/status: Betolvex, Insulin glargine, Duloxetine, Metoprolol, Bricanyl. Desired treatment: Review the relationship between alveolar crest and mandibular canal in 36–46.", "answer": "Review of CBCT scan dated 210702. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 35: bone height ≈ 6.6 mm; implant space ≈ 0.2 mm; nearby structure: anterior loop. Region 42: bone height ≈ 7.4 mm; implant space ≈ 2.7 mm; nearby structure: mental foramen. Region 22: bone height ≈ 5.8 mm; implant space ≈ 0 mm; nearby structure: mental foramen. Region 13: bone height ≈ 10.4 mm; implant space ≈ 8.2 mm; nearby structure: mental foramen. Region 11: bone height ≈ 17.9 mm; implant space ≈ 15.0 mm; nearby structure: anterior loop. Region 17: bone height ≈ 8.6 mm; implant space ≈ 5.4 mm; nearby structure: mandibular canal. Region 37: bone height ≈ 15.6 mm; implant space ≈ 14.2 mm; nearby structure: nasal floor. Region 41: bone height ≈ 10.1 mm; implant space ≈ 4.3 mm; nearby structure: anterior loop. Region 28: bone height ≈ 15.1 mm; implant space ≈ 9.4 mm; nearby structure: mandibular canal. Region 45: bone height ≈ 8.3 mm; implant space ≈ 1.0 mm; nearby structure: anterior loop. Maxillary sinus shows mild mucosal thickening bilaterally. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Diffuse radiolucency with irregular margin near 24; correlate clinically."}
{"id": "case_0044", "images": ["images/placeholder_0044.png"], "question": "Planning for implant placement verification. Brief history/status: Atorvastatin, Trulicity, Omeprazole, Calcichew-D3, Duroferon, Metoprolol, Bricanyl, Esomeprazole. Desired treatment: Provide detailed bone mapping and canal proximity data for 16–26.", "answer": "Review of CBCT scan dated 241020. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 31: bone height ≈ 5.7 mm; implant space ≈ 1.5 mm; nearby structure: mental foramen. Region 26: bone height ≈ 16.0 mm; implant space ≈ 11.7 mm; nearby structure: nasal floor. Region 36: bone height ≈ 21.3 mm; implant space ≈ 15.5 mm; nearby structure: nasal floor. Region 41: bone height ≈ 11.2 mm; implant space ≈ 8.6 mm; nearby structure: mandibular canal. Region 24: bone height ≈ 15.9 mm; implant space ≈ 12.2 mm; nearby structure: nasal floor. Region 47: bone height ≈ 17.4 mm; implant space ≈ 15.0 mm; nearby structure: sinus floor. Region 38: bone height ≈ 14.4 mm; implant space ≈ 10.9 mm; nearby structure: mental foramen. Region 35: bone height ≈ 15.7 mm; implant space ≈ 8.6 mm; nearby structure: mental foramen. Region 34: bone height ≈ 5.1 mm; implant space ≈ 0.9 mm; nearby structure: mental foramen. Region 33: bone height ≈ 11.3 mm; implant space ≈ 3.4 mm; nearby structure: anterior loop. Maxillary sinus shows mild mucosal thickening bilaterally. Impression: Normal trabecular pattern observed; cortical plates intact."}
{"id": "case_0045", "images": ["images/placeholder_0045.png"], "question": "Planning for follow-up after implant restoration. Brief history/status: Esomeprazole, Atorvastatin, Duloxetine, Insulin glargine, Levaxin, Amlodipine. Desired treatment: Assess sinus membrane integrity and bone height for implant feasibility in 14–24.", "answer": "Review of CBCT scan dated 220726. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 21: bone height ≈ 7.1 mm; implant space ≈ 1.9 mm; nearby structure: sinus floor. Region 27: bone height ≈ 17.8 mm; implant space ≈ 15.5 mm; nearby structure: nasal floor. Region 11: bone height ≈ 12.1 mm; implant space ≈ 7.0 mm; nearby structure: nasal floor. Region 32: bone height ≈ 20.2 mm; implant space ≈ 17.9 mm; nearby structure: anterior loop. Region 42: bone height ≈ 14.9 mm; implant space ≈ 11.7 mm; nearby structure: mental foramen. Region 23: bone height ≈ 17.2 mm; implant space ≈ 12.4 mm; nearby structure: mental foramen. Region 28: bone height ≈ 9.3 mm; implant space ≈ 5.6 mm; nearby structure: sinus floor. Region 15: bone height ≈ 16.5 mm; implant space ≈ 13.2 mm; nearby structure: anterior loop. Region 22: bone height ≈ 5.0 mm; implant space ≈ 0 mm; nearby structure: anterior loop. Region 43: bone height ≈ 10.8 mm; implant space ≈ 8.8 mm; nearby structure: nasal floor. Impression: Chronic apical periodontitis noted at 41 and 21; recommend endodontic consultation."}
{"id": "case_0046", "images": ["images/placeholder_0046.png"], "question": "Planning for evaluation for prosthetic design. Brief history/status: Insulin glargine, Betolvex, Duroferon, Duloxetine, Omeprazole. Desired treatment: Measure available vertical height and ridge width in 33–43 and 14–24.", "answer": "Review of CBCT scan dated 200120. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 43: bone height ≈ 12.0 mm; implant space ≈ 7.7 mm; nearby structure: mental foramen. Region 14: bone height ≈ 9.5 mm; implant space ≈ 5.8 mm; nearby structure: mandibular canal. Region 35: bone height ≈ 17.9 mm; implant space ≈ 10.7 mm; nearby structure: mandibular canal. Region 28: bone height ≈ 5.3 mm; implant space ≈ 3.8 mm; nearby structure: sinus floor. Region 21: bone height ≈ 4.3 mm; implant space ≈ 2.7 mm; nearby structure: mental foramen. Region 22: bone height ≈ 6.6 mm; implant space ≈ 2.1 mm; nearby structure: mental foramen. Region 34: bone height ≈ 7.3 mm; implant space ≈ 0.9 mm; nearby structure: anterior loop. Region 24: bone height ≈ 9.5 mm; implant space ≈ 4.5 mm; nearby structure: nasal floor. Region 41: bone height ≈ 17.5 mm; implant space ≈ 10.3 mm; nearby structure: sinus floor. Region 27: bone height ≈ 16.9 mm; implant space ≈ 11.6 mm; nearby structure: mental foramen. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: No radiographic evidence of acute infection or pathology detected."}
{"id": "case_0047", "images": ["images/placeholder_0047.png"], "question": "Planning for radiolucency investigation. Brief history/status: Bricanyl, Amlodipine, Duloxetine, Duroferon, Omeprazole, Esomeprazole, Trulicity. Desired treatment: Evaluate cortical thickness and spongy bone quality in 14–24.", "answer": "Review of CBCT scan dated 230523. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 18: bone height ≈ 20.5 mm; implant space ≈ 16.5 mm; nearby structure: anterior loop. Region 38: bone height ≈ 19.5 mm; implant space ≈ 18.1 mm; nearby structure: nasal floor. Region 43: bone height ≈ 17.5 mm; implant space ≈ 13.7 mm; nearby structure: mandibular canal. Region 24: bone height ≈ 20.2 mm; implant space ≈ 17.5 mm; nearby structure: sinus floor. Region 46: bone height ≈ 10.4 mm; implant space ≈ 6.0 mm; nearby structure: nasal floor. Region 23: bone height ≈ 4.1 mm; implant space ≈ 2.3 mm; nearby structure: nasal floor. Region 33: bone height ≈ 9.6 mm; implant space ≈ 1.9 mm; nearby structure: nasal floor. Region 11: bone height ≈ 20.9 mm; implant space ≈ 18.7 mm; nearby structure: mental foramen. Region 27: bone height ≈ 19.6 mm; implant space ≈ 11.7 mm; nearby structure: anterior loop. Region 41: bone height ≈ 4.1 mm; implant space ≈ 2.1 mm; nearby structure: mental foramen. Periapical radiolucency visible at 41, additional smaller lesion near 13. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Mild bone resorption near 35 and 27; stable post-surgical remodeling."}
{"id": "case_0048", "images": ["images/placeholder_0048.png"], "question": "Planning for follow-up after implant restoration. Brief history/status: Betolvex, Esomeprazole, Bufomix Easyhaler, Atorvastatin, Amlodipine. Desired treatment: Please analyze bone height, width, and proximity to critical anatomy across 36–46 and 14–24.", "answer": "Review of CBCT scan dated 230228. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 25: bone height ≈ 4.8 mm; implant space ≈ 2.7 mm; nearby structure: mental foramen. Region 38: bone height ≈ 21.3 mm; implant space ≈ 18.8 mm; nearby structure: mental foramen. Region 17: bone height ≈ 6.6 mm; implant space ≈ 1.2 mm; nearby structure: mental foramen. Region 35: bone height ≈ 5.6 mm; implant space ≈ 0 mm; nearby structure: sinus floor. Region 45: bone height ≈ 21.1 mm; implant space ≈ 19.8 mm; nearby structure: anterior loop. Region 33: bone height ≈ 11.3 mm; implant space ≈ 9.2 mm; nearby structure: sinus floor. Region 14: bone height ≈ 12.0 mm; implant space ≈ 6.0 mm; nearby structure: sinus floor. Region 37: bone height ≈ 19.6 mm; implant space ≈ 18.4 mm; nearby structure: anterior loop. Region 44: bone height ≈ 18.8 mm; implant space ≈ 17.6 mm; nearby structure: anterior loop. Region 15: bone height ≈ 5.6 mm; implant space ≈ 0.9 mm; nearby structure: anterior loop. Impression: Mild bone resorption near 42 and 35; stable post-surgical remodeling."}
{"id": "case_0049", "images": ["images/placeholder_0049.png"], "question": "Planning for assessment of residual ridge. Brief history/status: Omeprazole, Duroferon, Insulin glargine, Betolvex, Calcichew-D3. Desired treatment: Check for apical radiolucency or infection in regions 37, 31, and 17.", "answer": "Review of CBCT scan dated 210113. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 25: bone height ≈ 5.1 mm; implant space ≈ 0.3 mm; nearby structure: mandibular canal. Region 18: bone height ≈ 9.3 mm; implant space ≈ 2.6 mm; nearby structure: nasal floor. Region 42: bone height ≈ 12.1 mm; implant space ≈ 6.1 mm; nearby structure: sinus floor. Region 33: bone height ≈ 20.1 mm; implant space ≈ 13.3 mm; nearby structure: mental foramen. Region 13: bone height ≈ 15.6 mm; implant space ≈ 13.8 mm; nearby structure: sinus floor. Region 22: bone height ≈ 9.8 mm; implant space ≈ 4.8 mm; nearby structure: mandibular canal. Region 47: bone height ≈ 4.3 mm; implant space ≈ 0 mm; nearby structure: anterior loop. Region 46: bone height ≈ 7.6 mm; implant space ≈ 5.4 mm; nearby structure: nasal floor. Region 32: bone height ≈ 8.6 mm; implant space ≈ 3.1 mm; nearby structure: nasal floor. Region 14: bone height ≈ 14.3 mm; implant space ≈ 7.1 mm; nearby structure: mental foramen. Maxillary sinus shows mild mucosal thickening bilaterally. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: Mild bone resorption near 47 and 27; stable post-surgical remodeling."}
{"id": "case_0050", "images": ["images/placeholder_0050.png"], "question": "Planning for pre-implant radiological mapping. Brief history/status: Duloxetine, Bufomix Easyhaler, Omeprazole, Losartan, Metoprolol. Desired treatment: Check for apical radiolucency or infection in regions 11, 47, and 33.", "answer": "Review of CBCT scan dated 250212. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 38: bone height ≈ 16.7 mm; implant space ≈ 13.3 mm; nearby structure: mental foramen. Region 13: bone height ≈ 16.9 mm; implant space ≈ 15.5 mm; nearby structure: nasal floor. Region 46: bone height ≈ 10.2 mm; implant space ≈ 7.1 mm; nearby structure: sinus floor. Region 17: bone height ≈ 4.0 mm; implant space ≈ 0.4 mm; nearby structure: mental foramen. Region 26: bone height ≈ 8.7 mm; implant space ≈ 2.6 mm; nearby structure: nasal floor. Region 21: bone height ≈ 12.6 mm; implant space ≈ 7.9 mm; nearby structure: mandibular canal. Region 23: bone height ≈ 18.9 mm; implant space ≈ 12.7 mm; nearby structure: mandibular canal. Region 22: bone height ≈ 18.3 mm; implant space ≈ 13.3 mm; nearby structure: anterior loop. Region 28: bone height ≈ 14.3 mm; implant space ≈ 10.0 mm; nearby structure: mental foramen. Region 12: bone height ≈ 14.5 mm; implant space ≈ 9.6 mm; nearby structure: anterior loop. Metallic restorations cause mild streak artifacts affecting local clarity. Impression: No radiographic evidence of acute infection or pathology detected."}
{"id": "case_0051", "images": ["images/placeholder_0051.png"], "question": "Planning for implant placement verification. Brief history/status: Trulicity, Levaxin, Atorvastatin, Calcichew-D3, Esomeprazole, Bricanyl. Desired treatment: Assess implant site quality and need for sinus lift or graft in 34–44.", "answer": "Review of CBCT scan dated 230106. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 35: bone height ≈ 11.7 mm; implant space ≈ 10.4 mm; nearby structure: mandibular canal. Region 21: bone height ≈ 12.4 mm; implant space ≈ 8.8 mm; nearby structure: anterior loop. Region 27: bone height ≈ 12.2 mm; implant space ≈ 5.9 mm; nearby structure: mandibular canal. Region 12: bone height ≈ 9.2 mm; implant space ≈ 6.5 mm; nearby structure: anterior loop. Region 22: bone height ≈ 16.2 mm; implant space ≈ 11.4 mm; nearby structure: mental foramen. Region 31: bone height ≈ 14.0 mm; implant space ≈ 6.1 mm; nearby structure: mental foramen. Region 43: bone height ≈ 15.4 mm; implant space ≈ 12.7 mm; nearby structure: anterior loop. Region 16: bone height ≈ 10.9 mm; implant space ≈ 3.3 mm; nearby structure: nasal floor. Region 28: bone height ≈ 5.7 mm; implant space ≈ 0.8 mm; nearby structure: mandibular canal. Region 37: bone height ≈ 16.6 mm; implant space ≈ 12.1 mm; nearby structure: nasal floor. Maxillary sinus shows mild mucosal thickening bilaterally. Impression: Peri-implant bone loss at 42 consistent with early peri-implantitis."}
{"id": "case_0052", "images": ["images/placeholder_0052.png"], "question": "Planning for bone density and height measurement. Brief history/status: Duroferon, Metoprolol, Losartan, Atorvastatin, Omeprazole, Bricanyl, Bufomix Easyhaler. Desired treatment: Measure available vertical height and ridge width in 33–43 and 36–46.", "answer": "Review of CBCT scan dated 231004. Bone density within expected physiological range. Implant feasibility evaluated assuming 5 mm minimum bone width threshold. Region 15: bone height ≈ 6.8 mm; implant space ≈ 5.0 mm; nearby structure: mental foramen. Region 38: bone height ≈ 9.1 mm; implant space ≈ 5.1 mm; nearby structure: sinus floor. Region 46: bone height ≈ 19.1 mm; implant space ≈ 15.0 mm; nearby structure: anterior loop. Region 26: bone height ≈ 15.5 mm; implant space ≈ 13.9 mm; nearby structure: anterior loop. Region 36: bone height ≈ 7.2 mm; implant space ≈ 0 mm; nearby structure: nasal floor. Region 48: bone height ≈ 21.8 mm; implant space ≈ 16.7 mm; nearby structure: mental foramen. Region 16: bone height ≈ 14.3 mm; implant space ≈ 12.4 mm; nearby structure: sinus floor. Region 32: bone height ≈ 4.5 mm; implant space ≈ 1.4 mm; nearby structure: anterior loop. Region 13: bone height ≈ 15.5 mm; implant space ≈ 7.6 mm; nearby structure: sinus floor. Region 12: bone height ≈ 7.5 mm; implant space ≈ 5.3 mm; nearby structure: sinus floor. Impression: Residual ridge height insufficient in 42; sinus lift recommended."}
{"id": "case_0053", "images": ["images/placeholder_0053.png"], "question": "Planning for bone grafting assessment. Brief history/status: Trulicity, Atorvastatin, Bricanyl, Metoprolol, Losartan. Desired treatment: Please analyze bone height, width, and proximity to critical anatomy across 14–24